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Abstract
The University of Manchester; Lang’o Taabu Odondi; PhD; May 2011;
Causal modelling of survival data with informative noncompliance
Noncompliance to treatment allocation is likely to complicate estimation of causal effects in clinical
trials. The ubiquitous nonrandom phenomenon of noncompliance renders per-protocol and as-
treated analyses or even simple regression adjustments for noncompliance inadequate for causal
inference. For survival data, several specialist methods have been developedwhen noncompliance
is related to risk. The Causal Accelerated Life Model (CALM) allows time-dependent departures
from randomized treatment in either arm and relates each observed event time to a potential event
time that would have been observed if the control treatment had been given throughout the trial.
Alternatively, the structural Proportional Hazards (C-Prophet) model accounts for all-or-nothing
noncompliance in the treatment arm only while the CHARM estimator allows time-dependent
departures from randomized treatment by considering survival outcome as a sequence of binary
outcomes to provide an ‘approximate’ overall hazard ratio estimate which is adjusted for compli-
ance. The problem of efficacy estimation is compounded for two-active treatment trials (additional
noncompliance) where the ITT estimate provides a biased estimator for the true hazard ratio even
under homogeneous treatment effects assumption. Using plausible arm-specific predictors of com-
pliance, principal stratification methods can be applied to obtain principal effects for each stratum.
The present work applies the above methods to data from the Esprit trials study which was con-
ducted to ascertain whether or not unopposed oestrogen (hormone replacement therapy-HRT)
reduced the risk of further cardiac events in postmenopausal women who survive a first myocar-
dial infarction. We use statistically designed simulation studies to evaluate the performance of
these methods in terms of bias and 95% confidence interval coverage. We also apply a principal
stratification method to adjust for noncompliance in two treatment arms trial originally developed
for binary data for survival analysis in terms of causal risk ratio. In a Bayesian framework, we ap-
ply the method to Esprit data to account for noncompliance in both treatment arms and estimate
principal effects. We apply statistically designed simulation studies to evaluate the performance of
the method in terms of bias in the causal effect estimates for each stratum. ITT analysis of the Es-
prit data showed the effects of taking HRT tablets was not statistically significantly different from
placebo for both all-cause mortality and myocardial reinfarction outcomes. Average compliance
rate for HRT treatment was 43% and compliance rate decreased as the study progressed. CHARM
and C-Prophet methods produced similar results but CALM performed best for Esprit: suggesting
HRT would reduce risk of death by 50%. Simulation studies comparing the methods suggested
that while both C-Prophet and CHARM methods performed equally well in terms of bias, the
CALM method performed best in terms of both bias and 95% confidence interval coverage albeit
with the largest RMSE. The principal stratification method failed for the Esprit study possibly due
to the strong distribution assumption implicit in the method and lack of adequate compliance in-
formation in the datawhich produced large 95% credible intervals for the principal effect estimates.
For moderate value of sensitivity parameter, principal stratification results suggested compliance
with HRT tablets relative to placebo would reduce risk of mortality by 43% among the most com-
pliant. Simulation studies on performance of this method showed narrower corresponding mean
95% credible intervals corresponding to the the causal risk ratio estimates for this subgroup com-
pared to other strata. However, the results were sensitive to the unknown sensitivity parameter.
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Chapter1
Introduction and Motivation
1.1 Introduction
We begin this introductory chapter by briey outlining the broad context of our research
question followed by a synopsis of the motivating study/data. The next section presents
a discussion of causation in medical research and a review of research design focussing on
randomized controlled clinical trials and spelling out key design features, their classication,
merits and limitations as contrasted with observational studies. This is followed by a brief
review of reasons of association and the interplay between causal inference and statistics. The
next section provides a review of the framework of counterfactual causal modelling by rst
tracing the origin of the use of counterfactuals in empirical research in the rst quarter of the
last Century followed by an exposition of the use of counterfactuals and posttreatment vari-
ables to address noncompliance to treatment assignment in order to obtain well-dened causal
estimates. An outline of key assumptions implicit in causal modelling using counterfactuals
is then presented with a discussion of opposing viewpoints between proponents and critics of
causal modelling using counterfactuals. The section ends with a skeletal review of alternative
formulations of causal models. After a brief outline of the similarities between noncompli-
ance and missing data phenomenon, the subsequent section reviews propensity scores as a
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method of adjusting for confounding and extends it to building compliance prediction mod-
els (propensity to comply). This is followed by a review of dierent methods of estimating
treatment eects starting with intention-to-treat which ignores compliance information then
per-protocol analysis that evaluates treatment as received. The section ends with a brief de-
scription of methods which adjust for noncompliance while still retaining ideals of randomiza-
tion starting with instrumental variables and then `complier average causal eects' estimation
techniques. These two techniques are considered as an entry point to principal stratication
which is reviewed as a general framework for adjusting for noncompliance in both one and
two (possibly multiple) treatment arms. The chapter concludes with a statement of broad
aims and specic objectives of the present work and nally an outline of the whole thesis.
1.2 Research problem in context
Most research questions in the health sciences are causal in nature, for example, what is
the ecacy of a given treatment in a given population? A primary objective of most med-
ical research studies is to estimate causal eects when comparing two or more treatments
(interventions). Eective randomization of subjects between the treatments groups plays
a central role in permitting such statistical comparison (Lachin, 2000). In an ideal world
we would expect subjects to perfectly comply with their respective treatment assignments.
But reality is dierent and noncompliance to treatment assignment due to treatment dis-
continuation, switching or subject dropout from the study is a common feature in clinical
trials. Non-adherence to treatment allocation may take the form of either all-or-nothing or
partial noncompliance. Intention-to-treat (ITT) is the gold standard for ecacy analysis
under perfect compliance to treatment allocation. The ITT is an as-randomized analysis
where the treatment groups are compared as assigned and the resulting ITT estimators en-
joy the benet of randomization by preserving the baseline comparability between treatment
groups as it retains all randomized subjects. But in the presence of treatment noncom-
pliance, the ITT is likely to underestimate the treatment ecacy by mixing the eects of
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treatment compliers and non-compliers (White and Pocock, 1996). Noncompliance is mostly
a nonrandom phenomenon (Nagelkerke et al., 2000) and it is a challenge adjusting for such
potentially informative entities. We note here that using the term noncompliance may inad-
vertently confer/imply moral judgement and some authors suggest alternative terminology
like departures from treatment allocation (White, 2005). However, the present work will use
noncompliance in its simple sense to mean failure to comply with assigned treatment.
Many practical-problem studies involve time-to-event data, and such data are common in
many medical elds including clinical trials, cohort studies and epidemiology studies. Such
studies are commonly referred to as survival analysis, for example studying time to death
or myocardial reinfarction or re-emergence of a cancer tumour among others. While many
methods have been developed to estimate causal eects in the presence of treatment non-
compliance for continuous outcomes, less attention has been paid to analysis of survival data
(Nie et al., 2011). The Cox (1972) proportional hazards model is considered the standard
tool in analysis of survival data from randomized trials. Although the ITT estimates eective-
ness (treatment eect in usual or ordinary conditions) even when there is noncompliance with
treatment, the ITT estimates ecacy (treatment eect in ideal conditions) only under perfect
compliance. But noncompliance is ubiquitous (and often informative) which makes it unre-
alistic to consider non-compliers in a trial as a random subset of all patients under study.
In the presence of random noncompliance, simple regression techniques that adjust for
noncompliance would be adequate in making causal inference. But the nonrandom nature of
noncompliance is likely to complicate drawing inference about causal eects if present in any
trial. While per-protocol and as-treated analysis are the most commonly used methods to
supplement ITT in evaluating ecacy (Little et al., 2009; White, 2005), these post-hoc anal-
yses are bereft of the benets of randomization. They may be biased due to selection eects
which may be evident in dierent compliance behaviour in dierent arms. One solution is pro-
vided by application of the principal stratication framework (Frangakis and Rubin, 2002)
which permits adjustment based on a posttreatment variable like a noncompliance status,
which retains the ideals of randomization to produce well-dened causal eect estimates.
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The problem of ecacy estimation is even more complicated in the presence of two-
active treatment arms where the ITT may provide a biased estimator even under homo-
geneous (uniform) treatment eects assumption (Aalen, 1998; Baker and Kramer, 2005).
Possible noncompliance in both arms compounds the identication problem for such tri-
als (Brittain and Lin, 2005; Chiba, 2009). It is a challenge adjusting for possible non-
compliance in both arms due to resulting identication problem. For example, double-
blind placebo-controlled randomized clinical trials with active treatment may be compli-
cated by two levels of noncompliance: a part from simple noncompliance in both active and
placebo arms, an imperfect blinding may present an additional dierential compliances in
the two arms (Jin and Rubin, 2008). But baseline covariates which are plausible predictors
of compliance may be used to address such identication problems. Using such plausible
predictors in a Bayesian approach, we can develop marginal compliance models for each
treatment arm and apply principal stratication methods to construct causal models which
provide principal eects for each stratum (Roy et al., 2008).
In the next section we provide a brief summary of the study which motivated the present
work. We will analyse data from this study with the objective of addressing the problems
outlined above, i.e. adjusting for noncompliance in one and two treatment arms.
1.3 Motivating data: The Esprit study
The onset of menopause is often characterized by diminishing production of oestrogen hor-
mones due to a decline in ovarian function. The resulting physiological and biological changes
among such women's bodies commonly manifest themselves through unpleasant menopausal
symptoms like vasomotor (mostly hot ushes and night sweating), urogenital atrophy, insom-
nia, depression, fatigue, skin changes and increased irritability (Pecorelli and Fallo, 1998).
Poor management of these symptoms can impact negatively on the body leading to low qual-
ity of life among such women for the better part of the last third of their lives (Hill, 1996;
Rees, 2005). Hormone replacement therapy (HRT) is a treatment for oestrogen-deciency
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Table 1.1: Esprit study: baseline characteristics (adopted from Cherry et al. 2002)
HRT tablets Placebo
Number Mean (SD) Number Mean (SD)
or number (%) or number (%)
Age at admission (years) 513 62.3 (5.2) 504 62.9 (4.9)
Age at end education (yrs) 498 14.9 (1.2) 479 14.9 (1.2)
Age at last menses (years) 487 46.3 (5.8) 476 46.6 (5.7)
BMI (kg/m2) 507 26.8 (5.1) 500 26.7 (5.3)
Last occupation manual 499 286 (57%) 483 292 (60%)
Smoker at admission 513 276 (54%) 503 264 (52%)
Normally drinks 513 197 (38%) 504 177 (35%)
(> 1 unit alcohol/week)
White 511 496 (97%) 503 489 (97%)
History
Angina 512 140 (27%) 504 136 (27%)
High blood pressure 513 237 (46%) 504 211 (42%)
Stroke 513 39 (8%) 504 36 (7%)
Diabetes 513 79 (15%) 503 74 (15%)
Fracture (in previous 512 71 (14%) 503 97 (19%)
10 years)
Hysterectomy 513 140 (27%) 504 105 (21%)
Oral contraceptive use 509 187 (37%) 497 185 (37%)
Used HRT (> 12 months 512 62 (12%) 502 51 (10%)
before admission)
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symptoms which is mainly administered in two broad forms depending on whether a woman
has her uterus intact or not: unopposed oestrogen (oestrogen taken by itself) for those who
have had hysterectomy (removal of the uterus) or oestrogen with progestin for the non-
hysterectomized. The addition of progestin is meant to counteract the eects of estrogen on
the uterus like endometrial cancer, i.e. cancer of the lining of the uterus.
Although observational studies showed benets of HRT in lowering rates of coronary heart
disease (Grady et al., 1992; Grodstein and Stampfer, 1995), recent clinical trials (Barnabei
et al., 2005; Cherry et al., 2002; Grady et al., 2002) failed to conrm such benecial eects
among postmenopausal women. While HRT has been shown to oer no signicant benet or
harmful eect on cardiovascular risk reduction, HRT is still commonly prescribed to address
other postmenopausal symptoms like osteoporosis (Cho and Mukherjee, 2005; Rees, 2005).
The oEStrogen in the Prevention of ReiInfarction Trial (Esprit) (Cherry et al., 2002) was one
of the studies which revealed no HRT benet among postmenopausal women in England and
Wales. The present work uses data from the Esprit study to motivate the methods and anal-
yses considered herein. Table 1.1 provide a summary of some of the baseline characteristics
for each arm of the Esprit data.
The aim of the Esprit study was to ascertain whether or not unopposed oestrogen reduces
the risk of further cardiac events in postmenopausal women who survive a rst myocardial
infarction. Recruitment was conducted from 35 hospitals in England and Wales and involved
women aged between 50 and 69 years. A total of 14; 773 hospital records were inspected out
of which 11; 652 did not meet inclusion criteria for myocardial infarction. Out of the 3; 121
who met the inclusion criteria for myocardial infarction, 2; 104 were excluded mostly because
of previous myocardial infarction, history (previous use) of oestrogen, or vaginal bleeding.
Ultimately, the study comprised a total of 1017 women with 513 and 504 randomized to HRT
treatment and placebo arms respectively and monitored over two-year period.
Previous observational studies suggested that hormone replacement therapy prevented
cardiac events but there had been no randomized clinical trial on the same when the Esprit
study was started in 1996. Evidence from observational studies showed that unopposed
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oestrogen increased the risk of endometrial cancer although the addition of progesterone
reversed this eect. Additionally, there was evidence that oestrogen reduced risk of frac-
tures. There was also evidence of increased risk of breast cancer among the long term users
(> 5 years). Organizers of the Esprit trial argued that the benets (in terms of cardio-
vascular deaths) of giving unopposed oestrogen to a group at high risk of second infarc-
tion could outweigh any increased risk of endometrial cancer. The primary outcomes were
reinfarction or cardiac death and all-cause mortality. Although ITT analysis of the data
has been previously published (Cherry et al., 2002), the analysis took no account of com-
pliance data. The present work utilizes compliance data and apply specialist methods in
analysis to adjust for noncompliance in the active treatment arm of the the Esprit data
while considering two outcomes: all-cause mortality (ACM) and myocardial reinfarction or
cardiac deaths (MRCD). Assuming no carryover eects nor treatment switches, we dene
compliers as those participants who actually took HRT tablets up to a day before experi-
encing event of interest (ACM/MRCD) or end of interval/study, whichever occurred rst.
The rate of compliance with HRT treatment was generally poor (42% on average). Since
we consider several competing methods of analysis of data, we will apply statistically de-
signed simulation studies to evaluate the performance of these methods in terms of bias, root
mean-squared error and 95% condence intervals coverage.
Most studies designed to investigate ecacy often consider compliance with the experi-
mental treatment only while ignoring compliance with the control. Ignoring the compliance
data for the control group is likely to produce estimates that sacrice either lack of bias or
precision at the expense of the other, i.e. precision-bias tradeo (Sommer and Zeger, 1991).
For example, double-blind placebo-controlled randomized clinical trials with active treatment
present complications beyond simple noncompliance (Jin and Rubin, 2008). The rst compli-
cation is presented in the form of (ordinary) simple noncompliance to treatment assignment
for both active and placebo arms. A second complication may manifest itself in the presence
of imperfect blinding, e.g. detectable positive or negative side eects of the active treatment
which may unconceal blinding. Such a scenario is possible in the Esprit data where bleeding
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may breach blinding because it could make victims aware of their active HRT treatment as-
signment. The Esprit data also contained information on placebo compliance which may be
useful in extending simple compliance to account for dierential compliances in both active
treatment and placebo arms. Considering the Esprit data as a two-active treatment trial and
to address identication problem, we will select plausible separate predictors of compliance for
HRT treatment and placebo arms and apply principal stratication framework using the Roy
et al. (2008) model for survival data to adjust for noncompliance in both arms of the Esprit
data. We will also apply statistically designed simulation studies using Bayesian techniques
to evaluate the performance of this method in terms of bias and 95% credible intervals.
1.4 Causation in medical research
While philosophical origin of causal modelling may date as far back as the time of Aristotle,
philosopher David Hume (1739) is credited as the rst to posit a wholly empirical denition
of causality that laid the foundation for the modern concept of causality. The application of
causation in medical research is often focussed on the search for cause-eect relationships in
diseases (Belin and Normand, 2009). Causal research is commonly conducted using either
observational studies or randomized clinical trials. Although clinical trials are considered the
gold standard in establishing causation due to their ability to eliminate systematic pretreat-
ment dierences between the treatment groups, situations arise when clinical trials are not
feasible or ethical and epidemiologists often revert to observational studies to test hypothesis
about causation. However, any discussion of observational studies must remain cognisant to
an advise by Cochran (1965) of the need to imagine how the study would be conducted if it
were possible to do it by controlled experimentation.
In epidemiological studies, John Snow1 is recognized as the rst to conduct an observa-
tional study to investigate possible causes of a cholera epidemic in London in 1853. Snow
established that cholera death rates were much higher among people in areas who drew water
1http://www.johnsnow.matrix.msu.edu/
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from downstream River Thames (after possible contamination with sewerage) compared to
those from areas upstream who were supplied with water by the Lambeth Company.
On the other hand, James Lind2 is credited with performing the rst randomized clinical
trial in 1774. As a naval ocer and surgeon aboard the Salisbury, a ship carrying people
aicted with scurvy, he selected twelve patients with similar symptoms of scurvy (e.g. putrid
gums, the spots and lassitude, with weakness of the knees), allocated a range of exposures
to pairs of suerers. The result was a discovery of greater improvement among those who
received oranges and lemons each day, hence the well-known relationship between lack of vita-
min C as a cause of scurvy. We note the delity with basic ideals of randomized clinical trials
in Lind's experiment like using patients with similar symptoms to minimize selection bias.
Medical studies are mostly conducted to examine associations between exposures or risk
factors and disease outcomes, for example, assessing the eect of HRT treatment on alle-
viating postmenopausal symptoms. The early examples above show the pioneering work of
aggregating data and comparing groups to help identify causes. But comparison of groups
may reveal an association that is not necessarily causal. Apparent association can be at-
tributed to various factors that are not necessarily causal in nature. According to Jepsen
et al. (2004), reasons for associations in medical research may be attributed to one or more
of the following: bias, confounding, chance or an indication of a causal relation. We will
briey review each of these components of association (see Section 1.6). But before ex-
amining association between variables, we need to have a study designed and executed to
produce relevant data.
In attempt to obtain a true causal relationship between exposure and outcome, study
design and analysis phases need to be tailored to exclude other forms of association besides
causation. This underscores the importance of study design and in the next section we review
epidemiological study designs for cause-eect studies with focus on randomized controlled
trials by outlining key design features, main classications, their strengths and limitations as
contrasted with observational studies.
2http://www.jameslindlibrary.org/
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1.5 Research designs
A well-structured (objective) study design is central to the success of any medical research
(Wang, 2002). The two main types of research design are experimental and observational
studies (Boslaugh and Watters, 2008; van Belle et al., 2004). The quality of any research is
a function of its design: only an objective design is likely to produce credible inference. A
statistically designed study introduces the necessary ingredients that enhances the quality
of the research data (Vandenbroeck et al., 2006). In medical research, a study design and
background subject-matter knowledge is as important as the data it generates. While a
poor analysis applied to a well-designed study can be salvaged by an appropriate reanalysis,
no amount of sophisticated statistical manipulation can redeem a poorly designed study
(Campbell et al., 2007; Robins, 2001). According to Stephenson and Babiker (2000), the
range of medical studies can be broadly categorized according to either their purpose or study
designs. A clinical purpose may be to determine the incidence or prevalence of disease in a
population, to identify causes of disease or those at high risk of disease, to describe the natural
history of disease, to prevent the onset of disease or alter the course of disease in individuals or
populations. However, the present work considers medical studies classied by study design
where design here is used to mean the whole range of process from contemplating, collecting,
organizing to analyzing data prior to seeing outcome data (Rubin, 2008).
1.5.1 Randomized controlled clinical trials
The hallmark of an experimental study is the fact that the investigator (fully) controls the
allocation or assignment of treatments or exposure (Stolberg et al., 2004). Intervention
studies are often conducted to evaluate the ecacy of a treatment or therapy. Here ecacy
is used in the Cochrane (1972) sense to mean a measure of the benet derived from an
intervention under the ideal conditions of an investigation by answering the question, \does
the practice do more good than harm to people who fully comply with the recommendations?"
Intervention studies include experimental studies and randomized controlled trials. While
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experimental studies may include animals and plants, a distinguishing feature of clinical
trials is the fact that they involves human subjects (Laine et al., 2007).
According to the World Health Organization3, a clinical trial is any research study that
assigns human participants to one or more health-related interventions with the principal
objective of evaluating eects of specic health outcomes. Intervention as used here may
narrowly refer to treatment or in a wider context may include any form of clinical application
oered to study participants with a possible eect on their health status. Clinical trials have
revolutionized the practice and conduct of medical research in terms of the way diseases
are detected, prevented, treated, and early death avoided (Hackshaw, 2009). In addition
to playing a central role towards establishing ecacy for any new pharmaceutical product,
clinical trials are also commonly used in academia and public sector in evaluating existing
interventions, programs and therapies among other non-commercial products. No matter
the hue, a dening feature of good clinical trials is the rigour in scientically designing and
executing an experiment so as to generate clinical data that can be used to evaluate one or
more interventions on patients' population.
Randomized controlled trials (or simply clinical trials) are considered the gold standard
for ecacy in medical research (for evaluation of therapeutic or preventative interventions)
because the randomization procedure ensures that any comparisons between arms of the trial
reect causal eects and are not aected by any confounding bias (Cuzick et al., 1997; Fischer-
Lapp and Goetghebeur, 1999; Nagelkerke et al., 2000; Stuart, 2010). Besides providing an un-
biased evaluation of the intervention by avoiding confounding from other factors, a good clini-
cal trial minimizes variability in the estimate of treatment eect. While the goal of a superior-
ity trial is to prove benets of a new treatment over an existing one or placebo, non-inferiority
or equivalence trials are often designed to evaluate similarity in ecacy between two/more
treatments with the objective of identifying a cheaper one and/or one with less side-eects
(D'Agostino Sr et al., 2003). For the present work we consider data from superiority studies.
3World Heath Organization. International Clinical Trials Registry Platform:
http://www.who.int.ictrp/about/details/en/index.html
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1.5.2 Classification of clinical trials
Designing a good clinical trial is premised on asking an important research question and
answering it reliably (Pocock, 1983). For example, a therapeutic question is likely to be
considered important if the target disease is common, the outcome major (e.g. death), the
treatment is widely practicable and the question on its ecacy and safety has not already
been answered reliably. Although multiple terms have been used to describe dierent types
of randomized controlled trials, they may be best classied according to the objectives they
are designed to address. According to Jadad and Enkin (2007), randomized controlled trials
can be broadly classied according to either the aspects of intervention under investigation
or the way in which the participants are exposed to the intervention.
Clinical trials classied according to manner of exposure and response to the intervention
trials include parallel, crossover and factorial designs. The word parallel here could as well
be viewed to imply simultaneous comparison. Parallel designs is the most commonly used
design and is distinguishable by the fact that each group of participants is exposed to only
one of the study interventions (Pocock, 1983). In contrast, crossover design refers to a study
in which each of the participants are sequentially given all of the study interventions (Senn,
2002). While treatments are randomly allocated to participants in a parallel design, for a
crossover design it is the order in which the participants receive each of the study interventions
that is randomized. A dening feature of crossover design is the need of washout period
between subsequent treatment so as to avoid contamination while evaluating ecacy. This
characteristic makes crossover design more appropriate only for interventions that last a short
time within the patient. It also makes the design unsuitable if any of the treatments is a
cure in which case administering another treatment after the cure is self-defeating towards
evaluating treatment ecacy.
Another classication of clinical trials according to exposure is factorial designs which
besides permitting evaluation of two or more interventions, also allows evaluation of their
combination (interaction) and against a control (Jadad and Enkin, 2007). For example, a
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2 2 factorial designed to evaluate the eects of unopposed oestrogen and combined oestro-
gen and progestogen in reducing postmenopausal symptoms generates four sets of data for
analysis: data on women who received none of the interventions, women who received unop-
posed oestrogen, women who received combined oestrogen and progestogen, and women who
received both unopposed oestrogen and combined oestrogen and progestogen. We note that
it is possible to design more complex factorial designs with multiple factors. In comparison,
factorial designs provides more information than parallel designs because it includes possible
interaction in addition to eects of individual treatment.
The types of clinical trials used to evaluate dierent aspects of interventions can take the
form of explanatory or pragmatic trials. While explanatory trials are designed to establish
if an intervention works under ideal circumstances, on the other hand pragmatic trials are
designed to determine whether the intervention works under ordinary/usual practice. They
may be distinct by design but both exploratory and pragmatic designs are complementary
and most clinical trials combine both elements in investigating ecacy and eectiveness.
Owing to the extensive demands for safety by regulatory bodies, exploratory and prag-
matic clinical trials for pharmaceutical drugs are often rigorously implemented in four phases:
I, II, III and IV (Senn, 2007). We now discuss each of these phases in the next section.
1.5.3 Phases of clinical trials
Clinical research is often conducted in a series of steps and generally classied according to
the phase of development of the drug. Although all clinical phases may not be relevant to
some classes of drug and individual phases may not be clearly delineated, four broad phases
(I, II, III, and IV) are commonly used to dene any comprehensive clinical trial (Chow and
Liu, 2004). The rigour during the four phases is meant to address all aspects of a new drug
in terms of safety, eectiveness and consistent quality. For example, in the United States of
America, the approval of a new drug by the Federal Drug Agency (FDA) requires extensive
testing and evaluation of the drug through a series of all the four phases. We discuss the four
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phases below by spelling out the respective questions they are designed to address.
Phase I clinical trials is dened by the rst time a new treatment is tested on humans,
usually healthy volunteers (Hackshaw, 2009). Basically phase I trials are designed to answer
the question: is the treatment safe? This phase is often small scale involving only a few
participants and the trial is conducted at a single site or only at few dierent locations. The
primary aim of a phase I clinical trial is often to investigate the new drug's metabolic and
pharmacologic actions so as to nd an acceptable dose in terms of safety, tolerance absorption,
distribution, ecacy and side eects of a new treatment. Phase I drug trials are also referred
to as dose nding trials.
Following promising results (reasonably safe in people) from a phase I trial, phase II trials
are often conducted to answer the question: does the treatment work?. It is during phase
II when the drug is administered to target patients, i.e. those suering from the disorder
for which the drug is intended. The goal of a phase II trial is to investigate the feasibility
and level of activity of the drug or treatment by determining ecacy (eects on the target
patients who comply with treatment) and safety in a small number of closely supervised
patients. By administering varying doses of the new treatment, phase II trials are designed
to provide more information about the eective dosage of a drug, the severity of the side
eects, and how to manage the side eects. Compared to phase I, phase II trials usually
involve more participants. Phase II trials are also referred to as safety and ecacy trials.
Phase II trial produces data that can be used to design phase III trials (Hackshaw, 2009).
When data from phase II studies indicate that potential benets from a new treat-
ment outweighs possible hazards, in terms of safety and ecacy, an extended clinical trial
(phase III) is designed to provide additional information that can be used to evaluate the
overall risk-benet relationship of the drug. Phase III trials are designed to address the
question: does the new treatment work better than the standard/placebo treatment? Phase III
trials are principally conducted to ascertain whether the drug confers clinical benet in the
disease states for which eectiveness can be claimed with an acceptable incidence and nature
of adverse eects (Piantadosi, 2005). The key features of randomization and use of a compar-
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ison (control) group here form important ingredients towards providing a denitive answer
on whether the new treatment is better than the control, or the treatment is of similar eec-
tiveness but with other advantages e.g. tolerable side eects. Also phase III are often double-
blind trials, i.e. neither the patient nor the investigator knows which treatment is adminis-
tered. Compared to phases I and II, phase III trials are generally large trials enrolling subjects
at a wide variety of locations. Phase III trials are also referred to as comparative treatment
ecacy trials. This report considers Esprit data which was a product of phase III trial.
Once a treatment has been approved for the general public following phases I, II and
III, phase IV trials are usually conducted to answer the question: is the treatment safe over
time? Phase IV trials involves a drug with an approved indication, formulation and route of
administration. A phase IV trial is a post-marketing or surveillance study designed to extend
the information developed in pre-marketing trials, i.e. obtain additional information on the
risks associated with the drug/treatment, its benets and its optimal use. The primary aim
of a phase IV trial is to evaluate the long-term safety and eectiveness of a treatment. Phase
IV trials are also referred to as expanded safety trials and usually involve a very large number
of subjects. Overall the number of subjects in a trial usually increases with the progress in
phases, i.e. while phase I usually involves fewer subjects/volunteers, phase IV trials often
involves the largest number of subjects.
1.5.4 Key design features of clinical trials
In addition to inclusion and exclusion criteria protocol spelling which subjects are eligible and
illegible respectively in a clinical trial, three dening components of any clinical trial include
control group, randomization and blinding (Chow and Liu, 2004; Hackshaw, 2009). In the
next section we provide a brief discussion of each of these components. We however point
out that there is no control in a two-active arms trials where instead a standard treatment
with known ecacy may be used as a comparator to the experimental treatment.
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Role of control group
The use of comparable groups of study subjects in a clinical trial where one (treated) group
receives the intervention while the other (control) group receives no/standard intervention
allows us to estimate treatment eects. As a result of the comparison, treatment eects from
clinical trials are always relative by denition, i.e. we only dene ecacy of a treatment
relative to another, standard treatment or placebo.
The increased attention given to subjects in a research project may inuence their
response and hence study ndings. This so-called Hawthorne eect refers to the tendency
of people to alter their behaviour when they are subject to special attention in a research
setting (Hertogh et al., 2010). The use of a control group, especially in masked trials, evenly
`distributes' the Hawthorne eect on the trial ndings between the study groups. The use of
a control group tends to compensate for non-treatment related changes in disease status. In
general, the choice of a control intervention depends on available alternative treatments, for
example, it is unethical to give a patient placebo if an established/standard treatment exists
because doing so denies some subjects a known health benet.
Merits of randomization
As early as the rst quarter of last Century, both Neyman (1923) and Fisher (1925) iden-
tied randomization as a cornerstone in scientic experimentation. And as discussed above
(Section 1.5.1), controlled clinical trials derive their strengths from randomization proce-
dures which plays a central role in ensuring that bias does not weaken the study results
(Stolberg et al., 2004). Such biases (commonly) include human choices, beliefs or any other
factors besides those being studied that can aect results of a clinical trial. For example
if physicians or participants themselves choose the group, treatment assignments might be
personally inuenced and therefore unevenly slanted toward one side or the other resulting
in selection bias. Random allocation of subjects ensures that the intervention and control
groups are as similar as possible with respect to important determinants of outcome, both
known and unknown. As a result randomization generates comparable intervention groups
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which are alike in all important aspects except for the intervention each group receives.
In the process randomization prevents selection bias and insures against accidental bias by
producing comparable groups and eliminating the source of bias in treatment assignments
(Altman, 1991; Mathews, 2006). Randomization also provides a basis for the statistical in-
ference/methods used in data analysis by permitting the use of probability theory to express
the likelihood of chance as a source for the dierence between outcomes thus underscoring
the role of statistics in seeking cause-eect relationship.
However, despite its ability to protect a trial against selection bias and facilitate compara-
bility among groups, randomization does not guarantee that all groups at baseline are evenly
matched for all known and unknown risk factors. So while randomization may eectively
eliminate systematic dierences between study groups, it may fail to eradicate some group
dierences due to chance. But despite such limitations, randomization remains a central pil-
lar in trials by conferring one of the most important advantages that clinical trials have over
observational studies where statistical adjustment can only be made from known confounders
(Friedman et al., 1998). As Angrist and Pischke (2009) correctly point out, randomized trials
may not be the panacea for a trouble-free trial but in principle they solve selection bias which
is one of the most important problems that arises in many empirical research.
Importance of blinding
Granted every person is likely to have remarkable psychological abilities to aect her own
health. Knowledge of which treatment is given may result in bias because of possible psycho-
logical eects among participants and researchers in a clinical trial who may have expectations
associated with a particular treatment. Such bias may be minimized by concealing the treat-
ment given to each subject (Hackshaw, 2009). This is often achieved by use of double-blind
trials where both the subjects and any researcher involved in administering and/or assessing
the treatment is unaware of the treatment given. A well executed double-blind design pro-
tects against ascertainment biases by blinding both parties to the assigned treatment. We
note that the terms blinding and masking are often used interchangeably in the literature
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with proponents of the later arguing use of the former projects a negative reference.
But blinding may not be practical in some situations like when dealing with an emerging
epidemic where the aicted need prompt treatment. In such situations where it is not
possible to conceal (blind) trial interventions, it may be more meaningful to use objective
outcome measures that are devoid of personal opinions of both participant and researcher.
For example for a trial evaluating hypnotherapy for smoking cessation, we could scientically
measure serum or urinary nicotine as a marker of current smoking status instead of using a
questionnaire on self-reported quitting habit which is prone to biases, e.g. reporting bias or
recall bias. For a double-blind placebo control trials with an active treatment which causes
side eects, a breached blinding is likely to introduce two levels confounding in the form of
simple and dierential confounding (Jin and Rubin, 2008).
1.5.5 Limitations of clinical trials
Properly executed randomized controlled clinical trials are capable of providing the strongest
empirical evidence in any medical study by providing strong evidence of causality (Chow
and Liu, 2004; Hackshaw, 2009; Mathews, 2006; Piantadosi, 2005; Pocock, 1983). However,
conducting clinical trials may not be feasible in some situations due to ethical, nancial,
legislative, time or logistical constraints (Hackshaw, 2009; Hernan, 2004). For example, it is
immoral to give a treatment that is known to be worse or to withhold a treatment that is
better than standard practice or placebo. It is also generally unacceptable to conduct ran-
domized experiments of harmful exposures like cigarette smoking. Also in a trial comparing
heart transplant to medication, it is unlikely to gain approval of an ethical committee to
randomly allocate heart transplants. This is simply because hearts are in short supply and
the committee would most likely favour assigning them to subjects who are more likely to
benet from the transplant, rather than assigning them randomly among potential recipients.
Safety analysis is equally important (if not more) as ecacy analysis in the development
of a new drug (Quan et al., 2008). While safety of a new treatment is often evaluated alongside
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ecacy, it would be dicult to design a clinical trial with the exclusive objective of assessing
a treatment's safety without violating the fundamental principles of the Helsinki Declaration
on Ethical Principles for Medical Research involving Human Subjects which prioritizes the
health of participants. Such ethical considerations based on the Helsinki Declaration may
limit the exploration of scientic questions that clinical trials can address. Finally, some
treatments may need long time to manifest adverse side eects and consequently clinical trials
not lasting long enough may fail to detect such eects and may pose serious health risks.
From discussions above, randomization in clinical trials may be considered a necessary
but not sucient condition to address bias which could be introduced by other factors like
subversion of randomization (e.g. treatment switches and noncompliance). Randomization
only ensures that within the limits of chance variation, there are no systematic dierences
between the two groups in known and unknown prognostic factors so that any dierence in
outcome can be reasonably attributed to the eect of the intervention. Fidelity with protocol
implementation is key to producing good randomized controlled trials, a fact that makes
them the best way to estimate causal eects but still susceptible to aws, i.e. not perfect
thus a bronze standard (Berk, 2005). Although generally acceptable tools for causal inference,
randomized controlled clinical trials often suer from two major complications in the form
of treatment noncompliance and dropouts which can only be addressed by incorporating
additional assumptions (Jadad and Enkin, 2007; Mealli et al., 2004). And noncompliance to
treatment allocation imparts to a clinical trials some of the characteristics of an observational
study where the subjects themselves decide which group to enter (Heitjan, 1999). The next
section provide a brief review of observational studies and their designs.
1.5.6 Observational studies
As discussed above, causal questions are probably best answered in an experimental setting.
But reality often presents researchers with situations in which the only feasible option is data
from observational studies. Incorporating simple realistic assumptions together with statisti-
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cal aspects of the data can help reveal a putative causal association from observational studies
(Jewell, 2003). In an observational study the investigator only observes the outcomes due to
exposure on the study subjects e.g. she observes the course of a disease or the relation between
risk factors and outcomes. A dening characteristic of an observational study is the fact that
the investigator plays no role in assigning exposure to the study subjects. This makes obser-
vational studies vulnerable to methodological problems like selection bias. Although observa-
tional studies may not be ideal, sometimes they may be the only tool available to a researcher
to evaluate eectiveness of an intervention provided confounding (see Section 1.6) can be ef-
fectively controlled. From the foregoing the rst challenge would logically appear to be
designing an objective observational study that may enable us make valid causal inference.
1.5.7 Designs for observational studies
Since randomized controlled experiments are the accepted gold standard in establishing
causality, an observational study design can only be considered objective if it possesses the
appealing features of randomized experiments, i.e. a reliable observational study should
be designed to approximate randomized experiments as closely as possible. According to
Rubin (2007), such a study must be designed using only baseline information to create bal-
anced/similar subgroups in both the treated and control arms. And to ensure the objectivity
of the design, the design process must be performed without any access to outcome data.
This is discernable from the fact that a design informed by outcome data is prone to sub-
jective construction that is likely to introduce other forms of bias at the design stage hence
compromising the study's integrity.
Many methods have been developed to objectively create subgroups of similar treated
and control units that are balanced with respect to baseline covariates. Propensity scores
(see Section 1.10) is one such method where a subject's likelihood for inclusion is modelled
as the probability of receiving experimental treatment conditional on baseline covariates.
This makes the design objective since the balance confers on it the benets of randomized
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controlled experiments. In fact Heitjan (1999) remarks that data from such an objectively
designed observational study may be conceptualized as coming from a broken randomized
controlled experiment (e.g. due to noncompliance). Designs with similar features as those
of randomized controlled experiments except that the probabilities of treatment assignment
depend on covariates are often collectively referred to as regular designs (Rubin, 2004). Refer-
ring to them as regular designs confers on them acceptability to be analyzed and interpreted
causally just like randomized controlled experiments. As Rosenbaum (2010) observes, the
quality (overall integrity and validity) and strength of evidence provided by an observational
study is determined largely by its design, i.e. there is no substitute to a good study design.
While Rubin (2008) rightly conclude that for objective causal inference, design trumps anal-
ysis, Freedman et al. (2010) broadly remarks that a well-designed observational study can
be very informative.
Observational studies often take dierent forms. Three of the most common types of ob-
servational studies include cross-sectional, cohort and case-control studies. The next section
provide a brief description of each type spelling out their respective strengths and limitations.
Cross-sectional studies
A cross-sectional study identies at a point in time individuals with a dened disease, risk
factor, or other condition of interest. This is probably why Last (2001) equates cross-sectional
designs to prevalence studies which allows us to estimate the burden of disease using preva-
lence measures. A dening feature of cross-sectional studies is that both exposure and out-
come are measured simultaneously. As we will see (Section 1.6.1), this phenomenon falls
short of Hill's (1965) temporality criterion that cause precedes eect, hence this is one of
the reasons that makes cross-sectional studies less attractive for making causal inference in
medical research. But the descriptive nature of cross-sectional studies makes them gener-
ally suitable for data exploration purposes, i.e. providing a basis for subsequent extensive
cohort or case-control studies (Checkoway et al., 2004; Jepsen et al., 2004). A limitation of
cross-sectional studies is that they may identify only risk factors for prevalent, rather than
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incident, disease. For example, people with a prevalent disease often have a benign and long
lasting form of disease that is neither fatal nor readily treated. As a result, inference based
on their data may lack external validity, i.e. dicult to generalize.
Cohort studies
Cohort studies are probably the most commonly used in medical studies (Rothman et al.,
2008; van Belle et al., 2004). A cohort may be considered to mean a group of individu-
als identied on the basis of a common experience or characteristic; the cohort is usually
monitored over time from the point of assembly. Cohort studies are typically designed by
specifying two or more groups in a population that are free of the disease but dier by their
amount of exposure to a potential cause of the disease, for example, an epidemiological co-
hort study may be a follow-up of exposed and non-exposed dened groups that compares
disease rates during the time covered. A major advantage of cohort studies is that they allow
a researcher to investigate multiple outcomes within the same study, e.g. all-cause morality
and myocardial reinfarctions in Esprit study considered for the present work.
While statisticians mostly use the term longitudinal studies to mean repeated measures,
epidemiologists and social scientists on the other hand often use prospective cohort studies
and panel studies respectively (Sterne and Tilling, 2002; Toh and Hernan, 2008; Xing et al.,
2003). A dening feature of these studies is that they involve measurements obtained from the
same individuals on repeated occasions that provide a means for assessing changes over time.
Such a characteristic makes cohort studies one of the principal research strategies employed in
the medical and social sciences (Goldstein, 1979; Nesslroader and Baltes, 1979). Cohort stud-
ies are more likely to reveal true ecacy than cross-sectional observational studies because of
their ability to exclude time-invariant unobserved individual dierences in addition to observ-
ing the temporal order of events (Diggle et al., 2002). In the presence of measured explanatory
variables that are correlated with unit-specic unobservables, we can exploit the strength of
cohort studies to obtain consistent estimates of causal parameters (Halaby, 2004). Random-
ized controlled trials as discussed above may be considered a special subset of cohort studies
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owing to their prospective nature (Jadad and Enkin, 2007; Piantadosi, 2005; Rothman, 2002).
Loss to follow up is one of the common problems encountered in cohort studies. It
can lead to selection bias if those lost to follow up are systematically dierent from those
traced in terms of their exposure and disease status. An additional limitation of the cohort
design is in dealing with rare diseases where we would either need a large sample or long
follow up to accumulate enough cases to have sucient power to make meaningful inferences.
Cohort studies in such circumstances become very expensive and time consuming (Kuper and
Gilbert, 2005) even though Hulley et al. (2001) point out that using large sample sizes in
such situations minimizes chance as an explanation for the observed ndings. Next we briey
discuss case-control which may be suitable to study rare diseases.
Case-control studies
A distinctive feature of case-control study is that individuals are selected according to disease
or outcome status rather than exposure status. People with the disease or outcome of interest
are selected as cases, and a suitable group of individuals without the disease are selected
as controls. The rst step of identifying the cases makes case-control designs suitable for
studying rare outcomes which would otherwise require considerably large sample sizes in
cohort designs, for example. In such situations, retrospective studies of rare conditions may
be more ecient than prospective studies because individuals experiencing the rare outcome
can be found in patient records rather than following a large number of individuals to nd a
few cases. In general, case-control studies are generally relatively cheaper and quick to carry
out than cohort studies in this respect (Breslow, 1996; Breslow and Day, 1980).
Case-control studies have the intuitive appeal as a means of investigating etiology owing
to their key (guaranteed) feature that inferences about the association between exposure and
disease depend entirely on the exposure preceding the disease, a key criterion among Hill's
guidelines to assess cause-eect relationship (Section 1.6.1). We can think of a case-control as
a logical extension of a case series where the addition of a control group allows the frequency
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of exposure in cases to be expressed relative to people who are disease free (Stephenson and
Babiker, 2000). This intuitive appeal of case-control may however mask a problem of how to
select the most appropriate control group. Given that the exposure has already happened,
selecting controls who are more/less likely than the cases to have been exposed for reasons
unrelated to the outcome of interest will result in a biased association (e.g. odds ratio)
between exposure and disease. Case-control studies are commonly used as the method of
choice for the prompt investigation of a suspected adverse drug reaction in addition to giving
an ecient way of collecting covariate information for medical studies of rare diseases.
The fact that cases may report exposures dierently from controls has the potential to
introduce recall bias in case-control studies. However, this problem may be less serious if
the exposure is objectively assessed (for example, height), accurately recalled (for example,
age), or veried (for example, treatment received). Also selection of controls can introduce
selection bias. Despite these limitations, Kuper and Gilbert (2005) point out that case-
control studies can provide the same information as cohort studies in a shorter time and at
lower cost if designed and executed thoughtfully.
With the study designed and executed, the treatment has probably caused some eects.
But what maybe the other possible explanations for the underlying cause-eect relationship?
1.6 Reasons for association
Bias
Bias is a systematic error in a medical study that results in an incorrect estimate of the asso-
ciation between exposure and risk of a disease (Altman, 1991; Hennekens and Buring, 1987).
Basically bias is the deviation of results from the truth. Since inaccuracies during data collec-
tion are inevitable in any medical research, it is vital for every researcher to evaluate the role
of potential bias as an alternative explanation for an observed association, or lack of one, when
interpreting any study result. There are many types of bias but selection and information bias
39
may be considered the two most common types (Rothman, 2002; Rothman et al., 2008). The
propensity to select a study subject from one group and not the other gives rise to selection
bias because the resulting study populations being compared are strictly not comparable, i.e.
not a random sample of the population under study. Information or observation bias on the
other hand occurs if non-comparable information is obtained from each study group. Selection
bias error results from systematic dierences in characteristics between those who take part in
a study and those who do not. On the other hand information/measurement bias is systematic
error arising from inaccurate measurement or classication of subjects on study variables re-
sulting in inaccurate or incomplete data that allows introduction of false association.
Although bias may be unavoidable in practice, a researcher need to strive to evaluate the
magnitude and impact of any bias on the study results. Following recommendation by Zaccai
(2004), each medical research must be considered on its own merit in the context of its study
population since there is no universal or simple formula/template for assessing bias. The
presence of bias does not necessarily invalidate a research but valid estimation must ensure
delity between assumptions and their associated statistical properties (Rubin, 2010).
Confounding
Granted, confounding is both an ubiquitous and an enigmatic phenomenon in medical re-
search (Weisberg, 2010). Confounding may be described as a mixing/blurring of eects which
is caused by a third factor that is associated with both the exposure and independently aects
the risk of developing the disease. Formally, confounding can be dened as a distortion of the
estimated eect of an exposure on an outcome, caused by the presence of an extraneous factor
associated both with the exposure and the outcome (Greenland and Morgenstern, 2001; Last,
2001). Formally, a true confounder must satisfy three conditions (Hammal and Bell, 2002):
(i) It must be a risk factor for the disease in question (aect outcome),
(ii) It must be associated with the exposure under study (otherwise the variable becomes
a covariate if it is only associated with disease but not the exposure) and
(iii) It must not be an intermediate step in the causal pathway between the exposure and
the disease.
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The criteria above are necessary but may not be sucient (symmetric) in the sense that while
all confounders must satisfy them, a variable satisfying the criteria does not necessarily qualify
to be a confounder (McNamee, 2003). For example, this may be discernable from the fact that
a variable satisfying all the above conditions ignores the possibility that stratifying on one
variable may transform another variable into a confounder hence complicating identication
of the right confounder(s).
Confounding manifests itself in many forms, for example, confounding by indication is a
common problem in medical studies which results in selection bias (Ashby et al., 1998; Lok,
2008). Under confounding by indication, those subjects with more severe medical condition
are more likely to be prescribed a particular medication. Measurement of and control for
confounding may be considered two of the most dicult challenges in any medical research
(Rothman et al., 2008). Depending on the magnitude and direction of association with the
exposure and disease, a confounder may lead to either overestimation or underestimation
of an eect. In some (extreme) circumstances, confounding may even change the apparent
direction of an eect (Julious and Mullee, 1994; McNamee, 2003).
Although bias and confounding may work together, it is important to note that they may
work in same or dierent directions towards underestimating or overestimating treatment ef-
fects. While any medical research is susceptible to bias at any of the three stages (design, exe-
cution and analysis), confounding can be addressed either at the design stage or during analy-
sis (Boslaugh andWatters, 2008; Tai and Ilie, 2000). At the design stage, confounding can be
dealt with through dierent methods including randomization, restriction, and matching. On
the other hand standardization, stratication and multivariate analysis are the common sta-
tistical modelling techniques used to address confounding at the analysis stage. Each of these
method has its strength and limitations and none can comprehensively address confounding in
isolation (Greenland et al., 1999). But whether we control confounding at the design or analy-
sis phase, the rst step should always be to identify possible confounders since as Datta (1993)
correctly observe `you cannot exclude the explanation that you have not considered'.
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Time-varying confounding
Systematic inclusion of the element of time in medical studies may help strengthen the
causal inference by capturing the eects of variables that change with time. Time-varying
confounding is an important and challenging aspect of medical research that is often ignored
in standard statistical analysis (Bray et al., 2006). A patient's present medical state may
be a product of numerous past decisions. The course of her treatment might be inuenced
by her past state which in turn was inuenced by previous treatment decisions. A standard
statistical adjustment using the patients state in the past is inadequate and results in bias
since such analysis ignores information on the eect of past treatment (Lok, 2008).
A covariate is considered a time-dependent confounder if it both predicts the future treat-
ment and the future outcome, conditional on past treatment. Formally, a covariate is dened
to be a time-varying confounder for the eect of exposure on outcome provided it satises the
following three conditions (Fewell et al., 2004; Mark and Robins, 1993; Tilling et al., 2002):
(i) Past covariate values predict current exposure,
(ii) Past exposure predicts current covariate value and
(iii) Current covariate value predicts outcome.
In a study to examine the eects of highly active antiretroviral therapy (HAART) on human
immunodeciency virus (HIV)-related death, CD4 counts in people living with HIV is an
example of a time-varying confounder because low CD4 is more likely to prompt being put on
HAART while low CD4 is a risk factor for AIDS and death. Another example of time-varying
confounder is diagnosis of diabetes in a study of the eect of diet on risk of coronary heart dis-
ease (Young et al., 2010). Here diagnosis of diabetes is a time-dependent confounder because
a diagnosis of diabetes not only aects a patient's future dietary choices but is also a risk
factor for coronary heart disease. The prior diet also aects risk of diabetes in the future.
Related to time-varying confounder is the concept of time-modied confounding as intro-
duced by Platt et al. (2009). The key dierence between the two is the fact that values of the
confounding variable change over time for time-varying confounding while the eects of the
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confounder change over time for time-modied confounding. In essence time-modied con-
founding can occur with a time-invariant or time-varying covariate whereas time-varying con-
founding occurs only with time-varying covariates. Specically for a time-varying covariate,
time-varying confounding and time-modied confounding may therefore occur simultaneously.
In general the presence of confounders does not necessarily invalidate a medical study
but instead their presence indicates the need for the researcher to quantitatively measure the
confounder with which to assess its size and direction (Hammal and Bell, 2002). Confounding
can be present even when an association between a covariate and either the exposure or
outcome is not statistically signicant. The magnitude of confounding may be unrelated to
the magnitude of the p-value for the associations between a confounder and either exposure
or outcome. These observations may be considered as justication for the futility of attempts
to institute statistical tests for assessing confounding (Sonis, 1998).
Chance
Variations due to chance are an unavoidable consequence of sampling, but the eects can be
minimized by having a study that is suciently large. If a study does not have a statistically
signicant result, a researcher is often left wondering whether this is because the sample was
not big enough to detect it or there really is no dierence. Because of constraints like time
and cost, we often conduct studies using samples whose results we then project(extrapolate)
to make inference on an entire population. Random variation in any population manifests
itself when some chance factor results in the study outcomes not being representative of the
ultimate true values, even if bias and confounding are non-existent. As a remedy, variations
from the true values may be minimized by using large sample sizes and/or suciently longer
studies (Zaccai, 2004).
Researchers commonly use statistics in the analysis phase to evaluate the eects of chance
by quantifying the degree to which chance may account for the results observed. P-value and
condence intervals are the most commonly used accuracy statistics in this regard. For ex-
ample, 95% is the most commonly used condence interval in medical studies and a p-value
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of 0:05 is often taken as the test size. For a signicance test, a two-sided test size of 0:05
translates to a 95% condence interval. We however, note that statistical signicance does
not necessarily translate into clinical signicance. Commonsense and clinical experience are
necessary considerations to separate meaningful (although statistically insignicant) associ-
ation from a statistically signicant association that has no clinical/logical meaning (Jepsen
et al., 2004). The original ITT results of Esprit study revealed no statistically signicant
eects for HRT treatment compared to placebo, but this may have been due to small sample
size. In attempt to investigate causal relationships, we will perform ecacy analysis to ex-
plore potential principal eects for individual strata. Such analysis may be informative and
augment the knowledge gained from the ITT results.
Causation
At the heart of understanding most scientic and medical research enquiries lies the search
for causation (Desousa and Murrells, 2005). Avoiding bias, controlling for confounding and
ruling out chance guarantees internal validity of an association study. Provided the eects of
bias, confounding and chance are ruled out then causation becomes a possible explanation for
the exposure-disease association. The mantra correlation does not imply causation is now an
accepted truism among most quantitative and qualitative researchers. Determining when a
correlation is causal and when is it a result of confounding forms the basis of causal inference.
As Longford (2008) points out, causation can only be established from direct intervention
that excludes other sources of association.
Randomized controlled clinical trials are the ideal designs to examine causation because
they often eectively address other forms of association besides causality. But observational
studies may be less able to eliminate the alternative explanations of bias or confounding.
Failure to account for bias, confounding and chance can substantially threaten the validity
and quality of any medical study at all its phases. But the presence of these factors however,
doesn't necessarily imply that a study is scientically unacceptable (Zaccai, 2004). Instead
the study must be put in its right medical context. For example reporting bias in a study may
not necessarily mean that data was doctored to reect a predetermined outcome/interpretation.
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1.6.1 Bradford Hill’s criteria of causation
While acknowledging that we cannot explicitly prove causality, Sir Bradford Hill (1965) out-
lined systematic criteria originally for epidemiological studies involving observational data for
using scientic judgement that allows use of statistical association to infer causation. Hill's
landmark `checklist' is often referred to as the Bradford Hill's criteria of causation. He listed
nine guidelines including strength, consistency, specicity, temporality, dose response, biolog-
ical plausibility, coherence, experimental evidence and analogy. The experimental evidence
criterion (a scientic demonstration of cause-eect relationship under controlled conditions)
is implicit in a controlled clinical trial since it is experimental by design (and possibly by
execution and analysis). While temporality criterion (exposure must precede the disease) is
always satised for a clinical trial, dose response may not be always possible in the case of
one dose. The strength criterion (causation is strengthened if the association between the
exposure and disease is large) may be satised in trials through randomization which rules
out confounding and other associated spurious relationships. The coherence criterion which
ensures that the possibility of causation does not contradict established facts may be satised
in a trial's phases II which involves subjects with target medical condition. According to Cole
and Frangakis (2009), the consistency criterion (replicating results of a study using dierent
methods at dierent times) is guaranteed for by design in clinical trails since the investigator
controls allocation. But this is better argued in the knowledge that trials are mostly designed
to address a specic objective/disease in a target population and time. Also the specicity
criterion (one cause, one eect) may not apply for trials like the Esprit which may be used
to investigate multiple outcomes. Finally both biological plausibility (propensity to accept a
causal relationship premised on plausible biological mechanism) and analogy (the likelihood
to accept comparable arguments for causation) criteria may be assumed true for controlled
clinical trials although not easily provable.
We point out that although Hill's criteria were originally proposed for epidemiological
studies, many modern epidemiologists (e.g. Rothman et al. 2008) strongly refute the necessity
of some of the considerations. But to be fair Hill himself also acknowledged the causal
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limitation in using his guidelines by concluding that \None of my nine viewpoints can bring
indispensable evidence for or against the cause-and-eect hypothesis . . ." Although Hill's
guidelines may not be watertight in proving cause-eect relationship, they may be considered
a pioneer criteria that provide a basis for search of causation in modern medical research. As
Phillips and Goodman (2006) points out, considering both extremes of Hill's criteria may be
counterproductive towards the search of causation, i.e. while the overtly enthusiastic users
are prone to over-interpret Hill's criteria, cynics who often readily dismiss the criteria as
awed are likely to under-interpret them. A middle ground may be an objective compromise
where Hill's criteria are objectively applied as a basis of scientic thinking towards inferring
causation in controlled randomized trials. The underlying objectivity is what probably makes
Hill's criteria be considered a basis of the pragmatic intention-to-treat principle that evaluates
treatment eectiveness (Freedman, 2006; Newell, 1992).
1.7 Causal inference and statistics
But what is the role of statistics in search for causation? Central to many empirical or scien-
tic research is the search for cause-eect relationship (Dunn and Everitt, 1995) or what is
often referred to as causal modelling (Heckman, 1996; Hirano and Imbens, 2001). Research
in medicine and social sciences in recent years has led to phenomenal growth in causal mod-
elling as an extension of associational models in standard statistics. Most medical research
involve investigating complex multivariate relationships using data that are inuenced by
many factors. A primary objective of evidence-based medical research is to untangle vital
causal relationships from clinical trials data which aids in illuminating intervention policies
and treatments in management of diseases (Hackshaw, 2009; Rossi, 2010). The success of
such research is premised upon making educated and realistic assumptions about the struc-
ture of the data generation processes in order to obtain reliable results from such studies.
Modern empirical research has resulted in data explosion with causal inference as a main
interest which evaluates interventions towards eective management of emerging and chronic
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diseases in addition to informing policy formulation. Using structural equations and asso-
ciated directed graphs to describe causal relationships, Pearl (2009b) provides a powerful
defense for the necessity and legitimacy of causality as a subject of inquiry in statistics in
particular and empirical research in general.
While making causal inference is a multifaceted task which no single mechanical solution
may suciently solve. According to Heckman (2000), statistics alone cannot overcome our
inability to directly measure causal relations and Pearl (2009a) concurs that causal claims
cannot be exhaustively substantiated by statistical associations alone. Instead conclusions
about causal eects can be considered dependent (to a greater degree) on interpretation, the-
orizing or assumptions that are brought into play along with empirical data or observations.
Additionally it may be considered an accepted consensus among researchers that causal infer-
ence cannot be simply and directly made from empirical data, regardless of whether the data
is collected through ingenious research designs or summarized by advanced statistical models
(Blossfeld and Rohwer, 1997). Objectivity and the need to account for all relevant factors
are key to eective causal modelling. It may be counterproductive to put too much faith in
the promise of causal modelling approaches characterized by radical subjectivity. As a result
causal models necessarily need to acknowledge (and account for) the complexity of real life
to sustain objectivity by integrating the ingredients of intuition, logic and common sense.
The beauty of causal modelling is probably illustrated best by Wasserman (1999) in his
remark that `behind every adjusted association lurks a causal interpretation.' Association as
a product of statistical analysis makes statistics a handy and vital tool to infer causation.
But Wasserman (1999) was probably too harsh with his (restrictive) edict that there are
only two types of statisticians: those who do causal inference and those who lie about it.
Standard statistical inference only permits conclusion about observed association which can
be attributed to many reasons as discussed above (see Section 1.6). Although statistical
inference enables us rule out chance as a reason of association, the procedures do not provide
any information about which variable causes the other, or whether the apparent relationship
between the two variables is due to one being a confounder. A statistically designed study is
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likely to provide a meaningful and valid solution to answer a causal question as a product of
an objective study design properly executed to produce quality data. Causal inference may
then be viewed as a product of both qualitative (critical) reasoning and quantitative analysis.
The world is stochastic rather than deterministic and using probability theory allows
statistics to model such non-deterministic events, i.e. probability provides a language to
communicate the logic of uncertainty. Statistics is an indispensable tool in appreciating (via
models) the often enormous variability of biological data encountered in medical research
(Aalen and Frigessi, 2007; Campbell et al., 2007). This variability-statistics interplay is
probably captured best in the denition of a statistical model by Robins and Greenland
(1986) as `a mathematical expression for a set of assumed restrictions on the possible states
of nature'. Implicit in the denition is inclusion of assumptions as an acknowledgement
of the limitation to represent the often complex true state of nature. Statistical inference
is essentially an exercise in using observed data to learn/infer into what we do not observe
(parameters). Probability theory plays a central role in this endeavor which is also manifested
in the central role of randomization in designing experiments to establish causation. Causal
inference can be viewed as a combination of science and statistics where science dictates
model and statistics measures the magnitude of eect, for example, in estimating a treatment
eect, the eect should be both statistically concise and clinically sensible to be meaningful
and useful. Perhaps by obeying the rst commandment of statistical inference according to
Driscoll (1977), \Thou shalt not hunt statistical inference with a shotgun", an analysis must
not blindly seek and interpret statistical signicance as clinical signicance. As a discipline,
statistics is an important cog in the wheel of causal inference which makes it a necessary
(but not sucient) tool to infer causation. But as Pearl (2009a,b) rightly observed causal
inference is such a broad concept it need not be limited to the probabilistic language of
statistic. From the foregoing, it may be intuitively deduced that eorts to estimate causal
eects probably constitutes the most important application of statistics (Weisberg, 2010).
The framework of potential outcomes allows construction of structural models (science
and statistics) that facilitates valid causal inference. The next section provides a review of
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this concept and the implicit assumptions that permit causal inference.
1.8 Causal modelling with counterfactuals
Counterfactuals are an intuitive concept of causal modelling which is based on the poten-
tial outcomes approach that addresses the what if question. Considering a two-armed trial,
the counterfactual model presupposes that subjects under study have two theoretical out-
comes: one that would be observed if they were subjected to the treatment of interest and
the other one that would be observed if they were to be subjected to the alternative treat-
ment. Causal estimates then become comparisons of the potential outcomes that would have
been observed under dierent exposures of units to treatments. This appealing contrary-to-
fact concept to causal modelling was introduced by Rubin (1974), a fact that probably led
Holland (1986) to name them as Rubin causal models (RCM). However, we point out that
although Rubin (1974, 1977) formalized the modern statistical framework of counterfactuals,
his models builds on earlier concepts introduced by Neyman (1923) and Fisher (1926) who
considered potential yields of crop varieties on dierent plots of land whereby the plots were
randomly allocated to the varieties. Well, the modern concept of counterfactuals may be
traced back to philosopher David Hume (1748) who wrote
\we may dene a cause to be an object followed by another ... where, if the rst
object had not been, the second never had existed."
Implicit in Hume's denition lies the concept of conditional relationship built on a thought
experiment, i.e. hypothesizing on what would have happened under conditions contrary to
actual conditions.
Although the terms counterfactuals and potential outcomes are often used interchange-
ably, the meaning may dier depending on discipline of application. The use of the term
potential outcomes implicitly implies a prospective consideration with respect to treatment
assignment. In contrast, the term counterfactuals is often used to dene observed out-
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come and the outcomes which would have been observed (counter-to-fact) that the sub-
ject received an alternative treatment and hence denotes the outcomes retrospectively to
assignment (Hernan, 2004). According to Rubin (2006a), the prospective implication in po-
tential outcomes makes it more appealing since at the design stage no well dened potential
outcome is counterfactual while at least some of the potential outcomes are factual at the
analysis stage. We note that these two denitions are similar in meaning and can be al-
gebraically shown to be identical. In the present work we will use potential outcomes and
counterfactuals interchangeably.
The three basic ingredients used to dene causal eects are units, treatments and po-
tential outcomes (Rubin, 2004). These are the basic building blocks of a design which
Rubin (1975) collectively referred to as primitives. Here a unit refers to a physical object of
experimentation at a particular place and time, for example, the 1017 postmenopausal women
identied for our Esprit study. Treatment refers to the intervention assigned, for example,
HRT medication/tablets. Associated with every unit in a group are two potential outcomes,
for example, Y (1) and Y (0) if a woman were to receive HRT tablets and placebo respectively.
To dene a general model for causal eects, let A represent the treatment variable whose
eect on outcome Y we are interested in for a given population. Let i denote the unit of
observation or subject so that Ai denotes the observed level of the treatment in subject i
whose eect we wish to measure. Rubin causal models assumes that for each subject there
exists treatment specic outcomes Y (a) for each a2A, where a denotes a hypothetical level
of treatment. We point out that here Y may be a scalar or vector and its components may be
continuous or discrete. Further let X denote measured pretreatment covariates and let V 2X
denote specied pretreatment covariates whose associations with outcome are of interest, i.e.
all elements of V are in X but the converse may not be necessarily hold true hence we may
classify those elements in X but not in V as nuisance variables.
We call Y (a) a potential outcome because, until the time a decision is made about
treatment, the outcome Y (a) only remains potentially (latently) observable. If a sub-
ject receives treatment level a (A = a) then Y (a) is observed, otherwise Y (a) is not ob-
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served and is hence counterfactual. Let Yi(a) denote the outcome Y that we would ob-
serve in subject i if she receives level a of treatment. Causal eects are dened as com-
parisons of dierent potential outcomes Yi(a) for the same units i under dierent treat-
ment levels a and a0. This is a dening dierence between standard statistical inference
and causal inference in the sense that while the former involves a comparison of dier-
ent units under static conditions, the later goes a step further to compare the same unit
that is changed by an intervention (treatment) in time, i.e. making inference on aspects
of the data generation process (Pearl, 2001, 2009a). Formally we say there is a causal ef-
fect of treatment level a versus treatment level a0 in subject i at the time where treatment
is assigned if the outcomes diers under both conditions, i.e. Yi(a) 6= Yi(a0). The mag-
nitude of this eect can be dened in dierent ways, for example, the magnitude of the
individual-level causal eect of the treatment may take the form of dierence
i = Yi(a)  Yi(a0) or the ratio  i =
Yi(a)
Yi(a0)
; (1.1)
provided the outcome Yi(a
0) is non-zero. We note that the choice of the measure i aects
the interpretability of a summary measure of individual eects, e.g. quantifying the aver-
age causal eect in terms of risk dierence or risk ratio. Similarly, the choice of i aects
the interpretability of heterogeneity of individual eect magnitudes like causal interaction
(Hoer, 2005). Here we will consider the quantity  as the general measure of causal eect.
We however note that in reality we cannot directly compare potential outcomes Yi(a)
and Yi(a
0) (a 6= a0) for any individual subject i because the outcomes Yi(a) and Yi(a0) are
not simultaneously observable on subject i. For example in the case of a treatment and a
control, we can only observe one outcome and not both, i.e. we cannot observe the potential
outcome under the treatment state for those observed in the control state (and vice versa).
Consequently, we can never know the individual-level causal eects given by Equation (1.1)
above. This predicament makes it impossible to make causal inference without making
(generally untestable) assumptions. This dilemma is what Holland (1986) referred to as the
`fundamental problem of causal inference'.
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If we have a data set fYi; Zigni=1, i.e. a simple random sample of size n from the popula-
tion of interest where the variables Yi and Zi represent outcome and treatment assignment
variables respectively, then individual observations on the outcome Yi would follow the simple
observation rule (Morgan, 2001; Morgan and Winship, 2007):
Yi = ZiYi(a) + (1  Zi)Yi(a0);
where for a binary Z : Z=1 if randomized to treatment arm and 0 otherwise and A denotes
the observed level of treatment. We note that the set fY;A; Zg constitutes the observed data
whereas the full data needed to estimate (1.1) is composed of the set fY (a); Y (a0); A; Zg: the
distribution of the observed Yi contains only half the information contained in the distribu-
tions of the theoretical potential outcome variables. As a result, we cannot use the observed
variables Yi and Zi to identify the population distributions of either Yi(a) or Yi(a
0). For a
statistical solution, researchers typically focus attention on estimation of the average causal
eect (ACE) often dened as
ACE =  = E[Y (a)  Y (a0)] = Y (a)  Y (a0); (1.2)
where Y (a) and Y (a0) are population-level means of the corresponding individual-level po-
tential outcomes. The average causal eect quantity  is probably the most basic quantity
of interest in almost every causal study investigating the eects of a treatment. ACE is the
average gain in outcome that would be observed if a randomly selected individual were sub-
jected to the treatment of interest instead of taking an alternative treatment. Under proper
randomization (and perfect compliance), we can estimate  by comparing the means of Y
in the two arms (Rubin, 1978), i.e. under these conditions, the dierence in sample means
y(a)   y(a0) can be considered as an unbiased estimate of ACE  . This dierence is the
standard intention-to-treat (ITT) estimator for the eect of treatment assignment Z on the
outcome Y (see ITT estimation, Section 1.11.1).
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1.8.1 Key causal modelling assumptions
We now outline some of the main assumptions implicitly implied in dening counterfactuals
for causal inference that enables us to estimate the ACE as given by Equation (1.2) above and
its variants discussed later. First is the so-called overlapping distribution assumption: the
fact that every subject must have the potential (non-zero probability) to receive treatment:
0 < Pr(Ai = a) < 1. Second is the consistency assumption which helps relate the observed
data to the counterfactual data: Y (a)=Y j a for the observed A=a, and that the subject's
observed outcome is their counterfactual outcome, i.e. Y =Y (a) (dropping the subscript i for
simplicity). Implicit in the consistency assumption is the concept of exchangeability which
makes it possible to estimate treatment eects under no unmeasured confounding and non-
informative censoring assumptions (Cole and Hernan, 2008; Greenland and Robins, 1986;
Lindley and Singpurwalla, 2002). In the presence of noncompliance to treatment allocation,
exchangeability assumption posits that any counterfactual outcome under any treatment
level a is independent of the treatment actually received A, i.e. Y (a) ? A, where ? denotes
statistical independence (Dawid, 1979).
In the presence of noncompliance to treatment allocation, and to retain the ideals of
randomization, causal modelling is predicated on ve key assumptions (Angrist et al., 1996).
First is the randomization assumption (i.e. Z is randomly assigned) which posits indepen-
dence between assignment to treatment arm and potential outcomes, potential treatment
received and baseline covariates including pretreatment variables, i.e. Z ? fY (a); Y (a0); Xg.
However, it is important to note that Z ? fY (a); Y (a0); Xg 6=fZ ? Y;Xg: treatment assign-
ment is not independent of observed outcome since the observed outcome Y is a function both
of counterfactuals and treatment assignment, i.e. the observed data are many-to-one trans-
formation of full data (Tsiatis, 2006). This is discernable from the fact that we expect/want
the distribution of Y to depend on Z if the treatment is eective. Randomization plays
the key role to permit making causal inference by enabling the conceptualization of causal
questions in terms of real or hypothetical (counterfactual) manipulation, a fact that probably
justies the edict `there is no causation without manipulation' (Holland, 1986; Rubin, 1978).
53
In relation to consistency assumption above, randomization of the treatment is expected
to induce exchangeability hence enabling us estimate treatment ecacy. The other four
assumptions of causal inference include stable unit treatment value assumption (SUTVA),
exclusion restriction assumption, monotonicity assumption and non-zero average causal eect
of randomization mechanism Z on treatment receipt A.
One assumption implicit in the denition of counterfactuals which even randomiza-
tion by itself may not justify is what Rubin (1978) referred to as `no interference be-
tween treatment units' assumption. This assumption underlies what Cox (1958a) earlier
referred to as the independent action of treatment assumption. But Rubin (1980) for-
mally called it the stable unit treatment value assumption (SUTVA). Under SUTVA, we
assume no interaction between subjects so that potential outcomes of a subject are inde-
pendent of the exposure of all other subject, i.e. if z = z0 then Az = Az0 for subject i.
Moreover if z = z0 and a = a0 then Yz(a) = Yz0(a0) for subject i, where z; z0 and a; a0
are two dierent vectors respectively corresponding to randomization assignment and treat-
ment received by subject i. As a result the SUTVA assumption ensures consistency that
makes it possible to identify potential outcomes by ensuring that the potential outcome
of a certain treatment will be the same regardless of the treatment assignment mechanism
(Rubin, 1986). But we note that despite its plausibility, SUTVA assumption may be vi-
olated in some situations like when dealing with contagious disease like inuenza where
treatment eects may not be independent for patients in close proximity to each other.
In fact Frolich (2003) argues that due to possible interactions, departures from SUTVA
can increase proportionately with increase in the number of experimental units.
The exclusion restriction assumption posits that there is no direct eect of treatment
assignment (randomization) Z on the mean outcome Y except through treatment actually
received A. This assumption ensures that, for example, there is no anti-placebo eect which is
the tendency to feel worse after being unable to tolerate a treatment believed to be benecial.
A placebo eect on the other hand is the tendency to feel better from an inert treatment.
The exclusion restriction therefore implies that
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Yz(a) = Yz0(a) 8 z; z0: (1.3)
Assuming that the outcome Y is independent of the randomization mechanism Z enables
us to simplify notation so that Yz(a) = Y (a). Next is the monotonicity assumption which
implies that there is no access to treatment for subjects randomized to the control arm of
the trial. Generally this assumption implicitly implies that there are no deers, i.e. people
who would take the treatment opposite to what they are randomly assigned: Pr(A0=0)=1
if A0 represents placebo. Finally, the non-zero average causal eect of randomization Z on
the treatment A assumption which posits that E(A A0) 6=0, i.e. the treatment of interest A
is assumed to have a measurable eect compared to the alternative treatment A0.
In general, causal eects may be identied under three sucient assumptions (Cole and
Frangakis, 2009): exchangeability (no unmeasured confounders), positivity (existence of a
non-zero probability to receive treatment) and consistency. From the foregoing, we can ar-
gue that provided a researcher can credibly theorize that potential outcomes exist, then the
advantage of using counterfactuals lies in the fact that it allows the narrowing of focus of
causality to a single cause-eect relationship in addition to providing a clear denition of
causal eects and quantication of treatment eects. Only the theoretical leap in which re-
searcher hypothesizes about the existence of missing data (potential outcomes) and how that
such data is related to the data guarantees causal inference, i.e. unlike standard statistical
techniques, data may not necessarily speak for itself with causal models but only through
the (mostly) unveried assumptions made by the researcher, i.e. the science.
1.8.2 Criticisms of counterfactual models
Generally, every branch of scientic research has its proponents and critics and counterfac-
tual causal modelling is no exception to that truism. Causal modelling using counterfactuals
has its enthusiasts and critics (Greenland, 2004). Most criticisms of the counterfactual ap-
proaches is premised on the fact that in considering causes of past events, the models invoke
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distributions for events that never occurred and hence cannot be observed. As a conse-
quence, the critics argue that some important features of these distributions remain empiri-
cally untestable. Some authors point out as a weakness the fact that some causal inferences
based on counterfactuals depends entirely on untestable assumptions (Dawid, 2000). But
on the other hand others like Greenland et al. (1999) consider this `untestability' property
of counterfactuals as its principal strength arguing that it is natural to employ (untestable)
assumptions to address almost any important causal question which would otherwise remain
unanswerable without these assumptions, i.e. there would be no progress without assump-
tions. And Greenland (2004) adds that counterfactuals in fact help expose the limitations of
statistical inference which infers causation by addressing only the magnitude of associations
and the associated average causal eects while failing to account for the causal mechanisms
underlying those eects. Various assumptions like no confounding, specic statistical dis-
tributions and independence are some of the realistic (albeit often untestable) assumptions
that can be considered necessary evil for causal inference. In fact Greenland et al. (1999) ar-
gues that besides constructively aiding precise formulation of assumptions needed to identify
causal eects statistically, the counterfactual approach can also aid in developing techniques
for meeting those assumptions. In addition to giving simple and clear explanation of causal-
ity, models based on counterfactuals provide a rigorous theory for clarifying estimation of
treatment eects that have been adjusted for confounders which forms an integral component
of causal inference (Wasserman, 2000). But as Sobel (2000) remarks, the subject of causation
itself may be controversial, but the practical need for causal modelling may be considered
even more overwhelming.
Critics of use of counterfactuals in causal inference often criticize the approach for includ-
ing structural elements that cannot in principle be identiable by randomized experiments
which is considered the gold standard for making causal inference. Considered critically, this
may be a sound opposition because, for example, we cannot determine correlation among
potential outcomes since no two potential outcomes Y (a) and Y (a0) from distinct interven-
tions a 6=a0 can be observed on one unit. In fact according to Dawid (2000) the approach is
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less scientic because since such correlation are unobservable, they can only be considered
hypothetically. Referring to the framework `fatalism', Dawid considers the counterfactual ap-
proach to causal modelling not only unnecessary but also cumbersome. Instead Dawid (2004)
propose Bayesian causal modelling based on probability that is devoid of `distracting' meta-
physical ingredients. However, we note that Bayesian inference too involves elicitation of
priors which is often considered a subjective decision by mainstream frequentist statisticians.
In his criticism with regard to basing causal inference on unobserved counterfactuals,
Dawid (2000) illustrated his non-counterfactual cause-eect formulation by decomposing
causal inference into two components: eects of causes and causes of eects. The distinction
may be better understood by considering his two prototype sentences:
1. I have a headache. Will it be gone if I take aspirin?
2. My headache has gone. Is it because I took aspirin?
The rst sentence is a common medical (hypothetical) consideration aimed at predicting the
future to address a what if scenario. In that sentence we observe that Dawid's eects of
causes is equivalent to causal eects evaluated by counterfactuals as a comparison between
responses to dierent treatments/exposures. On the other hand, the second sentence is a
retrospective examination of the past, akin to legal search of evidence. This sentence essen-
tially denes the treatments themselves which cause the observed responses. The rhetorical
decompositions may be considered a philosophical criticism of counterfactuals but a common
thread connecting both arguments is the quest to empirically evaluate the impact of an in-
tervention on a response. No matter the hue of causality, the knowledge of causes is key to
understand, predict and inform the right intervention.
According to Arjas (2001), use of counterfactual models present the causal dilemma:
the contradiction of formalizing causal models on mental/hypothetical (and subjective) con-
straints instead of pure scientic reasoning. According to him the contradiction lies in the
fact that while the ingredients of counterfactuals are presented in terms of random variables,
by its very nature this leads to conditioning on unobservables hence violating the very basic
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tenets of probability theory. While Arjas (2001) considers use of mental constraints a limi-
tation in causal modelling, according to Hoer (2005) the strength of counterfactuals lies in
their ability to link metaphysical component of causality to empirical research.
Despite opposing viewpoints, counterfactuals are extensively used and appreciated in
many elds of causal modelling. As Lewis (1973) correctly observed decades ago all statements
about causality can be understood as counterfactual statements, both from a practical and
commonsense point of view. In fact in its defense, counterfactual enthusiasts argue that
the approach stimulates insights that not only help in recognition of shortcomings of pre-
vious methods but also promote development of new, intuitive and more generally valid
methods (Wasserman, 2000). According to Wasserman (1999), the unobserved potential
outcome is an intuitive causal modelling approach that can also be equivalently handled
by considering it as a missing data problem, i.e. like estimation in the presence of 50%
missing data. Although we do not observe them, causal inference is still possible because
we can make logically sound conditional inferences about counterfactuals (Maldonado and
Greenland, 2002). In the presence of complex (but ubiquitous) settings like noncompli-
ance, Rubin (2006a) argues that causal inference is best understood using counterfactu-
als. Also both Geng (2003) and Kluve (2004) agree that counterfactual models provide
the most precise denition and description of causal eects. The unifying framework of
counterfactuals may be discerned from Pearl's (2009b) observation that most statistical
approaches to causal modeling have equivalent counterfactual formulations. In general,
causal modelling in the counterfactual framework has been applauded as one of the in-
novative intellectual developments over the past few years (Sekhon, 2009). Also as a lan-
guage of inquiry, counterfactuals may not be more that a form of scientic common sense
(Phillips and Goodman, 2006). But we note that obtaining the average causal eects
often involves making some (mostly) untestable assumptions (see Section 1.8.1).
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1.8.3 Alternative formulations of causal effects
Pearl (1995, 1998) developed causal diagrams as an alternative formulation of causal models.
Causal diagrams is an integration of graph and probability theories which gives the formula-
tion its alternative name of graphical models for causal diagrams. This framework of causal
modelling is based on directed acyclic graphs. A directed acyclic graph (DAG) is a graph
made up of nodes connected by directed edges (arrows) such that there are no cycles and
no edges from a node to itself (Lauritzen, 1996, 2001). The objective is to use DAGs to
represent causal relationships in terms of probabilistic dependencies between random vari-
ables. Using graph theory terminologies, each node in a directed acyclic graph represents a
variable: X!Y implies variable X causes Y or equivalently X is a parent of Y , and Y is a
child of X. A causal path from X to Y (X!Y ) means X is an ancestor of Y , and Y is a
descendant of X. The relation X Z ! Y mean Z is a common cause of both X and Y .
In general DAGs convey the implicit causal assumptions through their missing arrows: an
arrow linking X to Y represents potential direct causality while missing links are exclusion
restrictions Pearl (1998).
Directed acyclic graphs can be used to encode conditional independence structures hence
inducing conditional probability (exchangeability) which is a central concept in causal mod-
elling by allowing us address identication problem in estimation of causal eects. This is
due to the causal Markov assumption which states that if X is not a cause of Y and Y
is not a cause of X, then X and Y are independent conditional on their common causes
(Spirtes, 2005). In DAG language, the causal Markov assumption states that each variable
is independent of its non-descendants and non-parents, conditional on its parents in the true
causal graph. The concept of d-separation (Pearl, 1988) provides the correct connection
between a causal DAG and probability distributions. D-separation is a Markovian represen-
tation that involves checking whether a set of vertices Z blocks all connections of a certain
type between X and Y in a graph:
X ! Y ! Z d-separation        ! X ? Zjd-sep Y;
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i.e. X is independent of Z conditional on Y in all distributions represented by the DAG.While
causal Markov assumption allows us to deduce statistical independence given d-separation,
it does not allow us to deduce statistical dependence in the absence of d-separation, what is
also referred to as d-connection (Robins and Hernan, 2009).
Also by adopting do-calculus notation (Pearl, 2009b), the causal eect of an intervention
Z on outcome Y can also be represented by Pr[Y j do(z)]. An equivalent representation to
this in the counterfactual formulation is provided by Pr[(Y (z)=y]:
ACE = E[Y j do(z)]  E[Y j do(z0)];
where the ACE is identiable if it can be estimated from observed data.
Finally, probability theory plays a central role in statistics by allowing manipulations
for valid inference and Suppes (1970) pioneered probabilistic causality which were also later
expanded by Eells (1991). Recently Steyer et al. (2000a,b, 2002) proposed an alternative
formulation of counterfactuals using classical probability theory. In introducing probability
causal model, they however point out that they are `not re-inventing the wheel' by presenting
a new theory but instead exploiting the wealth of probability theory to minimize ambiguity
in understanding the original counterfactual formulation. They argue that the probabilistic
formulation produce stochastic causal models unlike the deterministic nature of the original
formulation. Arjas and Parner (2004) also propose use of Bayesian probabilistic causal models
based on the general framework of marked point processes. We point out that we have
outlined these alternative formulations of causal model for completeness only since the present
work only applies the counterfactual framework of causal modelling.
1.9 Noncompliance and nonresponse
Complex, often unpredictable behaviours and dynamic lifestyles probably makes humans the
most dicult units for experimentation. Efron (1998) perhaps captures this phenomenon
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more succinctly in his observation that
\There could not be worse experimental animals on earth than human beings;
they complain, they go on vacations, they take things they are not supposed to
take, they lead incredibly complicated lives, and, sometimes they do not take
their medication."
A clinical trialist's task is probably complicated most by Efron's last observation which
is often manifested in the form of noncompliance to treatment assignment. Many trials
often suer the twin complications of noncompliance and nonresponse (Bellamy et al., 2007;
Horiuchi et al., 2007). Non-participation and drop-out may introduce bias whose magnitude
depends on how strongly its determinants are related to the respective parameter of interest,
e.g. hazard ratio (Hoer et al., 2005). These biased estimates may potentially threaten
the validity and credibility of the resulting causal eect estimates. These two apparently
similar complications can occur separately or simultaneously. The twin complications of
noncompliance and missing data collectively aect causal eect estimation (Dunn et al.,
2003; Frangakis and Rubin, 1999; Mealli et al., 2004; O'Malley and Normand, 2005; Peng
et al., 2004; Rubin and Zell, 2010). Ideally fully observed treatment compliance would be
adequate to handle missing outcome data with less complexities (Jo et al., 2010). But in real
trials, noncompliance information is always incomplete since we do not observe compliance
for subjects randomized to the control intervention.
It may be discerned from the foregoing that noncompliance to treatment is a common
phenomenon that is likely to complicate analysis of data from randomized studies (Dunn and
Goetghebeur, 2005). While it may be possible to closely monitor laboratory experiments
and ensure satisfactory compliance to treatment, it is often dicult to control compliance
behaviour in large scale eld experiments involving intensive treatment regimes. Imperfect
compliance has the net eect that the received treatment does not always agree with assigned
treatment. Noncompliance may arise from a variety of reasons either related to the treatment
or otherwise. Indeed evaluation of treatment eect is even complicated further if the reason
for noncompliance is related to the treatment itself like stopping medication due to adverse
side eects. When it is practically and ethically permissible, encouragement designs can be
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incorporated to help increase the level of compliance (Frangakis et al., 2002), e.g. oering
support information for pregnant women to stop smoking. While the present work considers
methods of accounting for noncompliance, but because of their similarity in occurrence and
eects on treatment eects estimation, we briey describe the key features of missing data
to illustrate some of the its similarity with noncompliance.
Missing data
A common feature in data are codes indicating lack of response such as don't know, refused or
intelligible. Dealing with such data poses a challenge and applying any missing data technique
requires establishing whether an underlying true value exists and, if so, whether that value
is unknown (Schafer and Graham, 2002). Missing data then refers to data values that were
intended to be collected but were not available for some reason. Missing (incomplete) data
is a common feature of cohort studies and more often than not it is the rule rather than
the exception. For example, subjects originally recruited into the study fail to participate in
one or more of the subsequent waves. The two main reasons that cause subjects to be lost to
follow up are death and dropout (Daniels and Hogan, 2008; Molenberghs and Kenward, 2007).
Unlike unbalanced studies arising by design, the missing data mechanism (the reason
of the missingness, i.e. description of possible relationship between measured variables and
probability of missing data) should be considered in the analysis of cohort data. The mech-
anism by which data is lost is critical to understanding the impact of missing data on the
conclusions, model validation and making reliable inferences. There are two main features
distinguishing missing data mechanisms in cohort data. The rst one is monotonic miss-
ingness where some subjects drop out from a study, for example, as a result of an adverse
treatment eect or lack of ecacy of the study treatment or simply the refusal of the subject
to continue the study. On the other hand, some data may be missing intermittently, for
example because of an illness, an invalid measurement or forgetfulness. This results in a non-
monotone pattern. Cohort studies generally suer from both of these types of missingness
and more often than not the collected data are incomplete with a non-monotonic structure.
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The classication proposed by Little and Rubin (2002) is based on the relationship between
the mechanism leading to complete or incomplete data (the missing data process) and the
mechanism controlling the actual value of the response of interest (the response process).
We adopt the terminologies of Little and Rubin (2002) in which a non-response process
is said to be missing completely at random (MCAR) if the missing data mechanism is inde-
pendent of both unobserved and observed data whereas we say data is missing at random
(MAR) if, conditional on the observed data, the missingness is independent of the unobserved
measurements. A process that is neither MCAR nor MAR is termed missing not at random
(MNAR). In the context of likelihood inference, and when the parameters describing the
measurement process are functionally independent of the parameters describing the missing-
ness process, MCAR and MAR are collectively referred to as ignorable while the non-random
MNAR process is referred to as nonignorable.
Let us dene Y  to denote the complete set of measurements which would be obtained
were there no missing values. We then partition this into Y  = fY (o); Y (m)g where Y (o)
denotes the observed measurements and Y (m) the lost (missing) ones. We observe the simi-
larity in representation here with the relationship between observed Y and potential outcomes
fY (0); Y (1)g. Further, we dene R as a missing indicator, i.e.
Ri =
(
1 if Yi 2 Y (o)
0 if Yi 2 Y (m):
(1.4)
From the above formulation it can be shown that the missing data indicator R plays a simi-
lar role as a noncompliance posttreatment variable S. The eects of noncompliance can be
evaluated by modelling it as missing data problem (Little and Rubin, 2000; Lumley, 2010;
Rubin, 2006b; Tsiatis, 2006; Wasserman, 1999; Xie and Heitjtan, 2004). While classifying a
particular missing data mechanism as MCAR, MAR or MNAR is often not clear-cut and may
not be done with certainty, this classication is useful in providing a guide to the relevant
analysis that would account for missing data. Apart from complications in data handling and
analysis, analysis in the presence of missing data can cause loss of eciency and/or introduce
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bias (Barnard and Meng, 1999). The challenge is even greater for survival data where event
(e.g. death) from competing risks, for example, may pose problems similar to nonignorable
missing data mechanism (Baker, 1998). MCAR may be equated to random noncompliance in
which case an ITT analysis (see Section 1.11.1) which ignores any information on compliance
to treatment assignment would be adequate. However, we note that although we obtain unbi-
ased estimates from such an analysis that excludes subjects with incomplete data (noncompli-
ers), the estimates will not be necessarily ecient (Enders, 2010; Feudjo-Tepie et al., 2006).
In general, appropriate modelling of noncompliance and/or missingness is key to estab-
lishing the right cause-eect relationship. From all of the reasons of association discussed
above (see Section 1.6), confounding is ubiquitous (Rothman et al., 2008) and it can be con-
trolled at the design stage by randomization or at the analysis stage by suitable adjustments.
The next section provides a brief review of propensity scores as one of the methods commonly
used to adjust for confounding. However, we note that although propensity scores were orig-
inally developed for observational studies, the concept may be extended to compliance (often
nonrandom) in controlled clinical trials.
1.10 Adjusting for confounding using propensity scores
Applying standard statistical methods (e.g. multiple and logistic regressions) to data with
time-varying confounders produce biased estimates (Cox, 1958a; Robins et al., 2000). On
the other hand ignoring them altogether results in residual confounding (Robins, 1989b).
Also statistical adjustment for confounders may not only fail to reduce bias but even in-
crease it (Robins, 1998b; Robins et al., 2000). Special methods have been developed to
address such situations. Although most of these methods were developed for observations
studies, some of them like the propensity scores have been modied for application to clinical
trials data (Jo and Stuart, 2009).
The concept of propensity scores was introduced by Rosenbaum and Rubin (1983) as a
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method of dealing with confounding caused by nonrandomized assignment of treatments in
observational studies. The propensity score for an individual can be dened as the conditional
probability of being treated given the individual's covariates (Last, 2001). Essentially the
propensity scores method replaces a collection of covariates with a single covariate that is a
function of the original ones. For example, for an individual i (i=1; : : : ; n) with vector Xi
of baseline covariates, the propensity score is the probability e(xi) of being treated (Zi=1)
versus not being treated (Zi=0):
e(xi) = Pr(Zi = 1jXi = xi);
where Z is the assignment indicator and is assumed independent given the covariates X. The
implication here is that conditioning on the propensity score, each experimental unit has the
same probability of being assigned to treatment just like in a randomized experiment. Using
logistic regression analysis, for example, we can estimate a propensity score (probability) that
a subject would have been treated on the basis of the measured covariates. In designing a
study, we discussed in Section 1.5.7 the importance of using baseline information to balance
both treated and control groups. Propensity scores is one such technique that can be used to
accomplish the task such that subjects in treatment and control groups with (nearly) equal
propensity scores will tend to have the same distributions of the covariates used and can be
considered similar. The resulting propensity score can then be used in three dierent ways
to adjust for the uncontrolled assignment of treatments as a (Rosenbaum, 2002):
(i) matching variable,
(ii) stratication variable, and
(iii) continuous variable in a regression model, i.e. analysis of covariance (ANCOVA).
Matching and stratication are the most commonly used methods in controlling for con-
founding (Rubin, 2006c). Under matching method, we select comparison groups with similar
background for example we match non-smokers with other non-smokers and smokers with
other smokers. On the other hand, for stratication we start by rst dividing the population
into strata composed of homogeneous members from which we obtain the comparison groups
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within each stratum. The stratication technique therefore ensures separate evaluation of
association between the exposure and disease only within homogeneous categories or strata
of the confounding variable.
While matching can be very laborious because of the continuous scale of the propensity
scores, the Achilles heels of stratication may be the curse of dimensionality arising from situ-
ations when we have to estimate many parameters in the presence of many strata. Estimating
many parameters from many strata some of which may be empty may result in reduced e-
ciency. Propensity scores can be used to eectively address this problem because it reduces all
the variables into a single score. According to Klungel et al. (2004), results from such propen-
sity scores estimation may provide clear causal interpretations without the need of further
model-based adjustments. Covariate balancing using propensity scores can considerably re-
duce bias in observational studies (D'Agostino, 1998) such that even when a model is misspec-
ied, the bias due to misspecication of the propensity scores may be relatively smaller com-
pared to misspecication in standard multivariable regression model (Klungel et al., 2004).
A lot of studies have been conducted to demonstrate the advantages of propensity scores
approach to causal modelling. In their seminal paper, Rosenbaum and Rubin (1983) demon-
strated that propensity scores adjustment is less sensitive to assumptions about the func-
tional form of the association of a particular covariate with the outcome (e.g., linear or
quadratic).Dehejia and Wahba (1999) showed how to estimate the impact of treatment on
a manpower training program observational study data using propensity scores methods in
addition to assessing the ecacy of the propensity scores methodology. According to De-
hejia and Wahba (1999), the propensity scores approach not only allows us to estimate the
treatment eect by exploring observed information contained in variables, but even in the
presence of important but unobservable covariates, applying propensity scores methods may
oer useful diagnostics on the quality of the comparison group. Using simulations studies,
Cepeda et al. (2003) demonstrated the superiority of propensity scores over logistic regres-
sion with respect to model robustness and empirical power. However, with respect to the
empirical coverage probability, bias, and precision, they found the propensity scores method
66
to be superior only when the number of events per confounder was low. They found logistic
regression to perform better on the criteria of bias and coverage probability when there were
more events per confounder. This observation can be attributed to the fact that summarizing
covariates to a single score may mask information and working with averages can potentially
conceal true data characteristics, i.e. curse of averages.
1.10.1 Selecting (compliance propensity) predictors
Although propensity scores were developed to adjust for confounding from measured vari-
ables in observational data where there is no randomization in treatment assignment, the
concept may be extended to model phenomenon in randomized controlled clinical trials
that exhibit traits similar to confounding. Compliance to treatment allocation (often a
nonrandom) is one such phenomenon. Compliance information can be a useful ingredient
in estimating treatment. Using baseline covariates, Follmann (2000) obtained the compli-
ance score (propensity to comply) from a logistic regression and used the compliance score-
treatment interaction in a two stage-regression procedure to estimate eect of treatment
among potential treatment compliers. However, we note that Follmann (2000) used data
from the treatment group to estimate the compliance score hence ignoring placebo compli-
ance. The present work investigates the eects of accounting for compliance with placebo
allocation on causal estimates by applying the concept to compliance scores to model propen-
sity to comply in individual arm of treatment.
Using propensity scores to select plausible predictors of compliance is an exercise in
variable selection which is often fraught with many problems. The challenge often lies in
the decision on which variables to select for the propensity model (Brookhart et al., 2006).
In ideal situations, subject matter with a detailed understanding of treatment assignment
mechanism would be a guide on choosing suitable variables but noncompliance being mostly
a nonrandom phenomenon is inuenced by many factors, both treatment related and extra-
treatment. With no benet of such knowledge and confronted with a large collection of base-
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line covariates, the challenge translates to choosing which terms to include so as to produce a
prediction model of compliance that is both well calibrated and discriminative and less opti-
mistic. The present work will address this issue (Chapter 3) hitherto not discussed/explored
much before by anyone else.
1.11 Estimating treatment effects
A principal objective in causal inference is to estimate treatment eects. In this section
we present methods for estimating treatment eects starting with the intention-to-treat es-
timation which ignores any form of compliance information and then consider two meth-
ods (instrumental variables and CACE estimation) which are special cases of the general
principal stratication framework which can be extended to adjust for noncompliance in
two (and possibly multiple) arms and other complicated applications as discussed in the
subsequent sections.
1.11.1 Intention-to-treat
Intention-to-treat (ITT) analysis is a strategy that compares the study groups in terms of the
treatment to which they were randomly assigned, irrespective of the treatment they actually
received or other trial outcomes. ITT estimate is a measure of the average causal eect of
randomization Z on outcome Y , i.e. for two subjects randomized to Z and Z 0 arms, the ITT
may be dened as
ITT = E[Y (Z)  Y (Z 0)] = E[Y (Z)]  E[Y (Z 0)]: (1.5)
The ITT is variously referred to as average treatment eect or average causal eect
(Freedman, 2006) Essentially the ITT is a measure of treatment eectiveness that can be
used to address Cochrane (1972) question; what would be the eect of oering treatment under
ordinary conditions? ITT analysis is performed according to assigned treatment group with
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no regard to protocol deviations and participant compliance or withdrawal. Most public
health policies are formulated based on the ITT measure because it reects the eect of
treatment under ordinary conditions. However, Hernan and Robins (2006) points out that
such a measure is prone to vary according to local conditions. The validity of ITT estimates
is premised on the fact that it retains the ideals of randomization principle that permits
comparisons between the treatment arms.
However, in the presence of noncompliance, ITT analysis may not be appropriate for
studies designed to evaluate treatment ecacy or equivalence. Performing ITT analysis on
such studies may potentially lead to misleading inferences. For example, Sheng and Kim
(2006) demonstrated that using ITT analysis for therapeutic equivalence trials increases the
chance of erroneously concluding equivalence. They attributed this result to the fact that the
direction and magnitude of changes in the type one error rate and power of the study depend
on the patterns of noncompliance, event probabilities, the margin of equivalence and other
(unobservable) factors. The assumption that ITT analysis operates under ordinary conditions
is rarely satised in practice because noncompliance and withdrawals are more of the norm
(practice) rather than exception in real life trials. The eectiveness of randomization is only
equivalent to ecacy under perfect treatment compliance. But in the presence of noncompli-
ance, ITT analysis may mask confounding (mostly due to selection bias) while comparing the
treatment arms hence potentially leading to misleading conclusions mostly by biasing (under-
estimating) ecacy towards the null (Greenland et al., 2008; Loeys et al., 2005) and/or loss
of power (Becque and White, 2008). Critics of ITT analysis often consider it an attempt to
dene away (trivialize) a serious epidemiological problem, especially when treatment received
is the subject of scientic interest for a study (Greenland and Morgenstern, 2001).
ITT analysis is considered the gold standard in estimating treatment eects (Fischer-Lapp
and Goetghebeur, 1999; Hackshaw, 2009; Pocock, 1983), i.e. ITT analysis of randomized con-
trolled trials provide the best unbiased inference with regard to causal knowledge (Goetghebeur
and Shapiro, 1996). However, by comparing the randomized treatment groups regardless of
compliance status the method is likely to fail in revealing a treatment's true therapeutic
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eects. Because it is an as-randomized analysis that ignores the compliance information, the
ITT estimate is a measure of the eect of treatment randomization rather than the eect of
treatment for those who actually received it. The strength of ITT lies in the fact that its
estimator is protected from selection bias by randomized treatment assignment.
However, for one-active treatment trials, ITT analysis generally provide a distorted (di-
luted) measure of the eect of the treatment itself because it averages eects from both
compliers and noncompliers, which often produces underestimated treatment ecacy (White
and Pocock, 1996). The problem is compounded for a two-active treatment arms trial where
the ITT may provide a biased estimator even under homogeneous treatment eects assump-
tion (Baker and Kramer, 2005). For example, a double-blind placebo-controlled randomized
clinical trials with an active treatment may present two levels of noncompliance: simple
compliance due to non-adherence to treatment allocation and possible dierential noncom-
pliance due to imperfect blinding (Jin and Rubin, 2008). These two levels of noncompliance
together are likely to result in biased ITT estimates. As a result there is need for methods
that account for potential noncompliance in both one and two treatment arms.
1.11.2 Per-protocol and as-treated analysis
To supplement ITT analysis, per-protocol and as-treated methods are the two commonly
used secondary analyses in estimating treatment ecacy (Little and Rubin, 2000; Lui, 2011;
Marcus and Gibbons, 2001; White, 2005). However, these secondary analysis methods can
potentially produce seriously biased estimates of treatment eects owing to selection bias
because the subjects compared cannot be considered a random sample of the population
under study (McNamee, 2009; Pocock and Abdalla, 1998). Per-protocol analysis compares
participants who did not deviate from protocol as outlined in the research design, i.e. censors
noncompliers. But such groups may be systematically dierent; for example, sicker partici-
pants may be more likely to take their medication than their relatively healthy counterparts
and the reasons for deviation may dier between the two groups. As a result the compara-
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bility is lost unless the deviations from protocol are genuinely random (Sheiner and Rubin,
1995). Also by discarding entire records of patients that violate the protocol, per-protocol
analysis may be wasteful of information/data and resources (Greenland et al., 2008).
As-treated analysis on the other hand evaluates the dierence in outcome between those
groups classied by treatment received. As a result as-treated analysis disregards assignment
in favour of receipt of treatment hence also violating randomization principle. The validity
of both per-protocol and as-treated analyses may be questionable because they both lack
the benets of randomization (Imbens and Rubin, 1997). With randomization violated, con-
founding factors associated with switching from the assigned treatments can potentially cor-
rupt the causal interpretation of treatment eects. Recently McNamee (2009) derived expres-
sions for the bias in per-protocol and as-treated estimates under nonrandom noncompliance.
1.11.3 Instrumental variables estimation
Regression techniques based on ordinary least squares may be considered the powerhouse of
most statistical analysis conducted to seek association between variables. However, ordinary
least squares fail to account for hidden bias which is prevalent in most medical studies hence
making it dicult to draw valid causal inference. Despite the elegance of propensity scores
(see Section 1.10), they can only control for measured confounding. As a solution, the
concept of instrumental variables was borne out of structural equation modelling and has
been a popular technique in econometrics since the 1920s (Wright, 1928).
Instrumental variables were originally introduced to improve ordinary least squares by
adjusting for hidden selection biases in observational studies and estimate causal treatment
eects on the outcomes of interest (Heckman et al., 2006). The instrumental variable tech-
niques have gained extensive use in medical research in estimation of treatment eects in the
presence of noncompliance in observational studies (Rosenbaum, 2002). Instrumental vari-
ables provide the simplest and most robust solution to both aspects of noncompliance, i.e.
in the presence of treatment dilution and/or treatment switch (Angrist, 2006). But just like
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in all aspects of causal modelling, eective use of instrumental variables is premised on some
untestable assumptions. For example, the strong ignorability assumption (treatment assign-
ment is random given observed covariates) allows use of instrumental variables to produce
consistent treatment eects estimates (Sobel, 2000).
The strong ignorability assumption is a common feature among econometricians where
it is usually referred to as selection on observables. Heckman and Robb (1985, 1988) and
Heckman and Hotz (1989) proposed a number of methods to estimate treatment eects that
correct for this type of selection bias. By incorporating suitable modelling conditions, they
applied the methods to longitudinal workforce data. These studies probably form the basis of
modern instrumental variable techniques. We can use instrumental variables to estimate how
much the variation in the treatment variable that is induced by the instrument (and only that
induced variation) aects the outcome measure. The induced variation is what econometri-
cians often refer to as exogenous variation which is said to identify the desired estimate.
An instrumental variable may be intuitively thought of as a device used to mimic sta-
tistical pseudo-randomization towards controlling for residual confounding. With that cue,
actual randomization in a randomized controlled trial becomes a special case of instrumental
variable (Newhouse and McClellan, 1998). A simple illustration of this is assigning people
to treatment or control groups at random on the basis of tossing a fair (unbiased) coin. The
outcome of the coin toss (heads or tails) becomes the instrumental variable since it induces
variation in the treatment variable. The resulting quasi-experiments may sometimes have
more desirable features compared to designed experiments in situations where the study
conditions may be more representative of real-world settings to the extent that the use of de-
signed experiments is less representative of the participants e.g. studies in which participants
are exclusively volunteers (Luellen et al., 2005).
A key advantage of instrumental variables is the fact that they can be used to control
unmeasured confounding (bias), i.e. suitably chosen instrumental variables produce consis-
tent estimates of the average causal eects even in the presence of unmeasured confounding
(Angrist et al., 1996). These results however only hold true provided the chosen instrument
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satises the above instrumental variable properties. A research would have to follow and ad-
here to very strict protocol for an identied instrument to have such properties, e.g. perhaps
only a double-blind clinical trial suce:
(i) due to the fact that the trial participants are more likely to receive treatment if they
were assigned to treatment (adherence to protocol, i.e. no treatment switches/deers),
(ii) because treatment assignment aects the outcome only through the value of the treat-
ment itself (exclusion restriction assumption) and
(iii) since the random assignment itself is a suitable instrument.
For a given outcome Y and treatment A, an instrumental variable Z may be applied
using a structural two-stage regression strategy (Angrist et al., 1996):
Yi = 0 + 1Ai + i; where Cov(A; ) 6= 0 and (1.6)
Ai = 0 + 1Zi + i; where Cov(Z; ) = 0; (1.7)
with the assumption 1 6= 0, i.e. existence of a non-zero eect of instrument. While most
studies consider dichotomous A and Z, we note that in principle A can be continuous and Z
constitute multiple arms.
Ordinary least-squares estimation of equation (1.6) produce biased and inconsistent esti-
mates of the eect of A if Ai is endogenous (i.e. endogeneity occurs when Ai is related to i).
This problem may be addressed by using the instrument variable Zi in equation (1.7) to
estimate A^i (e.g. A^i=0+1Zi  the predicted value of Ai) which is then substituted in
equation (1.6) instead of the actual Ai variable. Using A^i given Zi provide unbiased estimate
of the impact of Ai on Yi. It may be useful to think of equation (1.7) as `purging' A of
potentially confounding inuence (Linden and Adams, 2006), i.e. cov(A; ) 6= 0 implies con-
founding. In eect equation, (1.7) is an expression of our lack of knowledge in which group
is assigned to which treatment and the instrumental variable Z explains why one group is
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treated and the other is not. By substituting Equation (1.7) in Equation (1.6) we obtain
Yi = (0 + 10) + 11Zi + (1i + i)
= 0 + 

1Zi + i; Cov(Z; ) = 0:
The instrumental variable (IV), slope 1 , may then be estimated by ordinary least squares
regression techniques, i.e. by taking covariances with Z on both sides of the Equation (1.6),
cIV  ^1 = cov(Z; Y )cov(Z;A) : (1.8)
We observe that in the case of a perfect instrument (random assignment), a perfect
relationship exists between Z and A and the parameter 1 = 1, in which case the ITT
estimator and the instrumental variable estimator coincide, i.e. under perfect compliance.
However, this ideal case is rarely the case in practice since no randomization can be perfect,
instead most trials are plagued with noncompliance to treatment allocation. Using two
equations to describe the problem above implicitly satises the important assumption that
randomization Z has no eect on outcome Y other than through its eect on treatment A
(since cov(Zi; Ai)=0). This is the exclusion restriction assumption (Angrist et al., 1996) as
discussed previously (see Section 1.8.1). An additional assumption that 1 6=0 implies that
there is no treatment deers, i.e. no subjects taking treatment opposite to their assignment.
The problem of instrumental variable method may be compounded by small variations
in instrument measure between comparison groups. For example, when variation in the
likelihood of receiving a particular therapy is small between groups of patients based on an
instrumental variable, dierences in outcome due to this dierential use of the treatment
may be very small and hence dicult to assess. Furthermore the treatment eect may not
be generalizable to the population of patients whose treatment status was not determined by
the instrumental variable hence compromising the model's (external) validity. We note that
this problem mimics a characteristic of clinical trials where estimated treatment eects may
not be generalizable to a broader population. This limitation of instrumental variables may
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be viewed both as a curse and a blessing. It is a blessing in the sense that identifying and
using an appropriate instrumental variable improves the strength of observational studies
which will compare favourably to the gold standard clinical trials. But it is a curse if we
were to extrapolate results obtained by using inappropriate instrumental variables that may
lead to making invalid causal inferences. In general, instrumental variables provide unbiased
ecacy estimates compared to the ITT, per-protocol and as-treated approaches (Kim, 2010).
Although instrumental variables may be more useful in observational studies, we note
that the present study considers a double-blind randomized controlled trial and hence we have
a valid instrument (randomization), which is associated with received treatment and is most
unlikely to aect the outcome (moratlity/myocardial reinfarction) other than through treat-
ment received and shares no common causes with the outcome by virtue of randomization.
1.11.4 CACE: Complier average causal effect estimation
The complier average causal eect (CACE) estimator can be used to estimate treatment
ecacy in the presence of noncompliance. We note that CACE is also referred to as local
average treatment eect (LATE) in the econometrics literature (Imbens and Angrist, 1994;
Wooldridge, 2010) but here we will use CACE. In their seminal paper, Angrist et al. (1996)
demonstrated CACE as a valid estimate of the eect of treatment among the subpopulation
who would comply with their treatment assignment, i.e. provided there are some compliers,
CACE can be considered as the ITT estimate among the subgroup complying with treatment.
Given a two-armed placebo controlled trial and by using the potential outcome denition
of causal eects, we can classify participants into four latent (potential) complier types:
compliers, always-takers, never-takers and deers, which Frangakis and Rubin (2002) also
refers to as principal strata:
 compliers are subjects who would adopt whatever treatment they were assigned,
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 always-takers would always take the active treatment regardless of their treatment
assignment,
 never-takers would always take the control treatment regardless of their treatment
assignment and
 deers would take the treatment opposite to what they were assigned.
If we let Si denote the compliance type of subject i and based on a subject's joint
values of potential treatment received AZ ; Z 2 f0; 1g (for a two-armed trial), Angrist et al.
(1996) dened four mutually exclusive subgroups that results from cross-classication of
randomization and treatment received of subjects as follows:
Si =
8>>>>>><>>>>>>:
1; if (A0; A1) = (0; 1)
2; if (A0; A1) = (0; 0)
3; if (A0; A1) = (1; 1)
4; if (A0; A1) = (1; 0);
(1.9)
where types 1; 2; 3; 4 refers to compliers, never-takers, always-takers and deers respectively.
These compliance groups is what Frangakis and Rubin (2002) originally referred to as basic
principal strata (see next Section) while Little et al. (2009) referred to them as principal
compliance stratum. We will use compliance types and strata interchangeably for the present
work. For a simple case, the four unique subgroups may be collectively classied (collapsed)
into two of compliers (S=1) and noncompliers (S 6=1) (Cheng et al., 2009; Zhang, 2004).
Key to correct CACE formulation is the distinction between the denition of latent/true
compliance (potential true complier under both treatments) and observed compliance (com-
pliance under the treatment actually assigned). Since we can only observe compliance status
for the assigned treatment, a subject's full compliance status is incompletely observed, i.e.
unidentiable. For example, a subject complying with the active treatment assignment may
be a complier or an always-taker and a non-complier to the treatment of interest may be
a never-taker or a deer. Also if a subject is assigned to the control and complies, then
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that subject may be a complier or a never-taker. But a subject assigned to the control who
switches to the active treatment may be either an always-taker or a deer.
Stratication on a latent variable (compliance status) S is key to addressing the identi-
cation problem outlined above. The four strata dened by Equation (1.9) above includes
all subjects where the strata are dened by values of S under both (potential) treatment
assignments such that a subject will belong to the same stratum no matter her treatment
allocation. Because principal compliance (unlike observed compliance) is independent of the
assigned treatment, it can be validly used as a stratication variable in treatment compar-
isons, i.e. the compliance status S is independent of the treatment allocation hence induces
exchangeability. To distinguish between true and observed compliance, we observe that a
subject's delity with allocated active treatment results in `observed compliance' (complier
or never-taker) while true compliance is (at least partially) unobserved. For a simple case,
CACE may be dened as the average causal eect for the subpopulation of compliers (S=1).
For example, for two compliers in the treatment arm who actually receive treatment, a CACE
estimate may be dened as
CACE = E [Y1(1)  Y1(0)jS = 1] : (1.10)
The method of estimating CACE is not immediately explicit because the compliance
status S of individuals is generally unknown. However, we can estimate CACE from data
under SUTVA and random assignment of treatment assumptions together with the addi-
tional assumptions (Angrist et al., 1996): exclusion restriction, monotonicity and at least
some compliers (to ensure a nonzero denominator). As discussed previously (Section 1.8.1),
the exclusion restriction assumption posits that the treatment assignment only acts on the
outcome through the treatment received A. For a general setting (e.g. a=a0 arms) this implies
that for never-takers and always-takers, whose adopted treatment is the same regardless of
which treatment is assigned (i.e. no eect of randomization), the outcome Y is the same
regardless of which treatment is assigned, i.e. Y (a) = Y (a0) if a= a0. As a result these two
groups play no role in determining causality because they are not relevant for comparing the
77
target treatments (Palmgren and Goetghebeur, 2004; Sheiner and Rubin, 1995; Sommer and
Zeger, 1991). This may be discerned from the fact that both groups of compliers would not
change their behavior with respect to the target treatments. While the monotonicity of treat-
ment assignment and treatment actually received implies assuming no deers (Imbens and
Angrist, 1994), the non-zero denominator assumes that the population of interest includes
some compliers. Under these assumptions, Angrist et al. (1996) derived a CACE estimate as
E [Y (a)  Y (a0)] = E [Y (a)  Y (a0)jS = 1]Pr(S = 1) +
E [Y (a)  Y (a0)jS 6= 1]Pr(S 6= 1);
so that ITT = [!s  CACE] + [(1  !s) eect on noncompliers];
(1.11)
where !s is the estimated proportion of compliers in the treatment arm.
Because the exclusion restriction assumes that the eect of treatment on outcome is
only through the treatment actually received, it is then reasonable to assume no treatment
eect among noncompliers. And with the monotonicity assumption, the treatment eect for
always-takers and never-takers can be considered to be identically zero because they cannot be
induced to change treatment status through variation of treatment allocation (Frolich, 2003).
Using the exclusion restriction and no deers assumption, the last term on the right hand
side of the equation above is zero:
E [Y (a)  Y (a0)jS = 1] = E [Y (a)  Y (a
0)]
Pr(S = 1)
so that \CACE =
dITT
!^s
; (1.12)
i.e. CACE can be estimated from the ITT eect divided by the proportion of compliers. We
observe that the CACE estimate (1.12) provides a better ecacy estimate in the presence of
noncompliance and trivially CACE and ITT are equivalent in the presence of full compliance.
There is a relationship between CACE (1.12) and the instrumental variable estimate
given by Equation (1.8) (Dunn et al., 2003; Jo, 2002b; Zhang, 2004). Let the sample means
[y(a) y(a0)] be an unbiased ITT estimate (assume randomized treatment allocation). Also
let !(a) represent the proportion of participants in the treatment arm who received the new
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treatment of interest and let !(a0) be the proportion of participants in the control arm who
adopt the new treatment. Then Angrist et al. (1996) showed that !(a) is an unbiased estimate
of the proportion of compliers or always-takers (those who received the treatment they were
assigned), and !(a0) is an unbiased estimate of the proportion of always-takers (those who
adopt the treatment when assigned the control). Then [!(a) !(a0)] is an unbiased estimate
of the proportion of compliers, Pr(S = 1) and an unbiased estimate of CACE may then be
given by
\CACE  IV = y(a)  y(a
0)
!(a)  !(a0) ; (1.13)
i.e. the instrumental variable (IV) is equivalent to the estimated ITT eect divided by
dierence in the proportions that received the new treatment in the new treatment and control
arms. Equation (1.13) may provide a measure of ecacy, for example, the risk dierence
due to taking HRT tablets compared to placebo. We observe that the instrumental variable
estimator given by Equation (1.13) is an equivalent expression (sample analogue) of the CACE
estimator given by Equation (1.12) where the dierence [!(a) !(a0)] represents the proportion
of compliers !s. The two quantities may be identical but the CACE estimate does not
suer many of the possible limitations implicit in instrumental variables estimation. Using
potential-outcome formulation may even lead to more ecient CACE estimators compared
to the instrumental variable estimator (Little and Rubin, 2000).
1.11.5 Principal stratification
We observe from CACE estimation discussed above that using a posttreatment variable to
create strata induces (conditional) exchangeability which enables us to identify estimands
of interest which are well-dened causal eects. Frangakis and Rubin (2002) introduced
the principal stratication as a unifying framework for this approach of adjusting on post-
treatment variable (i.e. intermediate response pattern) which embodies characteristics of an
experimental unit and treatment, for example, compliance status S in a randomized trial en-
codes both ecacy and compliance behaviour. For CACE, the subdivision given by Equation
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(1.10) is an example of principal stratication into four principal strata: compliers, always-
takers, never-takers and deers. We can also obtain two principal strata of compliers and
noncompliers where the later is formed by combining all the other three strata. The four
strata is what Frangakis and Rubin (2002) referred to as basic principal stratication while
they referred to the possible permutations as principal stratications. We note that while
there may be multiple principal stratications (e.g. four or two as dened above), there is a
unique basic principal stratication with respect to a given posttreatment variable.
The principal stratication framework permits comparison of potential outcomes under
dierent assignments within principal strata to produce principal eects. A principal strata
is dened by two important properties (Frangakis and Rubin, 2002):
(i) the strata is not aected by treatment allocation and
(ii) comparison of principal eects within the strata produces well-dened causal estimates.
The denition implies that given baseline covariatesX and a bivariate posttreatment variable
S2(0; 1), then Z?fS(0); S(1); Y (0); Y (1)jXg which implies that potential outcomes are in-
dependent of the treatment assignment given the principal strata: fY (0); Y (1)g?ZjS(0); S(1); X.
As a result the treated and control units can be compared conditional on a principal stratum.
These properties demonstrate principal stratication as a powerful framework that is now
extensively applied in a wide variety of problems in causal inference. For example, in studies
to adjust for noncompliance, Roy et al. (2008) evaluated the eects of supervised exercise to
promote smoking cessation, Frangakis (2004) and Frangakis et al. (2004) evaluated the eects
of needle exchange programs in reducing HIV transmission among injection drug users while
Zhang et al. (2009) studied the impact of job training programs on re-employment. Princi-
pal stratication has also been used to address the prevalent twin problems in clinical trials
of noncompliance and nonresponse or missing data (Mealli and Rubin, 2002). For example
while Dunn et al. (2003) applied principal stratication in a mental health study, Frangakis
and Rubin (1999) used simulation studies in a principal stratication framework applied to
survival data to address all-nothing compliance followed by missing outcome. While Barnard
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et al. (2003) used Bayesian approach to address noncompliance with missing outcome data
to evaluate ecacy of New York City school voucher feeding program, Jin et al. (2010) re-
cently extended the study by using principal stratication framework to account for both
missing covariates and outcomes in the presence of complicated noncompliance. Also by us-
ing simulation studies that assumed all-or-nothing noncompliance, O'Malley and Normand
(2005) demonstrated the robustness of maximum likelihood estimation to departures from
outcome distribution outcomes and exclusion restrictions. Egleston et al. (2010) recently ap-
plied principal stratication in sensitivity analysis to account for abstinence in the estimation
of smoking cessation intervention eects.
The exibility of the principal stratication framework has led to its extension to complex
settings like truncation by death (Frangakis et al., 2007; Rubin, 2006a; Zhang and Rubin, 2003)
where death occurs before a primary outcome of interest is recorded hence resulting in cen-
sored records/measures, i.e. the outcome of interest is not observed and is not meaningful
(undened) for subjects who die. For example, in a study of HRT eects on ve-year my-
ocardial reinfarction survival, some women may die before ve years having not suered
reinfarction by the time of death, say, due to breast cancer at three years. The complica-
tion here is not limited to the undened survival time to myocardial reinfarction for such a
woman but by the fact that probability of her death from cancer may itself be aected by
HRT treatment. Application of principal stratication framework here would be based on
cross-classication of potential surrogates S(a) and S(a0) and not the unobserved S hence
permitting stratication on a bivariate survival outcome which is not aected by treatment
receipt. Mattei and Mealli (2007) proposed a principal stratication-based model to jointly
address three complications including noncompliance, missing outcomes and truncation by
death. Also in attempt to show the link between missing data due to death from non-
response and data truncation by death, Kurland et al. (2009) recently demonstrated the
common origin of both analysis in factorizations of the distribution of longitudinal data and
survival information. Even methods hitherto developed for observational studies like propen-
sity scores have been modied to adopt the principal stratication framework. For example,
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using baseline covariates as principal scores to address identication, Jo and Stuart (2009)
recently applied propensity scores in a principal stratication framework to estimate causal
eect within strata under principal ignorability assumption which posits that compliance
status is independent of potential outcome given observed information, i.e. they assumed
covariate information was sucient for estimating causal eects.
Simple methods would be adequate to adjust for random noncompliance if noncompliers
can be considered a random sample of the population under study (McNamee, 2009). But as
discussed above, this is seldom the case owing mostly to selection bias among other factors.
Noncompliance is often a nonrandom phenomenon in the sense that it is likely to be related
to a subject's risk of survival for example. Accounting for such informative noncompliance
is a challenge and the present work applies principal stratication in Chapter 6 to adjust
for possible informative noncompliance in two arms in the Esprit data while in Chapter 8
we apply statistically designed simulation studies to evaluate performance of the method in
terms of bias and 95% credible intervals. But before then we introduce in the next chapter
the fundamentals of survival data and some specialist methods of adjusting for potential
noncompliance in one and two treatment arms of trials investigating time-to-event outcomes.
1.12 Aims and objectives of present work
1.12.1 Broader aims
 Analyze Esprit data and adjust for noncompliance in one and two arms.
 Compare performance of statistical methods for analysing survival data in the presence
of random and nonrandom noncompliance in one active-treatment arm only.
 Evaluate performance of Roy et al. (2008) method which adjusts for noncompliance in
two treatment arms.
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1.12.2 Specific objectives
1. Review literature on causal modelling of treatment eects in the presence of noncom-
pliance (principal stratication).
2. Perform an in-depth analysis of the Esprit data using specialist methods that account
for noncompliance in one (active) treatment arm for both all-cause mortality and my-
ocardial reinfarction or cardiac deaths outcomes.
3. Consider how predictors of compliance should be selected by a review of general lit-
erature on model selection for prediction and select plausible separate predictors of
compliance for HRT treatment and placebo arms for the Esprit study.
4. Apply the principal stratication method by Roy et al. (2008) for survival data to
adjust for noncompliance in two treatment arms and apply it to analyse Esprit (adjust
for noncompliance in both HRT treatment arm and placebo arm) and estimate causal
eects among subpopulations characterized by dierent potential compliance behaviour
patterns, i.e. compare causal estimates for each stratum to overall causal estimates for
each arm (active and placebo arms).
5. Apply statistically designed simulation studies to evaluate performance of six statistical
methods for dealing with noncompliance in the context of a randomized controlled trial
comparing an active treatment and control in terms of survival when non-compliers
comply for part of their treatment period.
6. Apply statistically designed simulation studies in the context of a randomized controlled
trial comparing two-active treatments in terms of survival to evaluate performance of
Roy et al. (2008) method, i.e. bias due to noncompliance in two treatment arms.
83
1.13 Outline of the thesis
This report is organized in nine chapters. In this chapter, after the introduction and motivat-
ing data, we presented a brief review of study designs focussing on key concepts of randomized
controlled clinical trials, outlining their strengths and limitations and contrasting them with
observational studies. After a synopsis of reasons for association, the next section provided a
review of the concept of counterfactuals and its role in causal modelling, key assumptions and
the use of principal stratication framework to estimate causal eects. Chapter 2 presents
a review of key features of survival data and the specialist causal modelling methods for
survival data which adjusts for noncompliance in one and two treatment arms. For adjust-
ments in one arm, we consider methods for all-or-nothing and partial compliances. A brief
description of methods which adjust for noncompliance in two arms is followed by a review
of the principal stratication method by Roy et al. (2008) which adjusts for noncompliance
in two-active treatments' trials. In Chapter 3, we review some techniques of model selection
for predicting compliance to treatment assignment in each arm. After outlining the strengths
and limitations of standard stepwise regression procedures, we review penalized regression
methods and measures to evaluate performance of selected prediction models. The next
ve chapters provide results from analysis of the Esprit study and simulation studies. While
Chapter 4 presents the rst analysis of Esprit data using specialist methods adjusting for non-
compliance in one treatment arm, Chapter 5 presents the second analysis where we develop
separate prediction models of compliance for each treatment arm and Chapter 6 presents an
application of the principal stratication (Roy et al. 2008 model) to analyse the Esprit data
using Bayesian approach to adjust for noncompliance in both treatment arms. Chapter 7
presents a simulations study comparing the performance in terms bias, root mean squared
error and 95% condence interval coverage of the statistical methods applied in Chapter 4.
Chapter 8 presents the second simulations study using Bayesian methods to evaluate the
performance of the Roy et al. (2008) method applied in Chapter 6 in terms of bias due to
noncompliance in two treatment arms and 95% credible intervals. Finally Chapter 9 presents
discussions, novelty of present study, conclusions and possible extensions with future work.
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Chapter2
Causal Modelling of Survival Data with
Noncompliance
2.1 Introduction
This chapter reviews methods for modelling survival data in the presence of noncompliance in
one and two treatment arms. The rst section provides denition of key features of survival
data followed by an outline of the Cox (1972) proportional hazards models and accelerated
failure time models. The next section presents an outline of the relationship between the two
models which will be useful when comparing their performance using simulation studies in
Chapter 7. We also provide an outline of the relationship between hazard ratio and relative
risk which will be used in Chapter 6 for the Roy et al. (2008) method and the evaluation of its
performance in Chapter 8. The next section reviews the specialist methods used to adjust for
all-or-nothing and partial compliance. The nal Section provides a brief literature review of
methods for adjusting compliance in two treatment arms followed by a comprehensive review
of the principal stratication method by Roy et al. (2008) which adjusts for noncompliance
in two arms which is applied to the Esprit data in Chapter 6 and its performance evaluated
via simulations in Chapter 8.
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2.2 Key features of survival data
The choice of the primary endpoint may have a large impact on the design of a study and
a substantive change of method of analysis. Data from clinical trials in which the outcome
represents time-to-event produces what is commonly referred to as survival data. Survival
data diers from Normally distributed data in three distinct ways:
(a) the survival time is strictly positive unlike normal data that can take any value (in the
range 1;+1),
(b) survival data are generally not symmetrically distributed and often positively skewed
in contrast to normal data which is symmetric and
(c) there exists censoring or partially observed outcomes unlike normal data that often
have fully observed outcomes.
2.2.1 Censoring
Censoring is a dening characteristic of survival data and takes dierent forms: right, left
or interval censoring. Right censoring, also referred to as progressive censoring, is the most
common case of the three types of censoring (Collet, 2003). Right censoring can arise from
numerous causes, for example,
(1) There may be no event reported on a patient by the end of the study,
(2) The patient may have been lost to follow-up,
(3) The patients withdraws from the study and
(4) Patient experiences failure from alternative (competing) risk.
Causes 2  4 can be either informative or non-informative depending on whether the form of
censoring is dependent on the unobserved failure time. Censoring, even if non-informative,
must be accounted for in the analysis. Otherwise, results might be misleading and/or biased.
86
Right censoring are of two types, I and II, depending on what is considered a random
variable: time to end of study or the number of failures (events) at the end of study. In
type I, the researcher pre-species the number of failures (r n, where n is the number of
subjects) of interest at the beginning of the study and only terminates the study once this
number is realized. The process thus sets the time to end of study as a random variable.
This type of censoring commonly occurs in industrial or animal experimentation where items
or animals are put on test and observed until failure (O'Quigley, 2008). In contrast, in type
II right censoring, the researcher pre-species the time of terminating the study at which
time the number of failures are determined. This number of failures (r  n) now becomes
the random variable. Right censoring perhaps derives its name from the fact that the times
of failure to the right (larger than T ) are missing. Continuing with a study until a specied
number of events are realized may lead to an open-ended random tests. While this may
be appealing in indicating preference for type I right censoring, the process may not be
practical due to limited resources like time and costs. Type II censoring has the signicant
advantage in situations where it is important to know a priori the number of failures (e.g.
to achieve a pre-specied power of study). We however note that the censored (partially
observed) information still provides useful information (Lindsey, 2004) so that if we let U be
the observed time then we can dene U=min(T;C), where T and C denote survival time and
underlying censoring time respectively, i.e. U is the minimum (what comes rst) between T
and C. An example of right censored data can be realized when a patient leaves town before
an event of interest occurs, i.e. T >U .
On the other hand, for left censored data a failure time is only known to be before a
certain time, e.g. we may know that a particular patient died sometime before the rst month
but not exactly when this death occurred. Formally, a time to event T for a specic subject
in a study is considered to be left censored if it is less than a censoring time Cl (Cl<C), i.e.
the subject has already failed (realized event of interest) before being observed in the study
at time Cl. All we know for such subjects is that they have experienced the event (failed)
sometime before time Cl, but their exact event time is unknown. The exact lifetime T will be
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known if and only if T Cl. Thus in contrast to right censoring above, the observed time U is
dened as U=max (T;Cl). An example of left censoring is when a physician discovers cancer
during a routine visit for a dierent condition altogether hence the actual time of development
of cancer is unknown and the patient sustains `event' before initial time of observation.
Finally interval censoring is often used to reect uncertainty as to the exact times the units
failed within an interval. Lack of constant monitoring may be a cause of such type of data,
e.g. if we monitor patients after every three months and we realize that a particular patient
was alive at the last evaluation but dead by the next evaluation then the only information
we have is that she failed in the 3-6 months interval of time. Probably due to this nature
of periodic monitoring is what makes engineers in reliability studies refer to data that is
interval censored as inspection data. An example of interval censoring is data obtained when
a patient after surgery sustains event between two scheduled post-operation visits, i.e. the
event is only known to have occurred in between the two visits. In general, right censored
data is more prevalent in survival analysis of medical studies than left and interval censoring
(Lee and Go, 1997). Data from the Esprit study were right censored (type II).
According to Marubini and Valsecchi (1995), the principal aims of survival analysis in
the biomedical eld include:
(i) Estimation of failure time distributions, i.e. summarize the distribution of survival
times,
(ii) Compare the distributions of survival times among competing treatments so as to nd
the best treatment and
(iii) Prognostic evaluation of dierent variables, i.e. explore and understand the relationship
between survival time and important covariates.
2.2.2 Survival function and hazard rate
The two functions extensively used to describe survival times and which are of central im-
portance in the analysis of survival data are the survival function and the hazard functions
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(Everitt and Pickles, 1999; O'Quigley, 2008). The survival function S(t) describes the proba-
bility of an individual surviving beyond time t, i.e., the probability of experiencing the event
of interest after time t. Mathematically we can dene S(t)=Pr(T > t)=1  F (t).
The time scale t is often set so that t = 0 refers to the beginning of follow-up. S(t) has
the three properties:
(a) S(0) = 1 which implies that a patient is presumed alive at the beginning of the study,
(b) limt!1 S(t) = 0, i.e. given a suciently long study period all subjects studied will
denitely experience the event (fail) or loosely speaking no patient lives forever and
(c) S(t) is a monotonic, non-increasing, and nonnegative function implying that the prob-
ability of survival diminishes as the study progresses.
The probability density function f(t) is related to S(t) by
S(t) = 1  F (t) =
Z 1
t
f(u) du;
where by denition in statistical theory F (t) = Pr(T  t)= R t
0
f(u) du and f(t)=F 0(t).
A S(t)-time plot produces the survival curve which begins at S(0) = 1 and decreases to 0 as
t increases to innity.
An important aspect of the survival distribution is the hazard function h(t) which is also
known as the hazard rate or intensity or force of mortality and is dened as
h(t)= lim
t!0
Pr(t  T < t+ tjT  t)
t
; (2.1)
i.e. h(t) is the instantaneous (failure) rate of developing the event of interest in an arbitrar-
ily short time interval t, provided the subject is still at risk at time t (has not fallen ill
before time t). From the above Equation (2.1), h(t)t can be thought of as the approximate
probability of an individual who has not experienced the event by time t experiencing the
event in the next instant following t. However, we note that although h(t)t is a probability,
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technically the hazard rate h(t) is not a probability in the proper sense because it may take
on values greater than one, i.e. it has no upper bound.
Alternatively, the hazard rate can be interpreted as the average number of events in a unit
interval of time, hence why it is also commonly referred to as intensity. The incidence rate
then validly approximates the hazard rate that assumes piecewise constant rate, a scenario
that is realistic for short periods. In such applications incidence rates can be regarded as
estimates of a limiting (theoretical) hazard rate h(t), which epidemiologists often refer to
as the incidence intensity or force of morbidity (Rothman et al., 2008). Strictly speaking
however, incidence and hazard rates do not always coincide.
For a continuous random variable T the following relationships between S(t) and h(t)
holds:
h(t) =
f(t)
S(t)
=   d
dt
lnS(t); so that S(t) = exp

 
Z t
0
h(u) du

:
For all the three aims of survival analysis listed above, interest often lies in estimating
the distribution of failure time T , the hazard h(t) and modelling the relationship between
them and a subset of relevant covariates X. Inference from survival data analysis often
assumes noninformative censoring, i.e. T is independent of any mechanism which causes the
individual's survival time to be censored at C. This assumption is necessary so as to make
the distribution of T become identiable from the distribution of the observables. Practically
the assumption implies that the survival experience of censored individuals can be estimated
by using data on the uncensored individuals. This implies that if we consider a group of
all patients with same values of relevant prognostic factors, then a patient whose survival is
censored at time c is assumed representative of all other patients in that group who have
survived until that time.
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2.3 Accelerated failure time and proportional hazards models
Survival data is commonly modelled using either accelerated failure time (AFT) models or
proportional hazards (PH) models (Cleves et al., 2008; Collet, 2003). While PH models
are popular in medical research by comparing treatments using a hazard ratio, AFT models
estimate a factor by which a harmful/benecial treatment decelerates/accelerates life of those
taking them. In the next section, we briey describe both PH and AFT models and provide
a skeletal outline of their equivalence for special cases for Weibull distribution.
2.3.1 Accelerated failure time models
Since time is only meaningfully considered positive, most regression models to a function
of the survival time assumes that the regression model is applied to the logarithm of the
time. These models form the class commonly referred to as accelerated failure time (AFT)
models. The nomenclature is probably due to the fact that the eect of a covariate is to
multiply the time-scale on which events occur, i.e. the models mimics a clock running either
slower or faster than usual (to failure). In health sciences, AFT may be usefully interpreted
in terms of the speed of progression of a disease (Everitt and Pickles, 1999). The simplest
AFT model assumes that the survival times are exponential random variables (i.e. constant
survival rate). However, other parametric models such as the Gamma, Log-normal and more
general Weibull distributions can also be used.
An AFT model comparing two treatments can algebraically be represented by
S1(t)=S0 ('it) ;
where 'i often assume the form exp(X
0). The parameter 'i is commonly interpreted as the
accelerating factor for subject i compared with baseline patient group. Alternatively, consid-
ering treatmentA as the only (time-invariant) covariate, a simple AFT may be represented as
log T = 0A+ ; (2.2)
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where T denotes survival time, A the treatment indicator,  regression parameter to be
estimated and  is a random variable with a (parametric) distribution not dependent on
A, e.g.  often taken to assume an extreme value distribution: f() = exp[ exp()]. We
note that for Gaussian errors with no censoring, the AFT model (2.2) reduces to a linear
regression of log-survival time. On the other hand, a semiparametric variant of the model
(2.2) would not specify a parametric family for the distribution of . It may be worth noting
the fact that while parametric AFT models can be tted using maximum likelihood estima-
tion in a number of statistical packages, the semiparametric model requires more advanced
algorithms (Lin and Ying, 1995; Vittingho et al., 2005).
Interpretation of regression parameters for AFT models is composed of a dummy two-
arm treatment. For example, exp() can be interpreted as the multiplicative factor by which
the underlying survival time is multiplied such that if exp() = 3, then on average patients
on new a treatment (A = 1) would take a duration three times shorter to experience the
event of interest (fail) compared to patients on standard/placebo treatment (A=0). But this
interpretation may also be considered a limitation of the AFT model in cases where treatment
levels are continuous or even a mixture of both dummy and continuous scales. A solution to
this limitation is using the Cox PH model that can also account for time-varying covariates.
2.3.2 Proportional hazard models
The Cox (1972) proportional hazard (PH) model is probably the most widely used method in
survival data modelling (Lee and Go, 1997; O'Quigley, 2008; Pan, 2001). A dening feature
of this model is its demonstration that we can estimate the relationship between the hazard
rate and explanatory variables without having to make any assumptions about the shape of
the baseline hazard function unlike the parametric models. Since the distribution of survival
times is not necessarily specied, the Cox model is an example of a semiparametric model.
The Cox's PH models the hazard of event (e.g. death) as a function of covariates. In
the Cox PH regression model for survival data, t measures a convenient time axis and the
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hazard h(t) at time t. A Cox PH model to evaluate the eect of treatment A is given by
h(tjA) = h0(t) exp(A); (2.3)
where h(tjA) is the hazard of failing (e.g. death at time t given the treatment A) and h0(t)
is the baseline hazard, i.e. the underlying hazard in the presence of no treatment A. An
attractive aspect of the Cox model is the fact that h0(t) need not be specied.
2.3.3 Relationship between PH models and AFT Models
As discussed above the main dierence between PH and AFT models is eect of treatment
on hazards and time respectively: whereas a PH model assumes a multiplicative eect of a
covariate on the hazard, an AFT model assumes a multiplicative eect of a covariate on time.
In general the parameters of the PH and AFT models may not be comparable since they are
based on dierent scales, i.e. hazard ratio for PH models and time ratio for AFT models. An
important dierence is that while the baseline hazard function for a parametric PH model
need not be completely specied, the baseline hazard function for AFT model needs to have
a complete parametric specication.
A relationship between PH and AFT would be useful for comparison of performance be-
tween methods which provide results in terms of either formulation. For constant covariates,
the PH and AFT models coincide only for Weibull distribution (Collet, 2003; Cox and Oakes,
1984): there is a direct correspondence between Weibull PH and AFT in terms of hazard
ratio and time ratio parameters respectively:
exp() = 'p = [exp( #)]p ; (2.4)
so that  =  p log';
i.e. the hazard ratio is equivalent to the negative logarithm of the accelerated life parameter
hence for the exponential distribution (p=1),  =   log'.
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2.3.4 Hazard ratio-relative risk relationship
When applying the Roy et al. (2008) model for survival data (Chapters 6 and 8), we will
use relative risks (RR) to approximate hazard ratios (HR). Although HRs and RRs are often
used for time-to-event and binary outcomes respectively, for short follow-up and small event
rates, they can be shown to be algebraic approximations of each other (Symons and Moore,
2002; Wang, 2002). The proportional hazards model given by Equation (2.3) provides the
HR exp() as a measure of treatment eect on the treated compared to the untreated. We
can also dene the probability of experiencing an event (e.g. death) in the time interval [0; T ]
for the treated and untreated group respectively as
P1 = 1  exp[ H(T)e] and P0 = 1  exp[ H(T)];
where H(T )=
R T
0
h(t)dt is the the cumulative hazard function. The RR may then be dened as
RR =
P1
P0
=
1  exp[ H(T)e]
1  exp[ H(T)] =
1  (1  P0)e
1  (1  P0) u
1  [1  H(T)e]
1  [1  H(T)] = exp() = HR:
Given that every individual is prone to react dierently to any intervention, such heterogene-
ity in survival data may be captured using frailty models as described briey in the next section.
2.4 Heterogeneity and frailty
Assuming constant eects of treatment among subjects may be unrealistic in a heterogeneous
population. An individual's genetical/biological and physiological composition is likely to in-
uence her way to uniquely respond to an intervention. Heterogeneity of treatment eects re-
ects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse
eects, and utility for dierent outcomes. Formally, heterogeneity of treatment eects refers
to the dierential response to the same treatment by dierent patients (Kravitz et al., 2004),
i.e. a condition where some patients are more likely to experience a larger number of events
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than others due to some unknown, unmeasured or unmeasurable reason. From the foregoing,
unbiased ecacy estimation would require an eective way to account for such individual
variation among a group randomized to an intervention. Vaupel et al. (1979) introduced the
concept of frailties in survival data as a convenient way to to explicitly account for possible
unobserved heterogeneity (and correlations) among failure times. For the proportional haz-
ards model, frailty can be dened as a latent random eect that enters multiplicatively on
the hazard function h(t) (Cleves et al., 2008), i.e. if we let each individual to have a frailty
: individuals with a high value of  implies a high frailty and vice versa, then conditional
on the frailty, the hazard rate of an individual is often assumed to take the form
hi(tjX; ) = h0(t) exp(X 0i + i)
or equivalently
hi(tjX; ) = 0i h0(t) exp(X
0
i):
The frailty approach provides a convenient statistical modelling technique that enables us
to model possible heterogeneity (caused by unmeasured covariates) and/or address deviations
from proportional hazards assumption in models for survival data (Keiding et al., 1997;
Wienke, 2010). Considering a population as homogenous may not only be unrepresentative
(or unrealistic) but also analysis of such data is likely to produce biased ecacy estimates
(O'Quigley, 2008). Introducing frailty amounts to considering a heterogeneous sample, i.e.
subjects with dierent hazards.
Frailties are often introduced into a model as unobservable positive quantities which
assume specied distribution with standardized mean and variance to be estimated from
data, for example, from the frailty model above, i  N(0; 2). Since frailty cannot be
negative, the Gamma (along with log-normal) distribution is one of the most commonly used
frailty distribution (Clayton, 1978; Vaupel et al., 1979). Useful frailty distributions should
have an explicit Laplace transform (Aalen et al., 2008) and from a computational and analytic
perspective, the Gamma frailty distribution ts well with failure time data because it is easy
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to derive the closed form expressions of its various survival functions due to the simplicity of
the Laplace transform (O'Quigley, 2008). We will use a Gamma-distributed random variable
for hazard rates in our simulation studies (Chapters 7 and 8) to reect possible implicit
heterogeneous treatment eects among subjects.
2.5 All-or-nothing compliance methods
Noncompliance to treatment allocations often takes one of two forms (White, 2005): all-
or-nothing or partial compliance. Under all-or-nothing compliance, a subject is assumed to
have discontinued medication immediately after randomization or at a time of experiencing
a pre-specied event of interest. Partial compliance on the other hand utilizes the time till
treatment discontinuation or switching and hence accounting for attendant benets derived
from medication up to stoppage time. We note that all-or-nothing compliance may fail to
utilize time till stoppage of medication/intervention and any information of possible corre-
sponding benets of treatment taken till then. In this section we provide brief reviews of three
specialist methods of analysing survival data in the presence of nonrandom noncompliance in
one (active) arm. While the structural proportional hazards (C-Prophet) method adjusts for
all-or-nothing compliance, the Causal Accelerated Life Model (CALM) and the Causal Haz-
ard ratio Adjustment Regression Model (CHARM) methods adjust for partial compliance.
2.5.1 C-Prophet: Structural (causal) proportional hazard models
The ITT method is considered the gold standard due to its validity under the null. As
discussed above in section (2.3.2), for survival data if Z = 1 denotes the active experiment
arm, then the Cox proportional hazard model
h(tjZ) = h0(t) exp(Z);
is commonly used to estimate treatment ecacy. This approach is valid but we note that
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when experimental treatment has no eect ( = 0) then the survival distributions coincide
on both randomized arms. However, in the presence of noncompliance,  may fail to reveal
the true treatment eect by mixing (diluting) the eect on compliers with the absence of
eect on non-compliers.
All-or-nothing compliance is a common method that evaluates treatment eects by intro-
ducing a binary treatment indicator U which indicates whether a subject received treatment
(U=1) or nothing (U=0). The Cox model would then become
h(tjU) = h0(t) exp(U);
where, as before h(tjU) is the hazard rate for failure at time t given the exposure. How-
ever, when compliance is selective (nonrandom - individuals who comply are prognostically
dierent from those who do not) then the parameter  may carry no causal interpretation.
To estimate treatment ecacy in the presence of noncompliance, Loeys and Goetghebeur
(2003) proposed the Complier PROPortional Hazards Eect of Treatment (C-Prophet) as a
structural proportional hazards method to model all-or-nothing compliance. Besides assum-
ing uninformative (independent) censoring, C-Prophet satises the modelling assumptions as
outlined earlier:
(a) SUTVA: treatment received U , survival time T and randomization Z are assumed
independent and identically distributed (iid) so that the potential outcomes for each
subject are unrelated to treatment or outcome experienced by other individuals,
(b) Randomization assumption: (U; T ) ? Z
(c) No access to treatment on the control arm: Pr(U=0)=1 for all subjects and
(d) Exclusion restriction: Pr(T 1 > tjU = 0) = Pr(T 0 > tjU = 0), where T 0 and T 1 denote
counterfactual survival times in the control and active arms respectively.
To estimate the causal eect of treatment actually received, Loeys and Goetghebeur (2003)
proposed the causal (structural) C-Prophet model
h(tjZi = 1; Ui = u) = h(tjZi = 0; Ui = u) exp( 0u); (2.5)
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where Ui is the potential all-or-nothing treatment for subject i, i.e. the treatment that
would have been observed had subject i been randomized to the active treatment arm. But
we note that Ui is only observed on the experimental arm while it is latent on the control
arm. The model assumes noninformative censoring conditional on compliance for the ex-
perimental arm but censoring is assumed unconditionally noninformative in the control arm
(Goetghebeur and Loeys, 2003). While the rst part is a common assumption in `associa-
tional' survival models, the second part of unconditional noninformative censoring for the
control arm component ts counterfactual denition for causal interpretation.
The C-Prophet estimate (log hazard ratio  0 in model (2.5)) is a measure that com-
pares survival under experimental and potential control conditions in the treatable subgroup
fUi=1g. By comparing survival in the two arms conditional on all-or-nothing compliance
i.e. contrasting
Pr(T 0 > tjU = 1) = Pr(Ti > tjZ = 0; U = 1)
with
Pr(T 1 > tjU = 1) = Pr(Ti > tjZ = 1; U = 1);
exp( 0) provides the causal proportional hazard eect estimate among the compliers in the
treatment arm (subpopulation). A negative and positive  0 respectively implies a benecial
and harmful eects of the active treatment in the treatable subset. C-Prophet estimation
is predicated on the exclusion restriction assumption (Goetghebeur and Loeys, 2003), i.e.
in the subgroup fUi = 0g that would not have been treated when assigned to experimental
treatment, no eect of assignment on survival is assumed. The C-Prophet model (2.5) may
be considered a special case of the G-estimation with two level of treatments (G-estimation
is a general method for adjusting for time-varying confounding, (Robins et al., 1992)).
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2.6 Partial Compliance Methods
2.6.1 CALM: Causal Accelerated Life Models
Robins and Tsiatis (1991) introduced the structural accelerated failure time model for survival
data which accounts for time-dependent departures from randomized treatment in either arm
and relates each observed event time to a potential event time that would have been observed
if the control treatment had been given throughout the trial.
Let T , Z and A denote survival time, randomization arm and treatment receipt indicator
respectively. Then the dierence TZ=1 TZ=0 would provide an eective measure of treatment
allocation. But the fundamental problem in randomized trials posits that we cannot jointly
observe both potential survival times for one individual (Holland, 1986). However, under
suitable assumptions a statistical solution may be provided by the average causal eect (ACE)
of treatment allocation that is obtained by taking expectations over the whole population:
ACE = E[TZ=1]  E[TZ=0];
where ACE provides the ITT estimator (i.e. ACE=ITT) since the expectations are es-
timable from the two treatment arms by the randomization principle. Under ideal conditions,
estimating ecacy of active treatment would involve comparing survival times for subjects
complying with their active treatment assignment to those randomized to receive placebo
(never receive active treatment), i.e. comparing outcomes
T [Z=1; A(t)=1] with T [Z=0; A(t)=0] 8 t > 0:
But because A(t) is a post-randomization variable (cannot be assigned or controlled by
study design), we can observe only one survival time T =T [Z=z; A(t)=a], where z and a
are the assigned treatment and the particular treatment actually received respectively. Mod-
elling assumptions are required to help identify the ecacy parameter from the observed data.
Robins and Tsiatis (1991) dened the potential treatment-free survival timeW =T [Z;A(t)=0],
at time t>0, as the survival time from enrollment to the study if the control treatment had
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been given (or active treatment withheld) throughout the trial. This treatment-free survival
time (placebo prognosis) is linked to the observed survival time and to the observed treatment
received through a parametric Causal Accelerated Life Model (CALM):
Wi(') =
Z Ti
0
exp ['Ai(s)] ds; (2.6)
where ' measures the treatment's ecacy. The CALM model (2.6) provides a relation
between the (potential) placebo prognosis W to the observed event time Ti if subject i were
to receive active treatment according to the observed process Ai(t). The quantity exp(') can
be interpreted as the relative increase/decrease in survival if a subject was always on control
treatment compared to if always on active treatment. We will use the alternative exp( ')
which provides an intuitive interpretation of causal survival time ratio (Sterne and Tilling,
2002). We note that provided the assumption of no treatment access to the control holds then
Ti[Zi=0]=Wi: we would then observeWi in the placebo arm in the presence of no censoring.
On the other hand in the active treatment arm we only observe Wi for uncensored subjects
who would never receive active treatment. Besides censoring as a dening characteristic of
survival data, a second level of truncation often occurs at the end of a study when a trial
is ended. However, such an administrative censoring at the end of follow-up may introduce
bias (in estimating Wi(')) and White et al. (2002) suggested a user-specied recensoring
time (e.g length of study duration) to address this phenomenon.
The CALM model given by Equation (2.6) is also referred to as a rank preserving struc-
tural nested failure time model(Robins, 1994, 1998c; Robins and Tsiatis, 1991). It is structural
in the sense that the parameter ' provides a well-dened causal estimate and is not just an
associational interpretation derived from the ordinary accelerated failure time model. The
ability to adjust for time-varying confounding makes the implicit sequential modelling at
every stage be nested to the previous stage (Hernan et al., 2005; Korhonen et al., 1999; Lok
et al., 2004; Robins, 2000), i.e. the CALM model (2.6) can be re-expressed as
Wi(') =
R Ti
0
exp ['Ai(s)] ds=
R Di
0
exp(')ds+
R Ti
Di
ds
=Di exp(') + (Ti  Di)=Ti  Di [1 exp(')] ;
(2.7)
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where Di is the time unit subject i would have spent if it were on active treatment: we
observe Ti=Wi in the placebo arm because Di=0, but in the treatment arm Wi is observed
only if Di = 0 (in the absence of censoring). The quantity [1   '] 1 can be interpreted as
the fractional increase/decrease in survival time if subject i were always on active treatment
as opposed to never being on active treatment (Robins and Tsiatis, 1991). For example,
'=0:5 implies the remaining lifetime is doubled if always on active treatment and '= 1
implies it is halved if always treated as compared to never treated. Finally, the model is
rank-preserving in the sense that order of failure time is maintained among individuals when
they receive the same treatment, for example, if subject i would die before subject j had
they both been untreated (i.e. T a=0i < T
a=0
j ), then subject i would also die before subject j
if they had been treated (i,e. T a=1i < T
a=1
j ). This is what Robins (2008) refers to as identical
eect for the two subjects under time 0 intervention.
2.6.2 CHARM: Causal Hazard ratio Adjustment Regression Models
This method was proposed byWhite et al. (2004) to address partial noncompliance by viewing
survival outcome as a sequence of binary outcomes to provide an `approximate' overall hazard
ratio estimate which is adjusted for compliance. We note that this approach initially ignores
survival time by considering the outcome as binary.
We dene the following random variables for survival data to evaluate compliance with
active treatment (i.e. compliance with active if oered) while ignoring compliance with
placebo. Let Y represent survival status, for example, death (principal outcome of interest)
so that Y =1(0) if participant is dead (alive) by the end of the interval or study as the case
may be. Let Z=1(0) represent treatment or placebo arm while A=1(0) represent observed
treatment (placebo) receipt. Let S=1(0) represent a participant's latent (potential) compli-
ance behaviour. Further let  represent the probability of noncompliance, i.e. =Pr(S=0).
Given this setup, we can observe S as equal to A in the treatment arm but we cannot observe
the latent compliance S in the placebo arm.
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Assuming some form of compliance so that  > 0, let 0Z and 
1
Z respectively represent
the probabilities of death among noncompliers and compliers in the Z arm, i.e.
0Z = Pr(Y = 1jZ = z; S = 0) and 1Z = Pr(Y = 1jZ = z; S = 1);
where 0Z and 
1
Z may be assumed equal by randomization principle. Then the overall
probability of death in arm Z may be given by
Z = (1  )1z + 0z : (2.8)
We can use the above probabilities to dene RRITT and RRCACE as quantities based on the
risk ratio scale where RRITT is simply the ratio of 1 and 0 while CACE may be considered
as the ratio of 11 and 
1
0.
However, we note that while we can directly estimate RRITT; ; 
0
1; 
1
1 and 1, we may
not be able to directly estimate RRCACE; 
0
0 and 
1
0 because S is an unobservable (latent)
variable. For survival data, we can resolve this diculty by using the exclusion restriction
(ER) which assumes that the risk of death does not depend on the arm of randomization
given the treatment received, i.e. Y ? ZjA. The ER assumption then implies that
00 = 
0
1: (2.9)
We may use the ER assumption to nd CACE estimates. Following White et al. (2004), we
can subdivide survival data into small intervals and assume subjects on active treatment may
only stop treatment at the start of that interval. A suciently small interval may allow us to
assume constant hazard rates. Then by considering death as a sequence of binary outcomes
and using T to denote the interval in which death occurred, White et al. obtained an ITT
risk ratio in interval i as
ITTi =
Pr(T = ijT  i; Z = 1)
Pr(T = ijT  i; Z = 0) ; i = 1; : : : ; I: (2.10)
Using the counterfactuals framework, we can evaluate treatment eects by considering
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participants in the placebo arm. Now let the random variable S (the compliance-type) dene
the interval in which stopping (death/censoring) occurs, or I + 1 if no stopping occurs. For
participants on the control arm, S represents the counterfactual stopping interval, i.e. the
interval in which stopping would have occurred had they been allocated to the treatment
arm. White et al. (2004) then use an extended exclusion restriction assumption to obtain
CACE estimate in each interval i. With the extended exclusion restriction, we assume that
randomized allocation has no eect on any survivors to the start of interval i who would stop
treatment by the start of interval i, i.e.
Pr(T = ijT  i; S = s; Z = 1)
= Pr(T = ijT  i; S = s; Z = 0) 8 i = 1; : : : ; I; s  i: (2.11)
We observe that the extended exclusion restriction assumption (2.11) mimics a version
of the Markov property that the present is conditionally independent of the past. They then
considered the CACE in interval i as the risk ratio among those who survive to interval i
and who would not stop treatment before the end of interval i:
CACEi =
Pr(T = ijT  i; S > i; Z = 1)
Pr(T = ijT  i; S > i; Z = 0) : (2.12)
Both exclusion restriction (2.9) and extended exclusion restriction (2.11) assumptions may
enable us use the proportion of non-compliers to estimate the proportion of compliers used
in obtaining CACE estimate. White et al. then showed that
CACEi  ITTi(1  i)
1  i ITTi ; (2.13)
where i = Pr(Ai = 0jT = frm[o]  i; Z = 1) is the probability that a participant in the
active treatment arm who experienced event (e.g. died) in interval i had previously stopped
treatment, i.e. was non-complier by the time of her death.
Assuming short intervals in addition to EER assumption, White et al. (2004) showed
that we can extend the CACE estimate given by equation (2.12) above for discrete time case
to continuous (pooled) hazard rates at time t. By weighting the ITT(t) estimates from (2.10)
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we then CACE estimate for proportional hazards as
CACEPH(t) =
ITT(t)(1  (t))
1  (t) ITT(t) ; (2.14)
where =Pr (A=0jY =1; Z=1) ; is the noncompliance probability among participants in the
treatment arm who died. The CACEPH method is essentially a time-adjusted ITT estimate
that ts a Cox's PH model (HRITT) to provide a Causal Hazard ratio Adjustment Regression
model (CHARM) where the linear predictor in the control arm is zero and in the active arm
is a function of time, for example,
CHARM  h(t)=h0(t) exp[0Z + 1f(t)Z]; (2.15)
where f(t) can be specied as a combination of linear/quadratic function of time to event.
White et al. (2004) proposed two ways to obtain a constant CHARM estimate (2.15)
above:
(i) either allowing both HRITT and odds of noncompliance  to vary over time or
(ii) assuming time invariance for both HRITT and  so as to allow a simple CHARM ap-
proximation of (2.14) by
CHARM \CACEPH =
dHRITT(1  ^)
1  ^ dHRITT ; (2.16)
where =Pr (A=0jZ=1) represent the proportion of noncompliers randomized to the
treatment arm who experienced event of interest (e.g death).
Assuming a single death at a time is experienced, estimation procedure (ii) may be imple-
mented by estimating individual is for the dead non-compliers and using a logistic regression
model with these values to examine evidence of change or trend in the is (White et al., 2004).
For example,
logit (t) = 0 + 1t; (2.17)
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would represent a linear trend of noncompliance. Here the outcome would be 1 if a participant
is a noncomplier by the time of death and 0 if a complier by the time of her death, i.e.
 =
8<: 1; A = 0jY = 10; A = 1jY = 1:
In our analysis we will implement the complex procedure (i) above using the Stata com-
mand adjhr (White, 2002) which provides an `approximate' constant (overall) CHARM
estimate as a hazard ratio adjusted for compliance. We will also compare this with a sim-
ple CHARM estimate obtained using a two-stage regression strategy: logistic regression to
estimate  which is then substituted in Equation (2.16) above.
2.7 Modelling noncompliance in two treatment arms
Introduction
All the specialist methods considered above adjusted for noncompliance in one (active)
treatment arm while ignoring compliance in the placebo arm. The decision to ignore com-
pliance data for the control group is an exercise in precision-bias tradeo (Sommer and
Zeger, 1991). Imperfect compliance with placebo allocation results in possible noncompli-
ance in two arms. Such scenarios present further challenges given that even ITT estima-
tion here produce biased ecacy estimates even under homogeneous treatment assumption
(Aalen, 1998; Baker and Kramer, 2005; Robins, 1998a). For example, a double-blind placebo-
controlled randomized clinical trial with active treatment may present noncompliance at two
levels (Jin and Rubin, 2008): rst simple noncompliance with assignment in either arm (ac-
tive/placebo) and second dierential noncompliance with placebo in the presence of possible
imperfect blinding, e.g. due to adverse side eects of the active treatment which may un-
conceal blinding. The Esprit study is a candidate for such a scenario where bleeding would
reveal a victim's treatment allocation (active) and possible dierential noncompliance. This
presents further challenge/s.
105
2.7.1 Brief literature review
In their pioneer work, Efron and Feldman (1991) used compliance as a covariate in a re-
gression adjustment. However, their method has been criticized for the implicit strong as-
sumption of comparability in compliance between the active treatment and placebo arms
(Albert and DeMets, 1994). In the presence of selectivity eects, many methods have been de-
veloped to account for noncompliance in more than one treatment arm. For example, Robins
(1989a, 1994, 1999) introduced the structural mean models (SMM) whose parameter provide
well-dened ecacy estimates as functions of expected potential outcomes for the population
of subjects on treatment. In addition to exclusion restriction, the placebo link assumption
employed here posits that potential response to no active treatment is equal to the response
under control conditions, i.e. the assumption permits use of randomization in the estimation
procedures hence inducing exchangeability. Fischer-Lapp and Goetghebeur (1999, 2004) ap-
plied SMMs on a placebo-controlled double-blind trial of patients with mild hypertension in
the United Kingdom to assess the eect of baseline predictors on reduction of blood pressure.
While structural mean models were developed for continuous outcomes data, Vanstee-
landt and Goetghebeur (2003) developed the generalized structural mean models as an ex-
tension to handle non-linear average treatment eects. When those randomized to placebo
have no access to active treatment (no deers assumption holds), the estimator from struc-
tural mean models is equivalent to the instrumental variable estimator (Goetghebeur and
Fischer-Lapp, 1997; Robins, 1994). To relax the exclusion assumption in SMMs, Robins
and Rotznitzky (2004) imposed additional parametric modelling restrictions to account for
possibility of placebo having access to treatment. Robins (1994, 1997, 1998c) introduced
the structural nested mean models which adjusts for noncompliance in time-to-event data.
And Baker and Kramer (2005) used potential outcomes to construct maximum likelihood
estimates for discrete-time survival outcomes under all-or-nothing switching of treatments
where switching occurred immediately after randomization or at the start of the time period.
Principal stratication is another causal modelling framework whose exibility allows
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application to adjusting for noncompliance in more than one treatment arm. While it is
possible to perform pairwise ecacy comparisons in the presence of more than one active
treatment, a joint analysis is likely to provide additional analytical insights (Cheng and
Small, 2006). However, trials involving multiple treatments with possible noncompliance are
likely to present complex identication problems (Long et al., 2010; Roy et al., 2008). For
example, principal stratication of a three-armed trial (Z;A2f1; 2; 3g) produces a total of 27
principal strata dened by the set of 33 possible combinations. But all that we observe about
the principal strata is the value of A(z) corresponding to the treatment a that is actually
received. The rest remain unobserved which results in identication problem that can only
be addressed with additional assumptions, a solution that may limit generalization of results.
Most studies in the health sciences report results in terms of causal point estimates
premised on implicit assumptions. As a result, the validity/credibility of these estimates are
dependent on the accuracy of such assumptions. Manski (2007) refers to this phenomenon
as the as the law of decreasing credibility which posits that the measure of credibility of
inference is inversely proportional to the strength of underlying assumptions. In practice,
relaxing the assumptions may widen credibility of the results but at the price of making
point identication impossible, i.e. the estimates cannot be uniquely identied from the
probability distribution of observable outcomes (Cai et al., 2007). However, the estimates
may be partially identiable under mild assumptions which permit construction of upper and
lower bounds of the identication region of parameters (Manski, 1990, 1995, 2003). For ex-
ample, while Imbens and Angrist (1994) showed that relaxing the monotonicity assumption
by allowing deers breaks down point identication for a two-armed trial, Balke and Pearl
(1997) used linear programming to provide the `tightest' possible bounds on the average
treatment eects. Allowing deers is likely to complicate identication more in the presence
of two/more active treatments. Using method-of-moments approach under two sets of as-
sumptions obtained by decomposing the monotonicity assumption, Cheng and Small (2006)
derived sharp bounds for principal eects for a binary outcome in a three-armed trial and
constructed condence intervals for the corresponding identication regions of parameters
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with xed probability. For a control (0) and two active treatments (1 and 2), the rst part of
their monotonicity assumption posited that a subject in the control had no access to either of
the two active treatments and no treatment switches was permitted among those assigned to
the two active treatments. In addition, their second part, `extended monotonicity', assumed
similarity in compliance behaviour among those assigned to active treatment where a subject
complying with treatment 2 would have complied with treatment 1. We note that this is a
plausible assumption if treatment 1 is equally eective as treatment 2 but with possibly more
tolerable/same side-eects.
While Roy et al. (2008) proposed a principal stratication framework for two-active
treatment trials (no placebo) using baseline covariates to address identication problem, Long
et al. (2010) recently proposed a likelihood-based extension of the Cheng and Small (2006)
model to provide point causal estimands for a three-armed trial and general (continuous
or discrete) outcomes. Using Bayesian methods, they model the arm-specic compliances
directly while treating the principal compliance status as missing. This approach relaxes
the extended monotonicity assumption of Cheng and Small (2006) described above by not
making any assumptions about compliance behaviours for those subjects assigned to active
treatment. On the other hand, Fischer et al. (2011) also recently proposed a structural
mean modelling approach using baseline covariates predictive of compliance in individual
arm to obtain compliance-adjusted ecacy in a randomized-controlled trial comparing two
active treatments.
The next section provide a comprehensive review of the Roy et al. (2008) method which
uses principal stratication framework to adjust for noncompliance in two arms for a two-
active treatment trials with binary outcomes. Our objective will be to apply this model
to survival data using Bayesian methods (Chapter 6) and also to use simulation studies to
evaluate its performance in terms of bias and 95% credible intervals (Chapter 8).
108
2.7.2 Principal stratification for two-active treatment arms
Adopting notation from previous chapter for two-armed trial, let Z 2 f0; 1g denote a
randomization indicator: Z=1 indicate randomization to the new treatment (e.g. HRT treat-
ment) and Z =0 indicates randomization to control/placebo. In the present case 1 (Z =1)
will represent randomization to new treatment and 0 (Z = 0) randomization to standard
treatment. Let A 2 f0; 1g denote compliance with assigned treatment and dene Y 2 f0; 1g
to be the outcome of interest (e.g. death). We note that each subject has two potential com-
pliance levels A0 and A1 (compliance with standard and new treatment respectively) and two
potential outcomes Y0 and Y1 (outcome under standard and new treatment respectively). But
the observed compliance and outcomes are respectively given by A=ZA1 + (1   Z)A0 and
Y =ZY1 + (1  Z)Y0.
Analysis under this formulation utilizes baseline covariates X to modify the standard
assumptions for causal modelling outlined above with two additional assumptions (d and e):
(a) The stable unit-treatment value assumption (SUTVA),
(b) Randomization: Z ? fY0; Y1; A0; A1; Xg and
(c) The exclusion restriction: Pr(Y1jAZ ; X) = Pr(Y0jAZ ; X),
(d) Treatment access restriction: which posits no treatment switches among subjects.
(e) Monotonicity: Pr(A1 = 1jA0 = 1; X)  Pr(A1 = 1jA0 = 0; X), i.e. the probability of
compliance with treatment assigned by Z = 1 is higher among those who would comply
with treatment assigned by Z = 0, compared to those who would not.
The monotonicity assumption helps tighten the bounds of causal eects (Cheng and
Small, 2006; Roy et al., 2008). This version of monotonicity assumption is applicable to
Esprit study because there was no preference to one treatment over the other, i.e compliance
with HRT treatment would be more prevalent among those who would comply with placebo.
In our simulations, we reect this assumption through a pre-specied positive correlation
(sensitivity parameter ) between A0 and A1.
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Each subject is assumed to belong to one of four basic principal strata dened by unique com-
binations of (A0; A1) where the principal strata comprise the set S=f(0; 0);(1; 0);(0; 1);(1; 1)g.
The interest (next section) will be to seek the joint distributions [(Y0; Y1)jS = s] 8 s 2 S
which provides principal eects of interest for each stratum.
2.7.3 Causal model linking two marginal compliance models
We consider two active treatments A and B which we denote as 0 and 1 respectively. To
predict compliance to treatment allocation for each arm separately given a selected set of
predictors of compliance x0 = 1 and x1; : : : ;xn, we use the logistic models
logit [j(x)] =
 
nX
i=0
jixi
!
; j = 0; 1; (2.18)
where j(x) is the probability of compliance with allocated treatment j given set of covariates
X: the estimated probabilities of complying with arm-specic treatment allocation may then
be obtained using
^j(x) =
"
1 + exp
 
 
nX
i=0
^jixi
!# 1
; j = 0; 1; (2.19)
where  represent the log odds ratio estimates of compliance.
An important issue is how the two compliance behaviours are correlated. Following
Roy et al. (2008), we dene a non-negative sensitivity parameter  which is related to the
correlation  between compliances to treatment allocation (0=1) and is assumed positive. It
can then be shown that, if ^0(x) > ^1(x) then
 = 
s
^0(x)[1  ^1(x)]
^1(x)[1  ^0(x)]
: (2.20)
The joint probability distribution of compliance to treatment 0 and compliance to treat-
ment 1 is then a function of the arm-specic marginal compliance probabilities and  and
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can therefore be estimated for a given value of . We however note that,  is unknown in
general. Specically if U(x) = minf1; ^1(x)
^0(x)
g then Roy et al. (2008) showed that the joint
probabilities are given by:
^11(x) = Pr(A0 = 1jX)P (A1 = 1jA0 = 1; X)
= ^0(x)^1(x) + ^0(x)[U(x) ^1(x)];
^01(x) = Pr(A0 = 0jX)P (A1 = 1jA0 = 0; X)
= ^1(x)  ^0(x)^1(x)  ^0(x)[U(x)  ^1(x)];
^10(x) = Pr(A0 = 1jX)P (A1 = 0jA0 = 1; X)
= ^0(x)  ^0(x)^1(x)  ^0(x)[U(x)  ^1(x)];
^00(x) = Pr(A0=0jX)P (A1=0jA0=0; X)
= 1 ^0(x) ^1(x) + ^0(x)^1(x) + ^0(x)[U(x) ^1(x)];
(2.21)
where X is the set of covariates predictive of compliance in both arms and A1(A0) is an
indicator of compliance to HRT treatment (placebo) and ^ij(x) denote the probability of
being in the compliance subgroup ij as illustrated in Table (2.1).
Table 2.1: Compliance proportions for each stratum
Comply treat 1 (A1)
Yes (1) No (0)
Comply Yes (1) 11(x) 10(x)
treat 0 (A0) No (0) 01(x) 00(x)
Following principal stratication framework (Frangakis and Rubin, 2002), the possible
values of A0 and A1 dene a stratication factor S for the population of patients. For a dened
outcome variable Y (mortality/reinfarction for Esprit study), let Y0 and Y1 refer to potential
outcomes under treatment A and treatment B respectively. The four possible realizations of
(Y0; Y1) at each level of S (for example $11=Pr[Y0=1; Y1=1]) are as shown in Table (2.2).
The expression for stratum S = (0; 0) diers from the others because of the exclu-
sion restriction: $10(0; 0) = $01(0; 0) = 0. The joint distribution of potential outcomes
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Table 2.2: Probabilities for joint distribution of potential outcomes per stratum: [Y0; Y1jS].
(Y0; Y1)
A0 A1 S (0,0) (0,1) (1,0) (1,1)
0 0 (0,0) $00(0) 0 0 $11(0)
1 0 (1,0) $00(1) $01(1) $10(1) $11(1)
0 1 (0,1) $00(2) $01(2) $10(2) $11(2)
1 1 (1,1) $00(3) $01(3) $10(3) $11(3)
(Y0; Y1) for each stratum S; f(Y0; Y1jS;$) is assumed to be multinomial with probabilities
$(S)=Pr(Y0=y0; Y1=y1jS=s).
A crucial identication assumption for the Roy et al. (2008) model posits that Y ? XjS;Z,
where X represents the set of covariates predicting compliance. This assumption underscores
an integral component of the method which involves selecting suitable predictors of compli-
ance. In the next Chapter (Chapter 3), we attempt to address this by considering how predic-
tors of compliance should be selected by a review of general literature on model selection for
prediction and apply it to select plausible separate predictors of compliance for HRT treat-
ment and placebo arms for the Esprit study in Chapter 5. Although untestable, a comparison
of results using dierent sets of predictors may be used to test this assumption (Chapter 6).
After reparameterizing in terms of  (probability of experiencing event, e.g. death or my-
ocardial reinfarction) and  = f(; )) (log odds ratio of compliance for specied sensitivity),
Roy et al. (2008) showed that the observed-data likelihood is
L(; jY;A; Z;X)=
3X
s=0
[S=sZ ]
Y [1  S=sZ ]1 Y Pr(S=sjX; )G(s; A; Z); (2.22)
where S=sZ is the probability that observed Y =1, given S=s and allocation to arm Z, and
G(s; A; Z) =I(s=0)f1  Ag+ I(s=1)fA(1  Z) + (1  A)Zg
+ I(s=2)fAZ + (1  A)(1  Z)g+ I(s=3)A:
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where S=sZ is the probability that observed Y =1, given S=s and allocation to arm Z, and
Now Y and A are observed values; e.g. A=A1 if allocated to active treatment and A=A0
if allocated to placebo. We can decompose the expression (2.22) for each stratum:
L(; jY =1; A=1; Z = 1; X) = s=(0;1)1 Pr (S=(0; 1)jX; )
+ 
s=;(1;1)
1 Pr (S=(1; 1)jX; ) ;
L(; jY = 0; A=1; Z=1; X) =[1  s=(0;1)1 ] Pr (S=(0; 1)jX; )
+ [1  s=(1;1)1 ] Pr (S=(1; 1)jX; ) ;
L(; jY = 1; A=0; Z=1; X) =s=(0;0)1 Pr (S=(0; 0)jX; )
+ 
s=(1;0)
1 Pr (S=(1; 0)jX; ) ;
L(; jY = 0; A=0; Z=1; X) = [1  s=(0;0)1 ] Pr (S=(0; 0)jX; )
+[1  s=(1;0)1 ] Pr (S=(1; 0)jX; ) ;
L(; jY = 1; A=1; Z=0; X) = s=(1;0)0 Pr (S=(1; 0)jX; )
+ 
s=(1;1)
0 Pr (S=(1; 1)jX; ) ;
L(; jY = 0; A=1; Z=0; X) = [1  s=(1;0)0 ] Pr (S=(1; 0)jX; )
+ [1  s=(1;1)0 ] Pr (S=(1; 1)jX; ) ;
L(; jY = 1; A=0; Z=0; X) = s=(0;0)0 Pr (S=(0; 0)jX; )
+ 
s=(0;1)
0 Pr (S=(0; 1)jX; ) ;
L(; jY = 0; A=0; Z=0; X) = [1  s=(0;0)0 ] Pr (S=(0; 0)jX; )
+ [1  s=(0;1)0 ] Pr (S=(0; 1)jX; ) :
(2.23)
By the exclusion restriction 
s=(0;0)
1 =
s=(0;0)
0 , i.e.the risk of experiencing event of interest
(e.g. death) is independent of the arm of allocation among the people who would comply
with neither allocation. Writing
1= 
s=(0;1)
1 ; 2=
s=(1;1)
1 ; 3=
s=(0;0)
1 ; 4=
s=(1;0)
1 ;
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and
5=
s=(1;0)
0 ; 6=
s=(1;1)
0 ; 7=
s=(0;1)
0 ;
we obtain 7 parameters captured by  from the likelihoods above using logistic models:
Pr[Y =1jA=1; Z=1]=101 + 211;
Pr[Y =1jA=0; Z=1]=300 + 410;
Pr[Y =1jA=1; Z=0]=510 + 611;
Pr[Y =1jA=0; Z=0]=300 + 701:
(2.24)
We then obtain the stratum-specic relative risks of death as
11=

s=(1;1)
1

s=(1;1)
0
=
^2
^6
;
01 =

s=(0;1)
1

s=(0;1)
0
=
^1
^7
; (2.25)
10=

s=(1;0)
1

s=(1;0)
0
=
^4
^5
:
The ij provides principal (causal) eects in terms of causal risk ratios obtained as
means of posterior relative risks of event (death or reinfarction) for each stratum dened
by compliance type:
(i) 11: risk of event due to compliance with HRT treatment relative to placebo among the
subgroup of patients who would comply with either treatment allocation - S=(1; 1),
(ii) 01: risk of event due to compliance with HRT treatment only among women who would
comply if allocated to it - S=(0; 1) and
(iii) 10: risk of event due to compliance with placebo treatment only among the subgroup
who would comply if allocated to it - S=(1; 0).
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The parameters (2.25) can be estimated using Bayesian methods with suitable priors, for
example, U(0; 1) for uninformative priors.
To extend the methods which adjust for noncompliance in one treatment arm to adjusting
for noncompliance in two treatment arms, we will apply principal stratication using the
Roy et al. (2008) model reviewed above for survival data but which was originally proposed
for binary data. Using arm-specic compliance predictors (see Chapter 3), we develop a
causal model linking the two marginal models that allows us to estimate causal eects in
each stratum. By assuming all-or-nothing compliance to treatment allocation, we apply the
method to the Esprit data in Chapter 6 and apply statistically designed simulation studies
in a Bayesian setup to evaluate the performance of the method in terms of bias and 95%
credible intervals in Chapter 8.
Developing arm-specic compliance models given by Equations (2.18) and (2.19) is an
exercise in model selection, i.e. selecting plausible predictors of compliance with treatment
assignment for each trial arm. In the next Chapter (3) we consider model selection techniques
to obtain prediction models of compliance for each treatment arm, a challenge which has not
been addressed much in the literature and practice. The next chapter provides a review of
model selection techniques.
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Chapter3
Model Selection for Prediction
3.1 Introduction
In this chapter we review some of the methods for model selection with a focus on adopting the
methods to build prediction models for compliance with treatment allocation. We start with a
brief literature review on model selection then discuss the strengths and limitations of stepwise
regression procedures. For completeness, the next section briey outlines the methods of prin-
cipal components and partial least squares regression. The next section presents a review of
penalized regression techniques providing the bridge estimation as a Bayesian generalization
of best-subset, ridge and Lasso regressions. The nal section provides a summary of measures
for model validation which enable us evaluate the performance of selected prediction models.
3.2 Prediction models
Prediction is one of the principal objectives of statistical modelling besides estimation and
testing hypothesis. The purpose of a prediction model is to provide valid and reliable out-
comes for new observations. Statistical prediction involves selecting a subset of variables that
are predictive of a specied outcome. Developing an eective and useful prediction model is
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often accomplished after the twin processes of model selection and model assessment. Model
selection is the process of choosing a suitable subset of predictors from an original set while
model assessment on the other hand is the evaluation of models' stability when applied to
independent data. The main aims of model selection include accurate predictions and easy
interpretation (Harrell, 2001; Hastie et al., 2009). Accurate prediction is likely to provide
regression coecients with no/minimal bias, narrow condence intervals for the parameter
estimates and lower prediction error. A model composed of fewer, meaningful and clinically
most relevant predictors is easily interpretable. With a stable model, small changes in the
data do not result in large changes in either the subset of predictors used, the associated coef-
cients, or the predictions made from it. While accurate prediction is an integral component
of a model's internal validity, model stability is a measure of external validity that allows gen-
eralization/application of the model to new/independent data. Although both components
are desirable for eective prediction, internal validity is a prerequisite for external validity
(Steyerberg, 2009), i.e. it makes less statistical sense to assess a model that is poorly selected.
In general, validation lends credence to prediction models. For the present work we adopt the
general denition of validation by Harrell (2001) as a measure of performance of predictive
model on independent/new data.
Most clinical trials often record a number of prognostic and demographic baseline vari-
ables. Such variables might sometimes be used to adjust ITT comparisons for random im-
balances but they may also provide an insight into the propensity of subjects to comply with
treatment allocation. However, not all variables may predict compliance hence utilizing all
of them may add little or no information in analysis. Predicting compliance is essentially a
study in model selection. In general, prediction models use empirical data from a sample of
patients drawn from a larger population. But data from such sample are only important to
the extent that they are representative of the underlying population (Altman and Royston,
2000). Analysis of a representative empirical data is not only capable of revealing patterns
in the population but also models derived from it can provide accurate predictions for new
subjects from this population.
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However, a major risk in extrapolating information from a sample to a population is
the failure of predictions to generalize to new subjects outside the sample (Steyerberg, 2009).
This challenge may manifest itself in overtted prediction models where the data concentrates
in capturing specic trends and idiosyncrasies of the sample. Overtting the data is the major
cause of unreliable predictive models; it occurs when noise variables are retained as potential
predictors (Harrell, 2001). Overtting is what statisticians often refer to as the curse of
dimensionality, i.e. tting statistical model with too many parameters which is likely to
produce inated variance for the regression function (Hastie et al., 2009; Izenman, 2008).
Overtting implies that there is overoptimism about a model's performance in new subjects.
Overtting in prediction models can be dened as tting a statistical model with too many
degrees of freedom in the modelling process (Steyerberg, 2009). Overtting during this
process arise from two sources of variation: parameter uncertainty and model uncertainty.
While model uncertainty refers to level of complexity/specication of structure of model (e.g.
number of predictors), parameter uncertainty refers to potential instability of the coecients.
The two processes acting together impact on the number of degrees of freedom of a model
arising from the fact that on the one hand some degrees of freedom are used in estimation of
the coecients in a regression model (address parameter uncertainty) and on the other more
degrees of freedom are used in searching for the optimal model structure, i.e. addressing
model uncertainty. For example, this may arise from the predictor selection procedures.
Developing reliable and valid prediction models may be viewed as striking an informed
balance between curiosity and skepticism. On one hand, we use science to make discoveries
and advance knowledge while on the other hand we must subject such discoveries to stringent
tests like validation in order to eliminate any possibility of being fooled by chance (Babyak,
2004). So given the important role of model validation in the development of reliable predic-
tive models, how do we construct internally and externally valid models to predict treatment
compliance?
Stepwise variable selection procedures and best-subset selection are some of the most com-
monly used (and abused) model selection techniques (Draper and Smith, 1998; Harrell, 2001).
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Both methods use classical statistics like t and F tests for judging the signicance of indi-
vidual predictors and comparing two/more models respectively. But these tests are premised
on the assumption that the set of predictors and the models are pre-specied. However, the
truth is that the set of predictors or models are chosen adaptively according to algorithms
specic to each selection procedure. Results from such analysis are prone to `testimation'
(estimation after multiple testing) bias and such bias aects the variable selection process
itself due to model and parameter uncertainty (Chateld, 1995; Hesterberg et al., 2008). In
general, the resulting regression coecients are biased upwards in absolute value which may
then lead to misleading conclusions about the magnitude of eects.
While unbiased estimates are desirable, in the presence of many covariates this is obtained
at the price of large variances. Generally models with many covariates have small bias but
large variance and conversely models with few covariates have large bias but small variance
(Draper and Smith, 1998). Better predictions can be obtained by carefully balancing these
two extremes, i.e. trading a little bias for large reduction of variance. This bias-variance
tradeo is mostly achieved by penalized (shrinkage) regression techniques. Shrinkage means
constraining the coecients during estimation with the objective of increasing reliability to
ensure internal validity. Here shrinkage regression is a solution to overtting which draws
estimated regression coecients to less extreme values. Shrinkage estimation can be viewed
as a generalized technique of regression towards the mean (Wright and London, 2009).
The rst section of this chapter provides a review of the classical stepwise selection and
best subset regression together with their merits and limitations. This is followed by a review
of two types of multivariable regression methods: principal component regression and partial
least squares regression with a summary of their advantages and disadvantages. The next
section reviews modern selection techniques: ridge regression and Lasso (Least Absolute Se-
lection and Shrinkage Operator) methods, their merits and demerits and how they relate to
each other. Finally we look at model validation techniques and review two measures of perfor-
mance (calibration slope and discrimination/concordance c-statistic) to quantify optimism in
the selected prediction models. We use the terms covariates and predictors interchangeably.
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3.3 Stepwise and best subset regression
Stepwise variable selection is the most commonly used model selection technique (Harrell,
2001; Hastie et al., 2009). As a selection procedure, stepwise is implemented in three versions.
Forward selection begins with an empty model consisting of the intercept only. We then add
variables sequentially to the model until a predened stopping rule is satised. At each
step of the selection process, we add the variable whose inclusion results in the best t (i.e.
greatest increase in the summary measure). Some of the most commonly used summary
measures include R2, adjusted R2, residual sum of squares and deviance (Draper and Smith,
1998). A predened signicance level is typically used as a stopping criteria so that only
statistically signicant variables are added to the model. Backward elimination procedures
on the other hand begin with a saturated (full) model composed of all candidate predictor
variables. Using a predened stopping rule, the procedure sequentially removes variables
which contribute least to the model t. Stepwise selection is a variation combining both
forward and backward selection algorithms: at each step of the variable selection process,
after a variable has been added to the model, variables are allowed to be eliminated from
the model. For instance, if the p-value of a given predictor is above a specied threshold, it
is eliminated from the model. The iterative process is ended when a pre-specied stopping
criteria is satised.
Stepwise variable selection procedures produce nested sequences of models. The inherent
collinearity can cause predictors to compete hence making the selection of `important' pre-
dictors arbitrary. The competition and accompanying (potential) arbitrariness in selection
procedures often results in use of greedy algorithms (Hastie et al., 2009; Hesterberg et al.,
2008). Such model selection process is prone to make the best change at each individual
step independent of future eects. This can produce unstable models where relatively small
changes in the data is likely to cause one variable to be selected instead of another, after
which subsequent choices may be completely dierent. Best-subset selection is an attempt to
address this limitation by considering all subsets of variables of each size only limiting itself
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to a maximum number of best predictor subsets (Furnival and Wilson, 1974). Given p vari-
ables, best-subset selection nds the subset of size k2f0; 1; 2; : : : ; pg that provides smallest
residual sum of squares. A distinct advantage over stepwise procedures is the fact that with
best-subset regression, the best set of two predictors need not include the predictor that was
best when considered in isolation. However, because it considers a much greater number of
possible models, biases in inference are even larger (Draper and Smith, 1998).
Although overtting often results from too many predictors, using very few variables may
fail to reveal the true underlying structure of a prediction model from inadequate informa-
tion. Generally a saturated model often outperforms reduced models. When using stepwise
selection procedures, Harrell (2001) suggested the need for less stringent stopping rules like
Akaike's information criterion (AIC) to decide candidate variables to retain or discard. When
using backward elimination selection, Steyerberg et al. (2000) proposed using a p-value of 0:5
to allow deletion of some variables. In general, backward elimination performs better than
forward stepwise selection procedures in the presence of multicollinearity (Mantel, 1970).
Moreover, backward elimination initially allows examination of the full model which has the
correct standard errors and p-values. Later we consider use of backward elimination pro-
cedures to obtain reduced models. Stepwise selection procedures are implemented in most
statistical softwares. Best-subset regression may be implemented using the leaps package in
R1 software (Ihaka and Gentleman, 1996).
3.3.1 Limitations of stepwise selection procedures
While it may be objective to consider a subset and not individual potential predictors, the
best-subset selection method unlike stepwise methods fails in reducing dimension by selecting
more predictors. Moreover, the best subsets selection method can compare only the models
with the same number of predictors (Draper and Smith, 1998) hence restricting the number
of models that can be compared. The discrete process (variables either retained or discarded)
1http://www.r-project.org/
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inherent in the best-subset selection often exhibits high variance (Hastie et al., 2009) resulting
no reduction of the prediction error in the full model.
Despite their wide application in practice, stepwise selection procedures are associated
with many limitations (Austin and Tu, 2004; Wang et al., 2004). The principal drawbacks of
stepwise multiple regression include bias in parameter estimation, inconsistencies in results
from dierent model selection algorithms, and multiple hypothesis testing before estimation.
Although parsimony may be a desirable statistical practice, reliance on a single best model
may lead to loss of information from excluded predictors. Even smaller models with few
predictors is no guarantee of exclusion of noise variables. Excluding important predictors
can be very costly, for example, Steyerberg et al. (1999) demonstrated that excluding a true
predictor is worse than including a noise variable.
The stepwise selection procedures are based on test of hypothesis of individual parame-
ters. The process that produces the `nal' model fails to account for the inherent multiple
testing. In addition to `testimation' bias, the resulting standard errors are also invalid because
stepwise procedures fail to fully account for the search process (Harrell, 2001). Analysis of
the 'nal' model from stepwise selection procedures assumes that the selected predictors were
pre-specied which is not true since the predictors were selected adaptively according the se-
lection algorithm. Consequently comparison of any models produces biased results because
the analysis erroneously assumes the two models were xed in advance. Specically, variance
of the regression coecients calculated as if the selection were pre-specied will underesti-
mate standard errors and p-values in the resulting model (Harrell, 2001). The problem is even
acute for small data sets where stepwise procedures have limited power to select prognosti-
cally important predictors which in turn lead to lower predictive ability (Chateld, 1995).
The nal model derived from stepwise selection procedures are dependent upon the cor-
relation between individual predictors (Draper and Smith, 1998). This single model is not
guaranteed to be the best among candidate models and interpretation using such a model
includes only those predictors entered in that nal model while ignoring other predictors not
selected. Besides correlation, the nal model depends on the order of entry/exit of predic-
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tors into the model. Such a dependency is likely to result in inconsistencies among dierent
model selection algorithms. In general, excluding potential important predictors on account
of little/no correlation may lead to suboptimal decisions and limited predictability. The next
section reviews multivariate regression techniques which attempt to address the problem of
many predictors with high degree of correlation.
3.3.2 Principal component and partial least squares regressions
Ordinary least squares (OLS) estimation of regression coecients in the presence of more
predictors than number of observations and/or high degree of near collinearity among the
predictors performs poorly by producing very unstable estimates and very poor prediction
accuracy (Draper and Smith, 1998). Principal component regression (PCR) and partial least
squares regression (PLSR) provide a solution to both challenges by using linear combinations
of predictors instead of individual predictors (Vigneau et al., 1997). Strictly speaking PLSR
is a generalization of PCR.
The dierence between PCR and PLSR lies in the dierent ways they construct new
predictor variables (components) as linear combinations of the original predictor. While
PCR creates components to explain the observed variability in the predictor X variables
only, PLSR creates components to explain variability in both the predictor X and response
Y variable. As a results PLSR becomes PCR if it ignores the response during the pro-
cess of creating components to explain observed variability. In constructing the principal
components of X, the PLSR algorithm iteratively maximizes the strength of the relation of
successive pairs of X and Y component scores by maximizing the covariance of each X-score
with the Y variables. Because of its general strategy, PLSR is sometimes called Projection
to Latent Structures in the natural sciences (Abdi, 2010). The distinct advantage of both
methods lies in their use of linear combinations which leads to models that are able to t
the response variable with fewer components. We however note that whether or not this
reduction ultimately translates into a more parsimonious model, in terms of its practical use,
123
depends on the context. While PCR is a popular technique among social scientists, PLSR
enjoys large popularity among the natural sciences particularly in chemommetrics (compu-
tational chemistry) where it is heavily used in chemical analysis following developments in
spectroscopy (many highly correlated predictors) since the 1970s (Mevik and Wehrens, 2007).
PLSR is a generalized multivariate statistical technique with ability to model multiple
predictors as well as multiple responses, handle multicollinearity among predictors and help
make stronger predictions by creating independent components/latent variables directly on
the basis of cross-products involving the response variable/s. Some of its limitations include
greater diculty of interpreting the loadings of the independent latent variables (which are
based onX Y cross-product relations, not based as in common factor analysis on covariances
among the manifest predictors). The mix of advantages and disadvantages makes PLSR more
appealing as a predictive technique and not as an interpretive technique tool.
Theoretically PLSR should have an advantage over PCR but in most situations in practice
both methods achieve similar prediction accuracies (Wold et al., 2001). While PLSR usually
needs fewer latent variables than PCR (i.e. with the same number of latent variables) and
will cover more of the variation in the response Y , PCR will cover more of the variances in
predictor/s X. Frank and Friedman (1993) showed that both PCR and PLSR behave very
similar to ridge regression (next section). Although Hastie et al. (2009) showed that both
PCR and PLSR behave as shrinkage methods (next section), in some cases PLSR seems to
increase the variance of individual regression coecients, an observation which may mean
that PLSR is not always better than PCR. PLSR can be implemented as a regression model
to predict one or more responses from a set of one or more predictors using pls package in
R software (Mevik and Wehrens, 2007).
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3.4 Penalized regression techniques
Biased estimates may be more preferable than unbiased estimates in multivariate situations
to make better predictions. This phenomenon is what is commonly referred to as Stein
(1981) paradox owing to the fact that it appears to negate the principle of unbiased estima-
tion. Shrinkage is the principle of reducing/penalizing the regression coecients to improve
quality of predictions (Steyerberg, 2009). In the presence of multicollinearity, techniques that
penalize regression coecients can help improve ordinary least squares (OLS) estimates in
terms of both prediction and interpretation (Draper and Smith, 1998). Ridge regression is a
suitable alternative to OLS in the presence of multicollinearity among predictors is of primary
concern (Hoerl and Kennard, 1970). While OLS estimation in the presence of multicollinear-
ity is likely to produce poorly determined coecients where extreme positive coecients on
one variable can be canceled by similarly large negative coecient on related variables, ridge
regression addresses this problem by imposing a size constraint on the coecients. In eect
ridge regression includes all candidate predictors, but with considerably smaller (shrunk)
coecients compared to those from OLS (Draper and Smith, 1998; Miller, 2002).
By continuously penalizing the coecients, ridge regression achieves better prediction
performance through a bias-variance trade-o by minimizing the residual sum of squares
subject to the sum of the squares of the coecients bounded by a constant i.e.
Pp
j=1 
2
j  t,
where t is the constant. The ridge regression minimizes a penalized OLS:
^Ridge =
argmin

8<:
nX
i=1
 
Yi   0  
pX
j=1
Xi;jj
!2
+ 
pX
j=1
2j
9=; ;   0 (3.1)
where  is a positive scalar called penalty and is often chosen by cross-validation in practice.
We note that  = 0 corresponds to OLS regression. Bias would increase with an increase in .
Equation (3.1) can be equivalently represented in matrix form as:
^Ridge = [X
0X + I] 1X 0Y:
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The motivation of ridge regression lies in the addition of a positive constant (I) to
the diagonal of the X 0X matrix before inverting it which makes the problem nonsingular
even if X 0X is not of full rank. The variables used in ridge regression are standardized
(mean=0, variance=1) to make the penalty invariant to the scale of the original data. No
penalty is applied to the intercept because to do so would make the procedure dependent
on the origin chosen for the response. However, standardizing variables makes the resulting
ridge parameters dicult to interpret between models because the parameters are not on
natural scale. While the ridge parameter may not be the most useful for understanding the
amount of shrinkage performed, we can use the eective degrees of freedom (df) to measure
the impact of the penalty, where
df = trace
h
X (X 0X + I) 1X 0
i
: (3.2)
We note from the denition in Equation (3.2) above that for a model tted with p variables,
df0 = p (OLS model) and df ! 0 as  ! 1 (null model). In general, ridge regression can
do better than OLS on the full model provided we do not over-shrink (add more bias).
Although ridge regression produces shrunken regression estimates, it fails to reduce the
number of predictors since it always keeps all the predictors in the model. Comparatively
Breiman (1996) showed that while best-subset selection may produce a sparse model (fewer
predictors) than ridge regression, the former model is extremely variable (unstable) because
of its inherent discreteness unlike the later model which is more likely to be stable owing
to its continuous penalization. However, Harrell (2001) point out that ridge regression may
not be suitable for categorical predictors where the amount of shrinkage is dependent on the
choice of reference cell when creating dummy variables.
Tibshirani (1996) introduced the Least Absolute Shrinkage and Selection Operator (Lasso)
as an alternative to ridge regression with the distinct advantage that it accomplishes the twin
tasks of model selection and coecient shrinkage for nite values of the penalty parameter .
The Lasso minimizes the penalized OLS subject to the sum of the absolute values of the
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parameters bounded by a constant (i.e.
Pp
j=1 jjj  t):
^Lasso =
argmin

8<:
nX
i=1
 
Yi   0  
pX
j=1
Xi;jj
!2
+ 
pX
j=1
jjj
9=; ;   0: (3.3)
3.4.1 Variable selection using the Lasso
Asymptotic considerations of the Lasso leads to an interesting extension of using Lasso as
a variable selection method. Frank and Friedman (1993) showed that if the Lagrange term

P
j jjj in expression (3.3) is replaced by 
P
j jjjq where q ! 0+, then the minimization
will be identical to optimal variable (best-subset) selection. They however noted the diculty
in obtaining a unique solution of the function from the many local minima (up to 2p   1),
i.e. no closed form hence nonlinear solution.
In practice, variable selection using Lasso is a two-step procedure: in the rst step, the
Lasso algorithm identies/selects the important predictors (non-zero parameter estimates),
and step two applies ordinary linear regression to the selected predictors, i.e. if the matrix ~X
denotes the matrix containing only those columns j of X for which the lasso estimate ^j 6=0,
then the variable selection estimate is dened as
^Lasso = ( ~X
0 ~X) 1 ~X 0Y:
The steps above suggest a connection between Lasso and the ordinary variable selection.
But Ojelund et al. (2001) pointed out the dierence between Lasso and Lasso as a variable
selection method is that in variable selection only the parameters that turn out to be zero are
penalized (set to zero) while the others are estimated without any penalization. The number
of non-zero parameters will be the same for the two methods under a uniform shrinkage that
uses the same value of . However, in practice we often obtain fewer predictors when Lasso
is used as a variable selection method because we often deliberately select a larger value of
 for Lasso.
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3.4.2 Bayesian generalization of ridge and Lasso regressions
We observe that ridge regression and the Lasso dier only in the penalty form imposed on the
regression coecients. Specically ridge regression uses the squared L2 norm of parameters
while Lasso uses the L1 norm. The bridge regularization (Frank and Friedman, 1993) is a
generalization with best-subset, ridge regression and Lasso as its special cases:
^Bridge =
argmin

8<:
nX
i=1
 
Yi   0  
pX
j=1
Xijj
!2
+ 
pX
j=1
jjjq
9=; ; q  0; (3.4)
so that
L0 norm penalty : L0() =
Pp
j=1 I(j 6= 0) ) Best-subset;
L1 norm penalty : L1() =
Pp
j=1 jjj ) Lasso, and
L2 norm penalty : L2() =
Pp
j=1 
2
j ) Ridge regression:
In theory the L0 penalty is the ideal choice for variable selection because it directly penalizes
the size of model (design matrix is orthogonal). A choice of q 2 (0; 1] regularly gives estimates
that are 0 for some of the js. In particular, Lasso as a model selection method that penalizes
the number of parameters can be seen as limiting cases of bridge estimation as q ! 0 because
jjjq ! 0; 1 accordingly as j = 0 or j 6= 0 when q ! 0 (Clarke et al., 2009).
From a Bayesian perspective, the bridge equation (3.4) provides Bayesian estimates where
we can think of jjjq as the log-prior density for j (i.e. the best-subset selection) whereas
ridge regression and Lasso can be considered as Bayes estimates with dierent priors: the
independent double exponential (Laplace) distribution is the prior corresponding to Lasso
(q = 1) and the ridge regression is the posterior mode (and mean, its Gaussian) due to its
quadratic formulation (Hastie et al., 2009). Here q=0; 1; 2 respectively corresponds to best-
subset selection where the penalty  simply counts the number of nonzero parameters, the
Lasso and ridge regression. The Lasso (q=1) provide the smallest q such that the constraint
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region is convex hence making the optimization problem less dicult, i.e. the function
has only one minimum (Knight and Fu, 2000; Kyung et al., 2010; Park and Casella, 2008),
an observation that may be supportive of its twin roles in coecient shrinkage and model
selection.
3.4.3 Penalized maximum likelihood estimation
While ordinary least squares estimation is adequate for linear models with continuous out-
comes, optimal t to data in generalized linear models is obtained by maximizing the log
likelihood. However, in the presence of many predictors, maximizing the log likelihood often
results in tting noise and parameter estimates that are unstable (Moons et al., 2004). By
trusting too much in the trends of such data, the maximum likelihood estimation (MLE)
may produce spurious eects not reective of the true data. Penalized maximum likelihood
estimation (PMLE) is a generalization of the ridge regression method used to obtain more
stable parameters for linear regression models (Draper and Smith, 1998). Minimizing the
PMLE instead of the MLE is another bias-variance tradeo technique that can be used to
produce stable models in the presence of many predictors:
logL  0:5
X
(sii)
2; (3.5)
where L is the model's MLE adjusted (shrunk) by a penalty factor ,  estimates re-
gression coecients and si is a scaling/shrinkage factor for each i to make sii unit-
less. A major advantage of PMLE is the direct adjustment (during the model tting)
for overoptimism of the estimated regression coecients and predictive accuracy measures
(Harrell, 2001; van Houwelingen, 2001; Verweij and van Houwelingen, 1994).
Choosing the optimal penalty factor  is a challenge in PMLE. While various methods
including sample-splitting and cross-validation are often used to estimate the penalty factor,
Harrell (2001) pointed out that maximizing a modied AIC method is a more ecient method.
With r degrees of freedom (the number of tted predictors), the AIC is traditionally used to
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penalize the maximum log likelihood of a tted model such that the logL in Equation (3.5)
is often replaced by logL   r, where L is the maximum likelihood of the tted model. We
can translate the AIC to the model 2, i.e., the dierence in log likelihood between the model
with and without predictors) scale so that
2LR   2r; (3.6)
where 2LR is the likelihood ratio 
2 of the penalized model, but ignoring the penalty function.
Equation (3.5) denes AIC for ordinary maximum likelihood estimation. To nd the
optimum penalty factor for PMLE, Harrell (2001) proposed using a modied AIC dened as
2LR   2 df; (3.7)
where 2LR is the likelihood ratio 
2 of the penalized model and df is the eective degrees
of freedom, i.e. degrees of freedom after penalizing the tted predictors with penalty . We
note that the the higher the number of predictors, the higher the degrees of freedom and the
more likely the model is overtted. Ordinarily, the degrees of freedom is equal to the number
of predictors, but penalization ensures that the degrees of freedom eectively used in PMLE
is lower than the actual number of predictors hence decreasing the potential for overtting.
In practice, we use a trial and error process over a wide grid to nd the optimal penalty
factor. We obtain the optimal penalty factor opt as the penalty that maximizes the modied
AIC. Using equation (3.5), the tted model is penalized with opt. This penalty is also
called the tuning parameter and its estimate decides the model's complexity of the prediction
method used.
In matrix notation, equation (3.5) can be represented as logL   0:50P, where P is
the so-called penalty matrix often composed of covariances of the standardized coecients.
van Houwelingen and le Cessie (1990) showed that a uniform shrinkage factor s can be ob-
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tained from equation (3.5) using the relation:
s=
model 2   r
model 2
; (3.8)
where as before r denotes the degrees of freedom (df) of the predictors in the model and
2 for the model is calculated on the log-likelihood scale. We observe that s ! 0 for larger
numbers of predictors (r increases) or when the sample size is smaller (model 2 decreases).
In general, penalization aims at an improved predictive performance in a new data set by
balancing the t to the data and the stability of the estimates.
For the present study, we will apply PMLE of the original model composed of predic-
tors considered meaningful and use the modied AIC (3.7) where 2> 2r at each selection
iteration to obtain intermediate models for comparison of fewer predictors. We will then use
relation (3.8) to calculate uniform shrinkages as measures of quality of prediction t (see next
section for overoptimism). Using a wide grid search over the 0  50 range, we will obtain the
penalized coecients and report optimal penalty factors opt for each model.
A model selection procedure is likely to produce competing models. So how do we
choose from such a selection and what criteria do we use? The next section provides a brief
overview of validation measures that can be used to evaluate the performance of selected
prediction models.
3.5 Validation performance: optimism, calibration and discrimination
One of the negative consequences of overtting is optimism which means that there is a too
optimistic impression of model performance that may be achieved in new subjects from the
underlying population. Optimism can be dened as the dierence between true performance
and apparent performance (Steyerberg, 2009). Here the true performance refers to model
behaviour in the underlying population and apparent performance refers to the estimated
performance in the sample.
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Validation of statistical prediction models means the evaluation of their predictive abil-
ity. Following model development, we might be able to assess performance of prediction in
new/independent patients, i.e. external validation (Harrell, 2001; Hastie et al., 2009; Steyer-
berg, 2009). However, if further data is unavailable, we might seek to use original sample of
data for model development and validation. One approach is to randomly split the data into
two portions: one for model development/training and the other for model validation. But
such data splitting procedures are often considered suboptimal (Efron and Tibshirani, 1993)
and may fail to demonstrate the adequacy of the model when subjected to external validation
given the possibility to produce less representative subsamples for either model development
and/or validation. Bootstrap is considered the most ecient validation procedure (Harrell,
2001). As a validation technique, bootstrap repeatedly analyses subsamples of a given data
where each subsample is a random sample with replacement from the original sample. The
fact that each bootstrap samples will be relatively dierent than the original data set mimics
application to a dierent sample at every iteration hence providing reliable results (Anderson,
2005). Bootstrap validation allows calculation of predicted probabilities from a model which
can be compared with the actually observed outcomes.
Calibration and discrimination statistics are among the most eective and commonly
used measures of validation performance (Harrell et al., 1996; Steyerberg et al., 2004). Cal-
ibration (also called reliability) refers to how well the model predictions compare with the
observed outcomes. Calibration is essentially a measure of bias that evaluates the agreement
between observed and predicted probabilities. For example, if the average predicted propor-
tion of compliers to HRT tablet allocations among similar group of women is 80% and the
actual proportion complying is 80%, then the predictions are well calibrated. In measuring
calibration, it is sucient to focus on either an intercept or slope of a linear predictor and
not both (Steyerberg et al., 2004). However, in practice calibration is often quantied by
the calibration slope as originally proposed by Cox (1958b). The calibration slope can be
obtained from the validation plot which is a plot of observed probabilities against the pre-
dicted probabilities. The line from the validation plot can be dened with an intercept 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and a slope , where =0 and  =1 corresponds to a perfect calibration. The calibration
slope lies between 0 and 1 and the bigger, the better calibrated the model under study.
There is a relationship between the calibration slope and penalty factor in penalized
regression (Miller et al., 1993). For example, for a logistic model with the linear predictor as
the only covariate, the calibration slope is the estimated regression coecient , i.e.
logit(treatment compliance) = +   linear predictor: (3.9)
Copas (1983) and van Houwelingen and le Cessie (1990) demonstrated that the slope  of the
linear predictor is identical to the uniform shrinkage factor s given by Equation (3.8) above.
Discrimination refers to the ability of the model to distinguish between subjects with
positive or negative outcomes (e.g. the ability of a model to distinguish compliers with
treatment allocation from non-compliers). Discrimination is commonly measured using the
concordance (c)-statistic. For binary outcomes this statistic is identical to the area under
the receiver operating characteristic curve (Harrell, 2001). Given a random pair of patients
with dierent outcome values, the c-statistic can be interpreted as the likelihood of a patient
with the desirable outcome (complier) to have a higher predicted probability for having that
outcome than a patient without the outcome (e.g. non-complier). The c-statistic varies
between 0:5 (random predictions) and 1:0 (perfect prediction) and the higher the better
(Harrell et al., 1996; Miller et al., 1993). The concordance c-statistics can also be expressed
in terms of the widely used Somers (1962) Dxy rank correlation which is a measure of the
dierence between concordance and discordance probabilities (Harrell, 2001):
Dxy = 2(c  0:5); (3.10)
whereDxy=0 and 1 here implies random predictions and perfect discriminations respectively.
We will evaluate the predictive performance of our models using calibration slope, calcu-
late discrimination's concordance c statistics from the reported Dxy value and the percentage
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of optimism as implemented in the Design package in R software. However, it is worth
noting that good (or even perfect) calibration and discriminative ability are not sucient for
a model to be declared clinically useful. Only a model's ability to provide useful additional
information for clinical decision making makes application of a prediction model sensible. In
our case the quality of compliance information for both treatment arms would be crucial to
making relevant clinical decision.
Following the review, the next ve chapters provide applications of the methods discussed
thus far. Chapters 4, 5 and 6 provide analyses of the Esprit data. On the other hand Chapters
7 and 8 provide simulation studies which evaluate respectively the performance of specialist
methods adjusting for noncompliance in one treatment arm and Roy et al. (2008) method of
principal stratication adjusting for noncompliance in two treatment arms.
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Chapter4
Esprit Analysis I: Modelling Noncompliance
Effect in One Arm
4.1 The Esprit study background and data
The ITT analysis of the oEStrogen in the Prevention of ReiInfarction Trial (Esprit) data was
published in 2002 (Cherry et al., 2002). The aim of the Esprit study was to ascertain whether
or not unopposed oestrogen reduces the risk of further cardiac events in postmenopausal
women who survive a rst myocardial infarction. Previous observational studies suggested
that hormone replacement therapy (HRT) prevented cardiac events but there had been no
randomized clinical trails on the same. Evidence from observational studies also showed
that unopposed oestrogen increased the risk of endometrial cancer although the addition of
progesterone reversed this eect. Additionally, there was evidence that oestrogen reduced
risk to fractures. There was evidence of increased risk of breast cancer in long term users
(> 5 years). Organizers of the Esprit trial argued that the benets (in terms of cardiovascular
deaths) of giving unopposed oestrogen to a group at high risk of second infarction could
outweigh any increased risk of endometrial cancer. The study comprised a total of 1017
women aged between 50   69 years who were recruited from 35 hospitals in England and
Wales. 513 and 504 women were randomized to the treatment and placebo arms respectively
and monitored over 24 months (2)-year period. The primary outcomes were reinfarction or
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cardiac deaths and all-cause mortality. Although ITT analysis of the data has been previously
published, the analysis took no account of compliance data.
This chapter provides new set of results for the Esprit trial taking account of compliance
data as well as, for comparison, non-randomization based methods. Our analysis considers
two outcomes: all-cause mortality and myocardial reinfarction or cardiac deaths. All the
analysis in this Chapter are performed using Stata software (StataCorp, 2008) and the Stata
codes are shown in Appendix page 261.
4.2 Methods
We use ve classes of methods to evaluate HRT treatment. First we perform primary analyses
by intention-to-treat (ITT) with and without covariates. The six covariates included here
were agreed in the protocol prior to the study. They were chosen (before data inspection)
as factors likely to have a relation with the primary endpoints. We considered age (in years)
at entry, body mass index (BMI) as continuous variables. Smoking habit at recruitment
(never, ex-smoker, intending to give up, or current smoker) was also included. We classied
participants as smokers and non-smokers where the later group consisted those of who had
never smoked and those who gave up smoking at least in the last 2 years. Other covariates
considered were reported binary (yes/no) histories of hysterectomy, high blood pressure and
diabetes. The ITT analysis compared the rates of non-fatal reinfarction or cardiac death in
the 2 years after study entry, with observation time censored at reinfarction, death, or 24
months, whichever occurred rst. We used the Cox proportional hazards model to obtain
adjusted and unadjusted hazard ratios.
Secondly, we use per-protocol and as-treated methods to explore treatment ecacy al-
though these methods are regarded as suboptimal as discussed earlier. We assume perfect
compliance with placebo while considering compliance with HRT treatment and classify a
woman as a complier per-protocol if she strictly complied with assignment without interrup-
tion up to the end of month 23 of the study or until the time of event (death/reinfarction).
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As-treated analysis was a comparison of outcomes based on current treatment status, i.e.
comparing those women on treatment to those who are not. We also perform simple regression
adjustments to obtain `naive' treatment eects by using a time-invariant and time-varying
binary all-or-nothing noncompliance indicator as a covariate.
Thirdly we considered three specialist methods which attempt to provide unbiased HRT
treatment eect estimates by adjusting for all-or-nothing and partial noncompliance to treat-
ment assignment. For each of these methods we consider compliance with the active HRT
treatment while ignoring compliance with placebo, i.e. we evaluate treatment eects among
those women who actually took their HRT tablets given that they were randomized to the
treatment arm. For exploration and in attempt to describe the data, we subdivided the data
into 5 short intervals (0 3, 3 6, 6 12, 12 18 and 18 24 months) and assume constant
piecewise hazard rates for each interval. This subdivision with utilize compliance information
reported for respective intervals. We dene compliance as actual taking of HRT tablets up to
a day before experiencing event of interest (death/reinfarction) or end of study, whichever oc-
curred rst. The Esprit study did not permit treatment switches (from placebo to active) and
had no information on whether patients intermittently stopping and starting of medication.
Ignoring such scenarios together with our compliance denition may be considered plausible
with respect to the exclusion restriction assumption in the absence of carryover eects.
We used all-or-nothing compliance for the C-Prophet method. Although the CALM
method allows for multiple crossovers between treatment arms, our analysis for the present
work considered a unidirectional crossover where patients who stopped taking their tablets be-
came non-compliers and we utilized the time to stoppage of medication and a potential recen-
soring time specied at end of study (24 months). The C-Prophet, CHARM and CALMmeth-
ods were implemented using the Stata commands stcomply (Kim and White, 2004), adjhr
(White, 2002) and strbee (White et al., 2002) respectively (codes are shown on page 261).
For comparison and completeness, we also obtained a simple CHARM estimate by using
the treatment arm to estimate the counterfactual compliance in the control arm and then
adjusting the ITT estimate with the proportion of potential non-compliers who experienced
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the event of interest (White et al., 2004).
4.3 Results
There were 71 all-mortality deaths in total during the 2-year study period, i.e. 32 and 39
from treatment and placebo arms respectively. On the other hand there were a total of 123
myocardial reinfarction or cardiac deaths: 62 and 61 in the active treatment and placebo
arms respectively. Most of the all-mortality deaths (reinfarctions) were registered during the
early periods of the study with more than 64% (75%) events by month 10. While month
3 recorded the highest all-cause mortality rate at 15%, the highest myocardial reinfarction
or cardiac deaths were recorded in the rst month (23%). We analyse data for all-cause
mortality outcome to explore individual intervals for the Esprit data.
Table 4.1: All-cause mortality: incidence rates and survival distribution per interval
Intvl. Number alive at Survival Incidence
start of interval function rates
Treat Plcbo Treat Plcbo Overall Treat Plcbo Overall
(Dead) (Dead) (Dead)
0-3 506 (8) 491 (14) 0.984 0.972 0.978 (22) 0.00532 0.00936 0.00728
3-6 500 (6) 485 (6) 0.972 0.960 0.967 (12) 0.00399 0.00411 0.00405
6-12 494 (6) 475 (10) 0.961 0.941 0.951 (16) 0.00202 0.00348 0.00274
12-18 487 (7) 466 (9) 0.948 0.923 0.935 (16) 0.00238 0.00320 0.00278
18-24 481 (5) 465 (0) 0.938 0.923 0.930 (5) 0.00172 0.00000 0.00088
0-24 513 (32) 504 (39) 0.938 0.923 0.930 (71) 0.00270 0.00341 0.00305
Table 4.1 provide the incidence rates and survival distribution for each of the 5 intervals
for all-cause mortality. The rst 3 months recorded the highest incidence rates (IR) compared
to subsequent 6-months IR (Table 4.1) and even the overall 24 months IR. The rst 3-
months IR are about double (0:005 and 0:009 treatment and placebo respectively) compared
to the next 3-months IR (0:004 and 0:004). In general, Table 4.1 shows that mortality fell
(throughout) as the study progressed. In addition, the incidence rates in the treatment group
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was lower that in the placebo group for all intervals except the last one, 18  24 months.
Table 4.2: All-cause mortality: ITT hazard rates for each interval
Interval Number dead Haz. ratio SE P-value 95% CI
T(%) P(%)
0-24 32 (6.2) 39 (7.7) 0.795 0.190 0.335 0.498, 1.268
0-3 8 (1.6) 14 (2.8) 0.559 0.248 0.189 0.234, 1.332
3-6 6 (1.2) 6 (1.2) 0.971 0.561 0.959 0.313, 3.010
6-12 6 (1.2) 10 (2.1) 0.580 0.300 0.292 0.211, 1.597
12-18 7 (1.4) 9 (1.9) 0.744 0.375 0.557 0.277, 1.997
18-24 5 (1.0) 0 5:08 10 15 1:52 10 23 0.991 0 -
12-23 12 (1.6) 9 (1.2) 1.277 0.563 0.580 0.538, 3.030
Ttreatment; Pplacebo
There were 22 all-cause mortality (ACM) events in interval 1 with treatment and placebo
groups experiencing 8 and 14 deaths respectively. The last month of this interval (month 3)
accounted for 11 (50%) of the total ACM in this interval. Overall, ACM during interval
1 accounted for almost 31% of the total number of deaths during the study period. Al-
though the treatment eect is not statistically signicant (HR= 0:56, p-value= 0:189; 95%
CI:0:234; 1:332), the treatment appeared to be benecial compared to placebo and compar-
atively reduces the risk of ACM by about 44% (Table 4.2).
A total of 12 patients experienced ACM during the second interval. This constituted a
45% reduction from 22 ACMs in the previous interval. The 3-months IR for this interval
appear similar at about 0:004 for both treatment and placebo groups as Table 4.1 shows.
The equal number of ACMs (6 each) from both participants under treatment and placebo
may be an apparent manifestation of a stable IR across the intervals. Half of the ACMs in
interval 2 occurred during month 4. The 6 ACMs here were also evenly distributed between
treatment and placebo groups. However, there are only 2 ACMs from the placebo group by
the end of this interval. The piecewise hazard ratio for interval 2 is 0:97 (p-value= 0:959,
95% CI:0:313; 3:010). Hence despite being statistically insignicance, the treatment appears
to marginally reduce the risk for ACM by about 3%.
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There were 16 ACMs recorded in both intervals 3 and 4. Both intervals also recorded
less ACM from the treatment group, i.e. 6 and 7 compared to 10 and 9 from treatment and
placebo groups for respective intervals. The 6-months IR for both intervals almost remain the
same at about 0:002 and 0:003 for treatment and placebo groups respectively. This similarity
may be the source of stability and near-equal mortality rates at both intervals. However,
although both the treatment eects are not statistically signicant at both intervals, the
hazard ratio is apparently higher at interval 4 than at interval 3, i.e. treatment has more
than 40% chance to reduce the risk to ACM in interval 3 compared to a reduction of about
25% in interval 4.
There were a total of 5 ACMs in the last interval (18   24-months). All these ACMs
were exclusively registered from the treatment arm. The 6-months IR for this interval is the
lowest for the study at 0:002 for the treatment arm. 2 (40%) ACMs in this interval were
registered in month 19, while months 21; 22 and 23 each had one ACM. There were no ACMs
registered in the 20th and 24th months. In attempt to utilize all the data, we pooled both
intervals 4 and 5 into a single 12-months long interval that now has 21 ACMs. Hence we now
consider a total of 4 intervals.
A comparison of the smoothed hazard functions (Figure 4.1) indicates relatively lower
hazard rates for treatment compared to placebo. This is an indication of some form of benet
derivable from active treatment.
Figure 4.1: All-cause mortality: smoothed hazards for the 24 months
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4.3.1 ITT analysis
The original analysis (Cherry et al., 2002) revealed statistically non-signicant eects of HRT
with regard to both all-cause mortality (HRACM=0:790, p-value=0:340; 95% CI: 050; 1:27) and
myocardial reinfarction or cardiac deaths (HRMRCD=0:990, p-value=0:970, 95% CI: 070; 1:41).
For both all-cause mortality and myocardial reinfarction or cardiac deaths, the ITT
analysis considered the model below comprising 6 baseline covariates
h(t) = h0(t) exp
 
Treatment + Hysterectomy + Age + BMI
+Smoking + Blood Pressure + Diabetes
!
: (4.1)
The mean age at admission was 62:6 years, the youngest and oldest were about 50 and 70
years old respectively. The average BMI was about 26:7 kg/m2 where the lowest and and
largest BMI stood at 14:8 kg/m2 and 51:3 kg/m2 respectively. A total of 244 (24%) women
had a history of hysterectomy.
Table 4.3: PH ITT analysis: all-cause mortality and myocardial reinfarction
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
Covariate HR SE P-val 95% CI HR SE P-val 95% CI
Treatmenty 0.795 0.190 0.335 0.498, 1.268 0.993 0.179 0.967 0.697, 1.414
Treatmentz 0.805 0.195 0.369 0.501, 1.293 0.995 0.181 0.978 0.696, 1.422
Hysterectomy 0.436 0.156 0.021 0.216, 0.881 0.785 0.174 0.275 0.508, 1.213
Age (in yrs) 1.068 0.029 0.017 1.012, 1.127 1.024 0.020 0.227 0.985, 1.064
BMI 1.011 0.023 0.623 0.967, 1.058 1.027 0.018 0.123 0.993, 1.062
Smoking 1.113 0.280 0.671 0.680, 1.822 1.110 0.214 0.589 0.761, 1.619
B-Pressure 1.197 0.294 0.464 0.740, 1.937 1.587 0.300 0.015 1.096, 2.299
Diabetes 3.724 0.971 { 2.234, 6.207 2.718 0.556 { 1.820, 4.058
HR hazard ratio; yno covariates;zwith covariates; {p-value < 0:001
Table 4.3 provide results from the analysis of model (4.1) for both all-cause mortality and
myocardial reinfarction or cardiac deaths. For both outcomes, the HRT treatment is not sig-
nicantly dierent from placebo, both with and without covariates. The hazard ratios (HR)
for treatment are similar regardless of whether covariates are included or not. In general, the
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age of women at admission, histories of diabetes and hysterectomy are signicantly related
to survival from all-cause mortality (at 5% level of signicance). On the other hand histo-
ries of blood pressure and diabetes were statistically signicantly related to survival from
reinfarction or cardiac death. Although statistically insignicant, the analysis shows bene-
t of active treatment in reducing the risk of all-cause mortality by about 20% (HR= 0:80,
p-value=0:335, 95% CI: 0:498; 1:268). However, the analysis showed no dierence in eects
between the active treatment and placebo with regard to the risk of myocardial reinfarction
or cardiac death (HR=0:99, p-value=0:965; 95% CI: 0:697; 1:414). Also Table 4.4 shows we
obtain similar ITT results for the Esprit data under AFT (Weibull on HR scale) analysis.
Table 4.4: AFT (Weibull) ITT analysis: all-cause mortality and myocardial reinfarction
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
Covariate HR SE P-val 95% CI HR SE P-val 95% CI
Treatmenty 0.794 0.189 0.334 0.498, 1.268 0.994 0.179 0.973 0.698, 1.415
Treatmentz 0.804 0.195 0.367 0.500, 1.292 0.995 0.181 0.977 0.696, 1.422
Hysterectomy 0.432 0.155 0.019 0.214, 0.873 0.782 0.174 0.268 0.506, 1.209
Age (in yrs) 1.068 0.029 0.017 1.012, 1.127 1.028 0.018 0.115 0.993, 1.063
BMI 1.011 0.023 0.623 0.967, 1.058 1.029 0.018 0.098 0.995, 1.065
Smoking 1.094 0.277 0.723 0.665, 1.799 1.112 0.214 0.582 0.762, 1.622
B-Pressure 1.201 0.295 0.457 0.741, 1.944 1.591 0.301 0.014 1.099, 2.304
Diabetes 3.759 0.982 { 2.253, 6.271 2.747 0.561 { 1.840, 4.100
{p-value < 0:001;yno covariates; zwith covariates;pACM=0:669, pMRCD=0:507 (Equation 2.4)
Figure 4.2: All-cause mortality: overall survival proportions in the 2 treatment groups
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Although there was no noticeable dierence in survival proportions for myocardial rein-
farction or cardiac death between women on HRT treatment compared to those on placebo,
Figure 4.2 indicates a higher survival proportion among those women randomized to HRT
treatment compared to those on placebo for all-cause mortality outcome.
Overall, there was no evidence to suggest that the model violated the proportional hazards
assumptions for both all-cause mortality (2 =!2:51, p-value= 0:113) and myocardial re-
infarction or cardiac deaths (2=1:970, p-value= 0:161).
4.3.2 Per-protocol and as-treated analysis
Table 4.5: Number (percentage) of non-compliers since entry
Treat arm Time (months)
3 6 12 18 24
Active 149 (29%) 122 (41%) 259 (51%) 279 (54%) 294 (57%)
Placebo 118 (23%) 134 (27%) 157 (31%) 171 (34%) 184 (37%)
Table 4.5 shows the rate of noncompliance in the two treatment arms for all-cause mor-
tality. On average there was greater proportion of non-compliers among women randomized
to active treatment arm compared to those assigned to the placebo arm (Figure 4.3).
Figure 4.3: Variation of noncompliance proportion with time
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Table 4.6: Per-protocol and as-treated analyses
Analysis HR SE p-value 95% CI
Per-protocol
Mortality (ACM) 1.128 0.416 0.744 0.548, 2.322
Reinfarction (MRCD) 1.196 0.328 0.514 0.699, 2.045
As-treated
Mortality (ACM) 0.819 0.251 0.515 0.449, 1.494
Reinfarction (MRCD) 0.891 0.203 0.613 0.571, 1.392
Table 4.6 provide results from per-protocol and as-treated analyses for both all-cause
mortality and myocardial reinfarction outcomes. We classied compliers per-protocol as
those women who complied with their HRT tablets assignment without interruptions until
end of month 23 or until experiencing event, i.e. the per-protocol analysis censored all
women who violated protocol (non-compliers in both arms). On the other hand as-treated
method analyzed patients according to treatment they actually received regardless of their
original treatment assignment, i.e. analysis provided a comparison between women on HRT
treatment and those randomized to placebo together with non-compliers (since there were no
treatment switches from placebo to active). The rate of compliance per-protocol was about
42% (217=513) and 63% (319=504) in the active treatment and placebo arms respectively.
Per-protocol analysis suggests harmful treatment eects for both outcomes: while HRT
treatment increased the risk of death by about 13% (HRPP(ACM)=1:128; 95% CI: 0:548; 2:322),
it increased the risk of myocardial reinfarction by about 20% (HRAT(MRCD)=1:196; 95% CI:
0:699; 2:045). As-treated analysis on the other hand contradicted per-protocol results by
indicating marginal benets of treatment: now taking HRT treatment reduced the risks of
death and myocardial reinfarction by 18% and 11% respectively. Such a contradiction may
be a reection of suboptimal analysis using these two methods probably due to the fact that
they are both prone to breaching the canonical principle of randomization.
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4.3.3 Simple regression adjustments for noncompliance
We also performed regression adjustments of noncompliance by considering a binary (0=1)
(i) xed and (ii) time-varying all-or-nothing noncompliance indicator N using the models:
(i) h(tjZ;N)=h0(t) exp[1Z + 2N ] and (ii) h(tjZ;N)=h0(t) exp[1Z + 2N(t)];
where exp(^1) provides a naive treatment eect estimate and exp(^2) estimates the eect of
noncompliance (NCE) and time-varying noncompliance is tted as a time-varying covariate.
Table 4.7: Simple regression adjustments with binary noncompliance
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
e^1 e^2 SE P-val 95% CI e^1 e^2 SE P-val 95% CI
(i)
Trty 0.709 0.173 0.160 0.440, 1.145 0.907 0.168 0.599 0.631, 1.304
NCEz 1.673 1.493
(ii)
Trt 0.750 0.182 0.235 0.466, 1.206 0.931 0.170 0.696 0.651, 1.332
NCE 1.032 1.046
(i)Fixed noncompliance;(ii)Time-varying noncompliance;yTrttreatment; zNCEeect of noncompliance
Table 4.7 provides results for the simple regression adjustments with noncompliance. Sim-
ilar to ITT, the results show statistically insignicant treatment eects for both outcomes.
However, the regression adjustments also indicated benecial eects of treatment in reducing
the risk of death by 29% and 25% when adjusting for xed and time-varying noncompli-
ance respectively. The results also showed statistically insignicant marginal treatment ef-
fects for MRCD outcome: treatment reduced risk of myocardial reinfarction by 9% and 7%
respectively for xed and time-varying noncompliance. Although the results showed essen-
tially no eects of time-varying noncompliance for both outcomes, time-invariant noncompli-
ance had relatively greater eects in increasing the risk of death (67%) compared to increasing
risk of myocardial reinfarction (49%). Given that ordinarily we would expect noncompliance
to double the risks, these result may be an indication that the eects of noncompliance are
probably captured better under ACM outcome compared to MRCD.
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4.3.4 C-Prophet analysis
The C-Prophet method adjusted for all-or-nothing compliance in the treatment arm for both
ACM and MRCD where (as dened above) a woman was considered a complier if she took her
allocated HRT tablets up to a day before an event (ACM/MRCD) or end of study, whichever
came rst. On average, there were about 43% women compliers to ACM event and 45%
compliers to MRCD events in the active treatment arm: these are the women who actually
took HRT tablets up to a day before ACM/MRCD event or end of study.
Table 4.8: C-Prophet results for all-cause mortality and myocardial reinfarction
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
HRy 95% CI HRy 95% CI
0.656 0.334, 1.597 0.988 0.568, 1.931
yeects adjusted for compliance
Table 4.8 provide results for C-Prophet analysis in terms of hazard ratios adjusted for
compliance with HRT treatment. The results indicate an overall benet of HRT treatment in
reducing the risk for ACM by 34% (HRACM=0:66). Also similar to ITT analysis, there was no
overall reduction in on risk of MRCD from treatment compared to placebo (HRMRCD=0:99).
We also note a relatively wider corresponding 95% condence interval for the estimate of
treatment eect adjusted for compliance for the myocardial reinfarction outcome compared
to mortality. Kaplan-Meier (KM) plots (Figures 4.4 and 4.5) indicate that the latent ob-
served survival probabilities would be relatively lower compared to the predicted survival
probabilities in the placebo arm throughout the study period for both outcomes.
Figure 4.4: ACM: predicted vs observed KM plot
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Figure 4.5: MRCD: predicted vs observed KM plot
.85
.9
.95
1
P(s
urv)
0 5 10 15 20 25
_t
predicted survival observed survival
Survival in control arm
146
4.3.5 CHARM analysis
Table 4.9: CHARM results for all-cause mortality and myocardial reinfarction
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
Analysis ^0 exp(^0) SE p-val. ^0 exp(^0) SE p-val.
(95% CI) (95% CI)
ITT
Treatment -0.230 0.795 0.239 0.335 -0.007 0.993 0.180 0.967
(-0.698, 0.237) (-0.361, 0.346)
Adjustedy
Treatment -0.417 0.659 0.396 0.292 -0.012 0.988 0.301 0.951
(-1.193, 0.359) (-0.602, 0.577)
yfor crossovers, exp(^0) adjusted hazard ratio (treatment eect) estimate - Equation 2.15
Table 4.9 provide results for CHARM analysis in terms of hazard ratios. Ignoring
crossovers, the ITT results under CHARM are similar to those of obtained above (Section 4.3.1).
Specically, although the results show that the eects of HRT tablets were statistically in-
signicant, the treatment policy would reduce the risk of death by about 20% (HRACM=0:80)
compared to placebo while there was essentially no dierence in risk of myocardial reinfarc-
tion (HRMRCD=0:99) between those women randomized to HRT treatment and placebo.
On average there were about 58% (293=513) and 55% (281=513) crossovers from the
active treatment arm for ACM and MRCD outcomes respectively. The rst part of the
analysis using logistic model of noncompliance revealed statistically insignicant log odds
of noncompliance: 0:125 (p-value= 0:724) for ACM outcome and  0:392 (p-value= 0:130)
for MRCD outcome. The p-values from the test suggests that the odds do not vary with
time. It may then be considered meaningful to estimate constant hazard ratios. Adjusting
for unidirectional crossovers among non-compliers from active treatment to placebo arm,
CHARM estimate indicates a substantial treatment benet which would reduce the risk of
death by 34% compared to placebo. On the other hand adjusting for crossovers indicated no
eects on the risk of myocardial reinfarction which remained essentially unchanged. However,
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adjusting for noncompliance (crossovers) apparently introduced more variability as evident
in increase in the standard error (SE) and relatively wider 95% condence intervals (CI) for
the CHARM estimates adjusted for crossovers compared to SE for the ITT estimates. This
may be attributable to the fact that adjhr command evaluates the SE and corresponding
95% CI for the CHARM estimate conditional on odds of noncompliance.
Simple CHARM approximation
Table 4.10: Distribution of events in the active treatment arm
Interval (months) 1 (0-3) 2 (3-6) 3 (6-12) 4 (12-23) Overall (0-23)
C N C N C N C N C N
Events (active arm)
ACM # (%) 6 2 4 2 2 4 4 8 16 16
(2:7) (0:7) (1:9) (0:7) (1:0) (1:4) (1:9) (2:8) (7:3) (5:5)
MRCD # (%) 19 3 10 3 5 9 3 10 37 25
(8:2) (1:1) (4:7) (1:1) (2:5) (3:3) (1:6) (3:8) (16:0) (8:9)
CCompliers;NNon-compliers;ACMAll-cause mortality; MRCDMyocardial reinfarction.
Table 4.10 shows distribution (numbers and proportion in each complier/non-complier
classication) of both events of interest for the active treatment arm. Overall, there were
more MRCDs than ACMs in the active treatment arm, i.e. a total of 62 (37 compliers and
25 non-compliers) compared to 32 ACMs (16 for both compliers and non-compliers) in the
treatment arm. Analysis of the logistic model of compliance (2.17) produced the estimate
1(ACM)=0:080 (p-value = 0:129; 95% CI:  0:023; 0:184) for ACM and 1(MRCD) = 0:180
(p-value=0:001; 95% CI: 0:075; 0:284) for MRCD. Although it may not be a sucient test,
as an illustration/exploration we may consider the null hypothesis H0 : 1 = 0 true for
ACM but not MRCD given an apparently implied signicant time trend/inuence for the
MRCD outcome.
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Overall, we may then estimate the proportion of non-compliers randomized to treatment
who experienced ACM event as ^ACM=16=32=0:5. We use Equation (2.16) to approximate
the overall simple CHARM estimate for ACM as
CHARMACM=
0:795 (1  16=32)
1  (16=32 0:795) =0:660;
a result which indicates that on average, taking HRT tablets reduces the risk of ACM by 34%.
We observe that the simple CHARM estimates approximated by Equation (2.16) agrees with
that obtained using the adjhr command in Stata.
Also although the time trend apparently inuences treatment eects for the MRCD outcome,
for completeness and comparison we can calculate its CHARM (^MRCD=25=62) estimate as
CHARMMRCD=
0:993 (1  25=62)
1  (25=62 0:993) =0:988;
which indicates no dierence between HRT treatment and placebo for MRCD outcome, a
result that agrees with others above.
In general, for a given hazard ratio, the CHARM estimates decreases with increase in ^
values for both ACM and MRCD. Figure 4.6 shows the general variation of simple CHARM
estimates with compliance proportion () for ACM outcome.
Figure 4.6: Simple CHARM-compliance proportion relationship
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4.3.6 CALM analysis
Table 4.11: CALM results for all-cause mortality and myocardial reinfarction
All-cause mortality (ACM) Myocardial reinfarction (MRCD)
Analysis '^ exp('^) dHRx 95% CI ('^) '^ exp('^) dHRx 95%CI('^)
ITT
best -0.567 0.567 0.684 -1.541, 0.358 -0.022 0.978 0.989 -1.205, 0.892
Adjustedy
best -1.123 0.325 0.472 -2.100, 0.760 -0.009 0.991 0.995 -2.423, 1.548
Adjustedz
best -1.024 0.359 0.504 -2.408, 0.760 -0.020 0.980 0.990 -2.236, 1.548
lower bd -1.200 0.301 0.448 -3.000, 0.600 -0.100 0.905 0.951 -2.500, 1.500
upper bd -0.600 0.549 0.669 -2.400, 1.200 0.300 1.350 1.164 -2.100, 1.900
ycrossovers;zcrossovers+recensoring;bound;xdHR=exp('^)p:pACM=0:669,pMRCD=0:507 (Weibull, Eqn. 2.4)
For the CALM method, we considered a unidirectional crossover where those women
who stopped taking their HRT tablets were classied as non-compliers but no women cross
in the opposite direction. The analysis used the duration in months to stoppage of tablet
taking and specied the time of the end of study (24 months) as the potential recensoring
time. Table 4.11 provide results in terms of the acceleration parameter ' and equivalent
hazard ratios (assuming Weibull model) for the CALM method for both outcomes, all-cause
mortality (ACM) and myocardial reinfarction (MRCD). For interest, besides ITT we also
present results that adjust for crossovers only but not recensoring. CALM estimates are
obtained by grid search over a range of values of ' and computing the test statistic Z(')
and Z(') ' graph may be used to aid in visual assessment of the `best' grid choice (White
et al., 2002).
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The ITT estimates under CALM were '^ITT(ACM) =  0:567 and '^ITT(MRCD) =  0:022
for ACM and MRCD outcomes respectively. These results imply that for ACM outcome,
lifetime was used up only 0:567 times as fast when on treatment compared to when on placebo
or equivalently taking HRT treatment increased survival time 1:8-fold (e0:567) compared to
taking placebo. On the other hand, there was essentially no dierence in survival times
(e0:022 = 1:02) between women on HRT tablets and those on placebo for MRCD outcome,
results that agree with ITT estimates of the hazard ratio obtained above (Section 4.3.1).
The default grid search range ( 1; 1) under CALM procedures for both outcomes produced
no lower 95% condence interval limits for the corresponding ITT estimates, i.e possibly
indicating too narrow grid. Also graphs of Z(') against  using coarser grid searches (e.g
0:01 steps) showed evidence of non-monotonicity, i.e. a possible indication of non-unique ITT
Z-statistic estimate). The above ITT estimates were obtained by exploring grid search in
the ( 3; 2) range taking 0:6 steps for ACM outcome and ( 2:5; 2) range taking 0:4 steps for
MRCD outcome. The resulting Z(') vs ' graphs (Figures 4.7 and 4.8) showed no evidence
of non-monotonicity for both outcomes, indicating that the procedure captured the point
estimate Z(0) for the ITT Z-statistic. Our next interest is to assess the eect of adjusting
for noncompliance due to treatment crossovers (and possibly recensoring).
Figure 4.7: ACM: ITT under CALM
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Figure 4.8: MRCD: ITT under CALM
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Ordinarily it is plausible to expect adjusting for both crossovers (non-compliers switch-
ing from active to placebo) and recensoring to increase the estimated HRT treatment ef-
fect compared to placebo. On average there were about 58% (293=513) crossovers for
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the ACM outcome and 55% (281=513) for the MRCD outcome. Adjusting for crossovers
(CO) using the above coarse grid produced  ^ACM(CO) =  1:140 (95% CI:  1:994; 0:843)
and '^MRCD(CO)= 0:009 (95% CI:  2:423; 1:548), i.e. adjusting for noncompliance due to
crossovers from active to placebo arms resulted in a larger absolute value for the HRT ecacy
estimate compared to ITT, albeit with relatively wider corresponding 95% condence intervals.
Adjusting for both crossovers and censoring (recensoring at 24 months), the CALM
method's best grid search within the ( 2:5; 2) and ( 3; 2) ranges, which contain the 95%
condence intervals reported above, and taking 0:6 and 0:4 steps for ACM and MRCD out-
comes respectively produced '^ACM= 1:024, (95% CI:  2:408; 0:760) and '^MRCD= 0:020,
(95% CI:  2:236; 1:548). The results imply a further improvement in ecacy estimates:
compared to placebo, taking HRT treatment increased survival time 2:8-fold (e1:02) when the
outcome considered was ACM. But similar to previous results, the twin adjustments indicated
no dierence in survival time (e0:020=1:02) between those taking HRT tablets and placebo
for the MRCD outcome. Using the above ranges, the grid search produced the CALM point
estimate '^ as lying between  1:2 and  0:6 for ACM and between  0:1 and 0:3 for MRCD.
We observe that the results from the twin adjustments retained the upper condence limits
which is an indication of unchanged p-values under CALM procedure (White et al., 2002).
Also now the respective graphs of Z(') against ' for ACM outcome (Figure 4.9) and MRCD
outcome (Figure 4.10) indicate no evidence of nonmonotonicity, i.e. no lack of t.
Figure 4.9: ACM: Z(') vs ' graph (Esprit)
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Figure 4.10: MRCD: Z(') vs ' graph (Esprit)
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4.4 Conclusion and discussion
Overall the eects of active treatment were not statistically signicantly dierent from
placebo for the Esprit study. There were a total of 71 deaths over the two years of the
Esprit study: 32 and 39 from the treatment and control arms respectively. An equal number
(16) of women died among both compliers and noncompliers in the treatment arm. Al-
though ITT analysis revealed that active HRT treatment is not statistically dierent from
placebo, the treatment suggests positive benets in reducing the risk of death by about
20%. The study duration of two years may have been too short to reveal HRT eects on
myocardial reinfarction given that such signicant eects may only be demonstrated after
considerably long period of medication, e.g. 5 years (Chilvers et al., 2003). ITT analy-
sis ignored any compliance information, the results may be considered conservative due to
dilution eects by noncompliers.
On average a higher proportion of women complied with their placebo treatment (63%)
compared to those who complied with their HRT treatment (42%). Compliance rates for both
arms decreased as the study progressed (Figure 4.3). While per-protocol analysis suggested
HRT treatment would reduce risk for both mortality and reinfarction outcomes, as-treated
analysis showed marginal risk reduction due to HRT treatment. This contradictory results
may be attributable to the loss of randomization ideals by both per-protocol and as-treated
analysis: the per-protocol analysis censored all women non-compliers in both arms. Such an
analysis may fail to account for systematic dierence between compliers and noncompliers.
For example, the noncompliers would have stopped medication as a result of undesirable
(adverse) side eects like bleeding hence the analysis is likely to produce biased results because
the comparison is not between like with like. On the other hand, as-treated analysis simply
compared those women who received treatment to those who did not where the later group
comprised both women randomized to placebo and non-compliers. In eect, such an analysis
considered the non-compliers in the treatment arm as belonging to the placebo (assumes they
essentially received no treatment). As a result the analysis has the potential to introduce
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selection bias due to a violation of the randomization principle. In general, both per-protocol
and as-treated methods classify participants according to treatment received and analysis
based on such direct measures of treatment ecacy are prone to bias (e.g. selection bias).
The two methods are widely and justiably maligned as awed (Lee et al., 1991; Lui, 2011). In
fact according to Joe and Brensinger (2003) such invalid estimates of eect may essentially
explain nothing in terms of treatment ecacy.
Results from C-Prophet analysis suggested that on average complying with HRT med-
ication would reduce the risk of death by about 35% compared to placebo. Provided the
exclusion restriction holds the C-Prophet allows for causal estimation in the subpopulation
of compliers. However, a key challenge for inference on C-Prophet stems from the fact that the
all-or-nothing treatment indicator is unobserved in the placebo arm. Furthermore, C-Prophet
estimation is premised on the exclusion restriction assumption which is often restrictive and
may be violated in most trials. Also just like the other specialists methods considered for
this work, the application of C-Prophet estimation is limited to covariate-free models. The
exclusion restriction assumption may be considered as reasonably satised in the Esprit data
because it was a double-blind trial. However, participants were likely to know their treatment
hence likelihood of breaching the assumption. The no-deers assumption may be considered
satisfactory for the Esprit data because the participants only had access to the allocation
they were randomized to, i.e. no access to alternative treatment (or no switching).
In general, the CHARM estimates for ACM were similar to the estimates obtained from
C-Prophet analysis: compliance with HRT treatment compared to placebo reduced risk of
death by 34%. For a time-invariant hazard ratio and odds of noncompliance, simple weight-
ing of the ITT hazard ratio estimate using the proportion of noncompliance who experience
event of interest in the treatment arm provided an accurate CHARM estimate. Expect-
edly, the simple CHARM approximations for both ACM and MRCD indicated sensitivity to
proportion of compliance (Figure 4.6): higher proportion of compliers indicated more reduc-
tion in risk of experiencing both outcomes. The extended exclusion restriction assumption
(see Equation 2.11) is key to CHARM estimation and may be considered plausible for the
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Esprit data since we assume that a participant's past treatment had no eect on her present
risk to death. However, in practice the assumption is likely to be violated if the treatment
were to induce adverse side eects (e.g. bleeding) that can potentially aect compliance. Such
a breach may be addressed by allowing lagging of eects into successive intervals (White et al.,
2004), i.e. allowing treatment eect to last past the date of treatment stoppage. This would
however require use of more advanced statistical techniques such as time series in addition
to making other assumptions. The low rate of compliance (43%) in the Esprit study may
generally limit generalization the ndings, i.e. questionable external validity. Also despite
its appeal, the all-or-nothing compliance analysis may fail to account for the more prevalent
partial form of compliance. For example, noncompliance with chronic medication in practice
is rarely an all-or-nothing phenomenon (Sheiner and Rubin, 1995). We may extend the model
(possible with additional plausible assumptions) to account for partial compliance which is
more of the norm than the exception in real life. This may allow us to relax the assumption
so that participants are only assumed to stop treatment at the beginning of the interval.
Assuming a Weibull model for the Esprit data, on average the ITT under the CALM
procedures performed as well as both the CHARM and C-Prophet methods (on the hazard
ratio scale). By adjusting for both crossovers and censoring the CALM results indicated that
compared to placebo, HRT tablets reduced risk for all-cause mortality by half (50%). Also
twin adjustments of both crossovers and censoring indicated no change in the p-values by
retaining the upper condence limits under CALM procedure.
The proportional hazard assumption is key to validity of the Cox's model which also treats
covariates multiplicatively. For the Esprit data there was no evidence to suggest a violation
of the proportional hazards assumptions for both outcomes: all-cause mortality (2=2:51,p-
value=0:113) and myocardial reinfarction or cardiac deaths (2=1:970,p-value=0:161). But
other exible techniques could also be used, for example the Aalen (1989) additive model may
be used to explore the additive eects of covariates. In addition we could simultaneously con-
sider death from both reinfarction and cardiac attack. With multiple failures models, we could
use competing risk analysis to explore the individual causes of death simultaneously. This
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would enable us examine their respective eects on the survival rates among compliers. All
the covariates considered were assumed to be time invariant but we could extend the Cox PH
model to include time-dependent covariates that would account for amount of tablet dosage.
In general, all the the three specialist methods (C-Prophet, CALM and CHARM) were
applicable to the Esprit study. Overall, analysis of the Esprit data suggested that results on
possible eects of HRT treatment vary between methods. Performance of both C-Prophet and
CHARM methods were similar: compliance with HRT treatment would produce a reduction
of about 35% in risk of death compared to placebo. Although limited compliance information
would make all-or-nothing noncompliance classication plausible for C-Prophet analysis, the
CHARM method provided more exibility in adjusting for possible crossovers. Analysis using
the CALM method suggested that compliance with HRT treatment compared to placebo
would reduce the risk of death by half (50%). As a result we recommend the CALM method
which allows twin adjustments of crossovers (partial noncompliance) and recensoring.
In Chapter 7 we will apply statistically designed simulation studies to evaluate the per-
formance of all the specialist methods in terms of bias, root mean squared error and 95%
condence intervals coverage.
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Chapter5
Esprit Analysis II: Predicting Arm-specific
Compliance
The objective in this chapter is to apply methods developed in Chapter 3 to obtain plausible
predictors of compliance to treatment allocation up to 23 months in each treatment arm of
the Esprit study from the set of recorded baseline covariates to construct marginal (arm-
specic) compliance prediction models. We then validate the selected prediction models
using performance calibration and discrimination indices. For both the active treatment and
placebo arms, we consider a binary all-or-nothing compliance variable, i.e. women compliers
who took their HRT tablets and compliers who stuck with their placebo allocation without
interruptions. All the analysis in this Chapter (model selection and validation of selected
prediction models) are performed using the R Software (R Development Core Team, 2008) -
annotated codes are presented in Appendix on page 263.
5.1 Selecting predictors
Before performing any formal modelling, we choose the following 9 potential predictors of
compliance to treatment allocation on the basis of plausibility:
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1. History of hysterectomy: the risk of womb cancer from HRT may inuence noncom-
pliance among those with wombs. On the other hand women without wombs may
have no such fears making them more compliant with their treatment. Also since
unopposed HRT may induce endometrial bleeding, it may become less acceptable
to those with wombs.
2. Smoking: smokers may have dierent attitudes to risk than non-smokers which in turn
may inuence compliance to treatment, e.g. smokers may be more compliant in taking
the tablets with no fear of any risks. We use binary smoking status: never smokers and
others.
3. Social class: professionals and skilled women are likely to be more educated which may
inuence their attitudes towards HRT. We use three ordinal categories: professional,
skilled and others.
4. Age: attitudes towards HRT and possible risks may be dierent between older and
younger women. While older people may be used to some of the postmenopausal
symptoms, younger women may be more compliant with treatment hoping to relieve
some of the symptoms. Also older people might be less willing to tolerate side eects
like bleeding.
5. Cerebrovascular risks (CVD) was dened as a single predictor combining any history
of angina, blood pressure or stroke at baseline. A patient with a history of any of these
risk factors for future infarctions may feel more vulnerable than other patients and this
may aect their attitude to tablet taking.
6. Diabetes: diabetics often manage their condition/lives with intensive intervention on
lifestyle and risk factors compared to non-diabetics. While vulnerability for those with
history of the above risk factors may encourage them to take HRT tablets hoping to
benet from any protective eects, they might not wish to increase their burden of
medications. Hence diabetic women may have a dierent attitude to risk.
158
7. Fractures. Given the known eect of HRT to strengthen bone density, knowledge of a
history of fracture may make a patient more inclined to take the tablet.
8. Alcohol: knowledge of risk of breast cancer among those taking alcohol and HRT may
result in dierent compliance attitude to tablet between those who drink and those
who do not.
9. HRT history: unpleasant or pleasant experience/s from previous HRT use may inuence
decision to take the tablets again.
We used enhanced ordinary bootstrap1 resampling method (Davison and Hinkley, 1997;
Efron, 1979, 1983, 1986) by taking 200 bootstrap samples to estimate the bias due to
overtting and optimism for the models predicting compliance. We then use the result-
ing bias/overtting-corrected estimates of predictive accuracy to investigate the validity of
tted models and evaluate predictive performance in terms of percentage of optimism, cali-
bration slope and concordance c-statistics using Somers (1962) Dxy statistics (see Equation
3.10, Chapter 3) for each individual arm in ve models:
(i) Original model with all the 9 predictors without any selection:
logit() = 0 + 1Hysterectomy + 2Smoking status + 3Social-class+
4Age + 5CVD Risks + 6Diabetes + 7Fracture + 8Alcohol + 9HRT;
where  is the probability of compliance with treatment (placebo/HRT) allocation and
histories of hysterectomy, risks, diabetes, fracture, alcohol together with smoking status
are taken as binary 0=1 predictors.
(ii) Reduced model obtained from (i) above by stepwise backward elimination procedures
using AIC stopping rule and 0:10 signicance level for a variable to be retained in a model.
(iii) Model tted with the retained predictors in reduced model (ii) above but the predictors
assumed pre-specied (following suggestion by Harrell et al. 1996).
1Implemented in Design package in R
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(iv) Intermediate model composed of 6 variables constructed using penalized maximum
likelihood estimation with modied AIC (2>2df) to nd the penalty factor as dened
in the previous chapter (Equation 3.7).
(v) Lasso2 (Least Absolute Shrinkage and Selection Operator) model selection from the
original (i) above.
We also considered penalized maximum likelihood estimation regression versions of the
original and intermediate models above following discussion in Chapter 3 (Section 3.4). We
calculated a uniform shrinkage s using Equation (3.8). The penalized coecients are obtained
from a wide grid search over the 0  50 range and we report optimal penalty factors opt for
each model. Finally we compare the predictive performance of the above 5 models in terms
of calibration, discrimination and level of optimism for the the selected prediction model.
5.2 Results
A higher rate of noncompliance to treatment was recorded among patients randomized to the
active treatment arm (63%) compared to those randomized to placebo (42%). The association
between treatment and compliance to allocation was highly signicant (OR= 0:43; 95% CI
0:33; 0:55). Smoking status, history of diabetes and of HRT use had opposing eects in
predicting compliance in the individual arms for both the original and penalized models.
Women with histories of hysterectomy and cerebrovascular risks risks were more likely to
comply with either treatment allocation but association was stronger in the active arm.
Women with history of taking alcohol were more likely to comply if allocated placebo.
Results from Table (5.1) show the simple expected (uniform) shrinkage estimate for the
original model predicting compliance to HRT and placebo using 9 predictors as 0:76 and 0:47
respectively. This implies the models for predicting compliance to HRT would be less overt-
ted (24%) compared compared to those predicting compliance to placebo (53%). Penalizing
2Implemented using glmpath package in R
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Table 5.1: Original (9 predictors) model results: log odds ratio of predicting compliance (SE)
Coecients (log odds ratio)
Predictors Original Penalized Lasso
Plcbo Active Plcbo Active Plcbo Active
Hysterectomy 0.368 1.135 0.163 0.873 0.112 0.903
(0.244) (0.210) (0.159) (0.182) (0.240) (0.207)
Smoking -0.608 0.303 -0.318 0.244 -0.360 0.158
(0.203) (0.196) (0.144) (0.172) (0.193) (0.193)
Sclass1 (Skilled) 0.144 0.328 0.064 0.205 0.000 0.000
(0.219) (0.237) (0.149) (0.194)
Sclass2 (Professional) -0.353 -0.469 -0.158 -0.290 0.000 0.000
(0.391) (0.385) (0.259) (0.316)
Agez -0.011 -0.025 -0.005 -0.022 0.000 -0.007
(0.020) (0.019) (0.016) (0.017) (0.019)
CVD Risks -0.191 -0.380 -0.075 -0.293 0.000 -0.194
(0.195) (0.193) (0.142) (0.170) (0.188)
Diabetes -0.096 0.223 -0.046 0.139 0.000 0.000
(0.272) (0.267) (0.167) (0.217)
Fracture 0.109 0.011 0.054 0.008 0.000 0.000
(0.244) (0.274) (0.160) (0.222)
Alcohol 0.467 0.126 0.240 0.088 0.265 0.000
(0.207) (0.194) (0.146) (0.171) (0.202)
HRT 0.220 -0.336 0.092 -0.195 0.000 0.000
(0.337) (0.299) (0.179) (0.234)
Shrinkage (s) 0.471 0.760 0.635 0.804
opt 43.00 13.00
df 5.220 7.740
z log OR per year
Sclasssocial class
Plcboplacebo
s calculated using Equation (3.8) for r(df)=9
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the coecients resulted in substantial reduction/shrinkage of the log odds ratio estimates
(Table 5.1, columns 4 5). Penalization improved the original models by reducing the level
of overtting when predicting compliance to both HRT and placebo: models predicting HRT
compliance are now overtted by 20% and those predicting placebo by 36%. Although penal-
ization produced fewer eective degrees of freedom while predicting compliance to placebo
(df=5:22) compared to predicting compliance to HRT (df=7:74), the tradeo was a larger
optimal penalty factor: opt = 43 and 13 respectively. These results indicate better predic-
tion for compliance to HRT compared to compliance to placebo, i.e. the predictive model
for placebo was far more overoptimistic compared to HRT prediction.
Table 5.2: Intermediate (6 predictors) model results
Coecients (log odds)
Predictors Original Penalized Lasso
Plcbo Active Plcbo Active Plcbo Active
Hysterectomy 0.384 1.099 0.237 0.904 0.117 0.904
Smoking -0.607 0.293 -0.424 0.249 -0.367 0.168
Age -0.011 -0.019 -0.007 -0.019 0.000 -0.009
CVD Risks -0.190 -0.343 -0.112 -0.288 0.000 -0.203
Fracture 0.104 0.007 0.072 0.007 0.000 0.000
Alcohol 0.490 0.095 0.334 0.077 0.269 0.000
Shrinkage (s) 0.655 0.840 0.724 0.862
opt 20.00 10.00
df 4.300 5.030
s calculated using Equation (3.8) for r(df)=6
Analysis of the intermediate model comprising 6 predictors (Table 5.2) using all the three
criteria produced improved prediction of compliance to both HRT and placebo. In predicting
compliance to HRT and placebo the original models would be overtted by 16% and 34%
respectively. There was relatively less penalization of the coecients from the intermediate
model compared to the original model - small improvement (20% to 16%) in overtting for
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predicting compliance to HRT. However, there is signicant improvement in predicting com-
pliance to placebo with the optimal penalty now reduced to only twice (20) that for HRT com-
pliance (10) while it was more than three times (43 : 13) larger for the full model (Table 5.1).
Furthermore, the eective degrees of freedom are now almost similar (5:3 and 4) for predic-
tions of compliance to HRT and placebo.
Table 5.3: Selected predictors (log-odds ratios) of compliance for 3 criteria
Stepwise Intermediate Lasso
Active arm
Hysterecy (1:088) Hysterec (0:904) Smoking (0:249) Hysterec (0:903)
Smoking (0:331) Age ( 0:019) CVD Risks ( 0:288) Smoking (0:158)
CVD Risks ( 0:355) Fracture (0:007) Alcohol (0:077) CVD Risks ( 0:194)
Age ( 0:007)
Placebo arm
Hysterec (0:349) Hysterec (0:237) Smoking ( 0:424) Hysterec (0:112)
Smoking ( 0:552) Age ( 0:007) CVD Risks ( 0:112) Smoking ( 0:360)
Alcohol (0:494) Fracture (0:072) Alcohol (0:334) Alcohol (0:265)
yHysterectomy
The Lasso method in general selected similar predictors of compliance to both HRT
and placebo as those from the stepwise backward elimination but with signicantly re-
duced/shrunk estimates (Table 5.3). Specically, both Lasso and the stepwise selection
procedures selected the same predictors of compliance to placebo. But Lasso method also se-
lected age as a marginal additional predictor of compliance in the active treatment arm. The
coecients (log odds) produced by the Lasso model were more severely penalized compared
to those from the intermediate model.
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5.3 Validation performance of selected models
We used enhanced bootstrap on all aspects of models development (selection and estimation
procedures) to revalidate on samples taken with replacement from the whole sample and
apply on the 5 models above: the original composed of 9 predictors, the reduced model of
3 predictors, same reduced model with 3 predictors assumed pre-specied, the intermediate
of 6 predictors and the Lasso model. The reduced model was obtained from the original
model using stepwise backward elimination procedures using AIC stopping rule and 0:10
signicance level for retaining a predictor in a model. The variables selected for the reduced
model were consistently (90%) selected across bootstraps resamples. These were the same
predictors deemed important by the backward elimination algorithm.
The original model consisting of 9 predictors produced better predictions of compliance to
HRT than placebo (Table 5.4). While predicting compliance to HRT and placebo, the origi-
nal models would be overtted by 18% and 33% respectively. In addition, these models would
be optimistic by 6% and 9% respectively in predicting compliance to HRT and placebo. The
reduced model would also perform relatively better in predicting compliance to HRT com-
pared to predicting placebo - specically the reduced model predicting compliance to HRT
would perform better at distinguishing compliers from non-compliers (concordance c=0:620)
the reduced model predicting compliance to placebo (c=0:566). Reduced models predicting
compliance to placebo would be more optimistic (8%) than those predicting compliance to
HRT (6%). Predictions for compliance to HRT using the reduced model would be equally
well calibrated (slope=0:83) compared to predictions from the original model (slope=0:82).
As expected, the model with 3 predictors assumed pre-specied performed best in terms of
both calibration and discrimination among the 5 models considered in predicting compliance
to both HRT and placebo. These models also produced least optimistic ts for predicting
compliance to both arms. Specically predictions of compliance to both HRT and placebo
using the 3 predictors assumed pre-specied were almost perfectly calibrated (0:96 and 0:95)
and least optimistic (1% and 2%).
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Table 5.4: Validation performance: calibration,concordance and optimism
Model Calibration Optimism Concordance
slope (%) cz-statistics
(i) Original
Active 0.818 6.1 0.639
Placebo 0.671 8.6 0.573
(ii) Reduced
Active (hyst+smk+CVD) 0.827 5.8 0.620
Placebo (hyst+smk+alc) 0.667 8.1 0.566
(iii) Reducedy
Active (hyst+smk+CVD) 0.961 1.4 0.642
Placebo (hyst+smk+alc) 0.950 2.0 0.597
(iv) Intermediate
(6 predictors)
Active 0.879 4.1 0.636
Placebo 0.766 6.0 0.580
(v) Lasso
Active (hyst+smk+age+CVD) 0.935 2.3 0.647
Placebo (hyst+smk+alc) 0.925 2.3 0.595
hysthysterectomy
smk smoking status
alcalcohol
CVDcerebrovascular disease
ymodel assumed pre-specied
zc calculated from Dxy (see Equation 3.10)
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Validation of the model with 6 predictors produced good performance with intermedi-
ate measures between the original models of 9 predictors and the Lasso models (see below).
We observe that predictions of compliance to both HRT and placebo using the intermediate
model was equally good as predictions of compliance to HRT using the the reduced model.
For example predictions of compliance to placebo using the intermediate model was equally
optimistic (6%) as predictions of compliance to HRT using the reduced model. Overall, mod-
els from the intermediate model provided signicantly improved predictions of compliance to
both HRT and placebo in terms of calibration and optimism without aecting the capability
to distinguish (discriminate) between compliers and non-compliers.
Besides the reduced model tted with predictors assumed pre-specied, Lasso models
produced the best calibrated and discriminative models predictive of compliance to both
HRT and placebo (Table 5.4, lower panel). Predictions of compliance to both HRT and
placebo using the Lasso models were the least optimistic (2%) and almost perfectly calibrated
(slope= 0:93). Although the performance of Lasso models produced substantially shrunk
and improved estimates compared to the stepwise backward elimination method, the severe
penalization (considerably many coecients shrunk exactly to zero) have the potential to
exclude potential predictors (waste of data).
In the next chapter we link the two marginal models for each treatment arm into a casual
model that provides principal eects for each stratum. Specically, using the intermediate
model we choose common penalized predictors of compliance for both HRT treatment and
placebo (smoking status, history of hysterectomy, CVD risks, alcohol, fracture and age at
admission) and join the resulting two marginal models using an association model from which
we obtain relative risks for each stratum.
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Chapter6
Esprit Analysis III: Modelling Effects of
Noncompliance in Two Arms
6.1 Introduction
In this chapter we use the selected arm-specic predictors of compliance obtained in the pre-
vious Chapter 5 and apply Roy et al. (2008) method of principal stratication framework as
outlined in Section 2.7 to develop causal models linking the two marginal models in order to
obtain principal eects for each stratum. Applied to the Esprit data, one marginal model es-
timates arm-specic probability to comply with HRT treatment in the presence of six baseline
(penalized) covariates selected in Chapter 5 above which are predictive of compliance while
the other model estimates probability of compliance to placebo allocation using the same set
of predictors of compliance. We considered all-or-nothing compliance to treatment allocation
up to 23 months in the Esprit study. We used the intermediate model comprising 6 poten-
tial predictors of compliance considered for each arm including ve binary (0/1) variables:
histories of hysterectomy, smoking, cerebrovascular risks (CVD-angina or blood pressure or
stroke), fractures and alcohol. We also included age of patient at admission as a continuous
predictor variable. The Stata and WinBUGS codes are shown in Appendix on page 265.
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6.2 Linking two marginal compliance models
In the Esprit data there is compliance data for both the active HRT treatment and placebo.
Here placebo and HRT tablets are considered as treatment 0 and treatment 1 respectively.
Owing to poor compliance rates with HRT assignment for the Esprit data, we assume the
intermediate model comprising smoking status, history of hysterectomy, CVD risks, alcohol,
fracture and age at admission as common predictors of compliance for both HRT treatment
and placebo. We use logistic models to predict compliance with both treatments separately:
logit [j(x]) =
 
6X
i=0
jixi
!
; j = 0; 1
where j(x) is the probability of compliance with treatment allocation j given the selected
predictors x1; : : : ;x6. We estimated probabilities of complying with HRT treatment/placebo
allocations using:
^j(x) =
"
1 + exp
 
 
6X
i=0
^jixi
!# 1
; j = 0; 1;
where  estimates the log odds ratio of compliance estimated from the prediction model as
outlined before in Chapter 5.
6.2.1 Fitting the model
We estimated the causal risk ratio parameters ij (Equation 2.25) in a Bayesian setting using
WinBUGS1 (Spiegelhalter et al., 2004) within Stata (Thompson et al., 2006) software. We
used non-informative priorsN(0; 106), i.e. normal distributions with mean zero and large vari-
ance for all log odds ratio parameters j for potential predictors of compliance. We specied
uniform (0; 1) priors for the S=sZ (i; i=1; : : : ; 7) parameters, z=0; 1, S=(0,0),(1,0),(0,1),(1,1)
and set the sensitivity parameter =0; 0:2; 0:5 and 0:8. The choice of  were motivated by
the need to explore all possible compliance behaviours including conditional independence
1BUGS Project. BUGS: Bayesian Inference Using Gibbs Sampling
(http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/)
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(=0) and almost-perfect correlation (=0:8). We ran three chains: null starting values for
chain one, mean and median values from a trial run for chains two and three respectively.
For convergence assessment, we ran simulation for 101; 000 iterations for each of the three
chains and excluded the rst 1; 000 as burn-in. Posterior median relative risks (minimizing
linear loss function) provided Bayesian point estimates for each stratum.
First we use the prediction models to estimate log odds ratio of compliance to both HRT
(active) treatment and placebo for both ACM and MRCD outcomes separately. Next we
estimate the mean proportion of compliance ^0(x) and ^1(x) for all subjects. We then es-
timate stratum-specic joint compliance proportions under conditional independence (=0,
see Table 6.1) and for three other dierent values of sensitivity ( = 0:2; 0:5; 0:8), i.e. to
explore possible eects of . Finally we estimate causal eects in terms of posterior mean
relative risks of death for each stratum and compare them for the 4 values of  listed above.
6.3 Results
Results from Table (6.1) shows that the posterior median log odds ratios of compliance to
treatment were generally similar for both ACM and MRCD outcomes. Under conditional
independence (=0), patients with histories of hysterectomy were more likely to comply with
their treatment allocation if randomized to either placebo or HRT tablet. While smokers were
more likely to comply with treatment under HRT allocation, they were less likely to comply
under placebo. On the other hand women with history of alcohol use were more likely to
comply under placebo allocation only. On average, the results are comparable to those from
the previous chapter (Table 5.2).
The plot (Figure 6.1) of estimated compliance probabilities ^ij at dierent values of
sensitivity parameter  depicts how the joint compliance behaviour pattern/trend depends
on choice of the . We observe that the proportion of women who would comply with one
treatment allocation but not the other (S=(0; 1)) and (S=(1; 0)), decreased with increase
in the value of .
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Table 6.1: Median estimates (mean 95% CI) of the posterior distribution of compliance model
parameters for ACM and MRCD outcomes when =0 (conditional independence)
Parameter Placebo arm posterior Active treatment arm posterior
median log odds ratio (^0) median log odds ratio (^1)
ACM MRCD ACM MRCD
Intercept 0.837 0.737 -0.602 -0.656
(0.385, 1.309) (0.350, 1.127) (-1.068,-0.113) (-1.076, -0.258)
Hysterectomy 0.472 0.507 0.996 1.079
(0.001, 0.929) (0.059, 0.970) (0.607, 1.401) (0.682, 1.486)
Smoking -0.568 -0.545 0.227 0.315
(-0.983,-0.160) (-0.923, -0.172) (-0.188, 0.632) (-0.054, 0.063)
Agez 0:001 -0.008  0:027 -0.012
(-0.036, 0.038) (-0.046, 0.008) (-0.061,0.007) (-0.048, 0.022)
CVD Risks -0.188 -0.275 -0.282 -0.271
(-0.560,0.171) (-0.629, 0.087) (-0.650, 0.071) (-0.0631, 0.078)
Fracture 0.043 0.088 0.073 -0.050
(-0.408,0.487) (-0.357, 0.547) (-0.455,0.580) (-0.593, 0.470)
Alcohol 0.460 0.481 -0.052 0.135
(0.071, 0.854) (0.120, 0.863) (-0.417,0.312) (-0.237, 0.495)
z log OR per year
Figure 6.1: Compliance behaviour pattern for each stratum.
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Figure (6.1) shows that the proportion of patients who would have the same compliance
status under either treatment allocation increases as  increased, i.e. the estimated pro-
portion of women in stratum 3 (S = (1; 1)) and in stratum 0 (S = (0; 0)). The proportion
of subjects who would actually comply with either treatment allocation (S = (1; 1)) would
be generally higher than those who would not comply with either allocation (S = (0; 0)).
The proportion of patients who would comply with HRT tablets only (S=(0; 1)) would be
relatively lower compared to the proportion that would comply with placebo allocation only
(S=(1; 0)).
On average, the estimated median probabilities of compliance was higher among those pa-
tients allocated to placebo for both ACM (MRCD) outcomes (^0(x)=0:567 (0:565)) compared
to those on HRT tablets (^1(x)=0:461 (0:470)), i.e. the ratio U(x)=minf1; ^1(x)^0(x)g=0:795 (0:810).
We note the likelihood that a higher prevalence (proportion) of placebo compliance compared
to HRT may be a limitation of the model to eectively evaluate active HRT ecacy.
Table 6.2: Median compliance proportion per principal stratum for dierent values of 
Type Outcome: All-cause mortality Outcome: Reinfarction
(stratum)  
0 0.2 0.5 0.8 1 0 0.2 0.5 0.8 1
3 (1; 1) 0.264 0.296 0.353 0.406 0.460 0.266 0.303 0.359 0.417 0.456
2 (0; 1) 0.197 0.165 0.105 0.047 0 0.200 0.164 0.111 0.059 0.023
1 (1; 0) 0.303 0.262 0.211 0.155 0.105 0.300 0.263 0.206 0.142 0.102
0 (0; 0) 0.236 0.277 0.330 0.391 0.435 0.235 0.270 0.325 0.382 0.419
For the 4 strata at moderate value of sensitivity parameter  = 0:5 (Table 6.2), the
group with the highest prevalence was patients who would comply with either treatment
(^11 = 0:353 (0:359)) and the group with the lowest prevalence is those who would only
comply with HRT tablets (^01 = 0:105 (0:111)). The median probabilities of compliance
among those patients who would only comply with placebo and those who would not comply
with either treatment allocation were ^10=0:211 (0:206) and ^00=0:330 (0:325) respectively.
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Table 6.3: Causal risk ratio estimates (means of median posterior relative risks) for ACM
and MRCD (mean 95% CI) for each stratum for dierent values of : (a) All-cause mortality
(b) Myocardial reinfarction.
Compliance with Compliance with Compliance with
both HRT and placebo HRT only placebo only
 ^2(
s=(1;1)
1 ) ^6(
s=(1;1)
0 ) ^1(
s=(0;1)
1 ) ^7(
s=(0;1)
0 ) ^4(
s=(1;0)
1 ) ^5(
s=(1;0)
0 )
(a)
0 0.010 0.049 0.085 0.081 0.016 0.015
11=0:229 (0.008,2.833) 01=1:039 (0:345; 3:554) 10=1:031 (0.030,37.439)
0.2 0.011 0.044 0.100 0.097 0.019 0.016
11=0:271 (0.009,2.691) 01=1:017 (0.259,3.969) 10=1:152 (0.032,36.779)
0.5 0.014 0.039 0.137 0.140 0.024 0.018
11=0:385 (0.014,2.945) 01=0:962 (0.126,5.020) 10=1:289 (0.036,45.188)
0.8 0.024 0.037 0.206 0.291 0.033 0.017
11=0:659 (0.030,2.702) 01=0:725 (0.032,6.652) 10=1:875 (0.042,69.652)
(b)
0 0.010 0.025 0.108 0.144 0.093 0.126
11=0:094 (0.003,2.466) 01=0:746 (0.324,1.408) 10=0:748 (0.310,15.170)
0.2 0.010 0.126 0.130 0.170 0.104 0.124
11=0:089 (0.003,2.154) 01=0:766 (0.329,1.570) 10=0:832 (0.331,16.610)
0.5 0.010 0.125 0.182 0.198 0.115 0.124
11=0:088 (0.003,2.107) 01=0:941 (0.388,3.102) 10=0:920 (0.275,17.930)
0.8 0.027 0.124 0.196 0.105 0.085 0.125
11=0:225 (0.038,4.607) 01=1:726 (0.390,42.210) 10=0:706 (0.101,14.210)
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Table 6.3 provide causal risk ratio estimates (Bayesian principal eects) obtained from
mean posterior median relative risks for each stratum and corresponding mean 95% credible
intervals for dierent values of sensitivity parameter . Here a posterior relative risk  was
obtained as the ratio of two probabilities of experiencing an event due to compliance with
one treatment allocation relative to another in a stratum. Most of results (not all) show
posterior median relative risks of less than one for all values of  which indicates lower risks
for ACM and MRCD for those women randomized to HRT who would be highly compliant
with their treatment allocation. Of primary interest is the quantity 11=[
S=(1;1)
1 ][
S=(1;1)
0 ]
 1,
i.e. the posterior relative risk for mortality (or reinfarction) due to HRT treatment compared
to placebo for the subgroup which would comply with either intervention (type 3). The
results shows that the mean 95% credible intervals widened with increase in  values, an
indication of less correlation between HRT treatment and placebo compliances. Overall, the
results indicated that HRT tablets reduced risks for myocardial reinfarction more than the
reduction in risks for all-cause mortality.
For a moderate correlation value ( = 0:5), the results suggest that compliance with
HRT treatment compared to taking placebo among those who would comply with either
treatment reduced the risk for all-cause mortality by 61%, i.e. causal risk ratio 11=0:385,
95% CI : 0:014; 2:945. Also for this value of sensitivity parameter, compliance with HRT
tablets only would marginally reduce the risk of death by about 4%, i.e. causal risk ratio
01 = 0:962; 95% CI : 0:126; 5:020. On the other hand, compliance with placebo treatment
only would be harmful for all values of , for example, while compliance with placebo would
increase the risk for death by 29% (10=1:289; 95% CI : 0:036; 45:188) when =0:5, the risk
would increase substantially by 86% (10=1:875; 95% CI : 0:042; 69:652) when =0:8.
In general although the results suggest that compliance with HRT treatment compared
to placebo would signicantly reduce risks for both death and reinfarction among those
who would comply with either treatment, the estimates are very dierent from those ob-
tained earlier using specialist methods for one active arm and even ITT (see Chapter 4:
Tables 4.3, 4.8,4.9 and 4.11). This seems likely to be due to a failure of the method as
applied to Esprit data as may be deduced from the implausible causal risk ratio estimates
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obtained above especially for the very low risks (11) for reinfarction due to compliance with
HRT treatment compared to placebo among the highly compliant for all  values. We may
also discern lack of precision and/or failure in the method manifested in wider (`abnormal')
mean 95% credible intervals corresponding to the causal risk ratio estimates of ecacy due
to compliance with placebo treatment only (10) for both mortality and reinfarction out-
comes. Furthermore, we observe that these 95% credible intervals became wider as the
sensitivity parameter  increased.
The size of causal (principal) eects varied according to value of sensitivity parame-
ter. Risks for both death and reinfarction due to compliance with HRT tablets relative to
placebo for those who would comply with either treatment increased with increase in the
value of sensitivity parameter . Conversely, results show decrease in risks for both death
and reinfarction due to compliance with HRT treatment only as the value of  increases. As
expected the risk for death due to compliance with placebo only was higher regardless of
the level of sensitivity .
Table 6.4: Comparison of results from specialist methods and Roy et al. (2008) method
Specialist methods Roy et al. (2008) method
Hazard ratio (HR) RRz=!^11 + (1  !)^01

Outcome CALMy CHARM C-Prophet 0 0.2 0.5 0.8
Mortality 0.504 0.660 0.656 0.575 0.532 0.571 0.666
Reinfarction 0.990 0.988 0.988 0.374 0.327 0.289 0.411
yHR Weibull model (Table 4.4 & Equation 2.4); zRelative risk weighted using proportions in Table 6.2
Roy et al. (2008) argued that the two subgroups (types 3 and 2) who would comply with
either treatment and only active HRT treatment respectively may be of interest. Table 6.4
provide a comparison of results from the specialist methods (discussed in Chapter 4) which
considered compliance in the active treatment arm only while ignoring placebo compliance
and the posterior relative risks from the Roy et al. method which accounts for placebo compli-
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ance among the subgroup who would comply with active HRT treatment for dierent values
of sensitivity parameter. To obtain an overall ecacy estimate for comparison with special-
ist methods, we weighted the posterior relative risks (RR) with the proportion of compliance
for each stratum provided in Table 6.2: RR=!^11 + (1  !)^01, where !^= ^11=(^11 + ^01).
The hazard ratio estimates from both C-Prophet and CHARM methods were comparable
with the causal risk ratios from the Roy et al. method at high value of the sensitivity
parameter ( = 0:8) for all-cause mortality outcome. This may be an indication of (high)
correlation between compliances with placebo and HRT treatment. The CALM method also
produced comparable results to Roy et al. method at low value of the sensitivity parameter
(=0:2) for all-cause mortality outcome: compliance with HRT treatment relative to placebo
would reduce risk of death by 47%. But in general results from the Roy et al. method
were very dierent compared to those obtained by the specialist methods, i.e, the results
varied with change in the values of sensitivity parameter . The apparent failure of the Roy
et al. method may be attributed to the (strong/untestable) parametric assumption of the
association model linking the two marginal models.
Overall, the CALM method performed `best' among the specialist methods. Specically,
by adjusting for both crossovers and censoring the CALM results suggest compliance with
HRT treatment would reduce risk for mortality by half (HR=0:5) among those women who
would comply with HRT medication compared to those on placebo. The variation in ecacy
estimates from the Roy et al. method may be an indication of dierences in compliance
behaviour in the two arms. Perhaps the Roy et al. (2008) model captured the underlying
correlation between such compliance behaviours in respective arms using the sensitivity pa-
rameter , hence making the results dependent on it. But we do not know the value of 
and so the method should not be recommended for the Esprit data.
As outlined in Chapter 2 (Section 2.7), application of the Roy et al. (2008) method is
premised on plausibility of the the crucial (but untestable) assumption that the outcome is
independent of the set of covariates predictive of treatment compliance given a compliance
type and treatment assignment. Hence the task of selecting suitable predictors of treatment
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Table 6.5: Sensitivity analysis of the Roy et al. (2008) method: Relative risk (mean 95% CI)
All-cause mortality Myocardial reinfarction
 11 01 10 11 01 10
A
0 0.256 1.036 1.041 0.062 0.733 0.851
(0.040,3.750) (0.101,3.359) (0.299,41.897) (0.017,2.368) (0.296,1.383) (0.474,19.696)
0.2 0.243 1.007 1.128 0.057 0.744 0.863
(0.043,3.245) (0.080,3.525) (0.227,37.919) (0.016,2.889) (0.283,1.472) (0.449,21.909)
0.5 0.363 1.001 1.164 0.053 0.910 0.854
(0.053,2.847) (0.056,5.962) (0.078,41.729) (0.014,2.889) (0.295,3.180) (0.264,23.516)
0.8 0.623 0.709 1.741 0.208 1.753 0.471
(0.209,3.251) (0.045,6.932) (0.011,71.002) (0.129,3.494) (0.277,43.438) (0.027,15.675)
B
0 0.299 1.039 1.031 0.094 0.746 0.748
(0.008,2.833) (0.345,3.554) (0.030,37.439) (0.003,2.466) (0.324,1.408) (0.310,15.170)
0.2 0.271 1.017 1.152 0.089 0.766 0.832
(0.009,2.691) (0.259,3.969) (0.032,36.779) (0.003,2.154) (0.329,1.570) (0.331,16.610)
0.5 0.385 0.962 1.289 0.088 0.941 0.920
(0.014,2.945) (0.126,5.020) (0.036,45.188) (0.003,2.107) (0.388,3.103) (0.275,17.930)
0.8 0.659 0.725 1.875 0.225 1.726 0.706
(0.030,2.702) (0.032,6.652) (0.042,69.652) (0.038,4.607) (0.390,42.687 (0.101,14.210)
C
0 0.265 1.057 1.034 0.076 0.737 0.830
(0.041,2.419) (0.109,2.557) (0.197,31.790) (0.020,2.880) (0.291,1.439) (0.442,17.672)
0.2 0.262 1.011 1.137 0.067 0.761 0.828
(0.048,2.127) (0.084,2.063) (0.101,31.760) (0.017,2.620) (0.289,1.600) (0.392,1.961)
0.5 0.376 1.006 1.147 0.054 0.951 0.733
(0.065,2.516) (0.059,4.932) (0.032,39.478) (0.014,2.520) (0.321,3.566) (0.175,3.392)
0.8 0.648 0.717 1.712 0.216 1.316 0.438
(0.231,3.097) (0.044,6.119) (0.008,66.795) (0.089,5.420) (0.206,41.190) (0.027,11.020)
Model comprising A3 (Lasso),B6 (intermediate) and C9 (all) predictors of compliance
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compliance constitutes an integral part of ensuring plausibility of this assumption. A com-
parison of results for models composed of dierent sets of predictors may provide a form of
sensitivity analysis for this assumption. Table 6.5 show results in terms of causal relative risks
for models predicting compliance using three sets of predictors considered earlier in Chapter 3:
3; 6 and 9 predictors from Lasso, intermediate and all plausible predictors respectively.
The causal risk ratio estimates using 3, 6 and 9 sets of predictors were comparable for
all strata. In general, given a set of predictors, the results show same trend in principal
eects with respect to change in magnitude of the sensitivity parameter  for both outcomes
(mortality and reinfarction). Specically, the causal risk ratios suggest marginally lower risks
for both death and reinfarction when using fewer covariates selected using the Lasso method
of model selection compared to relative risks resulting from use of 6 and 9 predictors of
compliance. This may be an indication that the advantages of classical model selection are
transferable to the Roy et al. (2008) method via use of optimal marginal compliance models.
However, we note that while selecting plausible predictors of compliance forms an integral
component of the method, model selection only acts as an intermediate step that provides
covariates for marginal compliance prediction models which are then joined into a causal
model using the crucial but unknown sensitivity parameter.
Results from the sensitivity analysis above (Table 6.5) may be useful tool to demonstrate
the phenomenon that causal (principal) eects are dependent on the choice of covariates
predicting compliance. This may be an indication of failure (implausibility) of the Roy et al.
(2008) method as applied to the Esprit data owing to inadequate compliance data. Also the
method's dening assumption that the outcome is considered independent of the set of covari-
ates predicting compliance for a given stratum may not be plausible for the Esprit data es-
pecially with regard to history of hysterectomy and cerebrovascular risks given the likelihood
of association between these factors and treatment compliance and hence possible ecacy.
In Chapter 8 we will apply a statistically designed simulation study to evaluate the
performance of the Roy et al. (2008) method in terms of bias and 95% credible intervals
under both homogeneous and heterogenous treatment eects assumptions.
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Chapter7
Monte Carlo Study I: Performance of Statistical
Methods for Analysing Survival Data in the
Presence of Nonrandom Compliance
7.1 Introduction
The objective in this chapter is to evaluate six statistical methods used to analyse the Esprit
data: three naive and three specialist methods. The next section provides a summary of
statistical properties that will be used to compare the performance of estimators in this
chapter and the next one. In section three we outline the aims of the simulations followed
by a section that describes the simulations set-up. The next section presents details of the
six methods of analyses followed by the results and the nal section provide the conclusions.
7.2 Properties of statistical estimators
Statistical analysis in this chapter and next will involve comparing estimates from dierent
(competing) statistical methods. In this section we review some standard statistical concepts
that will help us make these comparisons. Most statistical inference involve use of point
estimators. Since such estimators are random variables, their desirable properties can be
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evaluated from the characteristics of their sampling distributions (Casella and Berger, 2001;
Shervish, 1995). Some of the desirable properties of estimators commonly used for statistical
inference include unbiasedness, mean square error and most ecient estimators.
7.2.1 Unbiased estimator
Bias is a prevalent phenomenon that can be introduced in a study at any state, e.g. during de-
sign or execution. It can mostly be controlled but very dicult to avoid all together. Bias may
ordinarily be described as the amount of deviation from the truth. We note that the statisti-
cal meaning of bias as used here is narrower that dened earlier in Chapter 1 (Section 1.6).
For a random sample from a population X1; X2; : : : ; Xn, let ^(X1; X2; : : : ; Xn) be an estimate
for the unknown parameter . An estimator ^ is said to be unbiased for  if
E[^(X1; X2; : : : ; Xn)] = ;
i.e. on average, the estimator is right (with zero bias): E(^)  = 0. Otherwise the estimator
is said to be biased if E(^) 6= . Formally, if ^ is an estimator of a parameter , then the
bias of ^ is dened as
Bias(^) = E(^)  :
The presence of bias will result in a parameter (e.g. mean hazard ratio or relative risk)
consistently overestimated or underestimated which implies inaccurate measure of ecacy.
7.2.2 Variance and mean squared error
The precision of estimates are often provided in terms of variance and/or width of condence
intervals. A condence interval provides a range of values around the mean that is likely
to contain the estimate. On the other hand, variance is a measure of a description of how
far individual values for a given dataset vary from the mean. Formally, a sample variance is
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dened as the average of the squared deviation from the mean:
Var(Xi) =
1
n  1
nX
i=1
(Xi   X)2;
where X is the mean of Xs and
p
Var(Xi) is the standard deviation.
An estimate with a smaller variance or narrower condence interval is considered com-
paratively more precise, i.e. the narrow condence interval and/or smaller variance indicates
less variability between individual values. We often consider an estimate as accurate if it is
precise and unbiased. A general criterion for assessing how good an estimator ^ is for  that
combines both its relative magnitude of bias and variance (precision) is the mean squared
error (MSE) which is dened as the expected value of the square of the sampling error:
MSE(^) = E(^   )2 = E[^   E(^) + E(^)  ]2
= E[^   E(^)]2 + 2E
h
(^   E(^))(E(^)  )
i
| {z }
=0
+E[E(^)  ]2
= E[^   E(^)]2 + [E(^)  ]2 = Var(^) + [E(^)  ]2
= Var(^) + [Bias(^)]2:
The MSE is a useful measure of overall accuracy (Collins et al., 2001): it is a sum of bias which
measures how far o the estimator is (on average and variance that measures the variability
of the estimator, i.e MSE(^)=Var(^) for an unbiased estimator. The MSE provide squared
values but sometimes it may be meaningful to use root mean squared error (RMSE)=
p
MSE.
We will use RMSE for our analyses to evaluate the performance (accuracy) of our estimators
in terms of bias.
A key concept behind a condence interval is coverage probability, i.e. the proportion of
the time that the interval contains the true specied value of interest (Burton et al., 2006;
Dodge, 2003). Simulation studies are often used to evaluate the performance of estimates from
competing methods in terms of the coverage probability where a higher coverage probability
is an indication that Type I error rate (see below) for testing a null hypothesis of no eect is
properly controlled (Collins et al., 2001). Following Burton et al. (2006), our simulation will
aim to show this using the nominal value of 95%.
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7.2.3 Most efficient estimator
Making a choice between two unbiased estimators in terms of their respective variances
(precision) is a challenge given the innite possibility of other estimators (Casella and Berger,
2001; Kapadia et al., 2005; Panik, 2005). The Cramer-Rao lower bound provide a solution
in which we choose the estimator with the least variance among the unbiased set, i.e. if
the variance for some  is equal to this lower bound, then there is no estimator that is
more precise. Specically, if ^ is an unbiased estimator of , then under some regularity
conditions1, the variance of ^ must satisfy the Cramer-Rao (CR) inequality
Var(^)   E

@2 logL
@2
 1
= CR(; n); (7.1)
where logL = Pni=1 log f(xi; ). If E(^) =  (unbiased) and strict equality holds in (7.1),
then ^ is the most ecient (or minimum variance bound) estimator of . In other words,
the most ecient estimator is the unbiased estimator whose variance equals the right hand
side of Equation (7.1).
7.2.4 Type I and Type II errors
In statistically testing hypothesis to evaluate any dierence between two treatments, the
possible errors include committing Type I error (false positive) and Type II (false negative).
Type I error occurs when a researcher concludes (on the basis of experimentation) that an
experimental treatment has a statistically signicant eect over the comparator, when in
fact it does not. Researchers often use p-values to estimate the probability of committing
Type I error, for example p<0:05 (also called 5% signicance level) means 1 in 20 chance of
committing Type I error.
On the other hand Type II error occurs when a researcher misses a signicant eect
1(i) the sample space 
 is independent of ; (ii) the derivatives @L=@; @2L=@2 exist for all admissible ;
and (iii) E(@ logL=@)=0.
181
of the treatment on an experimental group. Power of a test is the probability of making
the right decision when the null hypothesis is not correct, i.e. correctly concluding eect of
experimental treatment. Low power and small sample sizes are main causes of possible failure
to demonstrate eect if it truly exists (van Belle et al., 2004).
7.3 Aims of the simulations
We consider the methods dealing with noncompliance in the context of a randomized con-
trolled trial comparing an active treatment and control in terms of survival, using simulation
studies when non-compliers comply for part of their treatment period. The primary interest
is to compare performance in terms of induced bias and root mean squared error of methods
which assume all-or-nothing compliance (i.e. non-compliers do not take any of the assigned
treatment) throughout the study to methods assuming partial compliance, especially when
compliance is nonrandom. For comparison, these methods are also evaluated under random
compliance.
An important feature of methods which allow partial compliance in the active arm is
the assumption about duration of treatment eects. Such models assume that risks for the
non-compliers in the treatment arm, once they cease treatment, instantly revert to their coun-
terfactual `no treatment' risk, thus assuming that any eect of treatment stops immediately
one becomes a non-complier. To reect this, our simulation model assumed that treatment
eects stop immediately. In evaluating the results, it is also important to note the separate
eect of heterogeneous risks within groups on the performance of the proportions hazards
(PH) methods. Even with full compliance, application of a simple Cox PH model which as-
sumes homogeneous risks is likely to produce biased estimates of the treatment causal eect
in these circumstances. This is because the most frail people are selected out of the data in
the early stages so that the marginal hazard ratio for survivors actually changes over time.
The formula by Aalen (1998) shows the time relationship of the marginal hazard ratio, HR(t)
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say, when within group variation in risk follows Gamma distribution:
HR(t) = HR(0)

1 +  H(t)
1 +  HR(0) H(t)

; (7.2)
where H(t) is the cumulative baseline hazard to time t and  the standardized within-group
variance of the hazard rates. We will use this formula to predict the typical degree of bias
that would arise by tting a non-time dependent PH model even with full compliance. We
then use this prediction to gauge the extent to which any bias in the compliance adjusted
methods described above might be due to ignoring heterogeneity rather that a aw in the
compliance adjustment procedure.
7.4 Simulations design
The simulation study mimicked a two-armed randomized trial lasting 24 months with control
and active treatments; there were 2000 replications for each scenario in order to ensure cover-
age lies within two standard errors of the nominal 95% coverage probability (Tang et al., 2005).
Also to mimic Esprit data, each simulation assumed a sample size of 1000 with equal prob-
ability of being randomly assigned to either treatment arm.
Each individual had two potential hazard rates which do not vary with time: 1i and
0i depending on whether or not they were taking active treatment at that time. The
hazard rates f0ig, assumed constant over time, were generated from a Gamma distribution
with shape parameter 2 and scale parameter 0:006 so as to have mean 0:012 and variance
7:210 5. The simulation model considered events in each month separately. Time to event
for individual i was assumed to have an exponential distribution with parameter 0i or 1i
but the simulation model considered events in each month separately so that the parameter
could be changed according to treatment changes. Whether someone died and, if so, the
time to death was set in two steps: rst, the probability of dying in a given month, e.g. in
the control arm, was set equal to 1   exp( 0i) for an individual i, who had survived to
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the beginning of the month; random numbers from the uniform distribution were used to
decide if the individual actually died. Next, for those who died in a given month, the time, t,
since the beginning of the month was generated using random numbers and the conditional
distribution Pr[T <tjT <1]=[1  exp( t)]=[1  exp( )]. All those who survived to 24
months were treated as censored data in the analyses.
We assigned to each individual i a probability of noncompliance, 1i, at end of month one
of follow-up; for members in the control group, these referred only to potential noncompliance
if, counter to fact, they had been assigned to the active group. To achieve non-random
noncompliance, the conditional distribution log1ij0i for an individual's hazard rates in
the control arm was chosen using a random number algorithm for generating Normally-
distributed correlated data (Kleijnen, 1974). A positive correlation corresponded to the
assumption that more frail patients were less likely to comply with their treatment. The
choices for the correlation with log 1i resulted in corr(0i; 1i) =  = 0:5 in the main set
and, for comparison purposes =0:2; 0:8 and  0:5. The mean probability of noncompliance
1 in month one was set at 0:05 and 1i  log-normal with a SD of 0:03. All generated
values were in the range (0; 1). The proportion of new non-compliers, among those who
had been previously compliant, was assumed to decrease with time. This was achieved by
setting the probability of noncompliance ki in month k(k>1) for those compliant in month
k   1 as follows: ki = 1i for k = 2; : : : ; 6, ki = 0:41i for k = 7; : : : ; 12 and ki = 0:21i
for x= 13; : : : ; 18. We assumed no new noncompliance during the months 19-24. For new
non-compliers in month k, noncompliance was assumed to take eect at the end of month k.
Once a patient became a non-complier they remain so until end of the study.
In separate simulations compliance was assumed to be random but the overall probability
of noncompliance in any month was set with the same mean as before, e.g. for each person
the probability of noncompliance in month 1 was binomial with mean 1.
Our simulation models assumed a homogeneous treatment eect: that is 1i=[exp( )]0i
where exp( ) is the true causal hazard ratio, which was assumed to be either 0:5 or 1
(null model). In the analyses, when a subject in the active treatment arm became a non-
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complier, they instantly reverted to their risk 0i. Since the survival times are generated
to have an exponential distribution, itself a special case of the Weibull, the relationship
=  log' between the proportional hazard model parameter  and the accelerated failure
model parameter ' should hold.
7.5 Methods for comparison
Six analysis methods were applied to each simulated dataset. The three randomization-based
methods for noncompliance adjustment (d-f) are based on the structural models C-Prophet,
CALM and CHARM respectively while the other non-structural models (a-c) may be con-
sidered as naive regression approaches. The structural models are to some extent dened in
terms of partially unobserved variables while the regression models are dened in terms of
fully observed variables.
7.5.1 Notation
The following notation is used for all the methods:
 Z=1(0): denotes randomization to active (control) arm.
 Ti: time-to-event, which may not be observed in either group due to censoring.
 Wi: potential time-to-event if subject never received active treatment; only observed
in the control arm.
For all-or-nothing compliance models:
 U =1(0): potential compliance if oered active treatment. It is observed in the active
arm only.
 V = 1(0): refers to observed compliance with active treatment and is fully observed.
V =U in active arm and V = 0 in control arm.
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For time-dependent compliance models:
 V (t) = 1(0): refers to observed compliance with active status at time t and is fully
observed; V (t)=0 in control arm.
 C: time to potential noncompliance if oered active treatment, assuming those who
stop treatment remain non-compliant; observed for active arm only.
7.5.2 Methods
(a) CoxITT: this is the usual ITT Cox PH model that ignores noncompliance:
h(tjZi) = h0(t) exp(Zi); (7.3)
where h(tjZi) denotes the hazard rate for failure at time t given exposure, h0(t) is the
baseline hazard. Here HRITT is estimated by exp(^).
(b) CoxReg1: This Cox proportional hazards model attempts to allow for all-or-nothing
noncompliance through simple regression adjustment:
h(tjZi; Ni) = h0(t) exp[1Zi + 2(1  Vi)]; (7.4)
where V is xed over time. The naive treatment eect estimator is exp(^1) and the eect
of noncompliance is estimated by exp(^2). To apply this method to our partial compli-
ance simulated data, in the active arm V was set to zero if there was any noncompliance.
(c) CoxReg2: This also has a regression adjustment but now V(t) is time dependent to allow
for partial compliance:
h(tjZi; Ni) = h0(t) exp[1Zi + 2(1  Vi(t))]: (7.5)
This model was tted in Stata using the standard approach for time-varying covariates
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in PH models. We note that methods (b) and (c) implicitly assume random noncom-
pliance and are not expected to perform well when noncompliance is associated with
underlying risk, i.e. nonrandom.
(d) C-Prophet: This structural causal proportional hazards model assumes all-or-nothing
compliance and takes the following form:
h(tjZi = 1; Ui = u) = h(tjZi = 0; Ui = u) exp( 0u); (7.6)
where Ui is potential all-or-nothing compliance with active treatment for subject i.
Model (7.6) makes the exclusion restriction assumption (Imbens and Rubin, 1997):
that is, there is no eect of assignment to active arm on survival in the subgroup Ui=0
of non-compliers and that Ui is independent of randomization. These assumptions facil-
itate nonparametric identication of the survival distribution for potential compliers in
the control arm, and hence estimation of the log hazard ratio  0 for active versus con-
trol conditions in the subgroup (Ui=1) of potential compliers. In our implementation,
 0 is equivalent to  in the simulation model. Censoring for this method is considered
non-informative for the control arm as a whole, while in the active arm censoring is non-
informative conditional on compliance. To apply the model to our partial compliance
data, partial compliers were assumed to be completely non-compliant. The method
was implemented in Stata using the stcomply command (Kim and White, 2004).
(e) CALM: This structural Causal Accelerated Life Model relates observed event times, Ti,
to the potential event time Wi that would have occurred if, possibly contrary to fact,
the subject had received no active treatment:
Wi(') =
Z Ti
0
exp['Vi(t)] dt; (7.7)
where Vi(t) is the time-varying indicator of active treatment receipt The exclusion
restriction assumption here states that the baseline prognosis W is independent of
randomization (White and Goetghebeur, 1998). The acceleration factor ' is the causal
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eect of taking active treatment compared to control: for example, ' < 0 implies
that taking continuous treatment would extend `life' by a factor of exp( '). It is
important to note that censoring that is non-informative on the T-scale may become
informative on the W-scale. A key requirement in the CALM method is for the user to
provide a potential recensoring time on the W-scale for all subjects. In our simulations
which assume a xed follow-up time with censoring at 24 months, we followed the
recommendation by Walker et al. (2004) and set the recensoring time at the end of
study (24 months). The CALM method is implemented in Stata using the strbee
command (White et al., 2002) in a number of ways depending on which test is used to
nd ': '^ is the value for which a test of dierence in Wi between the two arms yields a
zero test statistic. Here we present results from use of the logrank test but results using
an alternative parametric test procedure based on the Weibull distribution were also
generated. Estimation was performed by grid search over a range of values of ' which
we specied as  3 to 1:5 for the non-null model and  2 to 2 for the null model with
step size of 0:01. Given that simulation event times were exponentially distributed, the
causal hazard ratio was estimated by  ^i=  log '^i.
(f) CHARM: White et al. (2004) used the term Complier Average Causal Eect (CACE)
for the possibly time-dependent estimand of this model but it is not immediately clear
how it relates to the causal hazard ratio in our simulation model. By viewing survival
data as a series of binary outcomes in consecutive unit time intervals, they dened
CACE in time interval j as the risk ratio among survivors to that interval who would
not stop treatment before end of interval j, i.e.
CACEj =
Pr[T = jjT > j   1; Z = 1; C > j]
Pr[T = jjT > j   1; Z = 0; C > j] ; (7.8)
where C is the potentially unobserved time to noncompliance. Key to obtaining the
CACE estimates (7.8) for each interval is the `extended exclusion restriction' assump-
tion that randomized allocation has no eect on any survivors to the start of interval
j who would stop treatment by the end of that interval (White et al., 2004). Imple-
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mentation of the method for continuous time requires two models to be tted to the
data; in the rst, log HRITT is modelled as a function of time and, in the second, the
log odds of crossover among subjects who experience events in the treated arm must
also be modelled as a function of time. Assuming short time intervals together with
the extended exclusion restriction, White et al. (2004) showed that
CACEPH(t) =
HRITT(t)[1  (t)]
1  (t)HRITT(t) ; (7.9)
where  is the proportion of noncompliance probability among those participants who
experience the event in the treatment arm. CACEPH is essentially a Causal Hazard
ratio Adjustment Regression model (CHARM) with a linear predictor which is zero in
the control arm and in the active arm is a function of time:
CHARM  h(t) = h0(t) exp[0Z + 1f(t)Z]; (7.10)
where f(t) can be specied as a combination of linear/quadratic function of time to event.
White et al. (2004) proposed two ways to estimate a constant CHARM:
(i) assume both ITT hazard ratio (HRITT) and odds of noncompliance  are constant
over time which allows a simple CHARM approximation by
CHARM \CACEPH =
dHRITT(1  ^)
1  ^ dHRITT : (7.11)
(ii) a more complex procedure that allows both HRITT and odds of noncompliance 
to vary over time.
We implement procedure (ii) above in our simulations by using the Stata command
adjhr (White, 2002) which provide an `approximate' overall (constant) CHARM estimate
as hazard ratio adjusted for compliance.
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Results from analyses of the simulations were summarized as follows. All methods were
treated as giving an estimate  ^ of  , the log causal HR in the simulation model even though
naive regression models were not expected to perform well and the theoretical relationship
between CHARM and  is not clear. We then calculated the mean of the estimators,
^
 , and
their corresponding root mean squared errors (RMSE) where RMSE(
^
 )=
q
[
^
    ]2 + var( ^).
In the table we show mean eect on the HR scale calculated as exp(
^
 ). We use a one-sided
t-test with = 0:05 to test for bias with t statistic
^
   
s=
p
2000
, where s is the standard devia-
tion of f ^ig. Assuming that s=0:20 or less, the simulation study was large enough to give
90% power to detect a bias of 0:01 or more on the  scale (i.e.
^
    ) for any statistical
method. A non-signicant test was taken as evidence of no important bias. Coverage was
dened as the proportion of simulations where the 95% Wald condence interval (or that
generated by Stata's strbee, adjhr or stcomply procedures) contained the true parameter
values. For simple regression adjustment models (7.4) and (7.5) we also report exp(
^
2) (eect
of noncompliance) to provide insight into how these models may mislead.
7.6 Results
The simulation allocated subjects almost equally in both arms: 503 and 497 for active and
control arms respectively. On average there were 9% (91=1000) deaths in total: 44 and 47
in the placebo and active treatment arms respectively. The rate of compliance was relatively
lower in the treatment arm (44%) compared to the placebo arm (61%). The proportion of
non-compliers experiencing event of interest in the active arm () decreased marginally with
increase in the value of sensitivity parameter  used, for example, while =72% for =0:2,
this reduced to an average of 68% for =0:8. The simulations showed an average crossover
of 57% (288=503) from the active to placebo arms (no switching from placebo to active
treatment was permitted). The resulting correlation  between hazard rates and probability
of compliance (used to induce non-randomness) was relatively smaller than the pre-specied
value, e.g. a pre-specied  = 0:5, produced a value of 0:26. These summary results are
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comparable to those of the Esprit data. We may then use the simulations to evaluate the
performance of 5 methods (ITT, 2 simple regression adjustments, C-Prophet, CHARM and
CALM) that were applied to the data in Chapter 4.
Using Equation (7.2) above, we estimated the degree of bias expected due to ignoring
frailty in methods which are partly based on PH models as follows: we assumed that if a
constant HR model is tted to data when in fact the marginal HR(t) changes monotonically
over time then we might expect that the constant model would produce an estimate some-
where near the middle of the range between HR(0) and HR(24). We therefore used (7.2) to
calculate HR(12) with HR(0)= . For the null model (7.2) gives HR(t)=1 for all t and there
is no bias. However when exp( ) = 0:5;  = 0:5 and H(12)= 0:144, we get HR(12)= 0:517.
In initial exploratory work we simulated full compliance trials under both homogeneous and
heterogeneous risk models when exp( ) = 0:5. The results gave exp(
^
 ) as 0:500 and 0:515
respectively. These ndings are in line with the above predictions, suggesting that our rough
method of estimating bias due to ignoring variation in frailty alone was adequate.
Tables 7.1 and 7.2 show results for the null model (exp( ) = 1) and non-null model
(exp( )=0:5) respectively under random and non-random compliance. Results from Table 7.1
show that the ITT method under both random and non-random compliance produced sim-
ilar results - statistically insignicant bias. When noncompliance was random, the simple
regression method adjusting for time-dependent noncompliance produced no bias (on the
HR scale); however, the method performed less satisfactorily (bias= 0:065) when compli-
ance was non-random. The regression method assuming all-or-nothing compliance performed
worse under both random and nonrandom scenarios. One can see the reason for bias from the
estimated eects of noncompliance in these models: in truth non-compliance had no eect
but, for example, in the non-random scenarios, the estimate for all-or-nothing noncompliance
implied that noncompliance decreased the risk of death by 20%, while in the time-dependent
noncompliance model suggests that it increased the risk of death by 25%.
The specialist methods (C-Prophet and CALM) produced no bias under random compliance.
While the CALM method was also unbiased under non-random compliance, the C-Prophet
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Table 7.1: Performance of methods under random and non-random compliance when causal
HR exp( )=1.
Model dHR Non-comply SE( ^i) RMSE( ^i) p-valuey 95% CI
(exp(
^
 )) (exp(
^
2)) Coverage
Random compliance
AONz compliance
(a) CoxITT 0.998 0.132 0.132 0.566 0.946
(b) CoxReg1 1.144 0.145 0.198 < 0:001 0.838
Noncompliance 0.647
(c) C-Prophet 1.009 0.186 0.186 0.031 0.893
Partial compliance
(d) CoxReg2 0.997 0.146 0.146 0.325 0.951
Noncompliance 0.997
(e) CALM 0.997 0.209 0.209 0.506 0.965
(f) CHARM 1.019 0.191 0.192 < 0:001 0.926
Non-random compliance: corr(0i; i)=0:5
AONz compliance
(a) CoxITT 0.999 0.128 0.128 0.836 0.952
(b) CoxReg1 1.072 0.142 0.159 < 0:001 0.923
Noncompliance 0.802
(c) C-Prophet 1.012 0.189 0.190 0.005 0.878
Partial compliance
(d) CoxReg2 0.935 0.142 0.157 < 0:001 0.957
Noncompliance 1.249
(e) CALM 0.999 0.214 0.214 0.761 0.961
(f) CHARM 1.024 0.202 0.204 < 0:001 0.923
Noncompliance eect - see Equations (7.4) and (7.5) zAONAll-or-nothing;
yTesting signicance of bias
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method resulted in a small bias (0:012) that was statistically signicant. The CHARM
method produced bias that was statistically signicant under both modes of compliance
with the bias under random compliance (0:019) relatively smaller compared to bias under
non-random compliance (0:024).
The SE and RMSE results show that there is a price to be paid for accounting for noncom-
pliance using the specialists (C-Prophet, CALM and CHARM) methods. However, adjusting
for noncompliance resulted in relatively more ecient estimates for the simple regression
methods (Cox Reg1 and CoxReg2) and the ITT method (CoxITT). Among the specialist meth-
ods, the C-Prophet and CHARM methods produced more ecient estimates of treatment
eects (smallest RMSE) under both random and non-random compliance modes compared
to the CALM method. However, the CALM method produced the best (largest) 95% CI
coverage rates for the corresponding estimates.
Table 7.2 shows results for the non-null scenario when the correlation between non-
compliance and baseline log hazards is 0:5. As expected, the ITT method produced biased es-
timates of ecacy with a greater bias under the random (0:147) and non-random case (0:164).
The bias was greater in the nonrandom case in all cases where noncompliance and baseline
hazards were positively correlated but less when there was a negative association (see Table 7.3).
Simple regression adjustment with an all-or-nothing, binary noncompliance variable re-
duced but did not eliminate the bias under both modes of compliance, the bias being 0:085
and 0:047 respectively for random and non-random compliance. The reason for these biases
can be seen in the biased estimates of the eect of noncompliance: while in reality it would
double the risk, the estimated eects implied that noncompliance increased the risk of death
by only 27% under random compliance and by 59% under non-random compliance. The
latter estimate is closer to the truth and hence the corresponding bias is less. Regression
adjustment with a time-dependent noncompliance variable failed to eliminate the bias when
compliance was random although the bias was small (0:011) while under non-random com-
pliance it was greater ( 0:019). Again, one can see the reasons for the size and direction of
these biases from the estimated eects of noncompliance: results from the time-dependent
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Table 7.2: Performance of methods under random and non-random compliance simulated
models when causal HR exp( )=0:5.
Model dHR Non-comply SE( ^i) RMSE( ^i) p-valuey 95% CI
(exp(
^
 )) (exp(
^
2)) coverage
Random compliance
AONz compliance
(a) CoxITT 0.647 0.147 0.297 < 0:001 0.557
(b) CoxReg1 0.585 0.178 0.238 < 0:001 0.830
Noncompliance 1.273
(c) C-Prophet 0.516 0.215 0.217 < 0:001 0.886
Partial compliance
(d) CoxReg2 0.511 0.179 0.181 < 0:001 0.902
Noncomply 1.964
(e) CALM 0.487 0.255 0.257 < 0:001 0.915
(f) CHARM 0.517 0.213 0.214 < 0:001 0.901
Non-random compliance: corr(0i; i)=0:5
AONz compliance
(a) CoxITT 0.664 0.144 0.318 < 0:001 0.495
(b) CoxReg1 0.547 0.177 0.198 < 0:001 0.917
Noncompliance 1.587
(c) C-Prophet 0.518 0.202 0.203 < 0:001 0.890
Partial compliance
(d) CoxReg2 0.481 0.173 0.177 < 0:001 0.937
Noncomply 2.454
(e) CALM 0.487 0.271 0.273 < 0:001 0.946
(f) CHARM 0.516 0.215 0.216 < 0:001 0.919
Noncompliance eect - see Equations (7.4) and (7.5)
zAONAll-or-nothing
yTesting signicance of bias
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noncompliance model suggest that the eect of noncompliance increased the risk of death
by 96% (close to the truth) while they suggest noncompliance more than doubled the risk of
death under the non-random mode of compliance.
All the three specialist methods (C-Prophet, CALM and CHARM) methods performed
consistently under both compliance modes to produce small bias (on HR scale) that was
statistically signicant. Both the C-Prophet and CHARM methods produced similar results
in terms of bias under both random (0:016 and 0:017) and non-random (0:018 and 0:016)
compliances. The CALM method also produced similar bias ( 0:013) under both random
and non-random compliance. Although statistically signicant, the biases under these three
methods were similar to that predicted for PH models which ignore heterogeneity.
In terms of SE and RMSE, the C-Prophet and CHARM methods produced more ecient
estimates of treatment eects under both random and non-random compliance modes com-
pared to the CALM method. Although estimates from the C-Prophet and CHARM methods
were equally ecient under random compliance, the C-Prophet method produced the most
ecient results under non-random compliance. Although the corresponding 95% CI coverage
rates for CHARM estimates were relatively better (large) compared to C-Prophet, overall the
coverage rate for CALM method was best under both random and non-random compliance
compared to other methods.
Adjusting for noncompliance under the specialists methods resulted in larger standard
errors (SE) than for the ITT method but the later had the largest RMSE. It is interesting to
note that in terms of RMSE, the non-specialist time-dependent regression methods performed
best even under non-random compliance. Among the specialist methods, C-Prophet and
CHARM were more ecient in terms of SE or RMSE than the CALM method.
Table 7.3 provides results for dierent correlations between hazards and noncompliance
probabilities, again with exp( ) = 0:5. The simple regression method adjusting for time-
dependent compliance performed best to produce unbiased estimate at low correlation of =0:2.
But the method produced larger bias with increase in correlations between the baseline haz-
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Table 7.3: Eect of hazard-noncompliance probability correlation on performance of methods:
exp(
^
 ) (RMSE) when exp( )=0:5 (where x=corr (0i; i))
Mean  CoxITT CoxReg1 C-Prophet CoxReg2 CALM CHARM
-0.5 0.632 0.621 0.513 0.544 0.485 0.519
(0.276) (0.279) (0.208) (0.191) (0.251) (0.199)
0.2 0.656 0.571 0.518 0.500 0.488 0.517
(0.307) (0.221) (0.219) (0.181) (0.263) (0.218)
0.5 0.664 0.547 0.518 0.481 0.487 0.516
(0.318) (0.198) (0.203) (0.177) (0.273) (0.216)
0.8 0.674 0.521 0.520 0.460 0.488 0.518
(0.330) (0.189) (0.229) (0.201) (0.278) (0.225)
xSet (attained) corr(0i; i) :  0:5 ( 0:13); 0:2 (0:11); 0:5 (0:26); 0:8 (0:44)
ard and probability of noncompliance. In contrast, adjusting for all-or-nothing compliance
resulted in smaller bias as correlations increased. The CALM method performed consistently
to produce bias of similar magnitude for all correlation values considered. Both C-Prophet
and CHARM methods produced similar (but biased) estimates of treatment eects; the size
of the bias was fairly consistent regardless of the correlation and was of the order expected
when within-group heterogeneity in risk is ignored in a proportional hazard model. However,
when the results were judged in terms of RMSE, C-Prophet and CHARM performed better
than CALM as before. The negative correlation scenario is interesting in that the all-or-
nothing regression method increased bias; this also occurred in some other simulations with
negative correlation although not all.
Finally, we observe that the resulting correlations between hazard rates and probability
of noncompliance from the simulations were smaller compared to the set values. This may
be an indication that the pre-specied correlation only controlled underlying hazard rates
while observed data exhibited further randomness.
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7.7 Discussion
The ITT and simple regression adjustments using binary noncompliance covariates produced
large bias. All of the methods performed reasonably well under the null model in terms
of bias. However, the simple regression approaches appeared to lead to a bias reduction
when noncompliance is treated as all-or-nothing under non-random compliance and the bias
was in the opposite direction to the causal treatment eect for time-dependent compliance
adjustment. On the basis of the results for the null model alone, the C-Prophet and CHARM
methods appeared to be the preferred specialist correction methods in the presence of random
and non-random compliances respectively when judged by the RMSE.
In the non-null case of interest, i.e. nonrandom compliance, the simple regression adjust-
ment methods cannot be recommended: they produce large bias which varied to some extent
according to the magnitude and direction of correlation between the risk and probability
of noncompliance. In this case and the random noncompliance case, the CALM method
performed consistently best in terms of bias, i.e. CALM method consistently produced sim-
ilar and smallest bias for the causal eect in one direction. The better performance of this
method, compared to the C-Prophet and CHARM methods would appear to be attributable
to the fact that it does not assume constant hazard rates. It is surprising that the all-or-
nothing assumption underlying the C-Prophet method did not appear to result in extra bias
compared to, say, the CHARM method. The C-Prophet produced the most ecient esti-
mates (smaller RMSE) under non-random compliance albeit with low coverage which may
be attributed to its implementation using jackknife procedures that may produce conserva-
tive variance estimates Goetghebeur and Loeys (2003). Overall the CALM method produced
the best coverage rate for the estimates under both random and non-random compliance
compared to other methods.
Considering nonrandom compliance may be more realistic than random compliance given
the fact that noncompliance is often associated to other individual patient conditions. In
a heterogeneous population, more frail patients are more likely to have higher probability
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of treatment noncompliance since more frail patients may fail to see the need to continue
treatment in the absence of immediate benets.
Duration of treatment is an important phenomenon in methods which accounts for partial
compliance. The specialist methods considered here may be extended to explore lagged
treatment eects (bias), if any, up to some specied period after stoping. Such extension
would help identify a method suitable for evaluating eects of treatment known to have long
washout eects.
Finally clinical trials often have baseline covariates recorded at the beginning of most
studies. Although it may not be straight forward for the specialist methods, incorporating
potential prognostic factors while accounting for nonrandom compliance may assist in eec-
tive evaluation of treatment ecacy. Specically, baseline covariates which predict treatment
compliance may be used to relax the exclusion restriction assumption (Jo, 2002a) whose ten-
ability is crucial for all the 3 specialist methods considered herein.
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Chapter8
Monte Carlo Study II: Evaluating Performance of
Method Adjusting for Noncompliance in
Two-Active Treatment Arms
8.1 Introduction
The objective in this chapter is to use simulations to evaluate potential bias induced by
noncompliance when estimating ecacy from survival data from a two-active armed treat-
ment trial. Specically we use statistically designed simulations study to evaluate the perfor-
mance of the Roy et al. (2008) model in terms of bias and 95% credible intervals as applied
to survival data. We begin by outlining the aims of the simulations followed by a description
of the simulation study design (set-up). The next section presents the methods of analysis.
For both homogeneous and heterogeneous treatment eects cases, we rst obtain the ITT
estimate by applying the Cox proportional hazard model (ignoring any treatment compli-
ance information) and evaluate resulting bias if viewed as estimating a causal hazard ratio.
Under the homogeneous treatment eect assumption, each stratum assumed constant risk
of death over time for both treatments A and B. For heterogeneous treatment eect case,
the potential treatment eects among non-compliers to treatment A and B were set to be
smaller than potential eects among compliers. Finally we present a comparison of the per-
formance with respect to bias and 95% credible intervals of the causal eects in terms of
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causal risk ratios obtained as means of posterior median relative risks for each stratum for
both homogeneous and heterogeneous scenarios at dierent values of sensitivity parameter .
The data are generated using Stata Software and analysis done in WinBUGS - see annotated
codes in Appendix (Page 273).
8.2 Aims of the simulations
We use statistically designed simulation studies in the framework of a randomized controlled
trial to compare two-active treatments in terms of survival to evaluate bias due to noncom-
pliance in two treatment arms. First we evaluate the eect on the intention-to-treat (ITT)
hazard ratio due to allocation to treatment B relative to treatment A where there can be non-
compliance in either arm. As a check on the simulations, we also evaluate the ITT eects in
each stratum. Next we apply Roy et al. (2008) model for survival data analysis (this analysis
model was originally proposed for nonrandom compliance for binary outcome). The analysis
requires specication a positive sensitivity parameter  which is chosen as a function of arm-
specic compliances and the correlation between compliances to treatment, i.e. parameter 
is not estimated from data. With two factors separately assumed predictive of compliance,
we rst construct arm-specic prediction models of compliance using logistic models from
which we estimate the probabilities of compliance to treatment in each arm. We then obtain
treatment eects for each stratum by in terms of causal risk ratios estimated from means of
posterior relative risks parameters (outlined in Chapter 2, Section 2.7, Equation 2.25) as the
ratio of probability of experiencing events/death among due to compliance with B relative
to A, compliance with either treatment B or A compared to nothing among corresponding
compliance types. Specically, using Bayesian methods we estimate mean posterior median
relative risks and corresponding mean 95% credible intervals of death in 3 dierent strata
dened by their respective compliance types (compliance with A and B, A only and B only)
while assuming nonrandom compliance under both homogeneous and heterogeneous treat-
ment eects assumptions. We use death as the generic event/endpoint/outcome of interest.
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8.3 Simulations design (set-up)
The simulation study mimicked a two-armed randomized trial with active treatments A and
B lasting 24 months. There were 2000 replications for each scenario to ensure coverage lies
within two standard errors of the nominal 95% coverage probability. Also to mimic Esprit
data, each simulation assumed a sample size of 1000 with equal probability of being randomly
assigned to either treatment arm.
Each subject had three potential hazard rates: 0i; Ai and Bi corresponding to risk
under no treatment and under treatment A and B respectively. The eects of both treat-
ments are assumed better than no treatment at all in all cases. The time-invariant hazard
rates f0ig were generated from Gamma distribution with shape and scale parameters 2 and
0:006 respectively so as to have mean 0:012 and variance 7:2 10 5. Each stratum assumed
constant risk of death over time for both treatments A and B. The simulation model consid-
ered events in each month separately. For a given month the probability of dying if a specic
treatment is taken in any stratum were taken as equal to 1 exp( Ai) and 1 exp( Bi) for
treatment A and B respectively. Random numbers from the uniform distribution were used
to decide which subjects actually died from either treatment arm. Time to death was taken
as the end of each month, i.e. the minimum time is 1 month for those who died in the rst
month while the maximum time is taken as 24. Subjects were allocated to treatment arms
at random and risks chosen according to arm and potential compliance type. No switching
of subjects between the treatment arms was assumed.
We considered all-or-nothing compliance to allocation for both treatments A and B up
to 24 months. Each subject belonged to one of four complier groups (principal strata): type
0 (S=(0; 0)) represent people who would be compliers to neither treatment, type 3 (S=(1; 1))
represent potential compliers to either treatment, types 1 (S=(1; 0)) and 2 (S=(0; 1)) rep-
resent compliers to treatment A only and B only respectively. The compliance types were
determined independently by a subject's associated risk factors X and her baseline risk of
death. The simulation method rst set the prevalence of covariates X (Table 8.1). Second
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the relationship between probabilities of compliance and a pair of covariates predicting com-
pliance is described by odds ratio (Table 8.2). Nonrandom compliance in each stratum was
introduced using a specied positive sensitivity parameter  which was chosen as a function of
arm-specic compliances and the correlation between compliances to treatment: we explored
dierent values of  = 0; 0:2; 0:5; 0:8. Random numbers (multinomial probabilities) were used
to determined actual number of compliers for each stratum. Thirdly the compliance type
was linked to the baseline hazard: we assigned highest ranked values of baseline risk 0i to
represent subjects who would not comply with either treatment allocation (type 0) while the
lowest ranked values of 0i are assigned to compliers of either treatment (type 3). From the
remaining middle set, we assign at random to either compliance to treatment A only (type
1) or treatment B only (type 2) according their respective weighted proportions as set for
simulation model (see later).
Compliance with treatment allocation is assumed to be predictable from two binary (0=1)
baseline covariates, which we may think of in the context of Esprit data as histories of hys-
terectomy and cerebrovascular disease (CVD) risks (angina or blood pressure or stroke). The
actual prevalence rates of histories of hysterectomy and CVD were set at 25% and 60% respec-
tively. Subjects were assigned and the joint prevalence rates were set as shown in Table 8.1.
Table 8.1: Prevalence of risk factor.
Hysterectomy No hysterectomy
CVD risk factors 0.15 0.45 0.60
No CVD risk factors 0.10 0.30 0.40
0.25 0.75
To link the risk factors and compliance, for each treatment arm, we specied three sets
of statistics
(a) the probability of compliance to treatment allocation in the absence of both risk factors;
this was 0:55 for A and 0:30 for B,
(b) a compliance odds ratio for hysterectomy: 2 for A and 5 for B and
(c) a compliance odds ratio for CVD risks: 4 for A and 3 for B.
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The joint eect of both factors on compliance was assumed to be multiplicative on the
odds ratio scale. This is the same as using a logistic model with no interaction term to obtain
actual compliance probabilities for individual cells (see Table 8.2). These assumptions imply
that the probabilities of compliance given a set of covariates X, A(x) and B(x), say for
groups A and B are such that A(x)>B(x).
Table 8.2: Compliance probabilities for treatments A and B.
Treatment A Treatment B
Hyst No hyst Hyst No hyst
CVD risks 0.907 0.830 CVD risks 0.865 0.563
No CVD risks 0.710 0.550 No CVD risks 0.682 0.300
We assume that potential compliance to treatment A and to B are positively correlated.
The strength of correlation can be expressed as a correlation coecient or as in Roy et al.
(2008), by a positive sensitivity parameter  (Chapter 2, Section 2.7, Equation 2.20) that is
a function of arm-specic compliances and the correlation  between compliances to treat-
ment. First we specied  = 0:5, but we also considered other values  = 0 (conditional
independence), 0:2; 0:8, and 1:0. We then worked out probability that compliance to A
Table 8.3: Compliance proportions by risk factors (for  = 0:5): A and B are marginal
compliance probabilities - A=11 + 10 and B=11 + 01.
Hyst+CVD Hyst+no No hyst No hyst Overall
CVD CVD no CVD (weighted)
Prevalence 0.150 0.100 0.450 0.300 1.000
B 0.865 0.682 0.563 0.300 0.541
A 0.907 0.710 0.830 0.550 0.746
U(x)= B
A
0.954 0.961 0.677 0.545 0.725
11 0.825 0.583 0.514 0.233 0.483
01 0.040 0.099 0.048 0.068 0.058
10 0.082 0.127 0.316 0.318 0.262
00 0.053 0.191 0.122 0.383 0.197
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is i and compliance to B is j, given x1 and x2, i.e. ij(x1; x2) for a given value of  (e.g.
Table 8.3 for =0:5). We used random numbers and the multinomial probabilities ij(x1; x2)
to decide the number of subjects for each of the four compliance types in a given simulation.
In the simulation models, we considered both homogeneous and heterogeneous treatment
eects. In some scenario, the potential treatment eects among non-compliers to treatment
A and B were set to be smaller than potential eects among compliers hence corresponding
to the heterogeneous treatment eects assumption. An homogenous treatment eect corre-
sponded to scenario when potential treatment eects were assumed same for all principal
strata: Ai
0i
=0:75 and Bi
0i
=0:50. For the homogeneous case Bi=[exp(D)]Ai, where exp(D)
is the true causal hazard ratio (THR), which was assumed to be 0:667 for each stratum. For
the heterogeneous case, the potential treatment eects among non-compliers to treatment A
and B were set to be smaller than potential eects among compliers. Specically we set the
causal HR at 0:667; 0:750; 0:778 and 0:800 for stratum 3; 2; 1 and 0 respectively, i.e. we set
best benet from treatment B relative to A for patients of type 3 (1; 1), with the hazard ratio
the same as in the homogenous case (THR(1;1)=0:667). The hazard rates for non-compliers
among type 2 (0; 1) patients was set to be relatively lower (Ai=
2
3
0i) compared to hazard
rates for non-compliers among type 3 patients. Conversely the hazard rates for non-compliers
among type 1 (1; 0) patients was set to be relatively higher (Bi=
7
12
0i) compared to hazard
rates for those classied to belong to type 3 (see Table 8.4). We use the ratio Bi
Ai
to obtain
causal eects of treatment B relative to A for the subgroup who would comply with either
treatment. (see denition of ij later).
For the Roy et al. (2008) model, we obtained the true relative risk (TRR), i.e. causal
risk ratio, as the ratio of average risk estimates for each arm in a group. Using moment
generating function results of Gamma distribution (i  Gamma(; k)), we calculated
TRR=
[1  (1 + 24B) k]
[1  (1 + 24A) k]
; (8.1)
i.e. TRR=0:729 (k=2) for the homogeneous case and for the heterogeneous case TRRS=0:729,
0:796; 0:824 and 0:847 for stratum S=3; 2; 1 and 0 respectively (Table 8.4).
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Table 8.4: Stratum-specic hazard rates (among patient compliers).
Type Homogeneous eects Type Heterogeneous eects
(stratum) A B THR TRR
y (stratum) A B THR TRRy
3 (1,1) 0.009 0.006 0.667 0.729 3 (1,1) 0.009 0.006 0.667 0.729
2 (0,1) 0.009 0.006 0.667 0.729 2 (0,1) 0.008 0.006 0.750 0.796
1 (1,0) 0.009 0.006 0.667 0.729 1 (1,0) 0.009 0.007 0.778 0.825
0 (0,0) 0.009 0.006 0.667 0.729 0 (0,0) 0.010 0.008 0.800 0.847
yTRR calculated according to Equation (8.1)
8.4 Analysis methods
All ITT results were assumed to provide an estimate D^ of D, the log causal HR in the
simulation model; then the mean of the estimators,
^
D, and their corresponding root mean
squared errors (RMSE) are calculated where RMSE(
^
D)=
q
[
^
D D]2+var(D^). In the table
we show mean eect on the HR scale calculated as exp(
^
D). We use a one-sided t-test with
=0:05 to test for bias with t-statistic
^
D D
s=
p
2000
, where s is the standard deviation of fD^ig.
Assuming that s = 0:50 or less, the simulation study was large enough to give 90% power
to detect a bias of 0:01 or more on the D scale (i.e.
^
D D) for any statistical method. A
non-signicant test was taken as evidence of no important bias.
The analysis begins by providing checks for the parameters set in the simulations. Next
we obtain the ITT estimate by applying the Cox proportional hazards (PH) model ignoring
treatment compliance in order to evaluate its bias (if any) for estimation of D. Specically
we evaluate the hazard ratio of death due to allocation to treatment B relative to treatment
A for both homogeneous and heterogeneous treatment eects cases using the Cox PH model
h(t) = h0(t) exp[Z] : Z =
8<: 1; if treatment B0; if treatment A ; (8.2)
where h0(t) is the baseline hazard for a subject allocated to treatment A.
205
To apply the Roy et al. (2008) model, we predicted arm-specic compliance using the
logistic models
logit [j(x)] =
 
2X
i=0
jixi
!
; j = 0; 1 (8.3)
where x0 = 1 and x1 and x2 (in the Esprit context) are histories of hysterectomy and CVD
risks. These factors were allowed to be separately predictive of compliance in each arm. From
the logistic model, we estimated the probabilities of arm-specic compliance with treatment
allocation using:
^j(x) =
"
1 + exp
 
 
2X
i=0
^jixi
!# 1
; j = 0; 1 (8.4)
In a Bayesian setting, we used non-informative priors: normal distributions with mean
zero and large variance, i.e. N(0; 106), for the two potential predictors of compliance in
each arm. We specied uniform (0; 1) priors for the probabilities (risks) of death in each
stratum given the arm of allocation and set the sensitivity parameter =0; 0:2; 0:5 and 0:8.
Considering both homogeneous and heterogeneous cases, we ran three chains: null starting
values for chain one, mean and median values from a trial run for chains two and three
respectively. For convergence assessment, we ran simulation for 11; 000 iterations for each of
the three chains and excluded the rst 1; 000 as burn-in.
For the Roy et al. (2008) model, the results provide a summary of the mean compliance
proportions for each treatment arm, performance of the resulting posterior median relative
risk for each stratum under both homogeneous and heterogeneous treatment eects assump-
tions. The stratum-specic relative risks estimates of ij are provided as ratio of probabilities
of death among potential compliers to treatment B relative to A for each stratum given the
arm of allocation. We used the corresponding standard deviation (SD) of the median of the
estimators, ~^ , to calculate RMSE(~^) =
q
[~^    ]2 + var(^) and used a one-sided t-test with
=0:05 to test for bias with t statistic
~^ 
SD=
p
30;000
, where SD is the standard deviation of fijg.
Assuming that SD= 2 or less, the simulation study was large enough to give 90% power to
detect a bias of 0:01 or more on the  scale for any statistical method. Also a non-signicant
test was taken as evidence of no important bias.
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We obtain causal risk ratio  as mean of posterior median relative risk (decision based on mini-
mizing linear loss function) for each stratum by estimating the ij parameters (Equation 2.25):
(i) 11 compares B with A in stratum S=(1; 1) using frailty relation (8.1) given above,
(ii) 01 compares B with 0 in stratum S=(0; 1), i.e. comparison of B with baseline and
(iii) 10 compares A with 0 in stratum S=(1; 0), i.e comparison of A with baseline.
8.5 Results
8.5.1 Checking on simulations
We obtained odds ratio estimates by tting a logistic model to each simulation. For a
moderate level of the sensitivity parameter  = 0:5, the mean compliance odds ratios for
hysterectomy were 2:015 and 5:105 for treatment A and B respectively, and the compliance
odds ratios for CVD risks were 4:041 and 3:025 respectively for treatment A and B. In
general, these results and simulation results for other values of  were in agreement with the
odds ratios pre-specied in the simulation design.
Table 8.5: Estimates of mean compliance proportion per stratum for dierent  values.
Homogeneous hazard rates Heterogeneous hazard rates
Stratum  
(type) 0 0.2 0.5 0.8 0 0.2 0.5 0.8
^B = ^11 + ^01 0.542 0.543 0.543 0.544 0.541 0.542 0.542 0.541
^A = ^11 + ^10 0.744 0.745 0.747 0.749 0.745 0.746 0.746 0.746
^11 (3) 0.426 0.449 0.484 0.518 0.425 0.449 0.483 0.518
^01 (2) 0.115 0.092 0.057 0.023 0.116 0.092 0.058 0.023
^10 (1) 0.319 0.296 0.261 0.227 0.320 0.297 0.262 0.228
^00 (0) 0.139 0.162 0.197 0.231 0.139 0.162 0.197 0.231
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Table 8.5 provide the mean (overall) proportion of compliance per stratum at dierent
values of the sensitivity parameter  for both homogeneous and heterogeneous hazard rates.
On average, the compliance proportion results were similar to the pre-specied probabilities
in the simulation design, for example while in Table 8.3, 11 = 0:483, the mean for the
simulations was ^11 = 0:478. The mean proportions of compliance per stratum are similar
for both cases: the mean proportion of compliance to treatment A was higher compared to
mean compliance to treatment B (e.g. ^A=75% and ^B =54% when =0:5). As per our
setup, the simulations ensured that potential compliers to either treatment (type 3) were
the most frequent type while potential compliers to treatment B only (type 2) would be the
least frequent no matter the value of . Overall, the mean proportion of compliance to either
treatment (type 3) and neither treatment (type 0) dominated (increased) as the sensitivity
parameter  increased. On the other hand, the mean compliance proportion reduced with
increase in  values among those people who would comply with one treatment only (type 1
and 2). We note the small proportion of potential compliers to treatment B only (type 2)
which approached total noncompliance as  gets close to 1 (perfect correlation). In general,
all the proportions of compliance were comparable to the expected weighted compliances
proportions of the preset values (see Table 8.3). Overall, the general patterns/trend of
compliance proportion was the same for both homogeneous and heterogeneous hazard rates.
8.5.2 Effect on ITT
Table 8.6: Homogeneous and heterogeneous ITT estimates.
THRy exp( ^D) SE(D^i) RMSE(D^i) p-value
Homogeneous 0.667 0.675 0.161 1.162 < 0:001
Heterogeneous 0.731z 0.762 0.155 0.161 < 0:001
yTrue hazard ratio, Table 8.4 (zweighted using proportions from Table 8.5)
Table 8.6 provide the ITT estimates for both homogeneous and heterogeneous cases.
The ITT hazard ratio 0:675 for the homogeneous treatment eects case model suggested
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that overall, the risk of death would reduce by 32% for those randomized to treatment B
compared to those randomized to treatment A. The resulting small bias (0:008) for the
ITT estimate was however statistically signicant. For the heterogeneous treatment eects
case, the ITT hazard ratio 0:762 indicated an overall reduction of risk of death by 24%
for those randomized to treatment B compared to treatment A. The resulting bias (0:031)
for the heterogeneous ITT estimate was also statistically signicant. We observe a bias-
precision tradeo where as expected the bias due to homogeneous hazard was relatively
smaller compared to bias from using heterogeneous hazard rates but the later had relatively
smaller SE compared to the former. However, in general we note that a study population is
more likely to be heterogeneous than homogeneous.
Table 8.7 provide estimates for each stratum in terms of hazard ratio for both homoge-
neous and heterogeneous hazard rates at dierent sensitivity parameter  values. All chosen
values of sensitivity parameter essentially produced an unbiased hazard ratio estimate for
eects of treatment B relative to A among those who would comply with either treatment
(S=(1; 1)). This may be discerned from ordinary expectation of high compliance rates with
treatment for this subgroup which is likely to reveal true eects of both treatments. For a
chosen value of sensitivity parameter , we also note similarity in the standard errors for the
corresponding causal hazard ratio estimates for both homogeneous and heterogeneous cases.
In general, we obtain biased hazard ratio estimates for eects of either treatment (A or B)
compared to nothing for all chosen values of sensitivity parameter. Although heterogeneous
rates produced an unbiased hazard ratio of eects of treatment B compared to nothing at a
moderate value of sensitivity parameter (=0:5), the tradeo was a large SE corresponding
to the estimate. Specically, we observe substantial bias in hazard ratio estimates of ecacy
due to compliance with treatment B compared to nothing at higher values of sensitivity
parameter ( = 0:8). We also note relatively large standard errors corresponding to these
estimates (and the SE dominates the corresponding RMSE) which may be attributed to the
almost `total' noncompliance phenomenon observed above for this stratum at almost perfect
correlation.
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Table 8.7: ITT treatment eects for each stratum: homogeneous and heterogeneous rates.
Homogeneous hazard rates Heterogeneous hazard rates
 exp( ^D) SE(D^i) RMSE(D^i) p-value exp(
^
D) SE(D^i) RMSE(D^i) p-value
THRy(1;1)=0:667

B
A

THR(1;1)=0:667

B
A

0 0.660 0.356 0.356 0.893 0.660 0.356 0.356 0.894
0.2 0.660 0.339 0.339 0.928 0.660 0.339 0.339 0.928
0.5 0.660 0.323 0.323 0.929 0.660 0.323 0.323 0.929
0.8 0.661 0.303 0.303 0.898 0.661 0.303 0.303 0.898
THR(0;1)=0:500

B
0

THR(0;1)=0:500

B
0

0 0.654 0.493 0.561 <0:001 0.740 0.505 0.639 <0:001
0.2 0.625 1.314 1.326 <0:001 0.708 1.323 1.368 <0:001
0.5 0.341 5.336 5.393 <0:001 0.408 5.544 5.547 0.949
0.8 0.018 17.738 18.045 <0:001 0.041 18.441 18.611 <0:001
THR(1;0)=0:750

A
0

THR(1;0)=0:750

A
0

0 0.668 0.274 0.297 <0:001 0.779 0.263 0.266 <0:001
0.2 0.670 0.286 0.409 <0:001 0.782 0.275 0.278 <0:001
0.5 0.667 0.307 0.421 <0:001 0.778 0.296 0.299 <0:001
0.8 0.664 0.329 0.350 <0:001 0.777 0.317 0.319 <0:001
yTrue hazard ratio (see Table 8.4)
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In contrast, using heterogeneous rates with higher sensitivity of parameters (=0:5 and 0:8)
produced small bias of 0:027 (though important) for hazard ratio estimate of ecacy due
to compliance with treatment A compared to nothing produced. In general, hazard ratio
estimates for treatment B compared to nothing among those who would comply with it
if oered produced larger biases and corresponding larger standard errors which increased
with increase in sensitivity parameter. The large standard errors may be a manifestation of
sparseness due to near `total' noncompliance as  approaches 1 (perfect correlation).
8.5.3 The Roy et al. (2008) method
Table 8.8 provide a comparison of the causal risk ratios (means of posterior median relative
risks) for each stratum at dierent sensitivity parameter  values under both homogeneous
and heterogeneous treatment eect assumptions. For the homogeneous case the resulting
biases in the relative risk estimates were all statistically signicant for all strata at all 
values. Compared to other strata, the causal risk ratio estimate of ecacy due to compliance
with treatment B relative to A among those who would comply with either treatment (type
3) consistently produced smaller biases for all  values considered. Specically the resulting
bias in the causal risk ratio estimate was smallest ( 0:019) for higher values of =0:8. On
the other hand, the causal risk ratio estimates of ecacy due to compliance with only one
treatment (A or B) produced larger biases for all values of .
Table 8.8 also show the causal risk ratio under heterogeneous hazard rates assumption.
For mild =0:2 value, the causal risk ratio for those who would comply with treatment B
only relative to nothing produced small bias ( 0:015), although important. Compared to
homogeneous case, we observe substantial increase in standard error values corresponding to
causal risk ratio estimates under heterogeneous hazard rate assumption. The causal risk ratio
estimate for treatment B compared to treatment A among the highly compliant subgroup
(potential compliers with either treatment) resulted in small bias (0:035) at moderate =0:5,
although the bias was statistically signicant. In general, causal risk ratios estimating com-
pliance with treatment B only compared to nothing were less biased (although statistically
signicant) under heterogeneous hazard rates assumption than for the homogeneous cases.
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Table 8.8: Performance of Roy et al. (2008) method: homogeneous and heterogeneous rates.
Homogeneous hazard rates Heterogeneous hazard rates
 ~^ (RR) SE(^ij) RMSE(^ij) p-value ~^ (RR) SE(^ij) RMSE(^ij) p-value
TRRz(1;1)=0:729 TRR(1;1)=0:729
0 0.688 0.153 0.158 { 0.837 0.211 0.237 {
0.2 0.676 0.146 0.155 { 0.804 0.186 0.201 {
0.5 0.653 0.128 0.149 { 0.764 0.151 0.155 {
0.8 0.710 0.114 0.116 { 0.797 0.176 0.189 {
TRR(0;1)=0:500 TRR(0;1)=0:500
0 0.476 0.291 0.292 { 0.530 0.302 0.303 {
0.2 0.579 0.290 0.301 { 0.485 0.305 0.305 {
0.5 0.641 0.292 0.324 { 0.529 0.319 0.320 {
0.8 0.593 0.311 0.325 { 0.573 0.803 0.812 {
TRR(1;0)=0:750 TRR(1;0)=0:750
0 0.995 0.091 0.261 { 0.913 0.256 0.303 {
0.2 0.989 0.129 0.272 { 0.841 0.285 0.299 {
0.5 0.874 0.246 0.275 { 0.553 2.300 2.308 {
0.8 0.567 0.428 0.465 { 0.713 0.720 0.721 {
zTrue relative risk (see Equation 8.1 and Table 8.4); {p-value< 0:001
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Worth noting is the fact that results presented in Table 8.8 were obtained after using the
same value of sensitivity parameter  for both data generation and analysis. An implication
here is the likelihood of the simulations to give an optimistic view of the Roy et al. (2008)
method, i.e. the method's dening distributional assumption expressed in  may be over
represented by rst specifying a  value to link the two marginal compliance model for each
treatment arm during data generation and using the same value again for compliance models
for each stratum in analysis.
Table 8.9 provide causal risk ratios (means of posterior median relative risks) and cor-
responding mean 95% credible intervals for each stratum under (a) homogeneous and (b)
heterogeneous treatment eect scenarios. A relative risk was obtained as ratio of posterior
median probability of death to that of survival in a stratum. In general the median probabil-
ities of death were lower among those who would comply with treatment B only compared to
those who would comply with treatment A only under both homogeneous and heterogeneous
treatment eect assumptions.
Potential compliers to treatment B only who were allocated to it had lowest estimate
(^1) of risk of death at all  values: the risk increased with increase in . In contrast, risk
of death estimates among those who would comply with treatment A only (^4) decreased
with increase in  values. As expected, the probability of death estimates among potential
compliers to either treatment (^2) was intermediate between the two risks of death among
those who would comply with only one treatment (A and B). Overall, for potential compliers
to either treatment we observe an increase in the risk of death under heterogeneous treatment
eect assumptions compared to the homogeneous case.
At low/moderate values of  under homogeneous treatment eect assumptions, the causal
risk ratio estimates of ecacy due to compliance with treatment B relative to A among the
subgroup who would comply with either treatment to which they were allocated were the least
biased (although statistically signicant). The resulting biases increased with increase in 
values. The corresponding 95% credible intervals for the causal risk ratio estimates became
narrower (smaller) as  increased for this subgroup, indicating gain in precision. On the other
hand the causal risk estimates had relatively larger biases under heterogeneous treatment
eect assumptions for all values of . Compared to type 3, the mean 95% credible intervals
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Table 8.9: Median probability of death, causal risk ratio (mean of posterior median relative risk)
of death (mean 95% CI) for each stratum for various values of (SZ =Pr[Y =1jS;Z] probability
of death in a stratum given treatment allocation): (a) Homogeneous and (b) Heterogeneous rates.
Comply with Comply with Comply with
both A and B B only A only
 ^2(
S=(1;1)
1 ) ^6(
S=(1;1)
0 ) ^1(
S=(0;1)
1 ) ^7(
S=(0;1)
0 ) ^4(
S=(1;0)
1 ) ^5(
S=(1;0)
0 )
TRR(1;1)=0:729 TRR(0;1)=0:500 TRR(1;0)=0:750
(a)
0 0.161 0.238 0.114 0.243 0.238 0.240
11=0:688 (0:420; 1:007) 01=0:476 (0:028; 1:010) 10=0:995 (0:808; 1:195)
0.2 0.158 0.238 0.139 0.243 0.233 0.236
11=0:676 (0:423; 0:993) 01=0:579 (0:039; 1:023) 10=0:989 (0:722; 1:258)
0.5 0.154 0.240 0.153 0.242 0.201 0.235
11=0:653 (0:429; 0:928) 01=0:641 (0:050; 1:055) 10=0:874 (0:260; 1:240)
0.8 0.168 0.240 0.138 0.237 0.123 0.226
11=0:710 (0:509; 0:956) 01=0:593 (0:038; 1:106) 10 = 0:567 (0:029; 1:311)
(b)
0 0.181 0.221 0.125 0.241 0.199 0.221
11=0:837 (0:531; 1:355) 01=0:530 (0:030; 1:040) 10=0:913 (0:433; 1:464)
0.2 0.178 0.226 0.114 0.240 0.185 0.224
11=0:804 (0:524; 1:241) 01=0:500 (0:023; 1:035) 10=0:841 (0:266; 1:393)
0.5 0.172 0.230 0.122 0.237 0.117 0.221
11=0:764 (0:528; 1:119) 01=0:529 (0:028; 1:095) 10=0:553 (0:030; 1:318)
0.8 0.174 0.223 0.119 0.220 0.146 0.215
11=0:797 (0:567; 1:250) 01=0:573 (0:029; 1:600) 10 = 0:713 (0:047; 1:695)
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for the causal risk ratio estimates of ecacy due to compliance with one treatment only
(A or B) were generally wider. These 95% credible intervals for causal risk ratio estimates
became wider with increase in  values.
8.6 Conclusion
The sensitivity parameter  had no eect on the ITT results and also the overall and stratum-
specic mean proportion of compliance for either treatment. This is expected given that ITT
ignores any nonrandom compliance information introduced in the form of . While the
principal eects among the subgroup who would comply with either treatment were smaller
than the ITT estimates under homogeneous treatment eects assumption, the eects were
larger than ITT for the heterogenous case. Overall, the principal eects for the subgroup
who would comply with treatment B only were smaller than ITT for both homogeneous and
heterogeneous cases.
Analysis using the Roy et al. (2008) model produced better results (less bias) than those
from ITT. In general, causal risk ratios estimating eects of treatment B relative to A among
the subgroup who would comply with either treatment produced the least bias (albeit sta-
tistically signicant) compared to other strata. The corresponding 95% credible intervals for
these estimates became narrower as the sensitivity parameter  values increased. Causal risk
ratio estimates (posterior median relative risks) for potential compliers to one treatment only
produced larger biases and corresponding wider 95% mean credible intervals which became
even wider with increase in  values. Potential compliers to treatment B only approached
total noncompliance as  approached perfect correlation. Such a phenomenon may be en-
countered in situations where treatment B produces unpleasant side eects prompting non-
compliance among those randomized to it, i.e. resulting in dominance by type 3 compliance
at the expense of type 2 (overall B compliance is sum of types 2 and 3).
In general, the causal risk ratio estimates varied a lot depending on the value of the (un-
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known) sensitivity parameter. As a result, the Roy et al. (2008) is likely to produce biased
results and should only be recommended if there is sucient knowledge about the compliance
behaviours/correlation between the respective treatment arms. Given such knowledge, sub-
group (stratum-specic) analyses may be useful in helping understand the nature of ITT bias
by utilizing compliance information which would augment ITT results in ecacy estimation.
Choosing non-compliers for a known inferior treatment from the tail of hazard rates' distri-
bution may provide a practical and eective evaluation of of principal eects, i.e. it may be
considered more meaningful to associate noncompliance with a lower set of ranked baseline
hazard rates and corresponding risk factors.
Overall, although the Roy et al. (2008) method performed well with regard to simulations,
it failed when applied to Esprit (Chapter 6) where data may have not satised the method's
underlying assumptions. This apparent failure of Roy et al. (2008) method as applied to
Esprit data may be attributed to its implicit (strong) distributional assumption in which
the outcome of interest is assumed independent of the set of baseline covariates predictive
of compliance to treatment given compliance type/stratum and treatment allocation. For
example, the risk factors are likely to be strongly predictive of outcome independent of their
relationship with compliance. In general, despite its central role which ensures identication
of principal eect estimates, this dening assumption is untestable and the method's appli-
cation is heavily dependent on availability and selection of suitable predictors of compliance
which is rarely a primary objective in trials and may only be feasible by exploiting data from
pilot studies which often require more time and resources.
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Chapter9
Discussion and Conclusions
This chapter provides a recap of the whole thesis. It begins with a review of the principal
objectives as spelt out at the onset. This is followed by a section providing a summary of
the novelty of the present study followed by discussions of the main results from Esprit data
analysis and simulations studies. The next section outlines possible extensions and directions
for future work while the nal section presents a summary and recommendations from the
present work.
9.1 Review of the objectives of present work
In this section we review the objectives of the present work as outlined in section 1.12 and
examine whether they have been achieved. The introductory chapter began by putting
our research question into context followed by a summary of the motivating data. After
introducing the concept of causation in medical research, we reviewed research designs with
focus on controlled randomized controlled clinical trials highlighting its key design features,
types and limitations as contrasted with observational studies. An outline of reasons of
association was followed by a a comprehensive review of the counterfactuals framework of
causal modelling, key causal modelling assumptions including conditional exchangeability
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(no unmeasured confounding) that enables us to make valid causal inference. We briey
discussed the problem of noncompliance to treatment assignment, showed its similarity with
nonresponse and how they can be addressed by counterfactual modelling by stratifying on
posttreatment variables. After that we reviewed propensity scores as a method of adjusting
for confounding extending its tenets to build prediction models for compliance to treatment
allocation. A summary of estimation methods of causal eects preceded a review of the use of
principal stratication (Section 1.11.5) as a general framework to address noncompliance by
conditioning on a bivariate posttreatment variable noncompliance that induces conditional
exchangeability to produce well-dened causal estimands.
After introducing key features of survival data (Chapter 2), we reviewed the two common
methods of analysing survival data: proportional hazards and accelerated failure time models
and outlined the relationship between them. This was followed by three specialists methods
of adjusting for noncompliance in one treatment arm. These methods were classied into
two types with the structural proportional hazards method C-Prophet adjusting for all-or-
nothing noncompliance while the causal accelerated life model (CALM) and causal hazard
ratio adjustment regression model (CHARM) adjusting partial compliance by utilizing time
till stoppage of treatment/event. We outlined the key assumptions for each of these methods
justifying suitability and discussing possible conditions of violations to Esprit data. Chapter
4 provide results for the analysis of the Esprit data using these specialist methods.
Model selection techniques applied to building prediction models for compliance with
treatment assignment is a challenge that has received less attention among researchers evalu-
ating treatment compliance/eects. Plausible predictors of compliance can be used to address
identication problem of causal estimands (Jo, 2002a; Little et al., 2009). In Chapter 3 we
reviewed model selection methods that can be adopted to produce plausible predictors of
compliance. We discussed the classical stepwise model selection techniques and pointed its
limitations before exploring the merits of penalized regression techniques. An exposition on
model validation enabled us evaluate the performance of selected models using optimism,
calibration and discrimination indices.
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For two-active treatment trials, the ITT provide a biased estimator for the true haz-
ard ratio even under homogeneous treatment eects assumption. Such ITT results may be
augmented by ecacy analysis among subgroups likely to comply with their treatment as-
signment. We applied the principal stratication method of Roy et al. (2008) for survival
data analysis to adjust for noncompliance in two arms (Section 2.7). Specically, we used
plausible baseline covariates predictive of compliance in each arm (Chapter 5) to construct
arm-specic compliance models from which we apply the Roy et al. model to develop causal
models linking the two marginal models using a pre-specied sensitivity parameter . We
used Bayesian methods (Chapter 6), to obtain principal eects for each principal stratum in
terms of causal risk ratios obtained from means of posterior median relative risk and their
corresponding 95% credible intervals.
We applied statistically designed simulation studies to evaluate the performance of the
specialist methods adjusting for noncompliance in one treatment arm in terms of bias, 95%
condence intervals coverage and RMSE (Chapter 7). Using simulations, we also evalu-
ated the performance of the Roy et al. (2008) model in terms of bias and 95% credible
intervals (Chapter 8).
9.2 Novelty of present work
Motivated by the Esprit study whose aim was to ascertain whether or not unopposed oestro-
gen reduced the risk of further cardiac events in postmenopausal women who survive a rst
myocardial infarction, this thesis:
1. Performed an in-depth analysis of the Esprit data considering two outcomes (all-cause
mortality and myocardial reinfarction or cardiac deaths) adjusting for noncompliance
in one (active) treatment arm by applying three specialist methods. The structural
proportional hazards method C-Prophet assumed all-or-nothing compliance where a
woman was considered compliant with medication if she took HRT tablets allocation
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up to a day before experiencing event (all-cause mortality or myocardial reinfarction
or cardiac deaths) or end of study, whichever came rst. On the other hand both
CALM and CHARM methods assumed partial compliance by utilizing the time under
treatment before stopping or death/study end (Chapter 4).
2. Applied statistically designed simulation studies to compare the performance of six
methods (three naive and three specialist above) in terms of bias, RMSE and 95%
condence interval coverage. The performance of both The C-Prophet and CHARM
methods performed was similar despite C-Prophet assuming the (restrictive) all-or-
nothing compliance. Overall, the results showed that the CALM method performed
consistently best to produce smallest bias and largest 95% CI coverage albeit with
relatively large RMSE (Chapter 7).
3. Considered the challenge of building compliance prediction models, an issue which
seems not to have received much attention before. Specically we applied model selec-
tion techniques to obtain the `best' predictors of treatment compliance in both sepa-
rate arms of treatment. Using penalized regression techniques with same predictors of
compliance in each arm, the Least Absolute Shrinkage and Selection Operator (Lasso)
selection method produced the best calibrated, most discriminative and least optimistic
models predictive of compliance to both HRT tablets and placebo: in predicting com-
pliance to both HRT and placebo, the Lasso models were the least optimistic (2%)
and almost perfectly calibrated (slope=0:93). However, the better performance by the
Lasso method in selecting potential predictors of compliance relative to other methods
came at the price of severely shrunk log odd estimates/coecients (Chapter 5).
4. Examined the eects of placebo compliance in compliance-adjusted analysis which may
provide a valid method to scientically investigate possible placebo eects (Kienle and
Kiene, 1997). Specically we used placebo data to assess whether results change when
we adjust for placebo compliance by applying Roy et al. (2008) model for survival
analysis (originally developed for binary outcome). We applied principal stratication
in a Bayesian framework to adjust for noncompliance in two treatment arms. Applied to
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the Esprit data, the results showed that for moderate sensitivity parameter (=0:5),
compliance with HRT treatment relative to placebo would reduce risk for all-cause
mortality by 43% among women who would comply with either treatment. Compared
to placebo, HRT tablets would generally reduce the risk of death and reinfarction among
the highly compliant women, i.e. subgroup who would comply with either treatment
allocation, for all other values of  (Chapter 6).
5. Evaluated the performance the Roy et al. (2008) method which estimates ecacy in a
two-active treatment arms' trial in the presence of nonrandom compliance. Specically
we applied statistically designed simulation studies to compared the performance of
the Roy et al. (2008) method in terms of bias and 95% credible intervals under both
homogeneous and heterogeneous hazard rate assumptions. The results showed more
bias under heterogeneous treatment assumption compared to homogenous treatment
eects assumption. Generally principal eects among the potentially highly compli-
ant subgroup were less biased (Chapter 8). Overall, the results were sensitive to the
unknown sensitivity parameter and hence the Roy et al. (2008) method should not be
recommended unless there is sucient information about compliance behaviour for each
treatment arm, i.e. the method's implicit strong distribution assumption not plausible
for Esprit data.
9.3 Discussion of results
9.3.1 Esprit data
Similar to the original results published for the Esprit study (Cherry et al., 2002), ITT esti-
mates showed no statistically signicant dierence in eect between taking HRT tablets and
placebo. However, the treatment suggested benecial eects in reducing the risk of all-cause
mortality by about 20%. On the other hand, the analysis revealed that compared to placebo,
HRT treatment had no statistically dierent eect on the risk of myocardial reinfarction or
cardiac death (HR=0:99). Analysing the Esprit data using the specialist methods produced
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similar results for both C-Prophet and CHARM: a benecial eect of HRT tablets over
placebo to reduce the risk for all-cause mortality by about 35% whereas there was no dier-
ence in eects between HRT treatment and placebo on the risk for myocardial reinfarction.
As expected, the (simple) CHARM estimate was sensitive to rate of compliance: substan-
tial risk reduction in the presence of higher proportion of compliance and less risk reduction
otherwise. CHARM analysis depends on satisfaction of the extended exclusion restriction
assumption. While this assumptions may be considered reasonable for the Esprit data, as-
suming that a subject's past treatment has no eect on her present risk to death may not
hold, for example, for an eective treatment with residual eects or a treatment likely to
induce unpleasant side eects hence prone to aect compliance rates. A probable solution
to address violation of the former is to adopt a suggestion by White et al. (2004) to use
time-series model (with additional structural assumptions) to account for residual treatment
eects. A general practical limitation for all the specialist methods is their application only
to covariate-free models which may deny them producing more ecient ecacy estimates
when (baseline) prognostic variables are accommodated.
The overall average rate of compliance with treatment was moderate at 43% and the
compliance rate decreased with time as the study progressed till completion. On average,
the mean proportion of compliers to placebo (57%) was higher compared to those complying
with HRT tablets allocation (46%). Histories of hysterectomy was a predictor of compliance
for both HRT tablet and placebo allocation. Smoking status predicted compliance to HRT
tablets allocation but not compliance with placebo allocation. Conversely history of alcohol
use was a predictor of compliance to placebo allocation only. The proportion of women who
would have the same compliance status under either treatment allocation (S = (1; 1) and
S = (0; 0)) increased with increase in the sensitivity parameter : the proportion of those
who would comply with either treatment allocation (S = (1; 1)) were generally higher than
those who would not comply with either allocation (S=(0; 0)). In general, the relatively low
rate of compliance in Esprit data may make it dicult to generalize the results.
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At moderate values of the sensitivity parameter , HRT tablets showed reduction in risk
of death among women who would comply with either treatment to which they were allocated:
by assuming conditional independence, principal stratication analysis suggested compliance
with HRT treatment relative to placebo would reduce risk of mortality by 42% among those
who would comply with either treatment. In general HRT tablets indicated benecial eects
compared to placebo for all other values of  among the subgroup who would comply with
either treatment allocation. However, causal risk ratios estimating ecacy of HRT treatment
only or placebo only (stratum 1 or 2) had relatively wider mean 95% credible intervals
compared to estimates for ecacy HRT over placebo among those who would comply with
either treatment (stratum 3). The risk for all-cause mortality for those complying with HRT
relative to placebo among potential compliers to either treatment increased with increase in
the value of sensitivity parameter . Conversely, the risk of all-cause mortality decreased
with increase in  among those who would comply with HRT treatment only. As expected
the risk of death was higher regardless of the level of sensitivity  among those who would
comply with placebo only.
A comparison of results from the Roy et al. (2008) method which adjusts for placebo
compliance and the specialist methods which only consider compliance with the active treat-
ment showed both C-Prophet and CHARM results were comparable to those from Roy et al.
method at high values of sensitivity parameter (=0:5 and 0:8) for all-cause mortality out-
come. On the other hand, CALM results were comparable to those for Roy et al. method at
low value of the sensitivity parameter (=0:2) for the same outcome (all-cause mortality).
In general, results from the Roy et al. were heavily dependent on the (unknown) sensitivity
parameter, an indication the results were sensitive to the (strong) implicit distributional as-
sumption which would make them less generalizable to situations where the assumption may
be breached, for example, where there is no information about the compliance behaviour for
either arm. Overall, the CALM method performed best compared to all the methods includ-
ing the Roy et al. at all the sensitivity parameter values considered. Specically, CALM
results suggested that compliance with HRT treatment would increase survival time 2:8-fold
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(equivalently 50% lower risk) compared to placebo for the all-cause mortality outcome. As
a result the CALM method should be recommended for analysing the Esprit data.
Variation in the HRT ecacy estimates from the Roy et al. model may be an indication
of dierence in compliance behaviour between those allocated to placebo and HRT treat-
ment. By adjusting for noncompliance in both arms, the Roy et al. (2008) method perhaps
accounts for potential correlation between compliance behaviours in respective arms through
the sensitivity parameter which implicitly makes the results depend on . The fact that
the results vary a lot with  and yet we do not know its value suggests benets of HRT
treatment among those who comply when allocated it, i.e. strong monotonicity assumption
(strong correlation in compliance behaviour between the two arms).
9.3.2 Monte Carlo: noncompliance in one arm
The ITT analysis produced bias as expected because of ignoring frailty and assuming constant
hazard ratios in the proportional hazards models. Simple regression adjustments of noncom-
pliance produced large bias under random compliance. Similarly, simple regression adjust-
ment of noncompliance performed poorest under non-null case in the presence of non-random
compliance: produced larger biases whose magnitude and direction depended on correlation
between the risk and probability of noncompliance. These sets of results suggest inadequacy
of simple regression adjustments for any form of noncompliance (random and nonrandom).
Under ideal conditions mimicking the null model alone, the C-Prophet and CHARM
methods produced the most precise results in terms of RMSE under both random and
nonrandom compliances scenarios. But the CALM method under random noncompliance
performed consistently `best' to produce similar and smallest bias for the causal eect in one
direction, probably because the method eectively accounts for non-constant hazard rates
better compared to C-Prophet and CHARM methods. Despite the (limiting) all-or-nothing
assumption, the C-Prophet produced the most precise estimates in terms of RMSE for the
nonrandom compliance case albeit with low 95% condence interval coverage.
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Overall the CALM method produced the best coverage rate for the estimates under
both random and nonrandom compliance compared to other methods. Probably because of
its potential robustness in accounting for partial compliance and good coverage probability,
the CALM method should be recommended among the specialist methods adjusting for
noncompliance in one treatment arm for the Esprit data.
9.3.3 Monte Carlo: noncompliance in two arms
For two active treatments, the ITT analysis produced biased ecacy estimates even under ho-
mogeneous treatment eects assumption. As expected, the overall and mean stratum-specic
proportion of compliance for either treatment does not depend on the value of the sensitivity
parameter . The principal eects for the subgroup who would comply with either treatment
were less than ITT under homogeneous case but larger than the ITT under heterogeneous
case. However, the principal eects for the subgroup who would comply with treatment B
only (types 2) were smaller than ITT for both homogeneous and heterogeneous cases.
Analysis using the principal stratication framework (Roy et al. 2008 model) produced
less biased results compared to ITT. The least biased causal risk ratio estimates were obtained
for the subgroup constituted by those who would comply with either treatment. Although
these estimates were statistically signicant, their corresponding 95% credible intervals be-
came narrower with increase in the sensitivity parameter  values. Conversely, the causal
risk ratio estimates of ecacy due to compliance with one treatment only (types 1 and 2)
produced larger biases and corresponding wider 95% credible intervals which became even
more wider with increase in  values. Potential compliers to treatment B only approached
total noncompliance as  approached perfect correlation (=1). Such a phenomenon may be
encountered in situations where treatment B produce unpleasant side eects prompting non-
compliance among those randomized to it, i.e. resulting in dominance by type 3 compliance
at the expense of type 2 (overall compliance with treatment B is the sum of types 2 and 3).
While Roy et al. (2008) originally used one continuous covariate, our simulation used two
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dichotomous covariates (mimicking histories of CVD risks and hysterectomy), hence possibly
utilizing more information. Also their (Roy et al., 2008) correlation set-up was deterministic
and xed for the model predicting arm-specic compliance and covariate while we specied
our compliance membership stochastically using tail distribution. This set-up was motivated
by the practicality that choosing non-compliers for a known inferior treatment from the
tail of hazard rates' distribution may provide a realistic representation of underlying risk
distribution in a heterogeneous population.
Provided there is sucient compliance information for each arm, subgroup (stratum-
specic) analyses may be useful in helping to understand the nature of ITT bias by utilizing
compliance information which may augment ITT results in ecacy estimation. Choosing
non-compliers for a known inferior treatment from the tail of hazard rates' distribution may
provide a practical and eective evaluation of treatment eects.
9.4 Extensions and directions for future work
The causal accelerated life models produce consistent estimates of causal eects (Robins and
Tsiatis, 1991). But since the method ignores the compliance selection mechanism, its exi-
bility may not readily extend to complicated data from studies with multiple switches. Also
a practical limitation of the CALM method as implemented using strbee Stata command is
the key requirement for the user to provide time for recensoring which may become informa-
tive (leading to bias) on a dierent scale (see Section 7.5). However, some trials may not have
a xed time of follow-up and such a situation may make using end of study as the potential
recensoring time restrictive (prone to bias). Recensoring itself is meant to account for no
assumption in the functional form of the model and an arbitrary choice of a recensoring time
would negate the objective of fewer assumptions to facilitate wider credibility. Also failure
to eectively account for the resulting potential informative censoring can have noticeable
eects on the results (Siannis et al., 2005). A possible extension would be to use frailty mod-
els to account for the correlation between failure and recensoring (Huang and Wolfe, 2002).
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Another solution may involve application or modication of marginal structural models for
so-called partial exposure regimes (Vansteelandt et al., 2009). We however note that although
CALM in general is readily able to handle such complex noncompliance scenarios, strbee
may present a limitation in implementing them.
Most clinical trial studies include records of baseline covariates. Although not straight-
forward, of interest would be extending the specialist methods considered for the present
work (C-Prophet, CHARM and CALM) to utilize such covariates which may help enhance
eciency during ecacy estimation. For the CALM method for example, identication prob-
lem may arise from possible informative censoring on the potential event time-scale which
is otherwise non-informative on the observed event time scale. Suitable baseline covariates
may be used to address identication problem on survival times in the presence of informa-
tive censoring (Ding, 2010). In general, recording good baseline predictors of compliance to
treatment allocation at the design stage may be useful for making causal conclusions that
goes beyond ITT inference (Goetghebeur and Loeys, 2002). For example, conditioning on
baseline covariates in a model may help address any residual confounding that may arise from
imbalance between randomized arms. Also extending the methods to utilize potential prog-
nostic (baseline) factors may help improve eciency in ecacy estimation under nonrandom
compliance scenario (Angrist and Pischke, 2009; White and Pocock, 1996). Given the central
role of exclusion restriction assumption and potential bias if its violated (Hirano et al., 2000),
using pretreatment covariates may help relax the exclusion restriction needed by all the 3
specialist methods considered in the present work because such covariates may allow us to
examine the assumption's tenability by assuming an additive eect of treatment assignment
(Jo, 2002a; Little et al., 2009). Also conditioning on baseline covariates may help preserve
(ensure) noninformative censoring that is crucial for the C-Prophet method.
Using Bayesian techniques in the principal stratication framework to adjust for noncom-
pliance in two treatment arms may be more informative by allowing us to incorporate subject
matter knowledge through informative prior distribution. The Bayesian setting is also suit-
able to model missing data (Daniels and Hogan, 2008; Gelman et al., 2004), hence allowing us
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to simultaneously address the prevalent twin challenges of noncompliance and missing data.
Specically, posterior simulation using Gibbs sampling framework combining the likelihood
with a prior distribution over the model parameters can be used to impute unobserved compli-
ance types and generate sampling parameters from the conditional posterior distribution for
ecient estimation. By treating model parameters as random variables, Bayesian inference
can be used to minimize ambiguity in inference (Dunson, 2001; Malako, 1999; Ntzoufras, 2009).
For example, interpretation of 95% credible intervals is devoid of repeated sampling inference
implicit in frequentist interpretation of 95% condence intervals. The application of principal
stratication framework could be extended to data with better compliance information to al-
low sequential prior updating for improved eciency in the resulting posterior estimates, i.e.
as aptly summed by Gelman et al. (2004) that today's posterior is tomorrow's prior. Also
given that clinical trials are often conducted to provide optimal treatment decisions, adopting
a Bayesian decision-theoretic framework would allow integration of the twin tasks of data
analysis and decision making, two issues which are classically treated separately (Brophy and
Joseph, 1995; Stangl, 1995, 2000), i.e. Bayesian statistical framework provides an intuitive
link between data and decision making (Lancaster, 2004; Lilford and Braunholtz, 2000).
Bayesian methods may also be used to address the problem of partial identiability when
estimating ecacy in the presence of more than one active treatment. This is discernible
from the fact that proper prior distributions are guaranteed to produce proper posterior
distributions even when the parameters are only partially identiable in the classical sense
(Christensen et al., 2010; Gelman and Hill, 2007; Jackman, 2009; Spiegelhalter, 2004). The
present work may be extended to more than two active treatment arms and for general
outcome (continuous or discrete) following the Bayesian framework introduced recently by
Long et al. (2010) to model the principal (arm-specic) compliances directly, instead of joining
them using an associational model (and ), by treating the principal compliance status as
missing data. Such an approach would avoid the assumption implicit in the Roy et al. (2008)
model that the sensitivity parameter is independent of covariates hence allowing estimation
under less stringent assumptions and hence permitting broader credibility.
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Comparison of two active treatments often involve an additional treatment administered
as a placebo to establish assay sensitivity which is dened as the ability of a study to distin-
guish between active and inactive treatments (Snapinn, 2000; Temple and Ellenberg, 2000),
i.e. a study that successfully demonstrates superiority has simultaneously demonstrated as-
say sensitivity. As a result such a trial ends up involving a minimum of three arms. The
principal stratication framework applied in the present work can be extended to multi-arms
trials. For a three-armed trials with binary outcomes, Cheng and Small (2006) applied the
principal stratication to derived sharp bounds on causal eects within principal strata us-
ing two sets of assumptions obtained by decomposing the monotonicity assumption into two:
rst assuming no access to treatment among those assigned to control and no treatment
switches among those assigned to the two active treatments and second assuming similar
compliance behaviour among those assigned to the active treatment. These extensions as-
sumed homogeneous treatment eects, correct compliance information and correct drop-out
model. An extension of the present work would involve sensitivity analysis to evaluate the
robustness from violations of these assumptions given the ubiquitous heterogeneous nature
of treatment eects.
Although reporting point estimates of ecacy measures is the most common practice
in medical research, point estimation is often achieved at the price of strong untestable
assumptions making the validity of the respective methods dependent on the accuracy of
such assumptions (Cai et al., 2008, 2007; Chiba, 2009; Chiba et al., 2007). We can broaden
credibility under relaxed assumptions by exhausting (partial) information from available
data to construct bounds on treatment eects. For example, Cai et al. (2007) used observed
covariate information to derive narrower and more informative nonparametric bounds on
treatment eects compared to natural (covariate-free) bounds. However, we note that this
method used observed covariates and may be extended to use counterfactuals in the principal
stratication framework.
Hormone replacement therapy treatment may be used to improve the quality of life
in the last third of women's lives to relieve postmenopausal symptoms, for example, va-
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somotor and urogenital atrophy (Pecorelli and Fallo, 1998). Apart from prevalent non-
compliance to treatment and possible missing data on outcomes, truncation-by-death may
further complicate research where quality of life is a primary outcome of interest. The
present work can be extended by applying the model proposed by Mattei and Mealli (2007)
based on principal stratication framework for jointly handling data with three complica-
tions: treatment noncompliance, missing outcomes following treatment noncompliance and
truncation-by-death. Stratifying on the posttreatment variable survival outcome would en-
able us make causal inference (address identication) in the principal stratum, i.e. the
subgroup of patients who would have survived under both treatments. The present work can
also be extended by adopting the proposal by Imai (2008)) which addresses identication
problem by formulating truncation-by-death as a contaminated data problem. Imai (2008)
contends that such a formulation may be exible enough and can be extended to estimating
ecacy in three-arm randomized experiments with noncompliance which would enable us
extend the HRT study to comparing two competing active treatments and a placebo hence
ability to establish assay ecacy.
9.5 Summary and recommendations
The aims and objectives as outlined at the onset of the present work have been achieved
(Section 9.1). This work has contributed novelty to modelling survival data with informative
noncompliance in one and two treatment arms. We applied specialist methods for adjusting
noncompliance in one treatment arm in data from the Esprit study (Chapter 4) and used
statistically designed simulation studies to evaluate their performance in terms of bias, root
mean squared error and 95% condence interval coverage (Chapter 7).
Intention-to-treat is the gold standard in evaluating treatment eectiveness by answering
the question `what is the eect of the treatment as randomly allocated?.' But in trials with
signicant proportion of non-adherence, the specialist methods could augment the analysis by
adjusting for noncompliance to provide a more realistic measure of the treatment's ecacy.
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In general, all the three specialist methods (C-Prophet, CALM and CHARM) were applicable
to the Esprit study. Key to C-Prophet method is noncompliance classication and exclusion
restriction assumption. Given the limited compliance information, noncompliance for the
Esprit study may be meaningfully classied as all-or-nothing. However, we note this as a less
desirable method although it performed well in simulations. And the exclusion restriction
assumption (i.e. no eect of assignment to active arm on survival in the subgroup of non-
compliers) may be considered plausible for the C-Prophet method because no switches were
allowed from the placebo to HRT arms. The crucial extended exclusion restriction assump-
tion (i.e. randomized allocation has no eect on any survivors to the start of an interval who
would stop treatment by the end of that interval) for the CHARM method may be considered
plausible for the Esprit study if we assume no carryover eects and probably short monthly
evaluations. Finally the exclusion restriction assumption is plausible for CALM method
(the baseline prognosis independent of randomized allocation) given the strict inclusion and
exclusion criteria for the study which would minimize chances of recruiting patients with
prognosis capable of inuencing/breaching treatment assignment. Moreover, recensoring us-
ing the study duration (24 months) would minimize possible information loss. Although both
C-Prophet and CHARM performed equally well, CHARM provided more exibility in adjust-
ing for possible crossovers from active to placebo arms. Overall, we recommend the CALM
method which apart from allowing twin adjustments of crossovers (partial noncompliance)
and recensoring also produced `least' biased treatment eects with `best' 95% condence
intervals coverage albeit with a relatively large root mean squared error.
Bradley Efron may have correctly identied model selection in regression as one of the
most important problems in statistics (Hesterberg et al., 2008) towards the end of last Cen-
tury. Hitherto this challenge has not been addressed in the context of prediction of compliance
to treatment allocation in causal modelling (covered in Chapters 3 and 5). Most authors in
the compliance literature say very little about this topic. A record of plausible predictors
of compliance can be used to eectively address identication problem of causal estimands
by reducing bias and weakening implicit assumptions (Little et al., 2009). From a clinical
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perspective, knowledge about predictors of compliance may be a valuable tool to inform
treatment decisions. As a result, there is need to adopt existing model selection methods for
accurate prediction (of compliance). After model selection, there is further need to use suit-
able validation measures (e.g. optimism, calibration and discrimination indices) to evaluate
performance of selected models. With (many) recorded baseline covariates, using penalized
regression techniques is recommended for building compliance prediction models. Advan-
tages of classical model selection may be transferable to the Roy et al. (2008) method which
adjusts for noncompliance in two-active treatment arms through use of respective optimal
marginal compliance models.
The presence of two active treatments complicates ecacy estimation due to possible
noncompliance in both arms. Here the ITT provide a biased estimator for the true hazard
ratio even under homogeneous treatment eects assumption. Applying the Roy et al. (2008)
model from the present work (Section 2.7 and Chapter 6) may be suitable in utilizing more
baseline information to model arm-specic compliance models to develop causal models link-
ing the two marginal models. The resulting principal eects provides ecacy estimates for
the dierent subgroups dened by compliance types. In evaluating performance of the model,
simulation studies (Chapter 8) revealed less biased results for the potentially most compliant
stratum, i.e. the subgroup that would comply with either treatment. Overall, the method's
performance was satisfactory but the results were heavily dependent on the level of sensitiv-
ity parameters and hence may not be recommended in the presence of known heterogeneous
treatment eects which produced large bias and wider corresponding 95% credible intervals.
It may only be recommended in the presence of sucient information about compliance
behaviours in respective arms.
Application of the Roy et al. (2008) method is premised on the plausibility of a dening
assumption that potential outcome is independent of the set of covariates predicting compli-
ance for a given stratum. This assumption may not be plausible for the Esprit data especially
with regard to history of hysterectomy and cerebrovascular risks which potentially have a
higher likelihood to be association with treatment compliance leading to possible ecacy. For
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example, while the unpleasant experience of bleeding may aect treatment compliance neg-
atively, those with history of CVD risks may comply with their treatment allocation with a
hope to derive any protective benets. Also the fact that resulting principal eects depended
on the choice of covariates predicting compliance may be a reason of failure of the Roy et al.
(2008) method as applied to the Esprit data given inadequate compliance information/data.
Results from our simulation studies (Chapter 8) were comparable to those of Roy et al.
(2008): less biased treatment eects for the potentially highly compliant subgroup, i.e.
women who would comply with either treatment. The dierence in simulations set-up for
compliance was that while Roy et al. originally set their simulations to have equal compliance
probability in each treatment arm, we had a higher proportion of compliance for treatment
A compared to treatment B in order to maintain U(x)=minf1; ^1(x)
^0(x)
g< 1. In addition, we
stochastically set the correlation between the two compliance using tail distributions while the
original set-up by Roy et al. (2008) was deterministic in nature. As a result our set-up may
be more representative of a heterogenous sample and suitable for survival data, i.e. choosing
non-compliers for a known inferior treatment from the tail of hazard rates' distribution to
provide a practical and eective evaluation of treatment eects.
All the methods considered in the present work were applied to the Esprit study which
did not have very high quality compliance data given that compliance was not an original
primary objective, i.e. less compliance information recorded. This may limit generalization
of the results obtained herein. Since the end of Esprit study, more data has been collected
which may be used for more informative analysis that would reect true/better eects of
HRT treatment among dierent subgroups (principal strata). Also duration of treatment is
an important phenomenon in methods which accounts for partial compliance. The specialist
methods considered here assumed that the eects of treatment ceased immediately a subject
stopped medication. This may not be reective of the true eects for medications with known
residual eects (Nagelkerke et al., 2000). But following suggestion by White et al. (2004),
we may incorporate time-series-like models that would extend the methods to account for
(latent) lagged treatment eects.
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Appendices: Annotated Stata, R and WinBUGS codes
Appendix I: Annotated Stata codes for Esprit data analysis (Chapter 4)
use espritdata.dta, clear
* ITT analysis for all-cause mortality and myocardial reinfarction
stset monthsacm, failure(dead)
stcox treat hysterec age bmi smk bpress diab
stcox treat
streg treat,dist(weib) nolog
streg treat hysterec age bmi smk bpress diab,dist(weib) nolog
*weibull _t treat,dead(_d) t0(_t0) hr
stset monthsmrcd, failure(mrcd)
stcox treat hysterec age bmi smk bpress diab, nolog
stcox treat
streg treat,dist(weib) nolog
streg treat hysterec age bmi smk bpress diab,dist(weib) nolog
* Testing PH assumption
qui stset monthsacm, failure(dead)
qui stcox treat hysterec age_admi bmi smk1 bldpress diab, /*
*/schoenfeld(sch1*) scaledsch(sca1*)
stphtest, detail
qui stset monthsmrcd, failure(mrcd)
qui stcox treat hysterec age_admi bmi smk1 bldpress diab, /*
*/schoenfeld(sch2*) scaledsch(sca2*)
stphtest, detail
* Per-protocol and as-treated analysis
stset monthsacm,failure(dead)
stcox treatpp
stset monthsmrcd,failure(mrcd)
stcox treatpp
stset monthsacm,failure(dead)
stcox treatat,tvc(treatat)
stset monthsmrcd,failure(mrcd)
stcox treatat,tvc(treatat)
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* Simple regression adjustment of noncompliance
stset monthsacm,failure(dead)
stcox treat noncomply
stcox treat,tvc(noncomply)
stset monthsmrcd,failure(mrcd)
stcox treat noncomply
stcox treat,tvc(noncomply)
* C-PROPHET analysis
replace complyacm=. if treat==0
stset monthsacm, failure(dead) id(idno)
stcomply treat complyacm, grfit convcrit(0.01)
replace complymrcd=. if treat==0
stset monthsmrcd, failure(mrcd) id(idno)
stcomply treat complymrcd, grfit convcrit(0.01)
* CHARM analysis
stset monthsacm,failure(dead)
adjhr treat,const
adjhr treat,xo1(monthstab1 comply1) const
stset monthsmrcd,failure(mrcd)
adjhr treat,const
adjhr treat,xo1(monthstab2 comply2) const
* CALM analysis (ITT, adjusting for crossovers and recensoring)
stset monthsacm, failure(dead)
strbee treat, psimin(-3) psimax(2) graph title(ACM: ITT under CALM)
*adjusting for crossovers only
strbee treat, xo1(monthstab1 comply1) psimin(-3) psimax(2)
*adjusting for crossovers and recensoring
strbee treat, xo1(monthstab1 comply1) endstudy(endsty) test(logrank) /*
*/psimin(-3) psimax(2) psistep(0.6) graph title(ACM: CALM with recensoring)
stset monthsmrcd, failure(mrcd)
strbee treat,psimin(-2.5) psimax(2) graph title(MRCD: ITT under CALM)
*adjusting for crossovers only
strbee treat, xo1(monthstab2 comply2) psimin(-2.5) psimax(2)
*adjusting for crossovers and recensoring
strbee treat, xo1(monthstab2 comply2) endstudy(endsty) test(logrank) /*
*/psimin(-2.5) psimax(2) psistep(0.4) graph title(MRCD: CALM with recensoring)
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Appendix II: Annotated R codes for compliance prediction models (Chapter 5)
set.seed(876543)
library(foreign)
library(Hmisc,T)
library(Design,T)
library(glmpath)
options(digits=3)
esp<-read.dta('p:esprit.dta')
attach(esp)
# full model
hyst<-as.factor(hyst)
sclass<-as.factor(sclass)
smoker<-as.factor(smoker)
diabet<-as.factor(diabet)
risks<-as.factor(risks)
alcoh<-as.factor(alcoh)
hrt<-as.factor(hrt)
fract<-as.factor(fract)
trt<-as.factor(trt)
esp<-data.frame(comply,hyst,smoker,sclass,age,risks,diabet,fract,alcoh,hrt,trt)
ddist<-datadist(esp)
options(datadist='ddist')
fit.full<-lrm(comply~hyst+scored(sclass)+risks+diabet+age+smoker+fract+alcoh+hrt,
x=T,y=T)
validate(fit.full,method="boot",B=200,bw=T,rule='aic',sls=.1,type='individual')
# full reduced model
esp.fred<-data.frame(comply,hyst,risks,alcoh)
ddist.fred<-datadist(esp.fred)
options(datadist='ddist.fred')
fit.fred<-lrm(comply~hyst+risks+alcoh,x=T,y=T)
fit.fred
validate(fit.fred,method="boot",B=200)
# placebo arm
fit0<-update(fit.full, subset=trt==0)
validate(fit0,method="boot",B=200)
# placebo arm reduced model
hyst0<-as.factor(hyst[trt==0])
smk0<-as.factor(smoker[trt==0])
alc0<-as.factor(alcoh[trt==0])
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comply0<-as.factor(comply[trt==0])
esp.red.0<-data.frame(comply0,hyst0,smk0,alc0)
ddist.red.0<-datadist(esp.red.0)
options(datadist='ddist.red.0')
fit.red.0<-lrm(comply0~hyst0+smk0+alc0,x=T,y=T)
fit.red.0
validate(fit.red.0,method="boot",B=200)
# active arm
fit1<-update(fit.full, subset=trt==1)
validate(fit1,method="boot",B=200)
# active arm reduced model
hyst1<-as.factor(hyst[trt==1])
risks1<-as.factor(risks[trt==1])
smk1<-as.factor(smoker[trt==1])
comply1<-as.factor(comply[trt==1])
esp.red.1<-data.frame(comply1,hyst1,risks1,smk1)
ddist.red.1<-datadist(esp.red.1)
options(datadist='ddist.red.1')
fit.red.1<-lrm(comply1~hyst1+risks1+smk1,x=T,y=T)
fit.red.1
validate(fit.red.1,method="boot",B=200)
# LASSO regression and bootstrapping
xpred<-matrix(c(hyst,smoker,sclass,age,risks,diabet,fract,alcoh,hrt),ncol=9)
yresp<-matrix(c(comply),ncol=1)
esppath<-glmpath(xpred,yresp,family=binomial)
par(mfrow=c(2,1))
plot.glmpath(esppath,type='coefficients')
plot.glmpath(esppath,type='aic')
esppath$b.predictor[esppath$aic==min(esppath$aic),]
boot.lasso<-bootstrap.path(xpred,yresp,B=200,method='aic',trace=F)
plot(boot.lasso)
plot(boot.lasso,type='pairplot')
# validating final selected Lasso model
fit.lasso<-lrm(comply~hyst+risks+alcoh,x=T,y=T)
validate(fit.lasso,method="boot",B=200)
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Appendix III: Annotated WinBUGS+Stata codes-noncompliance in 2 arms (Chapter 6)
model Roy08modelEsprit{
# WinBUGS: predicting compliance in placebo and active arms
for (i in 1:1017){
comply0[i]<-comply[i]*equals(trt[i],0)
comply0[i]~dbern(p0[i])
logit(p0[i])<-lambda00+lambda0[1]*hyst[i]+lambda0[2]*smoker[i]+
lambda0[3]*(age[i]-mean(age[]))+lambda0[4]*risks[i]+
lambda0[5]*fract[i]+lambda0[6]*alcoh[i]
comply1[i]<-comply[i]*equals(trt[i],1)
comply1[i]~dbern(p1[i])
logit(p1[i])<-lambda10+lambda1[1]*hyst[i]+lambda1[2]*smoker[i]+
lambda1[3]*(age[i]-mean(age[]))+lambda1[4]*risks[i]+
lambda1[5]*fract[i]+lambda1[6]*alcoh[i]
# compliance probability for each treatment arm
mu0[i]<-pow((1+exp(-((lambda00+lambda0[1]*hyst[i]+lambda0[2]*smoker[i]+
lambda0[3]*(age[i]-mean(age[]))+lambda0[4]*risks[i]+lambda0[5]*fract[i]+
lambda0[6]*alcoh[i])*equals(trt[i],0)))),-1)
mu1[i]<-pow((1+exp(-((lambda10 + lambda1[1]*hyst[i]+lambda1[2]*smoker[i]+
lambda1[3]*(age[i]-mean(age[]))+lambda1[4]*risks[i]+lambda1[5]*fract[i]+
lambda1[6]*alcoh[i])*equals(trt[i],1)))),-1)
# likelihoods- risks of death for individual stratum (same for MRCD outcome)
# L(pi,beta|Y=1,A=1,Z=1,X) - u(0,1) prior for pis
dead3[i]<-dead[i]*equals(strata[i],3)
dead3[i] ~ dbern(pi11_1[i])
pi11_1[i]<-pi1[1]*mu01[i]+pi1[2]*mu11[i]
# L(pi,beta|Y=1,A=0,Z=1,X) - u(0,1) prior for pis
dead2[i]<-dead[i]*equals(strata[i],2)
dead2[i] ~ dbern(pi10_1[i])
pi10_1[i]<-pi1[3]*mu00[i]+pi1[4]*mu10[i]
# L(pi,beta|Y=1,A=1,Z=0,X) - u(0,1) prior for pis
dead1[i]<-dead[i]*equals(strata[i],1)
dead1[i] ~ dbern(pi11_0[i])
pi11_0[i]<-pi1[5]*mu10[i]+pi1[6]*mu11[i]
# L(pi,beta|Y=1,A=0,Z=0,X) - u(0,1) prior for pis
dead0[i]<-dead[i]*equals(strata[i],0)
dead0[i] ~ dbern(pi10_0[i])
pi10_0[i]<-pi1[3]*mu00[i]+pi1[7]*mu01[i]
#compliance probability ratio
u_x[i]<-min(1,mu1[i]/mu0[i])
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# compliance probabilities for each stratum - phi=0,0.2,0.5 and 0.8
mu11[i]<-mu0[i]*mu1[i]+0.5*mu0[i]*(u_x[i]-mu1[i])
mu01[i]<-mu1[i]-mu0[i]*mu1[i]-0.5*mu0[i]*(u_x[i]-mu1[i])
mu10[i]<-mu0[i]-mu0[i]*mu1[i]-0.5*mu0[i]*(u_x[i]-mu1[i])
mu00[i]<-1-mu0[i]-mu1[i]+mu0[i]*mu1[i]+0.5*mu0[i]*(u_x[i]-mu1[i])
}
# non-informative priors for parameters
for (k in 1:6) {
lambda0[k] ~ dnorm(0.0,1.0E-6)
lambda1[k] ~ dnorm(0.0,1.0E-6)
}
lambda00 ~ dnorm(0.0,1.0E-6)
lambda10 ~ dnorm(0.0,1.0E-6)
# uniform priors for the pis
for (w in 1:7) {
pi1[w] ~ dunif(0,1.0)
}
# mean posterior estimates
m_mu0<-mean(mu0[]); m_mu1<-mean(mu1[]); m_ux<-mean(u_x[]); m_mu11<-mean(mu11[]);
m_mu01<-mean(mu01[]); m_mu10<-mean(mu10[]); m_mu00<-mean(mu00[]);
tau11<-pi1[2]/pi1[6]; tau01<-pi1[1]/pi1[7]; tau10<-pi1[4]/pi1[5]
}
# WinBUGS calling script
display('log')
check('C:/model.txt')
data('C:/data.txt')
compile(3)
inits(1,'C:/inits1.txt')
inits(2,'C:/inits2.txt')
inits(3,'C:/inits3.txt')
gen.inits()
update(1000)
set('lambda00')
set('lambda0')
set('lambda10')
set('lambda1')
set('m_mu0')
set('m_mu1')
set('m_ux')
set('m_mu11')
set('m_mu01')
set('m_mu10')
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set('m_mu00')
set('pi1')
set('tau11')
set('tau01')
set('tau10')
dic.set()
update(10000)
dic.stats()
coda(*,'C:/coda')
save('C:/log.txt')
quit()
* Calling WinBUGS from Stata
use "C:\espritdata.dta", clear
* transforming data to stata format
wbarray comply trt hyst smoker age risks fract alcoh dead strata, /*
*/ format(%3.0f %3.0f %3.0f %3.0f %8.2f %3.0f %3.0f %3.0f %3.0f %3.0f) /*
*/ noprint saving(C:\data.txt,replace)
* Model fitting
wbscript, sav(C:\script.txt,replace) model(C:\model.txt) data(C:\data.txt) /*
*/ inits(C:\inits.txt) coda(C:\coda) burn(1000) update(10000) chain(3) /*
*/ set(lambda00 lambda0 lambda10 lambda1 m_mu0 m_mu1 m_ux m_mu11 m_mu01 /*
*/ m_mu10 m_mu00 pi1 tau11 tau01 tau10) dic log(C:\log.txt) quit
* running the bugs program
wbrun, script(C:\script.txt) winbugs(c:\Program Files\WinBUGS14\winbugs14.exe)
* Reading the MCMC results
wbcoda,root(C:\coda) clear multichain chain(3) id(chain)
* summarising the results
wbstats lambda00 lambda0* lambda10 lambda1* m_mu0 m_mu1 m_ux /*
*/ m_mu11 m_mu01 m_mu10 m_mu00 pi1* tau11 tau01 tau10
267
Appendix IV: Annotated Stata codes for simulations comparing methods (Chapter 7)
capture program drop thesis2010C7
set seed 819726345
set more off
program thesis2010C7, rclass
set obs 1000
gen endsty=24
gen id=_n
gen byte trt=uniform()<=0.5
gen death=0
gen comply=1
*initializing for 95% CI calculation
gen cvitt=0
gen cvcox1=0
gen cvcox2=0
gen cvcproph=0
gen cvcalm=0
gen cvcharm=0
*generating correlated hazard rate and probability of nocompliance-Kleijnen (1974)
*baseline hazard rate=haz0: mu1=0.012, sd1=0.00845, alpha: mu2=0.05, sd2=0.0354
gen rho=0.5
gen z=invnormal(uniform())
gen haz0=rgamma(2,0.006)
quietly sum haz
local mu1haz=r(mean)
local sd1haz=r(sd)
gen alpha=exp(-3.199+0.6374*invnorm(uniform()))
quietly sum alpha
local mu2alpha=r(mean)
local sd2alpha=r(sd)
gen probnoncomply=abs(rho*(`sd2alpha'/`sd1haz')*haz+`mu2alpha'- /*
*/rho*(`sd2alpha'/`sd1haz')*`mu1haz'+sqrt(1-rho*rho)*`sd2alpha'*z)
gen haz1=haz0/2
sort probnoncomply
gen noncomply1=probnoncomply
gen noncomply2=0.4*noncomply1
gen noncomply3=0.2*noncomply1
.....
gen rno1=uniform()
gen event1=0
replace event1 =1 if trt==0 & rno1<(1-exp(-haz0))
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replace event1 =1 if trt==1 & rno1<(1-exp(-haz1))
recode death 0=1 if event1==1
gen time=0.5 if event1==1
recode comply 1=0 if trt==1 & rno1<=noncomply1 & death==0
gen noncomply_t = 0.51 if trt==1 & rno1<=noncomply1 & death==0
.....
gen rno7=uniform()
gen event7=0 if death~=1
recode event7 0=1 if death~=1 & trt==0 & rno7<(1-exp(-haz0))
recode event7 0=1 if death~=1 & trt==1 & comply==1 & rno7<(1-exp(-haz1))
recode event7 0=1 if death~=1 & trt==1 & comply==0 & rno7<(1-exp(-haz0))
recode death 0=1 if event7==1
recode time .=6.5 if event7==1
recode comply 1=0 if trt==1 & rno7<=noncomply2 & death==0
recode noncomply_t .= 6.51 if trt==1 & rno7<=noncomply2 & death==0
.....
gen rno13=uniform()
gen event13=0 if death~=1
recode event13 0=1 if death~=1 & trt==0 & rno13<(1-exp(-haz0))
recode event13 0=1 if death~=1 & trt==1 & comply==1 & rno13<(1-exp(-haz1))
recode event13 0=1 if death~=1 & trt==1 & comply==0 & rno13<(1-exp(-haz0))
recode death 0=1 if event13==1
recode time .=12.5 if event13==1
recode comply 1=0 if trt==1 & rno13<=noncomply3 & death==0
recode noncomply_t .= 12.51 if trt==1 & rno13<=noncomply3 & death==0
.....
gen rno19=uniform()
gen event19=0 if death~=1
recode event19 0=1 if death~=1 & trt==0 & rno19<(1-exp(-haz0))
recode event19 0=1 if death~=1 & trt==1 & comply==1 & rno19<(1-exp(-haz1))
recode event19 0=1 if death~=1 & trt==1 & comply==0 & rno19<(1-exp(-haz0))
recode death 0=1 if event19==1
recode time .=18.5 if event19==1
.....
gen rno24=uniform()
gen event24=0 if death~=1
recode event24 0=1 if death~=1 & trt==0 & rno24<(1-exp(-haz0))
recode event24 0=1 if death~=1 & trt==1 & comply==1 & rno24<(1-exp(-haz1))
recode event24 0=1 if death~=1 & trt==1 & comply==0 & rno24<(1-exp(-haz0))
recode death 0=1 if event24==1
recode time .=23.5 if event24==1
gen cens=0
recode cens 0=1 if death==1
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recode time .=24 if death==0
gen noncomply=1 if comply==0
replace noncomply=0 if comply==1
.....
quietly count if death==1 /*totdeath*/
quietly count if noncomply==1 /*noncomply10*/
quietly count if noncomply==1 & trt==0 /*noncomply10*/
quietly count if noncomply==1 & trt==1 /*noncomply10*/
* ITT analysis
stset time death, id(id)
stcox trt,nohr
local ittest=_b[trt]
local sditt=_se[trt]
replace cvitt=1 if `ittest'-1.96*`sditt'<=ln(0.5)&`ittest'+1.96*`sditt'>=ln(0.5)
quietly count if cvitt==1
gen totcvitt=r(N)
sum totcvitt
local covitt=r(mean)/1000
di "`covitt'" "`ittest'"
return scalar covitt=`covitt'
return scalar ittest=`ittest'
* coxreg1- simple regression adjustment with 0/1 time-invariant noncompliance
stset time death, id(id)
stcox trt noncomply,nohr
local cox1=_b[trt]
local sdcox1=_se[trt]
local noncox1=_b[noncomply]
replace cvcox1=1 if `cox1'-1.96*`sdcox1'<=ln(0.5)&`cox1'+1.96*`sdcox1'>=ln(0.5)
quietly count if cvcox1==1
gen totcvcox1=r(N)
sum totcvcox1
local covcox1=r(mean)/1000
di "`cox1'" "`noncox1'" "`covcox1'"
return scalar covcox1=`covcox1'
return scalar cox1=`cox1'
return scalar noncox1=`noncox1'
* coxreg2 - simple regression adjustment with 0/1 time-varying noncompliance
stset time death, id(id)
stcox trt, tvc(noncomply) nohr
matrix bcox2=e(b)
matrix vcox2=e(V)
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local cox2=bcox2[1,1]
local noncox2=bcox2[1,2]
local sdcox2=sqrt(vcox2[1,1])
replace cvcox2=1 if `cox2'-1.96*`sdcox2'<=ln(0.5)&`cox2'+1.96*`sdcox2'>=ln(0.5)
quietly count if cvcox2==1
gen totcvcox2=r(N)
sum totcvcox2
local covcox2=r(mean)/1000
di "`cox2'" "`noncox2'" "`covcox2'"
return scalar covcox2=`covcox2'
return scalar cox2=`cox2'
return scalar noncox2=`noncox2'
*C-PROPHET analysis: HR estimate got as cprophet in stcomply2 ado file
replace comply=. if trt==0
stset time,fail(death)
stcomply2 trt comply
local cprophet=log(r(cprophet))
local sdcproph=_se[trt]
replace cvcproph=1 if `cprophet'-1.96*`sdcproph'<=ln(0.5)& /*
*/`cprophet'+1.96*`sdcproph'>=ln(0.5)
quietly count if cvcproph==1
gen totcproph=r(N)
sum totcproph
local covcproph=r(mean)/1000
di "`cprophet'" "`covcproph'"
return scalar cprophet=`cprophet'
return scalar covcproph=`covcproph'
*CALM analysis
stset time death, id(id)
strbee trt, xo1(noncomply_t noncomply) endstudy(endsty) /*
*/test(logrank) psimin(-2) psimax(2) psistep(0.01)
local calm=r(psi)
local sdcalm=_se[trt]
replace cvcalm=1 if `calm'-1.96*`sdcalm'<=ln(0.5)& `calm'+1.96*`sdcalm'>=ln(0.5)
quietly count if cvcalm==1
gen totcvcalm=r(N)
sum totcvcalm
local covcalm=r(mean)/1000
di "`calm'" "`covcalm'"
return scalar calm=`calm'
return scalar covcalm=`covcalm'
*true correlation from the simulations
corr haz0 probnoncomply
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local corrhaznonc=r(rho) /*corrhaznonc*/
*CHARM analysis
stset time death, id(id)
adjhr trt, xo1(noncomply_t noncomply) const
matrix bcharm=e(b)
matrix vcharm=e(V)
local charm=bcharm[1,1]
local sdcharm=sqrt(vcharm[1,1])
replace cvcharm=1 if `charm'-1.96*`sdcharm'<=ln(0.5)&`charm'+1.96*`sdcharm'>=ln(0.5)
quietly count if cvcharm==1
gen totcvcharm=r(N)
sum totcvcharm
local covcharm=r(mean)/1000
di "`charm'" "`covcharm'"
return scalar covcharm=`covcharm'
return scalar charm=`charm'
*simple CHARM approximation (White et al., 2004): adjusting ITT with theta
* calculating theta=pr(death) among non-compliers in the treated group
quietly count if group==1 & death==1
gen totdeadtrt=r(N)
sum totdeadtrt
local deadtrt=r(mean) /*deadtrt*/
quietly count if noncomply==1 & trt==1 & death==1
gen tottheta=r(N)
sum tottheta
local theta0=r(mean)
local theta=`theta0'/`deadtrt' /*theta*/
local charms=(exp(`ittest')*(1-`theta'))/(1-`theta'*exp(`ittest')) /*charms*/
.....
simulate totdeath=r(totdeath) noncomply10=r(noncomply10) /*
*/ noncomply0=r(noncomply0)noncomply1=r(noncomply1) theta=r(theta) /*
*/ corrhaznonc=r(corrhaznonc) ittest=r(ittest) cox1=r(cox1) /*
*/ noncox1=r(noncox1) cox2=r(cox2) charms=r(charms) noncox2=r(noncox2) /*
*/ cprophet=r(cprophet) calm=r(calm) charm=r(charm) covitt=r(covitt) /*
*/ covcox1=r(covcox1) covcox2=r(covcox2) covcalm=r(covcalm) /*
*/ covcproph=r(covcproph) covcharm=r(covcharm), reps(2000):thesis2010C7
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Appendix V: Annotated Stata+WinBUGS codes for simulations implementing
Roy et al. (2008) model (Chapter 8)
/*Stata codes generating simulation data*/
capture program drop Roy08simthesis2010C8
set seed 918273645
set more off
program define Roy08simthesis2010C8, rclass
drop _all
set obs 1000
gen id=_n
/* two risk factor distribution*/
gen hyst=_n<251
gen risk=_n<151
replace risk=1 if _n>250 & _n<701
gen byte trt=uniform()<=0.5
/* setting marginal compliance probs in H=R=0 for each stratum - state 1*/
gen compA_00=0.55
gen compB_00=0.30
/* odds ratios-effects of hyst*/
gen orhystA=2
gen orriskA=4
gen orhyriA=8
/* odds ratios - effects of risk factors*/
gen orhystB=5
gen orriskB=3
gen orhyriB=15
/* filling marginal compliance probs in remaining risk factor subgroups*/
gen compA_11=orhyriA*compA_00/(1-compA_00+orhyriA*compA_00)
gen compA_10=orhystA*compA_00/(1-compA_00+orhystA*compA_00)
gen compA_01=orriskA*compA_00/(1-compA_00+orriskA*compA_00)
gen compB_11=orhyriB*compB_00/(1-compB_00+orhyriB*compB_00)
gen compB_10=orhystB*compB_00/(1-compB_00+orhystB*compB_00)
gen compB_01=orriskB*compB_00/(1-compB_00+orriskB*compB_00)
gen u11=compB_11/compA_11
gen u10=compB_10/compA_10
gen u01=compB_01/compA_01
gen u00=compB_00/compA_00
replace u11=1 if u11>1
replace u10=1 if u10>1
replace u01=1 if u01>1
replace u00=1 if u00>1
/*joint compliance prob following Roy etal 2008 for different phi values - state 2*/
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gen phi=0.5
gen mu11_11=compA_11*compB_11+phi*compA_11*(u11-compB_11)
gen mu01_11=compB_11-compA_11*compB_11-phi*compA_11*(u11-compB_11)
gen mu10_11=compA_11-compA_11*compB_11-phi*compA_11*(u11-compB_11)
gen mu00_11=1-compA_11-compB_11+compA_11*compB_11+phi*compA_11*(u11-compB_11)
gen mu11_01=compA_01*compB_01+phi*compA_01*(u01-compB_01)
gen mu01_01=compB_01-compA_01*compB_01-phi*compA_01*(u01-compB_01)
gen mu10_01=compA_01-compA_01*compB_01-phi*compA_01*(u01-compB_01)
gen mu00_01=1-compA_01-compB_01+compA_01*compB_01+phi*compA_01*(u01-compB_01)
gen mu11_10=compA_10*compB_10+phi*compA_10*(u10-compB_10)
gen mu01_10=compB_10-compA_10*compB_10-phi*compA_10*(u10-compB_10)
gen mu10_10=compA_10-compA_10*compB_10-phi*compA_10*(u10-compB_10)
gen mu00_10=1-compA_10-compB_10+compA_10*compB_10+phi*compA_10*(u10-compB_10)
gen mu11_00=compA_00*compB_00+phi*compA_00*(u00-compB_00)
gen mu01_00=compB_00-compA_00*compB_00-phi*compA_00*(u00-compB_00)
gen mu10_00=compA_00-compA_00*compB_00-phi*compA_00*(u00-compB_00)
gen mu00_00=1-compA_00-compB_00+compA_00*compB_00+phi*compA_00*(u00-compB_00)
.....
/*compliance types: 0=00, 1=10, 2=01,3=11 */
gen compno=runiform()
gen type=cond(compno<mu00_00, 0,cond(compno<mu00_00+psi10_00, 1,/*
*/cond(compno<mu00_00+psi10_00+mu01_00, 2,3))) if hyst==0 & risk==0
return scalar n00_00=`n00_00' /*mean count if type==0 & hyst==0 & risk==0*/
return scalar n10_00=`n10_00' /*mean count if type==1 & hyst==0 & risk==0*/
return scalar n01_00=`n01_00' /*mean count if type==2 & hyst==0 & risk==0*/
return scalar n11_00=`n11_00' /*mean count if type==3 & hyst==0 & risk==0*/
replace type=cond(compno<mu00_10, 0,cond(compno<mu00_10+psi10_10, 1,/*
*/cond(compno<mu00_10+mu10_10+mu01_10, 2,3))) if hyst==1 & risk==0
return scalar n00_10=`n00_10';n10_10=`n10_10';n01_10=`n01_10';n11_10=`n11_10'
replace type=cond(compno<mu00_01, 0,cond(compno<mu00_01+psi10_01, 1,/*
*/cond(compno<mu00_01+mu10_01+mu01_01, 2,3))) if hyst==0 & risk==1
return scalar n00_01=`n00_01';n10_01=`n10_01';n01_01=`n01_01';n11_01=`n11_01'
replace type=cond(compno<mu00_11, 0,cond(compno<mu00_11+psi10_11, 1,/*
*/cond(compno<mu00_11+mu10_11+mu01_11, 2,3))) if hyst==1 & risk==1
return scalar n00_11=`n00_11';n10_11=`n10_11';n01_11=`n01_11';n11_11=`n11_11'
.....
return scalar enotype00=`enotype00'=round(`n00_00'+`n00_10'+`n00_01'+`n00_11',1)
return scalar enotype10=`enotype10'=round(`n10_00'+`n10_10'+`n10_01'+`n10_11',1)
return scalar enotype01=`enotype01'=round(`n01_00'+`n01_10'+`n01_01'+`n01_11',1)
return scalar enotype11=`enotype11'=round(`n11_00'+`n11_10'+`n11_01'+`n11_11',1)
.....
drop type /* allow (start) independent generation of type - state 3*/
gen haz0=rgamma(2,0.006)
sort haz0 hyst risk /*ranking wrt to baseline hazard to help choose the 4 types */
gen partno=runiform()
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/*choosing number compliant for H=R=0: n from 1 to 300 */
gen comp23=n1000/(n1000+n0100)
gen type=3 if _n<=n1100
replace type=0 if _n>300-n0000 & _n<=300
replace type=1 if _n>n1100 & _n<=300-n0000 & partno<=comp23
replace type=2 if _n>n1100 & _n<=300-n0000 & partno>comp23
/*choosing number compliant for H=0, R=1: n from 301 to 750 */
replace comp23=n1001/(n1001+n0101)
replace type=3 if _n>300 & _n<=300+n1101
replace type=0 if _n>750-n0001 & _n<=750
replace type=1 if _n>300+n1101 & _n<=750-n0001 & partno<=comp23
replace type=2 if _n>300+n1101 & _n<=750-n0001 & partno>comp23
/*choosing number compliant when H=1,R=0: n from 751 to 850 */
replace comp23=n1010/(n1010+n0110)
replace type=3 if _n>750 & _n<=750+n1110
replace type=0 if _n>850-n0010 & _n<=850
replace type=1 if _n>750+n1110 & _n<=850-n0010 & partno<=comp23
replace type=2 if _n>750+n1110 & _n<=850-n0010 & partno>comp23
/*choosing number compliant when H=R=1: n from 851 to 1000 */
replace comp23=n1011/(n1011+n0111)
replace type=3 if _n>850 & _n<=850+n1111
replace type=0 if _n>1000-n0011 & _n<=1000
replace type=1 if _n>850+n1111 & _n<=1000-n0011 & partno<=comp23
replace type=2 if _n>850+n1111 & _n<=1000-n0011 & partno>comp23
.....
/* specifying heterogeneous hazard rates for each stratum*/
/*HR-heteg-(AB)-11:(0.009,0.006),01:(0.008,0.006),10:(0.009,0.007),00:(0.010,0.008)*/
/*HR-homog-(AB)-11:(0.009,0.006),01:(0.009,0.006),10:(0.009,0.006),00:(0.009,0.006)*/
gen haza11=(3/4)*haz0;gen hazb11=haz0/2;gen haza01=(2/3)*haz0;gen hazb01=haz0/2;
gen haza10=(3/4)*haz0;gen hazb10=(7/12)*haz0;gen haza00=(5/6)*haz0;gen hazb00=(2/3)*haz0
/*gen haza11=(3/4)*haz0;gen hazb11=haz0/2;gen haza01=haza11;gen hazb01=hazb11;*/
/*gen haza10=haza11;gen hazb10=hazb11;gen haza00=haza11;gen hazb00=hazb11*/
/* linking baseline hazard rates to compliance types and arm-trt0=A,trt1=B*/
gen haz=haz0
replace haz=haza00 if trt==0 & type==0
replace haz=hazb00 if trt==1 & type==0
replace haz=haza10 if trt==0 & type==1
replace haz=hazb10 if trt==1 & type==1
replace haz=haza01 if trt==0 & type==2
replace haz=hazb01 if trt==1 & type==2
replace haz=haza11 if trt==0 & type==3
replace haz=hazb11 if trt==1 & type==3
/* selecting overall noncompliers for treat A and B */
gen noncompA=1 if trt==0 & type==0 | trt==0 & type==2
recode noncompA .=0 if trt==0
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gen noncompB=1 if trt==1 & type==0 | trt==1 & type==1
recode noncompB .=0 if trt==1
/* mean compliance: noncomplyA and noncomplyB */
return scalar noncomplyA=`noncomplyA'
return scalar noncomplyB=`noncomplyB'
.....
/* correlations between baseline hazards and noncompliance for A and B: */
return scalar corhazA=`corhazA' /* corr(noncomplyA,haz0) */
return scalar corhazB=`corhazB' /* corr(noncomplyB,haz0) */
.....
gen death=0
gen rand1=runiform()
gen event1=0
replace event1 =1 if rand1<(1-exp(-haz))
recode death 0=1 if event1==1
gen time=1 if event1==1
.....
gen rand24=runiform()
gen event24=0 if death!=1
replace event24 =1 if death!=1 & rand24<(1-exp(-haz))
recode death 0=1 if event24==1
recode time .=24 if event24==1
recode time .=24 if death==0
/* itt analysis - no correction for noncompliance*/
stset time death, id(id)
stcox trt /* effitt */
/* ITT effects in each stratum (stratum analysis)-comparing efficacy of B to A*/
stset time death, id(id)
stcox trt if type==3 /* eff11 */
stcox trt if type==2 /* eff01 */
stcox trt if type==1 /* eff10 */
stcox trt if type==0 /* eff00 */
/*logistic model predicting arm-specific compliance*/
gen complyA=0 if noncompA==1
replace complyA=1 if noncompA==0
logit complyA hyst risk
gen complyB=0 if noncompB==1
replace complyB=1 if noncompB==0
logit complyB hyst risk
keep complyA complyB trt hyst risk type death
save "C:Roy08simsdata.dta",replace
end
simulate mn_haz0=r(mn_haz0) sd_haz0=r(sd_haz0) n00_00=r(n00_00) /*
*/ n10_00=r(n10_00) n01_00=r(n01_00) n11_00=r(n11_00) n00_10=r(n00_10) /*
*/ n10_10=r(n10_10) n01_10=r(n01_10) n11_10=r(n11_10) n00_01=r(n00_01) /*
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*/ n10_01=r(n10_01) n01_01=r(n01_01) n11_01=r(n11_01) n00_11=r(n00_11) /*
*/ n10_11=r(n10_11) n01_11=r(n01_11) n11_11=r(n11_11) enotype00=r(enotype00) /*
*/ enotype10=r(enotype10) enotype01=r(enotype01) enotype11=r(enotype11) /*
*/ tot00=r(tot00) tot10=r(tot10) tot01=r(tot01) tot11=r(tot11) /*
*/ haz_00=r(haz_00) haz_10=r(haz_10) haz_01=r(haz_01) haz_11=r(haz_11) /*
*/ mn_trt1=r(mn_trt1) noncomplyA=r(noncomplyA) noncomplyB=r(noncomplyB) /*
*/ nod1trt0=r(nod1trt0) nod1trt1=r(nod1trt1) corhazA=r(corhazA) /*
*/ corhazB=r(corhazB) consA=r(consA) compAh=r(compAh) compAr=r(compAr) /*
*/ consB=r(consB) compBh=r(compBh) compBr=r(compBr) orcAhyst=r(orcAhyst) /*
*/ orcArisk=r(orcArisk) probcA=r(probcA) orcBhyst=r(orcBhyst) /*
*/ orcBrisk=r(orcBrisk) probcB=r(probcB) effitt=r(effitt) eff11=r(eff11) /*
*/ eff01=r(eff01) eff10=r(eff10) eff00=r(eff00), reps(2000):Roy08simthesis2010C8
model Roy08sim{
# WinBUGS+Stata: predicting compliance in placebo and active arms
for (i in 1:1000) {
complyA[i]~dbern(pA[i])
logit(pA[i])<-(lambda0[1]+lambda0[2]*hyst[i]+lambda0[3]*risk[i])*equals(trt[i],0)
complyB[i]~dbern(pB[i])
logit(pB[i])<-(lambda1[1]+lambda1[2]*hyst[i]+lambda1[3]*risk[i])*equals(trt[i],1)
# compliance probability for each arm
muA[i]<-pow((1+exp(-(lambda0[1]+lambda0[2]*hyst[i]+lambda0[3]*risk[i]))),-1)
muB[i]<-pow((1+exp(-(lambda1[1]+lambda1[2]*hyst[i]+lambda1[3]*risk[i]))),-1)
# likelihoods - risks of death for individual stratum
# L(pi,beta|Y=1,A=1,Z=1,X) - u(0,1) prior for pis
death3[i]<-death[i]*equals(type[i],3)
death3[i] ~ dbern(pi11_1[i])
pi11_1[i]<-pi1[1]*mu01[i]+pi1[2]*mu11[i]
# L(pi,beta|Y=1,A=0,Z=1,X) - u(0,1) prior for pis
death2[i]<-death[i]*equals(type[i],2)
death2[i] ~ dbern(pi10_1[i])
pi10_1[i]<-pi1[3]*mu00[i]+pi1[4]*mu10[i]
# L(pi,beta|Y=1,A=1,Z=0,X) - u(0,1) prior for pis
death1[i]<-death[i]*equals(type[i],1)
death1[i] ~ dbern(pi11_0[i])
pi11_0[i]<-pi1[5]*mu10[i]+pi1[6]*mu11[i]
# L(pi,beta|Y=1,A=0,Z=0,X) - u(0,1) prior for pis
death0[i]<-death[i]*equals(type[i],0)
death0[i] ~ dbern(pi10_0[i])
pi10_0[i]<-pi1[3]*mu00[i]+pi1[7]*mu01[i]
# ratio of compliance probability: B/A
u_x[i]<-min(1,muB[i]/muA[i])
# compliance probabilities for each stratum -phi=0,0.2,0.5,0.8
mu11[i]<-muA[i]*muB[i]+0.5*muA[i]*(u_x[i]-muB[i])
mu01[i]<-muB[i]-muA[i]*muB[i]-0.5*muA[i]*(u_x[i]-muB[i])
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mu10[i]<-muA[i]-muA[i]*muB[i]-0.5*muA[i]*(u_x[i]-muB[i])
mu00[i]<-1-muA[i]-muB[i]+muA[i]*muB[i]+0.5*muA[i]*(u_x[i]-muB[i])
}
# Also considered general phi without pre-specification: phi~dunif(0,1.0)
# non-informative priors for parameters
for (k in 1:3) {
lambda0[k] ~ dnorm(0.0,1.0E-6)
lambda1[k] ~ dnorm(0.0,1.0E-6)
}
# uniform priors for the pis=risk/probabilities of event
for (p in 1:7) {
pi1[p] ~ dunif(0,1)
}
# mean posterior estimates
m_muA<-mean(muA[]);m_muB<-mean(muB[]);m_ux<-mean(u_x[]);m_mu11<-mean(mu11[]);
m_mu01<-mean(mu01[]);m_mu10<-mean(mu10[]);m_mu00<-mean(psi00[]);
tau11<-pi1[2]/pi1[6];tau01<-pi1[1]/pi1[7];tau10<-pi1[4]/pi1[5]
}
# script calling WinBUGS
display('log');check('C:/Roy08C8/model.txt');data('C:/Roy08C8/data.txt')
compile(3);inits(1,'C:/Roy08C8/inits1.txt');inits(2,'C:/Roy08C8/inits2.txt')
inits(3,'C:/Roy08C8/inits3.txt');gen.inits();update(1000);set('lambda0')
set('lambda1');set('m_muA');set('m_muB');set('m_ux');set('m_mu11') set('m_mu01')
set('m_mu10');set('m_mu00');set('pi1');set('tau11');set('tau01') set('tau10')
dic.set();update(10000);dic.stats();coda(*,'C:/Roy08C8/coda')
save('C:/Roy08C8/log.txt');quit()
*Stata calling WinBUGS
use "C:\RoyChp8\Data4Stata-05.dta", clear
* transforming data to stata format
wbarray complyA complyB trt hyst risk type death, /*
*/ format(%3.0f %3.0f %3.0f %3.0f %3.0f %3.0f %3.0f) /*
*/ noprint saving(C:\RoyChp8\data.txt,replace)
* Model fitting
wbscript, sav(C:\RoyChp8\script.txt,replace) model(C:\RoyChp8\model.txt) /*
*/ data(C:\RoyChp8\data.txt) inits(C:\RoyChp8\inits.txt) coda(C:\RoyChp8\coda) /*
*/ burn(1000) update(10000) chain(3); set(lambda0 lambda1 m_muA m_muB m_ux m_mu11 /*
*/ m_mu01 m_mu10 m_mu00 pi1 tau11 tau01 tau10) dic log(C:\RoyChp8\log.txt) quit
* running the bugs program
wbrun, script(C:\RoyChp8\script.txt) winbugs(c:\Program Files\WinBUGS14\winbugs14.exe)
* Reading the MCMC results
wbcoda,root(C:\RoyChp8\coda) clear multichain chain(3) id(chain)
* summarising the results
wbstats lambda0* lambda1* m_muA m_muB m_ux /*
*/ m_mu11 m_mu01 m_mu10 m_mu00 pi1* tau11 tau01 tau10
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